<SEC-DOCUMENT>0001104659-22-090692.txt : 20220815
<SEC-HEADER>0001104659-22-090692.hdr.sgml : 20220815
<ACCEPTANCE-DATETIME>20220815090912
ACCESSION NUMBER:		0001104659-22-090692
CONFORMED SUBMISSION TYPE:	S-1
PUBLIC DOCUMENT COUNT:		20
FILED AS OF DATE:		20220815
DATE AS OF CHANGE:		20220815

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Nuvectis Pharma, Inc.
		CENTRAL INDEX KEY:			0001875558
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				862405608
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-266857
		FILM NUMBER:		221162711

	BUSINESS ADDRESS:	
		STREET 1:		1 BRIDGE PLAZA, SUITE 275
		CITY:			FORT LEE
		STATE:			NJ
		ZIP:			07024
		BUSINESS PHONE:		360-837-7232

	MAIL ADDRESS:	
		STREET 1:		1 BRIDGE PLAZA, SUITE 275
		CITY:			FORT LEE
		STATE:			NJ
		ZIP:			07024
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1
<SEQUENCE>1
<FILENAME>tm2223302d1_s1.htm
<DESCRIPTION>FORM S-1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 159.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 159.5pt"></P>

<P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; color: #231F20"><FONT STYLE="font-size: 10pt"><B>As filed with the U.S. Securities and Exchange Commission on
August 15, 2022.</B></FONT><B><FONT STYLE="font-size: 10pt"></FONT></B></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0; color: #231F20"><FONT STYLE="font-size: 10pt"><B>Registration No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><B>UNITED STATES</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"></P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; color: #231F20"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="font-size: 10pt; margin: 0 auto; width: 25%"><DIV STYLE="border-top: Black 1pt solid; font-size: 10pt"></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><B>FORM&nbsp;S-1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><B></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><B>REGISTRATION STATEMENT</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><B>Under</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"></P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; color: #231F20"><B>The Securities Act of 1933</B></P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; color: #231F20"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: rgb(35,31,32)"><FONT STYLE="font-size: 14pt"><B>Nuvectis
Pharma,&nbsp;Inc.</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20">(Exact name of Registrant as specified
in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; text-align: center; border-bottom: Black 1pt solid; width: 34%; font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #231F20"><B>Delaware</B></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; text-align: center; border-bottom: Black 1pt solid; width: 33%; font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #231F20"><B>2834</B></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; text-align: center; border-bottom: Black 1pt solid; width: 33%; font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #231F20"><B>86-2405608</B></FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="text-align: center; font-size: 10pt">(State of incorporation</TD>
    <TD STYLE="text-align: center; font-size: 10pt">(Primary Standard Industrial</TD>
    <TD STYLE="text-align: center; font-size: 10pt">(I.R.S. Employer</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="text-align: center; font-size: 10pt"> or organization)</TD>
    <TD STYLE="text-align: center; font-size: 10pt">Classification
Code Number)</TD>
    <TD STYLE="text-align: center; font-size: 10pt">Identification Number)</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><B>1 Bridge Plaza</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><B>Suite&nbsp;275</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><B>Fort Lee, NJ, 07024</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><B>(201) 614-3150</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"></P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; color: #231F20">(Address, including zip code, and telephone number, including area code, of
registrant&rsquo;s principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><B>Ron Bentsur,
M.B.A.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><B>Chairman and Chief Executive Officer</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><B>Nuvectis Pharma,&nbsp;Inc.</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><B>1 Bridge Plaza</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><B>Suite&nbsp;275</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><B>Fort Lee, NJ, 07024</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><B>(201) 614-3151</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"></P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; color: #231F20">(Name, address, including zip code, and telephone number, including area code,
of agent for service)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="font-size: 10pt; margin: 0 auto; width: 25%"><DIV STYLE="border-top: Black 1pt solid; font-size: 10pt"></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: #231f20"><B><I>Copy
to:</I></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: #231f20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><B>Matthew
W. Mamak</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><B>Alston&nbsp;&amp;
Bird LLP</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><B>90 Park
Avenue</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><B>New York,
NY 10016</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><B>(212) 210-1256</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="font-size: 10pt; margin: 0 auto; width: 25%"><DIV STYLE="border-top: Black 1pt solid; font-size: 10pt"></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Approximate
date of commencement of proposed sale to the public: </B></FONT>As soon as practicable after the effective date of this Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; color: #231f20">If any of the securities being registered on this form
are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under the Securities Act of 1933 check the following box.
<FONT STYLE="font-family: Wingdings">&#120;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; color: #231f20">If this Form&nbsp;is filed to register additional securities
for an offering pursuant to Rule&nbsp;462(b)&nbsp;under the Securities Act, please check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same offering. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; color: #231f20">If this Form&nbsp;is a post-effective amendment filed
pursuant to Rule&nbsp;462(c)&nbsp;under the Securities Act, check the following box and list the Securities Act registration statement
number of the earlier effective registration statement for the same offering. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; color: #231f20">If this Form&nbsp;is a post-effective amendment filed
pursuant to Rule&nbsp;462(d)&nbsp;under the Securities Act, check the following box and list the Securities Act registration number of
the earlier effective registration statement for the same offering. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; color: #231f20">Indicate by check mark whether the registrant is a
large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company.
See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; &ldquo;smaller reporting company&rdquo;
and &ldquo;emerging growth company&rdquo; in Rule&nbsp;12b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 25%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231F20">Large accelerated filer</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231F20"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="font-size: 10pt; width: 25%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 25%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231F20">Accelerated filer</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231F20"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 15%">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231F20">Non-accelerated filer</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231F20"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231F20">Smaller reporting company</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Wingdings">&#120;</FONT>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify"></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231F20"></FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Emerging growth company</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Wingdings">&#120;</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20">If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new
or revised financial accounting <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; margin: 0pt 0; font-size: 10pt; color: #231F20"><B>The Registrant hereby amends this Registration Statement on such date or
dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that
this Registration Statement shall thereafter become effective in accordance with Section&nbsp;8(a)&nbsp;of the Securities Act of 1933,
as amended, or until the Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting
pursuant to said Section&nbsp;8(a), may determine.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: #ea1d2d"><B>The information
in this preliminary prospectus is not complete and may be changed. Neither we nor the selling security holders may sell these securities
until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an
offer to sell these securities, and it is not soliciting offers to buy these securities in any jurisdiction where the offer or sale is
not permitted.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-family: Sans-Serif; font-size: 9pt; color: Red"><B></B></FONT><B><FONT STYLE="color: #ea1d2d">PRELIMINARY PROSPECTUS&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SUBJECT TO COMPLETION DATED
AUGUST &nbsp;&nbsp;&nbsp;, 2022</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2223302d1_s1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>1,015,598 Shares of Common Stock</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Up to 909,091 Shares of Class&nbsp;Common Stock
Issuable Upon Exercise of the Pre-Funded Warrants</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Up to 2,040,170 Shares of Class&nbsp;Common
Stock Issuable Upon Exercise of the Preferred Investment Options</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20"><B>Nuvectis
Pharma,&nbsp;Inc</B></FONT><B>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; color: #231f20">This prospectus relates
to the offer and resale from time to time by the selling securityholders named in this prospectus (the &ldquo;Selling Shareholders&rdquo;)
of shares of common stock, par value $0.00001 per share (&ldquo;Common Stock&rdquo;) of Nuvectis Pharma,&nbsp;Inc., a Delaware corporation
(&ldquo;Nuvectis&rdquo;, the &ldquo;Company&rdquo;, &ldquo;we&rdquo;, &ldquo;us&rdquo; or &ldquo;our) consisting of (i)&nbsp;up to: 1,015,598
shares of our Common Stock issued in connection with our private placement offering (the &ldquo;Shares&rdquo;); (ii)&nbsp;up to 2,040,170
shares of Common Stock that may be obtained upon the exercise of preferred investment options to purchase shares of Common Stock (the
 &ldquo;Investment Options&rdquo;); and (iii)&nbsp;up to 909,091 pre-funded warrants to purchase shares of Common Stock issued in a private
placement (the &ldquo;Pre-Funded Warrants&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; color: #231f20">We will not receive
any proceeds from the sale of the securities under this prospectus, although we could receive up to $19,765,056 upon the exercise of all
of the Investment Options and Pre-Funded Warrants. Any amounts we receive from such exercises will be used for working capital and other
general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; color: #231f20">Information regarding
the Selling Shareholders, the amounts of shares of Common Stock that may be sold by them and the times and manner in which they may offer
and sell the shares of common stock under this prospectus is provided under the sections titled &ldquo;Selling Shareholders&rdquo; and
 &ldquo;Plan of Distribution,&rdquo; respectively, in this prospectus. We have not been informed by any of the Selling Shareholders that
they intend to sell the common stock covered by this prospectus and do not know when or in what amount the Selling Shareholders may offer
the common stock for sale. The Selling Shareholders may sell any, all, or none of the common stock offered by this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; color: #231f20">Our Common Stock is
listed on the Nasdaq Capital Market under the symbol &ldquo;NVCT&rdquo;. On August&nbsp;12, 2022, the last reported sale price of our common
stock was $8.71 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; color: #231f20">We are an &ldquo;emerging
growth company&rdquo; and a &ldquo;smaller reporting company&rdquo; as defined under the U.S. federal securities laws and, as such, have
elected to comply with certain reduced reporting requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; color: #231f20"><B>Investing in our
common stock involves a high degree of risk. See &ldquo;Risk factors&rdquo; beginning on page&nbsp;8.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; color: #231f20"><B>Neither the Securities
and Exchange Commission nor any other state securities commission has approved or disapproved of these securities or passed upon the accuracy
or adequacy of this prospectus. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">You should rely only on the information
contained in this prospectus. We have not authorized any dealer, salesperson or other person to provide you with information concerning
us, except for the information contained in this prospectus. The information contained in this prospectus is complete and accurate only
as of the date on the front cover page&nbsp;of this prospectus, regardless of the time of delivery of this prospectus or the sale of any
securities. This prospectus is not an offer to sell these securities and we are not soliciting an offer to buy these securities in any
state where the offer or sale is not permitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20">The date of this prospectus is
August 15, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: rgb(35,31,32)"><B>Table of Contents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 95%"><A HREF="#sp1"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABOUT THIS PROSPECTUS</FONT></A></TD>
    <TD STYLE="width: 5%; text-align: right"><A HREF="#sp1"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#sp2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROSPECTUS SUMMARY</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#sp2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#sp3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RISK FACTOR SUMMARY</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#sp3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#sp4"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE OFFERING</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#sp4"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#sp5"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#sp5"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#sp6"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RISK FACTORS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#sp6"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#sp7"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USE OF PROCEEDS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#sp7"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#sp8"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DIVIDEND POLICY</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#sp8">37</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#sp21"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL
    CONDITION AND RESULTS OF OPERATIONS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#sp21"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#sp20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BUSINESS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#sp20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#sp19"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MANAGEMENT</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#sp19"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">84</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#sp18"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXECUTIVE COMPENSATION</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#sp18"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">90</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#sp17"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PRINCIPAL STOCKHOLDERS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#sp17"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">98</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#sp16"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CERTAIN RELATIONSHIPS AND RELATED-PARTY TRANSACTIONS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#sp16"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#sp14"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF CAPITAL STOCK</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#sp14"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#sp13"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S.
    HOLDERS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#sp13"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">105</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#sp12"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LEGAL MATTERS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#sp12"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">111</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#sp11"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXPERTS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#sp11"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">111</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#sp10"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#sp10"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">111</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#sp10a"><FONT STYLE="text-transform: uppercase">Incorporation of Certain Information by Reference</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#sp10a">112</A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: #231f20"><B><A NAME="sp1"></A>About this Prospectus</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">In this prospectus, unless the context suggests
otherwise, references to &ldquo;Nuvectis Pharma,&rdquo; &ldquo;Nuvectis,&rdquo; the &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;us&rdquo;
and &ldquo;our&rdquo; refer to Nuvectis Pharma,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; color: #231f20">This prospectus is
part of a registration statement on Form&nbsp;S-1 that we filed with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;). Under
this registration process, the Selling Shareholders may, from time to time, sell the securities offered by them described in this prospectus
through any means described in the section titled &ldquo;Plan of Distribution&rdquo;. We will not receive any proceeds from the sale by
such Selling Holders of the securities offered by them described in this prospectus. This prospectus also relates to the issuance by us
of the shares of Common Stock issuable upon the exercise of any Investment Option or Pre-Funded Warrant. We will receive proceeds from
any exercise of the Investment Options and Pre-Funded Warrants for cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; color: #231f20">Neither we nor the
Selling Shareholders have authorized anyone to provide you with any information or to make any representations other than those contained
in this prospectus or any applicable prospectus supplement or any free writing prospectuses prepared by or on behalf of us or to which
we have referred you. Neither we nor the Selling Shareholders take responsibility for and can provide no assurance as to the reliability
of, any other information that others may give you. Neither we nor the Selling Shareholders will make an offer to sell these securities
in any jurisdiction where the offer or sale is not permitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; color: #231f20">We may also provide
a prospectus supplement or post-effective amendment to the registration statement to add information to, or update or change information
contained in, this prospectus. Any statement contained in this prospectus will be deemed to be modified or superseded for purposes of
this prospectus to the extent that a statement contained in such prospectus supplement or post-effective amendment modifies or supersedes
such statement. Any statement so modified will be deemed to constitute a part of this prospectus only as so modified, and any statement
so superseded will not be deemed to constitute a part of this prospectus. You should read both this prospectus and any applicable prospectus
supplement or post-effective amendment to the registration statement together with the additional information to which we refer you in
the section of this prospectus titled &ldquo;<I>Where You Can Find More Information</I>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">ii</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<DIV STYLE="padding-right: 10pt; border: Black 1pt solid; padding-left: 10pt">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><B><A NAME="sp2"></A>Prospectus Summary</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20"><I>This summary highlights information contained
in greater detail elsewhere in this prospectus and does not contain all of the information that you should consider in making your investment
decision. Before investing in our Common Stock, you should carefully read this entire prospectus, including our financial statements and
the related notes thereto included elsewhere in this prospectus. You should also consider, among other things, the information set forth
under the sections titled &ldquo;Risk Factors,&rdquo; &ldquo;Special Note Regarding Forward-Looking Statements,&rdquo; and &ldquo;Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations,&rdquo; in each case appearing elsewhere in this prospectus.
Unless the context otherwise requires, we use the terms &ldquo;Nuvectis,&rdquo; &ldquo;Nuvectis Pharma,&rdquo; the &ldquo;Company,&rdquo;
 &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our&rdquo; and similar designations in this prospectus to refer to Nuvectis Pharma,&nbsp;Inc.
and, where appropriate, our subsidiaries.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">We are a biopharmaceutical company focused
on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations.
Our precision medicine approach translates key scientific insights relating to the oncogenic drivers and pathway addiction of cancer into
potent and highly selective anticancer drugs. In addition, we will investigate the relevance of specific mutations and other DNA alterations
as a potential patient selection marker and to identify synthetic lethality targets. This work could support our use of a tumor agnostic
development strategy wherein we enroll patients based on the cancer&rsquo;s genetic and molecular features without regard to the type
or location of the cancer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20"><B>NXP800 (HSF1-Pathway Inhibitor)&thinsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">We have licensed exclusive world-wide commercial
rights to NXP800, a clinical-stage novel Heat Shock Factor 1 (&ldquo;HSF1&rdquo;) pathway inhibitor, which was developed at the Institute
for Cancer Research (&ldquo;ICR&rdquo;) in London, England. Cancer cells actively exploit HSF1 to overcome diverse stresses and promote
biological activities crucial for their survival, progression, immune evasion, and metastasis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">In preclinical studies, treatment with NXP800
inhibited tumor growth in xenografts models of human ovarian cancer. In addition, a genetic mutation in the AT-rich interactive domain-containing
protein 1A (&ldquo;ARID1a&rdquo;) gene has been identified as a potential biomarker for treatment sensitivity and patient selection. Based
on this work, we plan to clinically investigate NXP800 in Ovarian Clear Cell Carcinoma (&ldquo;OCCC&rdquo;) and endometrioid ovarian carcinoma,
and to investigate the utility of ARID1a deficiency as a patient selection marker. The genetic screening for the ARID1a mutation is a
standard part of the commercially available screening panels being utilized in the clinic for cancer patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">The ongoing Phase 1 study of NXP800 is comprised
of two parts: dose-escalation Phase 1a, initiated in December&nbsp;2021, to be followed by an expansion Phase 1b. In the Phase 1a, the
safety and tolerability of NXP800 is being evaluated in patients with advanced solid tumors to identify a dose and dosing schedule for
the Phase 1b. In the Phase 1b, the safety and preliminary anti-tumor activity of NXP800 will be evaluated, initially in patients with
OCCC and endometrioid carcinoma and possibly in patients with other types of solid tumors. Additional preclinical studies are currently
being conducted to identify development opportunities for NXP800 in additional solid tumor types.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20"><B>NXP900</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">NXP900 is a preclinical-stage drug candidate
designed to preferentially inhibit the Proto-oncogene c-Src (&ldquo;SRC&rdquo;) and YES1 kinases. NXP900 was discovered at the University
of Edinburgh. SRC is aberrantly activated in many cancer types, including solid tumors such as breast, colon, prostate, pancreatic and
ovarian, while remaining predominantly inactive in non-cancerous cells. Increased SRC activity is generally associated with late-stage
cancers, metastatic potential and resistance to therapy, and correlates with poor clinical prognosis. YES1 gene amplification has been
reported to be implicated in several tumors including lung, head and neck, bladder and esophageal cancers. Furthermore, it has been found
that YES1 gene amplification is a key mechanism of resistance to Epidermal Growth Factor Receptor (&ldquo;EGFR&rdquo;) or (Human Epidermal
Growth Factor Receptor 2 (&ldquo;HER2&rdquo;) inhibitors. A recent, peer reviewed study published in Nature Communication which was not
sponsored by the Company, has shown positive effects of using NXP900 in combination with the leading EFGR inhibitor, Tagrisso, to overcome
Tagrisso resistance in Tagrisso-resistant cell lines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">Preclinically, NXP900 has been shown to
inhibit SRC and YES1 kinases and substantially inhibit growth of primary tumors and bone metastases in several triple negative breast
cancer (&ldquo;TNBC&rdquo;) animal models.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">We plan to initially develop NXP900 in solid
tumors where SRC and/or YES1 are implicated. We anticipate submitting an IND or an equivalent submission with a foreign agency in early
2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">Since our inception in 2020, we have devoted
all of our efforts and financial resources to organizing and staffing our company, business planning, raising capital, acquiring, discovering
product candidates and securing related intellectual property rights and conducting research and development activities for our programs.
We do not have any products approved for sale and have not generated any revenue from product sales. We may never be able to develop or
commercialize a marketable product. We have not yet successfully completed any pivotal clinical trials, obtained any regulatory approvals,
manufactured a commercial-scale drug, or conducted sales and marketing activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20"><B>Our Strategy<SUP></SUP></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">Our strategy is to build a global biopharmaceutical
company through the identification, development, and commercialization of therapeutics to address unmet medical needs in oncology with
an initial focus on patients with OCCC and endometrioid ovarian cancers. We intend to leverage our core competencies of target selection,
drug profiling and clinical and regulatory execution to build a pipeline of product candidates targeting cancers driven by genetic alterations.
The key elements driving our business strategy include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt">establishing a leadership position in targeted oncology therapeutics, utilizing the synthetic lethality approach by inhibiting the
HSF1 pathway in ARID1a-mutated cancers and/or protein deficiency as a biomarker;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt">advancing our lead product candidate, NXP800, through clinical development towards regulatory decision-making in OCCC and endometrioid
ovarian cancer;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt">maximizing the therapeutic potential for NXP800 by leveraging in vivo preclinical data in additional ARID1a-mutated tumor types, as
a monotherapy and possibly in combination with other approved therapies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt">positioning NXP900 as a differentiated SRC kinase inhibitor with improved activity against solid tumors compared to the existing SRC
kinase inhibitors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt">maximizing the therapeutic potential of NXP900 by generating additional in vivo preclinical data to highlight the benefits of inhibiting
YES1 on antitumor activity;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt">deploying our proven clinical, regulatory and business development/licensing expertise to further expand our targeted oncology pipeline
for patients with unmet medical needs; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt">evaluating opportunities to accelerate development timelines and enhancing the commercial potential of our products in collaboration
with third parties, including potential ex-U.S. collaboration opportunities.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: #231f20"><B>Risk Factors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: #231f20">An
investment in our Common Stock is subject to a broad range of risks and should only be made after a careful consideration of such
risks. For a discussion of some of the risks you should consider before purchasing our Common Stock, you are urged to carefully
review and consider the section entitled &ldquo;Risk Factors.&rdquo;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<DIV STYLE="padding-right: 10pt; border: Black 1pt solid; padding-left: 10pt">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20"><B><A NAME="sp3"></A>Risk Factor Summary</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">Our business is subject to a number of risks,
including risks that may prevent us from achieving our business objectives or may adversely affect our business, financial condition,
results of operations, cash flows and prospects that you should consider before making a decision to invest in our Common Stock. These
risks are discussed more fully in the section titled &ldquo;Risk factors&rdquo; beginning on page&nbsp;8, of this prospectus include
the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; color: #231f20">
<TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt">We have a
limited operating history, have not completed any clinical trials to date, have no products approved for commercial sale and have
not generated any revenue, which may make it difficult for investors to evaluate our current business and likelihood of success and
viability.</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt">We have incurred losses since our inception and have not generated any revenue. We expect to incur continued losses for the foreseeable
future and may never achieve or maintain profitability.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt">Our ability to generate revenue and achieve profitability depends significantly on our ability to achieve several objectives relating
to the discovery or identification, development, regulatory approval and commercialization of our current or future product candidates.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt">We will require substantial additional capital to finance our operations and achieve our goals. If we are unable to raise capital
when needed or on terms acceptable to us, we may be forced to delay, reduce or eliminate our research or product development programs,
any future commercialization efforts or other operations.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt">We are substantially dependent on the success of our lead product candidate, NXP800, for which we commenced a Phase 1 clinical trial
in December&nbsp;2021.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt">Clinical trials are very expensive, time consuming and difficult to design and implement, and involve uncertain outcomes. Furthermore,
results of earlier preclinical studies and clinical trials may not be predictive of results of future preclinical studies or clinical
trials. Our current or future product candidates may not have favorable results in later clinical trials, if any, or receive regulatory
approval.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt">If we fail to demonstrate safety and efficacy to our stakeholders, we may need to terminate development programs, our reputation may
be harmed, and our business will suffer.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt">The COVID-19 pandemic could adversely impact our business, including our clinical trials and clinical trial operations.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt">The development and commercialization of pharmaceutical products are subject to extensive regulation, and we may not obtain regulatory
approvals for NXP800, NXP900, or any future product candidate, on a timely basis or at all.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt">The manufacture of any of our current or future product candidates is complex. Our third-party manufacturers may encounter difficulties
or interruptions in production, which could delay or entirely halt their ability to supply any of our current or future product candidates
for clinical trials or, if approved, for commercial sale.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt">Our future success depends on our ability to retain our executive officers and key employees and to attract, retain and motivate qualified
personnel and manage our human capital.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt">We currently have 10 full-time employees and we will need to grow the size and capabilities of our organization, and we may experience
difficulties in managing this growth.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt">If we are unable to obtain and maintain patent protection or other necessary rights for our products and technology, or if the scope
of the patent protection obtained is not sufficiently broad or our rights under licensed patents is not sufficiently broad, our competitors
could develop and commercialize products and technology similar or identical to ours, and our ability to successfully commercialize our
products and technology may be adversely affected.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
</DIV>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<DIV STYLE="padding-right: 10pt; border: Black 1pt solid; padding-left: 10pt">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">We were
incorporated in July&nbsp;2020 under the laws of the State of Delaware under the name Centry Pharma,&nbsp;Inc., and changed our name
to Nuvectis Pharma,&nbsp;Inc. in July&nbsp;2021. Our principal executive offices are located at 1 Bridge Plaza, 2<SUP>nd</SUP>
Floor, Fort Lee, NJ 07024, and our telephone number is (201) 614-3150. Our website address is www.nuvectis.com. The information
contained in or accessible from our website is not incorporated into this prospectus, and you should not consider it part of this
prospectus. We have included our website address in this prospectus solely as an inactive textual reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20"><B>Implications of being an emerging growth
company and a smaller reporting company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">We qualify as an &ldquo;emerging growth
company&rdquo; as defined in the Jumpstart Our Business Startups Act of 2012, as amended. As an emerging growth company, we may take advantage
of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies. These provisions include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt">being permitted to only two years of audited financial statements in addition to any required unaudited interim financial statements
with correspondingly reduced &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo;
disclosure in this prospectus;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt">reduced disclosure about our executive compensation arrangements; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt">not being required to hold advisory votes on executive compensation or to obtain stockholder approval of any golden parachute arrangements
not previously approved; and an exemption from the auditor attestation requirement in the assessment of our internal control over financial
reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">We may take advantage of these exemptions
for up to five years or such earlier time that we are no longer an emerging growth company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">We would cease to be an emerging growth
company on the date that is the earliest of (i)&nbsp;the last day of the fiscal year in which we have total annual gross revenues of $1.07
billion or more; (ii)&nbsp;the last day of our fiscal year following the fifth anniversary of the date of the completion of our initial
public offering; (iii)&nbsp;the date on which we have issued more than $1.0 billion in nonconvertible debt during the previous three years;
or (iv)&nbsp;the date on which we are deemed to be a large accelerated filer under the rules&nbsp;of the Securities and Exchange Commission
(&ldquo;SEC&rdquo;). We may choose to take advantage of some but not all of these exemptions. We have taken advantage of reduced reporting
requirements in this prospectus. Accordingly, the information contained herein may be different from the information you receive from
other public companies in which you hold stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">We have elected not to &ldquo;opt out&rdquo;
of the exemption for the delayed adoption of certain accounting standards and, therefore, we will adopt new or revised accounting standards
at the time private companies adopt the new or revised accounting standard and will do so until such time that we either (i)&nbsp;irrevocably
elect to &ldquo;opt out&rdquo; of such extended transition period or (ii)&nbsp;no longer qualify as an emerging growth company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">We are also a &ldquo;smaller reporting company,&rdquo;
meaning that the market value of our stock held by non-affiliates is less than $700 million and our annual revenue was less than $100
million during the most recently completed fiscal year. We may continue to be a smaller reporting company after this offering if either
(i)&nbsp;the market value of our stock held by non-affiliates is less than $250 million or (ii)&nbsp;our annual revenue was less than
$100 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700
million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions
from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we
may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form&nbsp;10-K and,
similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
</DIV>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20"><I>Recent Developments</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Private Placement of Shares of Common Stock, Preferred
Investment Options, and Pre-Funded Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><BR>
On July&nbsp;27, 2022, we entered into definitive agreements for the issuance and sale in a private placement (the &ldquo;Private Placement&rdquo;)
of 1,015,598 shares of its common stock, par value $0.00001 (the &ldquo;Common Stock&rdquo;) and pre-funded warrants to purchase up to
an aggregate of 909,091 shares of Common Stock at a purchase price of $8.25 per share, referred to as the Pre-Funded Warrants. The investors
in the Private Placement also received preferred investment options to purchase up to an aggregate of 1,924,689 shares of Common Stock,
referred to as the Investor Investment Options. The Investor Investment Options will have an exercise price of $9.65, will become exercisable
commencing six months following the date of issuance and will have a term of three and one-half years from the date of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The Private Placement closed on July&nbsp;29, 2022. Gross
proceeds to the Company from the Private Placement are approximately $15.9 million. The Company intends to use the net proceeds from the
Private Placement for working capital and other general corporate purposes. See &ldquo;Use of Proceeds.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">In connection with the Private Placement, the Company entered
into a registration rights agreement (the &ldquo;Registration Rights Agreement&rdquo;) with the Selling Shareholders. Pursuant to the
Registration Rights Agreement, the Company is required to file a resale registration statement (the &ldquo;Registration Statement&rdquo;)
with the Securities and exchange Commission (the &ldquo;SEC&rdquo;) to register for resale of the Shares, the shares issuable upon exercise
of the Pre-Funded Warrants and the Investment Options (as defined below) by August&nbsp;15, 2022. Pursuant to the Registration Rights
Agreement, the Registration Statement shall be declared effective within 45 days after July&nbsp;27, 2022, or in the event of a full review
by the SEC, 75 days from July&nbsp;27, 2022. The Company will be obligated to pay certain liquidated damages to the investor if the Company
fails to file the resale registration statement when required, fails to cause the Registration Statement to be declared effective by the
SEC when required, of if the Company fails to maintain the effectiveness of the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">H.C. Wainwright &amp; Co. (&ldquo;Wainwright) acted
as the placement agent in connection with the Private Placement. Pursuant to the engagement agreement, Wainwright was paid a cash fee
equal to 7% of the gross proceeds and a management fee of 1% of the gross proceeds. The Company also paid Wainwright $85,000 for non-accountable
expenses. As part of their compensation, certain designees of Wainwright received preferred investment options to purchase up to an aggregate
of 115,481 shares of Common Stock, referred to as the Placement Agent Investment Options (and together with the Investor Investment Options,
the &ldquo;Investment Options&rdquo;). The Placement Agent Investment Options have an exercise price of $10.3125, per share will become
exercisable commencing six months following the date of issuance and have a term of three and one-half years from the date of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<DIV STYLE="padding-right: 10pt; border: Black 1pt solid; padding-left: 10pt">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: rgb(35,31,32)"><B><A NAME="sp4"></A>The
Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231F20"><B>Shares of common stock outstanding immediately prior to the Private Placement. </B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 58%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231F20">12,717,794</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231F20"><B>Shares of common stock offered by the Selling Shareholders</B>&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231F20">Up to 1,015,598 shares</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231F20"><B>Pre-funded warrants offered by the Selling Shareholders </B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231F20">Up to 909,091 pre-funded warrants</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231F20"><B>Preferred investment options offered by the Selling Shareholders </B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231F20">Up to 2,040,170 preferred investment options</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231F20"><B>Use of proceeds </B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231F20">We are not selling any securities
    under this prospectus and we will not&nbsp; receive any proceeds from the sale of shares of Common Stock by the Selling
    Shareholders. We will receive up to an aggregate of&nbsp; approximately $19,764,147 from the exercise of the preferred
    investment&nbsp; options, assuming the exercise in full of all of the preferred investment&nbsp;options. We will receive up to an
    aggregate of approximately $909 from the exercise of the pre-funded warrants. We intend to use the net proceeds of the Private
    Placement for working capital and general corporate purposes. See &ldquo;Use of Proceeds.&rdquo;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231F20"><B>Nasdaq Capital Market symbol </B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231F20">&ldquo;NVCT&rdquo;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231F20"><B>Risk factors </B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231F20">Investment in our Common Stock involves substantial risks. You should read this prospectus carefully, including the section entitled &ldquo;Risk Factors&rdquo; and the financial statements and the related notes to those statements included in this prospectus, before investing in our Common Stock.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231F20"></FONT> The number of shares of our Common Stock outstanding after the Private Placement is based on 14,642,483 shares of our Common Stock outstanding as of August&nbsp;5, 2022, and excludes:</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt">296,590 shares of Common Stock issuable upon exercise of options outstanding under our 2021 Global Equity Incentive Plan as amended
and restated (the &ldquo;2021 Plan&rdquo;), at a weighted average exercise price of $3.99 per share as of June&nbsp;30, 2022;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt">228,893 shares of Common Stock issuable upon the exercise of warrants under the 2021 Plan to purchase Common Stock and underwriter
warrants associated with the 2022 IPO at a weighted exercise price of $3.41 per share as of June&nbsp;30, 2022;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="font-size: 10pt">193,557 shares of restricted stock granted to the Company&rsquo;s three founders on July&nbsp;27, 2021;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="font-size: 10pt">349,580 shares of restricted stock issued under the 2021 Plan;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="font-size: 10pt">752,937 shares of Common Stock to be reserved for future issuance under the 2021 Plan; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="font-size: 10pt">2,040,170 shares of Common Stock issuable upon the exercise of the Investment Options.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
</DIV>
<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<DIV STYLE="padding-right: 10pt; border: Black 1pt solid; padding-left: 10pt">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center; color: #231f20"><B><A NAME="sp5"></A>Special Note Regarding Forward-looking
Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Certain matters discussed in this report may constitute
forward-looking statements for purposes of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;) and the Securities
Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), and involve known and unknown risks, uncertainties and other factors
that may cause our actual results, performance or achievements to be materially different from the future results, performance or achievements
expressed or implied by such forward-looking statements. The words &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;expect,&rdquo;
 &ldquo;plan,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;could,&rdquo; &ldquo;intend,&rdquo; &ldquo;target,&rdquo; &ldquo;project,&rdquo;
 &ldquo;contemplate,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;predict,&rdquo; &ldquo;would,&rdquo; &ldquo;potential,&rdquo;
 &ldquo;continue,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;may,&rdquo; &ldquo;expect&rdquo;
and similar expressions are generally intended to identify forward-looking statements. These forward-looking statements are based on management&rsquo;s
current expectations and assumptions about future events, which are inherently subject to uncertainties, risks and changes in circumstances
that are difficult to predict.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">Our actual results may differ materially
from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation, those discussed
under the captions &ldquo;Risk Factors,&rdquo; and elsewhere in this report. All written or oral forward-looking statements attributable
to us are expressly qualified in their entirety by these cautionary statements. Such forward-looking statements include, but are not limited
to, statements about:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#11162;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="color: #231f20">our expectations for increases or decreases in expenses;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#11162;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="color: #231f20">the success and timing of our clinical trials and preclinical studies, including safety and efficacy
of our product candidates, patient accrual, unexpected or expected safety events, and the usability of data generated from our trials;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt">expectations for incurring capital expenditures to expand our research and development and manufacturing capabilities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt">estimates of the sufficiency of our existing cash and cash equivalents and investments to finance our operating requirements, including
expectations regarding the value and liquidity of our investments;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="font-size: 10pt">expectations for generating revenue or becoming profitable on a sustained basis;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt">the impact of health epidemics, including the COVID-19 pandemic, on our business and the actions we may take in response thereto;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="font-size: 10pt">developments and projections relating to our competitors and industry;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="font-size: 10pt">our expectations about how market trends will affect our business;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt">our and our licensors&rsquo; ability to obtain, establish, maintain, protect and enforce intellectual property and proprietary protection
for our products and technologies and to avoid claims of infringement, misappropriation or other violation of third-party intellectual
property and proprietary rights;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt">our ability to attract and retain key personnel and to manage our future growth effectively;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">&#10146;</FONT></TD><TD STYLE="font-size: 10pt">expectations for future capital requirements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">&#10146;</FONT></TD><TD STYLE="font-size: 10pt">the volatility of the trading price of our Common Stock; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt">our expectations regarding the period during which we qualify as an emerging growth company under the Jumpstart Our Business Startups
Act.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">We have
based the forward-looking statements contained in this prospectus primarily on our current expectations and projections about future
events and trends that we believe may affect our business, financial condition, results of operations, prospects, business strategy
and financial needs. The outcome of the events described in these forward-looking statements is subject to risks,
uncertainties, assumptions and other factors described in the section captioned &ldquo;Risk Factors&rdquo; and elsewhere in this
prospectus. These risks are not exhaustive. Other sections of this prospectus include additional factors that could adversely impact
our business and financial performance. Furthermore, new risks and uncertainties emerge from time to time and it is not possible for us to predict
all risks and uncertainties that could have an impact on the forward- looking statements contained in this prospectus. We cannot assure
you that the results, events and circumstances reflected in the forward-looking statements will be achieved or occur, and actual results,
events or circumstances could differ materially from those described in the forward-looking statements. You should, however, review the
factors and risks and other information we describe in the reports we will file from time to time with the SEC after the date of this
prospectus. See &ldquo;Where You Can Find More Information.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">In addition, statements that &ldquo;we believe&rdquo;
and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available
to us as of the date of this prospectus, and while we believe such information forms a reasonable basis for such statements, such information
may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or
review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to
unduly rely upon these statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">You should read this prospectus and the
documents that we reference in this prospectus and have filed as exhibits to the registration statement of which this prospectus forms
a part with the understanding that our actual future results, levels of activity, performance and achievements may be materially different
from what we expect. We qualify all of our forward-looking statements by these cautionary statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">The forward-looking
statements made in this prospectus relate only to events as of the date on which such statements are made. We undertake no obligation
to update any forward-looking statements after the date of this prospectus or to conform such statements to actual results or revised
expectations, except as required by law.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
</DIV>
<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Risk Factors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center; color: #231f20"><B><A NAME="sp6"></A>Risk Factors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20"><I>Investing in our Common Stock involves
a high degree of risk. You should consider carefully the risks and uncertainties described below, together with all of the other information
in this prospectus, including the section titled &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results
of Operations&rdquo; and our financial statements and related notes, before making a decision to invest in our Common Stock. Our business,
results of operations, financial condition and prospects could also be harmed by risks and uncertainties that are not presently known
to us or that we currently believe are not material. If any of the risks actually occur, our business, platform, reputation, brand, results
of operations, financial condition and prospects could be materially and adversely affected. In such event, the market price of our Common
Stock could decline, and you could lose all or part of your investment.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Risks Related to Our Finances and Capital Requirements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><B><I>Our limited operating history
may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">We are a clinical stage biopharmaceutical
company with a limited operating history. We were incorporated in Delaware in July&nbsp;2020 and commenced operations in May&nbsp;2021.
Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, identifying, investigating,
licensing and evaluating potential product candidates, and establishing arrangements with third parties for the manufacture of initial
quantities of our lead product candidate and component materials. Our lead product candidate is in early clinical development, and our
second drug candidate is in preclinical development. We have not yet demonstrated our ability to successfully initiate, conduct or complete
any clinical trials, obtain marketing approvals, manufacture a commercial-scale product or arrange for a third party to do so on our behalf,
or conduct sales, marketing and distribution activities necessary for successful product commercialization. Consequently, any predictions
about our future success or viability may not be as accurate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">We will need to transition at some point
from a company with a research and development focus to a company capable of supporting commercial activities related to the full product
life cycle. We may not be successful in such a transition.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><B><I>We have incurred losses since
inception and anticipate that we will continue to incur losses for the foreseeable future. We may never achieve or maintain profitability.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Investment in biopharmaceutical product
development is a highly speculative undertaking and entails substantial upfront capital expenditures and significant risk that our current
or potential future product candidates will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval
and become commercially viable. We are still in the early stages of development of our product candidates and initiated our first clinical
trial in December&nbsp;2021. We have no products approved for commercial sale and have not generated any revenue from product sales to
date. We continue to incur significant research and development and other expenses related to our ongoing operations. In addition, as
a business with a limited operating history, we may encounter unforeseen expenses, difficulties, complications, delays and other known
and unknown factors, such as the COVID-19 pandemic.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">We have incurred losses in each period
since we commenced operations. Since inception through the end of June&nbsp;30, 2022, we had an accumulated deficit of $19.4 million.
Those losses mainly include the following: (1), $6.3 million in research and development expenses excluding licensing agreements, (2)&nbsp;in
connection with the exclusive licensing agreement related to our lead product candidate, NXP800, we paid an upfront payment of $3.5 million,
and (3)&nbsp;in connection with the exclusive licensing agreement related to NXP900, we also paid an upfront payment of $3.5 million.
We expect to continue to incur significant losses for the foreseeable future, and we expect these losses to increase substantially if
and as we continue our research and development efforts and submit IND applications for our lead product candidate; conduct preclinical
studies and clinical trials for our current and future product candidates; seek marketing approvals for any current or future product
candidate that successfully completes clinical trials; experience any delays or encounter any issues with any of the above; establish
a sales, marketing and distribution infrastructure and scale-up manufacturing capabilities to commercialize any current or future product
candidates for which we may obtain regulatory approval; obtain, expand, maintain, enforce and protect our intellectual property portfolio;
hire additional clinical, regulatory and scientific personnel; and operate as a public company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Risk Factors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Our lead product candidate, NXP800, is in clinical development
and our second product candidate, NXP900, is in the preclinical stage of development. Both product candidates will require additional
preclinical studies, clinical development, regulatory review and approval, substantial investment, access to sufficient clinical and commercial
manufacturing capacity and significant marketing efforts before we can generate any revenue from product sales. The Phase 1 study for
NXP800 started in December&nbsp;2021 and NXP900 has yet to enter clinical trials. To date, we have not generated any revenue from our
product candidates. Our ability to generate revenue will depend on a number of factors, including, but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timely completion of our preclinical studies and clinical trials, which may be significantly slower or more costly than anticipated and will depend upon the performance of third-party contractors;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">successful submissions of IND applications to the FDA and any additional comparable applications;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion of IND enabling studies necessary for the IND or comparable submission, as appropriate;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether we are required by the FDA or similar foreign regulatory authorities to conduct additional clinical trials or other studies to support the approval and commercialization of our current or future product candidates;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA&rsquo;s and similar foreign regulatory authorities&rsquo; acceptance of the safety, potency, purity, efficacy and risk to benefit profile of our current or future product candidates;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the prevalence, duration and severity of potential side effects or other safety issues experienced with our current or future product candidates, if any;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timely receipt of necessary marketing approvals from the FDA and similar foreign regulatory authorities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the actual and perceived availability, cost, risk profile and safety and efficacy of our current or future product candidates, if approved, relative to existing and future alternative cancer therapies and competitive product candidates and technologies;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability and the ability of third parties with whom we contract to manufacture adequate clinical and commercial supplies of our current or future product candidates, to remain in good standing with regulatory authorities and to develop, validate and maintain commercially viable manufacturing processes that are compliant with cGMP;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to successfully develop a commercial strategy and to commercialize any current or future product candidate in the United States and internationally, if approved for marketing, reimbursement, sale and distribution in such countries and territories, whether alone or in collaboration with others;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">patient demand for our current or future product candidates, if approved; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="text-align: justify; width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to establish and enforce intellectual property rights in and to our current or future product candidates.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Many of the factors listed above are
beyond our control and could cause us to experience significant delays or prevent us from obtaining regulatory approvals or commercializing
our current and future product candidates. Even if we can commercialize any current or future product candidates, we may not achieve profitability
soon after generating product sales, if ever.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Risk Factors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B><I>We will require substantial
additional funding. Raising additional capital may cause dilution to our existing stockholders, or require us to relinquish proprietary
rights. If we are unable to raise capital as needed, we may be compelled to delay, reduce or eliminate our product development programs
or commercialization efforts.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">We expect our expenses to increase in
parallel with our ongoing activities, particularly as we continue our discovery and preclinical development activities to identify new
product candidates and initiate clinical trials of, and seek marketing approval for, any of our current or future product candidates.
In addition, if we obtain marketing approval for any of our current or future product candidates, we expect to incur significant commercialization
expenses related to product sales, marketing, manufacturing, and distribution. Furthermore, we expect to incur significant additional
costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection
with our continuing operations. We cannot be certain that additional funding will be available on acceptable terms, or at all. Until such
time, if ever, as we can generate substantial product revenue, we expect to finance our operations through a combination of public or
private equity offerings, debt financings, governmental funding, collaborations, strategic partnerships and alliances or marketing, distribution
or licensing arrangements with third parties. To the extent that we raise additional capital through the sale of equity or convertible
debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences
that adversely affect your rights as a stockholder. Debt financing and preferred equity financing, if available, may involve agreements
that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital
expenditures or declaring dividends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">If we raise additional funds through
collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish
valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may
not be favorable to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">If we are unable to raise capital when
needed or on attractive terms, we could be forced to delay, reduce or eliminate our discovery and preclinical development programs or
any future commercialization efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><B><I>Major public health issues, and
specifically the pandemic caused by the coronavirus COVID-19 outbreak, could have an adverse effect on our clinical trials, financial
condition, results of operations, and other aspects of our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">In March&nbsp;2020, the World Health
Organization declared the outbreak of COVID-19 to be a pandemic. The COVID-19 pandemic is having widespread, rapidly evolving, and unpredictable
impacts on global society, economies, financial markets, and business practices. During 2021, there was a wide distribution of several
vaccinations and medicines to overcome the pandemic. We have shifted our operations to co-exist along with the pandemic, including encouragement
of vaccinations to all of our employees worldwide.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The uncertainty to which the COVID-19
pandemic impacts the Company&rsquo;s business, affects management&rsquo;s judgment and assumptions relating to accounting estimates in
a variety of areas that depend on these estimates and assumptions. COVID-19 did not have a material influence on these estimates and judgements
since the Company began operations in 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The Company continues to face relative
uncertainty as to the remaining intensity and duration of and the nature and timeline for recovery from the COVID-19 pandemic going forward
and how all of that impacts the Company, including the extent to which potentially permanent changes clinical trial operations have been
caused by the pandemic. The Company has taken the approach of managing the pandemic (to the extent that it continues to remain a significant
factor) via strengthening its balance sheet and cash assets and avoiding debt while focusing on cost controls. Some factors from the COVID-19
outbreak or any outbreak caused by any variant of COVID-19 that may delay or otherwise adversely affect our clinical trial programs, as
well as adversely impact our business generally, include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical sites, and delays enrolling patients in our clinical trials or increased rates of patients withdrawing from our clinical trials following enrollment as a result of contracting COVID-19, being forced to quarantine, or not otherwise being able to complete study assessments, particularly for older patients or others with a higher risk of contracting COVID-19;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Risk Factors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">diversion of healthcare resources, including clinical trial investigators and staff, away from the conduct of clinical trials to focus on pandemic concerns which could result in delays to our partner companies&rsquo; clinical trials;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations on travel, including limitations on domestic and international travel, and government-imposed quarantines or restrictions imposed by key third parties that could interrupt key trial activities, such as clinical trial site initiations and monitoring;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">interruption of, or delays in receiving, supplies of our product candidates from our contract manufacturing organizations due to staffing shortages, or production slowdowns or stoppages;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disruptions and delays caused by potential workplace, laboratory and office closures and an increased reliance on employees working from home across the healthcare system; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disruptions in or delays to regulatory approvals, inspections, reviews or other regulatory activities as a result of the spread of COVID-19 affecting the operations of the FDA or other regulatory authorities.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">We currently rely on third parties for
certain functions or services in support of our clinical trials and key areas of our operations. If these third parties themselves are
adversely impacted by restrictions resulting from the COVID-19 outbreak, we will likely experience delays and/or realize additional costs.
As a result, our ability to commence and complete clinical trials in timely fashion, obtain regulatory approvals for, and to commercialize,
our current and future product candidates may be delayed or disrupted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><B>Risks Related to the Development
of our Product Candidates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><B><I>Our discovery and preclinical
development approach focuses on the development of precision medicines for patients with genetically defined cancers and may never lead
to marketable products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The patient populations for our product
candidates and potential future product candidates are limited to those with specific target mutations and may not be completely defined
but are substantially smaller than the general treated cancer population and we will need to screen and identify these patients with the
targeted mutations. Successful identification of patients is dependent on several factors, including achieving certainty as to how specific
genetic alterations respond to our current product candidates or any future product candidate and, if necessary, developing companion
diagnostics to identify such genetic alterations. Furthermore, even if we are successful in identifying patients, we cannot be certain
that the resulting patient populations for each mutation will be large enough to allow us to successfully obtain approval for each mutation
type and commercialize our products and achieve profitability. In addition, even if our approach is successful in showing clinical benefit
by downregulating the HSF1 pathway in tumors harboring an ARID1a mutation or alteration, we may never successfully identify additional
oncogenic mutations for other genes. We do not know if our approach of treating patients with genetically defined cancers will be successful;
and if our approach is unsuccessful, our business will suffer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><B><I>We are very early in our development
efforts and are substantially dependent on our lead product candidate, NXP800. If we are unable to advance NXP800, NXP900 or any of our
other future product candidates through preclinical and clinical development, obtain regulatory approval and ultimately commercialize
NXP800, NXP900 or any of our other future product candidates, or experience significant delays in doing so, our business will be materially
harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">NXP800, our lead product candidate,
only recently started to be tested in human subjects. Our ability to generate product revenues will depend heavily on the successful clinical
development and eventual commercialization of NXP800 or future product candidates. Our second drug candidate, NXP900, has begun IND-enabling
studies or similar studies required by a foreign regulatory agency. Depending on the results of these IND-enabling studies, we may not
be able to submit an IND application with the FDA or a similar submission with a foreign regulatory agency and, therefore, may not be
able to conduct clinical trials for NXP900. In addition, our drug development programs may contemplate the development of companion diagnostics,
which are assays or tests to identify an appropriate patient population. Companion diagnostics are subject to regulation as medical devices
and must themselves receive marketing authorization from the FDA or certain other foreign regulatory agencies before they may be marketed.
If a companion diagnostic is essential to the safe and effective use of any of our current and future product candidates, the FDA must
conclude that the companion diagnostic meets the applicable standard for safety and effectiveness or for substantial equivalence for use
with our product candidates before either the product candidates or companion diagnostic may be marketed in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Risk Factors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Negative results in the development of our lead product candidate
may also prevent or delay our ability to continue or conduct clinical programs or receive regulatory approvals for our other future product
candidates. For example, although we believe, based on preclinical studies of OCCC models that demonstrated tumor growth inhibition, that
this cancer type might be particularly sensitive to NXP800, this may not prove true in clinical testing for any or all of the target indications.
Moreover, anti-tumor activity may be different in each tumor type that we plan to evaluate in clinical trials. Therefore, even though
we plan to potentially pursue tumor-agnostic clinical development of NXP800, the tumor response may be low in patients with some cancers
compared to others. As a result, we may be required to discontinue development of NXP800 for patients with those tumor types and/or mutations
due to insufficient clinical benefit, while continuing development in a more limited population of patients. Consequently, in order to
obtain regulatory approval, we may have to reach agreement with the FDA on defining the optimal patient population, study design and size,
any of which may require significant additional resources and delay our clinical trials and ultimately the approval, if any, of any of
our other future product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">We may experience setbacks that could
delay or prevent regulatory approval of, or our ability to commercialize, our current or future product candidates, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">negative or inconclusive results from our preclinical studies or clinical trials or positive results from the clinical trials of others for product candidates similar to ours leading to their approval, and evolving to a decision or requirement to conduct additional preclinical testing or clinical trials or abandon a program;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">product-related side effects experienced by patients or subjects in our clinical trials or by individuals using drugs or therapeutics that we, the FDA, other regulators or others view as relevant to the development of our current or future product candidates;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in submitting IND applications or comparable foreign applications or delays or failure in obtaining the necessary approvals from regulators to commence a clinical trial, or a suspension or termination of a clinical trial once commenced;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">conditions imposed by the FDA or comparable foreign authorities regarding the scope or design of our clinical trials, including our clinical endpoints;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in enrolling subjects in clinical trials, including due to the COVID-19 pandemic, and completion of clinical trials, including under GCP or good laboratory practice (&ldquo;GLP&rdquo;) requirements;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability to maintain compliance with regulatory requirements, including cGMPs, and complying effectively with other requirements pertaining to the quality of our current or future product candidates;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">high drop-out rates of subjects from clinical trials;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">inadequate supply or quality of our current or future product candidates or other materials necessary for the conduct of our clinical trials;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">greater than anticipated clinical trial costs;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability to compete with other therapies;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">poor efficacy of our current or future product candidates during clinical trials;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Risk Factors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">trial results taking longer than anticipated;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">trials being subjected to fraud or data capture failure or other technical mishaps leading to the invalidation of our trials;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the results of our trials not supporting application for conditional approval in the European Union;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unfavorable FDA or other regulatory agency inspection and review of a clinical trial site;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure of our third-party contractors or investigators to comply with regulatory requirements or otherwise meet their contractual obligations in a timely manner, or at all;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays related to the impact of the spread of the COVID-19 pandemic, including the impact of COVID-19 on the FDA&rsquo;s ability to continue its normal operations;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays and changes in regulatory requirements, policy and guidelines, including the imposition of additional regulatory oversight around clinical development generally or with respect to our technology in particular; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">varying interpretations of data by the FDA and similar foreign regulatory agencies.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">In addition, because we have limited
financial and personnel resources and are focusing primarily on developing our lead product candidate, we may forgo or delay pursuit of
other future product candidates that may prove to have greater commercial potential and may fail to capitalize on viable commercial products
or profitable market opportunities. If we do not accurately evaluate the commercial potential or target market for a future product candidate,
we may relinquish valuable rights to those future product candidates through collaboration, licensing, or other royalty arrangements in
cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such future product
candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><B><I>Clinical drug development involves
a lengthy and expensive process with uncertain outcomes, clinical trials are difficult to design and implement, and any of our clinical
trials could produce unsuccessful results or fail at any stage in the process.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Clinical trials conducted on humans
are expensive and can take many years to complete, and outcomes are inherently uncertain. Failure can occur at any time during the process.
Additionally, any positive results of preclinical studies and early clinical trials of a drug candidate may not be predictive of the results
of later-stage clinical trials, such that drug candidates may reach later stages of clinical trials and fail to show the desired safety
and efficacy traits despite having shown indications of those traits in preclinical studies and early-stage clinical trials. A number
of companies in the pharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or
adverse safety profiles, notwithstanding promising results in preclinical studies or earlier phases of clinical trials. Therefore, the
results of any future clinical trials we conduct may not be successful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Clinical trials may be delayed, suspended
or prematurely terminated because costs are greater than we anticipate or for a variety of reasons, such as:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay or failure in reaching agreement with the FDA or a comparable foreign regulatory authority on a trial design that we are able to execute;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Risk Factors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="text-align: justify; width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay or failure in obtaining authorization to commence a trial, including approval from the appropriate independent review board (&ldquo;IRB&rdquo;) to conduct testing of a candidate on human subjects, or inability to comply with conditions imposed by a regulatory authority regarding the scope or design of a clinical trial;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay in reaching, or failure to reach, agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: Red">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability, delay or failure in identifying and maintaining a sufficient number of trial sites, many of which may already be engaged in other clinical programs;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay or failure in recruiting and enrolling suitable volunteers or patients to participate in a trial;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay or failure in developing and validating companion diagnostics, if they are deemed necessary, on a timely basis;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure of patients to complete a trial or return for post-treatment follow-up;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability to monitor patients adequately during or after treatment;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical sites and investigators deviating from trial protocols, failing to conduct the trial in accordance with regulatory requirements or dropping out of a trial;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure to initiate or delay of or inability to complete a clinical trial as a result of a clinical hold imposed by the FDA or comparable foreign regulatory authority due to observed safety findings or other reasons;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">negative or inconclusive results in our clinical trials, and our decision to or regulators&rsquo; requirement that we conduct additional preclinical studies, clinical trials or that we abandon one or more of our product development programs; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability to manufacture sufficient quantities of a drug candidate of acceptable quality for use in clinical trials.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">We rely and plan to continue to rely
on CROs, contract manufacturing organizations (&ldquo;CMOs&rdquo;) and clinical trial sites to ensure the proper and timely conduct of
our clinical trials. Although we have and expect that we will have agreements in place with CROs and CMOs governing their contracted activities
and conduct, we will have limited influence over their actual performance. As a result, we ultimately do not and will not have control
over a CRO&rsquo;s or CMO&rsquo;s compliance with the terms of any agreement it may have with us, its compliance with applicable regulatory
requirements, or its adherence to agreed-upon time schedules and deadlines, and a future CRO or CMO&rsquo;s failure to perform those obligations
could subject any of our clinical trials to delays or failure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Further, we may also encounter delays
if a clinical trial is suspended or terminated by us, by any IRB or ethics committee, by a Data Safety Monitoring Board, or by the FDA
or European Medicines Agency (&ldquo;EMA&rdquo;), or other regulatory authority. A suspension or termination may be due to a number of
factors, including failure to conduct the clinical trial in accordance with regulatory requirements, inspection of the clinical trial
operations or trial site by the FDA, EMA or other regulatory authorities, exposing participants to health risks caused by unforeseen safety
issues or adverse side effects, development of previously unseen safety issues, failure to demonstrate a benefit from using a drug candidate,
or changes in governmental regulations or administrative actions. Therefore, we cannot predict with any certainty the schedule for commencement
or completion of any currently ongoing, planned or future clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Many of the factors that cause, or lead
to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of marketing approval for our
current or future product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">If we experience delays in the commencement
or completion of, or suspension or termination of, any clinical trial for our drug candidates, the commercial prospects of the drug candidate
could be harmed, and our ability to generate product revenues from the drug candidate may be delayed or eliminated. In addition, any delays
in completing our clinical trials will increase our costs, slow down our drug candidate development and approval process and jeopardize
regulatory approval of our drug candidates and our ability to commence sales and generate revenues. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Risk Factors</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The occurrence of any of these events
could harm our business, financial condition, results of operations and prospects significantly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><B><I>Difficulty in enrolling patients
could delay or prevent clinical trials of our current or future product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Identifying and qualifying patients
to participate in clinical studies of our current or future product candidates is critical to our success. The timing of completion of
our clinical studies depends in part on the speed at which we can recruit patients to participate in testing our current or future product
candidates and we may experience delays in our clinical trials if we encounter difficulties in enrollment. Further, because we are focused
on patients with specific indications and genetic mutations, our ability to enroll eligible patients may be limited and may result in
slower enrollment than we anticipate. Our clinical trials will compete with other clinical trials for current or future product candidates
that are in the same therapeutic areas as our current or future product candidates, which may reduce the number and types of patients
available to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Clinical trials may be subject to delays
as a result of patient enrollment taking longer than anticipated or greater than anticipated subject withdrawal. We may not be able to
initiate or continue clinical trials for our current or future product candidates if we are unable to locate and enroll a sufficient number
of eligible patients to participate in these trials as required by the FDA or foreign regulatory authorities. We cannot predict how successful
we will be at enrolling subjects in future clinical trials. The enrollment of patients depends on many factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">patient eligibility and exclusion criteria defined in the protocol;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the size of the patient population required for analysis of the clinical trial&rsquo;s primary endpoints and the process for identifying patients;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential disruptions caused by the COVID-19 pandemic, including difficulties in initiating clinical sites, enrolling and retaining participants, diversion of health care resources away from clinical trials, travel or quarantine policies that may be implemented, and other factors;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the proximity of patients to clinical trial sites;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the design of the trial;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to recruit clinical trial investigators with the appropriate competencies and expertise;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinicians&rsquo; and patients&rsquo; perceptions as to the potential advantages and risks of the product candidate being studied in relation to other available therapies, including any new products that may be approved for the indications we are investigating;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the availability of competing commercially available therapies and other competing product candidates&rsquo; clinical trials;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to obtain and maintain clinical trial subject informed consents; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the risk that subjects enrolled in clinical trials will drop out of the trials before completion.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">If we are unable to locate and enroll
sufficient eligible patients to participate, as required by the FDA or similar regulatory authorities, we may be unable to initiate or
continue clinical trials for our current or future product candidates. If necessary, we intend to engage third parties to develop companion
diagnostics for use in our clinical trials. If such third parties are unsuccessful, our difficulty in identifying patients with the targeted
genetic mutations for our clinical trials would be increased. If we are unable to include patients with the targeted genetic mutations
or patients with well-defined serious unmet medical needs, we may be unable to participate in the FDA&rsquo;s expedited review and development
programs, including breakthrough therapy designation and fast track designation, or otherwise seek to accelerate clinical development
and regulatory timelines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<!-- Field: Split-Segment; Name: 2 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><FONT>Risk Factors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><B><I>Our preclinical studies and clinical
trials may fail to demonstrate adequately the safety, potency, purity, efficacy or any other necessary pharmacological properties of any
of our current or future product candidates, which would prevent or delay development, regulatory approval and commercialization.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Before obtaining regulatory approvals
for the commercial sale of our current or future product candidates, including NXP800 and NXP900, we must demonstrate through lengthy,
complex and expensive preclinical studies and clinical trials that our current or future product candidates are both safe and effective
for use in each target indication. Preclinical and clinical testing is expensive and can take many years to complete, and its outcome
is inherently uncertain. Failure can occur at any time during the preclinical study and clinical trial processes, and, because our current
product candidates are in an early stage of development, there is a high risk of failure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The results of preclinical studies and
early clinical trials of our current or future product candidates may not be predictive of the results of later-stage clinical trials.
Although product candidates may demonstrate promising results in preclinical studies and early clinical trials, they may not prove to
be effective in subsequent clinical trials. Additionally, while we initiated the first clinical trial for NXP800 in December&nbsp;2021,
clinical trials for any of our current or future product candidates, as is the case with all oncology drugs, it is likely that there may
be side effects associated with their use. Results of our trials could reveal a high and unacceptable severity and prevalence of these
or other side effects. In such an event, our trials could be suspended or terminated, and the FDA or comparable foreign regulatory authorities
could order us to halt or cease further development of or deny approval of our current or future product candidates for any or all targeted
indications. Drug-related side effects could also affect patient recruitment into the study or patient willingness to remain in the study
and therefore affect our ability to complete clinical trials. Drug-related side effects could also result in potential product liability
claims. Any of these occurrences may harm our business, financial condition and prospects significantly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><B><I>The FDA and comparable foreign
regulatory authorities may not accept data from any preclinical or clinical trials we may conduct in foreign countries.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The FDA&rsquo;s acceptance of data generated
for patients recruited outside the United States from clinical trials conducted in whole or in part outside the United States may be subject
to certain conditions, if accepted at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Although the FDA has the authority to
accept foreign data as part or even the sole basis for marketing approval, the FDA generally does not approve an application on the basis
of foreign data alone unless (i)&nbsp;the data is applicable to the U.S. population and U.S. medical practice, (ii)&nbsp;the trials were
performed by clinical investigators of recognized competence and pursuant to GCP regulations, and (iii)&nbsp;the FDA&rsquo;s clinical
trial requirements were met. Many foreign regulatory authorities have similar approval requirements. In addition, any clinical study conducted
in whole or in part outside of the United States would be subject to the applicable local laws of the jurisdiction where the trial was
conducted. We cannot guarantee that the FDA or comparable foreign regulatory authority will accept data from trials conducted in whole
or in part outside of the United States, which may result in the need for additional trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><B><I>We may not be able to submit IND
applications to commence additional clinical trials on the timelines we expect, and even if we are able to, the FDA may not permit us
to proceed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Our CTA and IND for NXP800 with the
MHRA and the FDA, respectively have been approved. However, if we experience manufacturing delays or any other delays, we may be unable
to file additional CTAs,&nbsp;IND applications or other clinical research authorizations for other product candidates on our expected
timelines. Moreover, while we have obtained CTA and IND approvals, we cannot be sure that issues will not arise that suspend or terminate
such clinical trials. Any failure to file CTAs,&nbsp;IND applications or other clinical research authorizations will adversely impact
our expected timelines to obtain regulatory acceptance for the commencement of our trials and may prevent us from completing our clinical
trials or commercializing our products on a timely basis, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><B><I>We currently have no marketing
and sales organization and have limited experience in marketing products. If we are unable to establish marketing and sales capabilities
or enter into agreements with third parties to market and sell any approved product candidates, we may not be able to generate product
revenue.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">We will have to compete with other pharmaceutical
and biotechnology companies to recruit, hire, train and retain marketing and sales personnel. If we are unable or decide not to establish
internal sales, marketing, and distribution capabilities, we may pursue arrangements with third-party sales, marketing, and distribution
collaborators regarding the sales and marketing of our products, if approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><FONT>Risk Factors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">There can be no assurance that we will
be able to develop in-house sales and distribution capabilities or establish or maintain relationships with third-party collaborators
to commercialize any product in the United States or overseas.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><B><I>We face substantial competition,
which may result in others discovering, developing or commercializing products before or more successfully than we do.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">While we believe that our scientific
knowledge, technology, and development expertise provide us with competitive advantages, we face potential competition from many different
sources, including major pharmaceuticals, specialty pharmaceuticals and biotechnology companies, academic institutions and government
agencies, and public and private research institutes that conduct research, development, manufacturing, and commercialization. Many of
our competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing,
regulatory approvals, and product marketing than we do. Our competitors may compete with us in recruiting and retaining qualified scientific
and management personnel and establishing clinical trial sites and patient recruitment for clinical trials, as well as in acquiring technologies
complementary to, or necessary for, our programs. As a result, our competitors may discover, develop, license, or commercialize products
earlier or more successfully than we do.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">If our product candidates, NXP800 and
NXP900, are approved for the indications for which we are currently conducting or planning preclinical and clinical trials, they will
likely compete with competitor drugs and other drugs that are currently in development. The availability of reimbursement from government
and other third-party payors will also significantly affect the pricing and competitiveness of our products. Our competitors may also
obtain FDA or other regulatory approval for their products more rapidly than we do, which could result in our competitors establishing
a strong market position before we are able to enter the market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><B>Risks Related to Government Regulation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Denial
of or delay in our receipt of required regulatory approvals may prevent or delay commercialization of our current or future product candidates
and our ability to generate revenue may be materially impaired</I></B></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The research, testing, manufacturing,
labeling, approval, sale, marketing and distribution of drug products are, and will remain, subject to extensive regulation by the FDA
in the United States and by the respective regulatory authorities in other countries where regulations differ. We will not be permitted
to market our current or future product candidates in the United States until we receive the respective approval of an NDA from the FDA,
or in any foreign countries until we receive the requisite approval from the respective regulatory authorities in such countries. The
time required to obtain regulatory approval, if any, by the FDA, EMA and comparable foreign authorities is unpredictable, but typically
takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion
of the regulatory authorities and the type, complexity and novelty of the product candidates involved. Regulatory authorities have substantial
discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval
and require additional nonclinical studies or clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Obtaining regulatory approval requires
the submission of extensive nonclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication
to establish the product candidate&rsquo;s safety and efficacy. Securing regulatory approval also requires the submission of information
about the product manufacturing process, and in many cases the inspection of manufacturing, processing, and packaging facilities by the
regulatory authorities. Our current or future product candidates may not be effective, may be only moderately effective or may prove to
have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or
prevent or limit commercial use, or there may be deficiencies in cGMP compliance by us or by our CMOs that could result in the candidate
not being approved. Moreover, we have not obtained regulatory approval for any drug candidate in any jurisdiction and it is possible that
none of our existing drug candidates or any drug candidates we may seek to develop in the future will ever obtain regulatory approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><FONT>Risk Factors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Our drug candidates could fail to receive,
or could be delayed in receiving, regulatory approval for many reasons, including any one or more of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA, EMA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be unable to demonstrate to the satisfaction of the FDA, EMA or comparable foreign regulatory authorities that a drug candidate is safe and effective for its proposed indication;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the results of clinical trials may not meet the level of statistical significance required by the FDA, EMA or comparable foreign regulatory authorities for approval;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be unable to demonstrate that a drug candidate&rsquo;s clinical and other benefits outweigh its safety risks;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA, EMA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the data collected from clinical trials of our drug candidates may not be sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States or elsewhere;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon review of our clinical trial sites and data, the FDA or comparable foreign regulatory authorities may find our record keeping or the record keeping of our clinical trial sites to be inadequate;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies may fail to meet the requirements of the FDA, EMA or comparable foreign regulatory authorities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA, EMA or comparable foreign regulatory authorities may fail to approve the companion diagnostics we contemplate developing internally or with partners; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the change of the medical standard of care or the approval policies or regulations of the FDA, EMA or comparable foreign regulatory authorities may significantly change in a manner that renders our clinical data insufficient for approval.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The time and expense of the approval
process, as well as the unpredictability of future clinical trial results and other contributing factors, may result in our failure to
obtain regulatory approval to market NXP800, NXP900 or any other drug candidates we may seek to develop in the future, which would significantly
harm our business, results of operations and prospects. In such case, we may also not have the resources to conduct new clinical trials
and/or we may determine that further clinical development of any such drug candidate is not justified and may discontinue any such programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">In addition, even if we were to obtain
regulatory approval in one or more jurisdictions, regulatory authorities may approve any of our drug candidates for fewer or more limited
indications than we request, may not approve prices we may propose to charge for our products, may grant approval contingent on the performance
of costly post-marketing clinical trials (referred to as &ldquo;conditional&rdquo; or &ldquo;accelerated&rdquo; approval depending on
the jurisdiction), or may approve a drug candidate with a label that does not include the labeling claims necessary or desirable for the
successful commercialization of that drug candidate. Any of the foregoing circumstances could materially harm the commercial prospects
for our drug candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><FONT>Risk Factors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><B><I>Obtaining and maintaining regulatory
approval of our current or future product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory
approval of our current or future product candidates in other jurisdictions.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Obtaining and maintaining regulatory
approval of any of our current or future product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain
regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have
a negative effect on the regulatory approval process in other jurisdictions. For example, even if the FDA grants regulatory approval of
a product candidate, similar foreign regulatory authorities must also approve the manufacturing, marketing and promotion of the product
candidate in those countries. Drug product approval procedures vary among jurisdictions and can involve requirements and administrative
review periods different from, and greater than, those in the United States, including additional preclinical studies or clinical trials
as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions
outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction.
In some cases, the price that we intend to charge for our products is also subject to approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">We may also submit marketing applications
in other countries. Regulatory authorities in jurisdictions outside of the United States have requirements for approval of product candidates
with which we must comply prior to marketing in those jurisdictions. Obtaining similar foreign regulatory approvals and compliance with
similar foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the
introduction of our products in certain countries. We do not have any product candidates approved for sale in any jurisdiction, including
international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with
the regulatory requirements in international markets and/or receive applicable marketing approvals, our target market will be reduced
and our ability to realize the full market potential of our current or future product candidates will be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><B><I>Even if we receive regulatory
approval of our current or future product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review,
which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements
or experience unanticipated problems with our current or future product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">If any of our current or future product
candidates are approved, activities such as the manufacturing, labeling, packaging, storage, advertising, promotion, sampling, and record
keeping for the products will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety
and other post-marketing information and reports, registration, as well as ongoing compliance with cGMP regulations. Drug manufacturers
and any CMOs responsible for any product manufacturing processes are required to comply with extensive FDA and comparable foreign regulatory
authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMP regulations and any applicable
foreign equivalents. As such, we and our CMOs will be subject to continual review and inspections to assess compliance with cGMP and adherence
to commitments made in any NDA, other marketing application, and previous responses to inspection observations. Accordingly, we and others
with whom we work must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production
and quality control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The FDA or a comparable foreign regulatory
authority may also impose requirements for costly post-marketing nonclinical studies or clinical trials (often called &ldquo;Phase 4 trials&rdquo;)
and post-marketing surveillance to monitor the safety or efficacy of the product. If we or a regulatory authority discover previously
unknown problems with a product, such as adverse events of unanticipated severity or frequency, production problems or issues with the
facility where the product is manufactured or processed, such as product contamination or significant not-compliance with applicable cGMP
regulations, a regulator may impose restrictions on that product, the manufacturing facility or us. If we or our third-party providers,
including our CMOs, fail to comply fully with applicable regulations, then we may be required to initiate a recall or withdrawal of our
products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Later discovery of previously unknown
problems with our current or future product candidates, including adverse events of unanticipated severity or frequency, or with our third-party
manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in the following, among other
things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions on the manufacturing of the product, the approved manufacturers or the manufacturing process;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions on the labeling or marketing of a product;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><FONT>Risk Factors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions on product distribution or use;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">requirements to conduct post-marketing studies or clinical trials;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal of the product from the market;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">product recalls;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">warning or untitled letters from the FDA or comparable notice of violations from foreign regulatory authorities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal of the FDA or other applicable regulatory authority to approve pending applications or supplements to approved applications;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines, restitution or disgorgement of profits or revenues;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension or withdrawal of marketing approvals;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension of any of our ongoing clinical trials;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">product seizure or detention or refusal to permit the import or export of products; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">consent decrees, injunctions or the imposition of civil or criminal penalties.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">In addition, regulatory authorities&rsquo;
policies (such as those of the FDA or EMA) may change and additional government regulations may be enacted that could prevent, limit or
delay regulatory approval of our current or future product candidates. If we are slow or unable to adapt to changes in existing requirements
or the adoption of new requirements or policies, or if we are otherwise not able to maintain regulatory compliance, we may lose any marketing
approval that we may have obtained, which would adversely affect our business, prospects and ability to achieve or sustain profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Non-compliance with European Union requirements
regarding safety monitoring or pharmacovigilance can also result in significant financial penalties. Similarly, failure to comply with
the European Union&rsquo;s requirements regarding the protection of personal information can also lead to significant penalties and sanctions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The FDA&rsquo;s policies may change
and additional government regulations may be enacted that could prevent, limit or delay marketing approval of our current or future product
candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or
if we are not able to maintain regulatory compliance, this may adversely affect, or even lead to the rescission of, the marketing approval
that we may have obtained, which would adversely affect our business, prospects and ability to achieve or sustain profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><B><I>A variety of risks associated
with marketing our current or future product candidates internationally could materially adversely affect our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">We plan to seek regulatory approval
of our current or future product candidates outside of the United States and expect that we will be subject to additional risks related
to operating in foreign countries including: differing regulatory requirements; unexpected changes in tariffs, trade barriers, price and
exchange controls; economic weakness, including inflation, or political instability in particular foreign economies and markets; compliance
with tax, employment, immigration and labor laws for employees living or traveling abroad; foreign currency fluctuations that result in
increased operating expenses, reduced revenue, and other obligations incident to doing business in another country; potential liability
under the Foreign Corrupt Practices Act of 1977 or comparable foreign regulations; and challenges enforcing our contractual and intellectual
property rights, especially in countries that do not recognize intellectual property rights to the same extent as the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><FONT>Risk Factors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><B><I>The insurance coverage and reimbursement
status of newly approved products is uncertain. Our current or future product candidates may become subject to unfavorable pricing regulations,
third-party coverage and reimbursement practices, or healthcare reform initiatives, which would harm our business. Failure to obtain or
maintain adequate coverage and reimbursement for new or current products could limit our ability to market those products and decrease
our ability to generate revenue.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Adverse pricing limitations may hinder
our ability to recoup our investment in one or more of our current or future product candidates, even if any such current or future product
candidate we may develop obtains marketing approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Our ability to successfully commercialize
any current or future product candidates will depend in part on the coverage and reimbursement for the products and related treatments
from government health administration authorities and third-party payors, such as private health insurers and health maintenance organizations.
These organizations decide which medications they will pay for and establish reimbursement levels. If coverage and adequate reimbursement
is not available, or the approved reimbursement amount is not high enough, we may be unable to establish or maintain pricing sufficient
to generate a return on our investment and may be unable to successfully commercialize our current or future product candidates. Reimbursement
by a third-party payor may depend upon a number of factors, including, but not limited to, the third-party payor&rsquo;s determination
that use of a product is a covered benefit under its health plan, safe, effective and medically necessary, appropriate for the specific
patient, cost-effective, and neither experimental nor investigational. If coverage and adequate reimbursement is not available, or the
approved reimbursement amount is not high enough, we may be unable to establish or maintain pricing sufficient to generate a return on
our investment and may be unable to successfully commercialize our current or future product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">A primary trend in the U.S. healthcare
industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting
coverage and the amount of reimbursement for particular medications. In general, the prices of medicines under such systems are substantially
lower than in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">There is also significant uncertainty
related to the insurance coverage and reimbursement of newly approved products, and coverage may be more limited than the purposes for
which the medicine is approved by the FDA or comparable foreign regulatory authorities. In the United States, the principal decisions
about reimbursement for new medicines are typically made by CMS. As a result, the coverage determination process is often a time consuming
and costly process that may require us to provide scientific and clinical support for the use of our products to each payor separately,
with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. It is difficult
to predict what CMS will decide with respect to reimbursement for fundamentally novel products such as ours. Reimbursement agencies in
Europe may be more conservative than CMS. Our inability to promptly obtain coverage and profitable payment rates from both government-funded
and private payors for any approved products we may develop could have a material adverse effect on our operating results, our ability
to raise capital needed to commercialize our current or future product candidates, and our overall financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><B><I>Healthcare legislative measures
and changes in policies, funding, staffing and leadership at the FDA and other agencies could hinder or prevent the commercial success
of our products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">In the United States, there have been
a number of legislative and regulatory changes to the healthcare system that could affect our future results of operations and the future
results of operations of our potential customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">In recent years, there has been heightened
governmental scrutiny over the manner in which biopharmaceutical manufacturers set prices for their marketed products, which has resulted
in several recent government inquiries as well as federal and state legislation designed to, among other things, increase drug price transparency,
review the relationship between pricing and manufacturer patient programs, reduce the cost of drugs under Medicare, and reform government
reimbursement for drug products. Congress and the executive branch have each indicated that they will continue to seek new legislative
and/or administrative measures to control drug costs, making this area subject to ongoing uncertainty. At the state level in the United
States, legislatures have also increasingly passed legislation and implemented regulations designed to control drug product pricing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><FONT>Risk Factors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">While we cannot predict what impact
these laws or policies will have in general or specifically on any product we may commercialize in the future, such efforts by the government
and payors may result in downward pressure on reimbursement, which could negatively affect market acceptance of new products. Any rebates,
discounts, taxes costs or regulatory or systematic changes on healthcare may have a significant effect on our profitability in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Given recent federal and state government
initiatives directed at lowering the total cost of healthcare, the executive branch, Congress and state legislatures will likely continue
to focus on healthcare reform and the reform of the Medicare and Medicaid programs. While we cannot predict the full outcome of any such
government action or legislation, it may harm our ability to market our products and generate revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Furthermore, regulatory authorities&rsquo;
assessment of the data and results required to demonstrate safety and effectiveness can change over time and can be affected by many factors,
such as the emergence of new information, including on other products, changing policies and agency funding, staffing and leadership.
We cannot be sure whether future changes to the regulatory environment will be favorable or unfavorable to our business prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><B><I>Our future relationships with
customers and third-party payors in the United States and elsewhere may be subject to applicable anti-kickback, fraud and abuse, false
claims, transparency, health information privacy and security and other healthcare laws and regulations, which could expose us to criminal
sanctions, civil penalties, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Healthcare providers, physicians and
third-party payors in the U.S. and elsewhere will play a primary role in the recommendation and prescription of any current or future
product candidates for which we obtain marketing approval. Our future arrangements with third-party payors and customers may expose us
to broadly applicable fraud and abuse and other healthcare laws and regulations, including, without limitation, the federal Anti-Kickback
Statute and the federal False Claims Act, which may constrain the business or financial arrangements and relationships through which we
sell, market and distribute any current or future product candidates for which we obtain marketing approval. In addition, we may be subject
to transparency laws and patient privacy regulation by the federal and state governments and by governments in foreign jurisdictions in
which we conduct our business. The applicable federal, state and foreign healthcare laws and regulations that may affect our ability to
operate include, but are not necessarily limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under federal and state healthcare programs, such as Medicare and Medicaid;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal civil and criminal false claims laws and civil monetary penalty laws, including the federal False Claims Act, which impose criminal and civil penalties, including civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, including the Medicare and Medicaid programs, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government; the federal Health Insurance Portability and Accountability Act of 1996 (&ldquo;HIPAA&rdquo;), which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and their respective implementing regulations, which impose obligations on covered healthcare providers, health plans, and healthcare clearinghouses, as well as their business associates that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><FONT>Risk Factors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal Open Payments program, which requires manufacturers of certain drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&rsquo;s Health Insurance Program, with specific exceptions, to report annually to CMS, information related to &ldquo;payments or other transfers of value&rdquo; made to &ldquo;covered recipients,&rdquo; which include physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors, and teaching hospitals) and applicable manufacturers. Applicable group purchasing organizations also are required to report annually to CMS the ownership and investment interests held by the physicians and their immediate family members. The SUPPORT for Patients and Communities Act added to the definition of covered recipient practitioners including physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists and certified nurse-midwives effective in 2022. Data collection began on August&nbsp;1, 2013 with requirements for manufacturers to submit reports to CMS by March&nbsp;31, 2014 and 90 days after the end of each subsequent calendar year. Disclosure of such information was made by CMS on a publicly available website beginning in September&nbsp;2014; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; state and foreign laws that require pharmaceutical companies to comply with the pharmaceutical industry&rsquo;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers; state and foreign laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">In November&nbsp;2020, HHS finalized
significant changes to the regulations implementing the Anti-Kickback Statute, as well as the Physician Self-Referral Law and the civil
monetary penalty rules&nbsp;regarding beneficiary inducements, with the goal of offering the healthcare industry more flexibility and
reducing the regulatory burden associated with those fraud and abuse laws, particularly with respect to value-based arrangements among
industry participants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Efforts to ensure that our business
arrangements with third parties will comply with applicable healthcare laws and regulations may involve substantial costs. It is possible
that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or
case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation
of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and
administrative penalties, including, without limitation, damages, fines, imprisonment, exclusion from participation in government healthcare
programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations, which could have a material adverse effect
on our businesses. If any of the physicians or other healthcare providers or entities with whom we expect to do business, including our
collaborators, is found not to be in compliance with applicable laws, it may be subject to criminal, civil or administrative sanctions,
including exclusions from participation in government healthcare programs, which could also materially affect our businesses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><B><I>If we fail to comply with environmental,
health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse
effect on the success of our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">We are subject to numerous environmental,
health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and
disposal of hazardous materials and wastes. Our operations may involve the use of hazardous and flammable materials, including chemicals
and biological and radioactive materials. Our operations also may produce hazardous waste products. We currently contract with third parties
for the conduct of our manufacturing efforts and preclinical studies and clinical trials and such third parties are responsible for disposal
of these materials and wastes. However, we cannot eliminate our risk of contamination or injury from these materials. In the event of
contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability
could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><FONT>Risk Factors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Although we maintain workers&rsquo;
compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous
materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental
liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or
radioactive materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><B>Risks Related to our Intellectual
Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><B><I>We currently hold a license to
certain intellectual property rights relating to our lead product candidate, NXP800 and to NXP900, as well as intellectual property rights
relating to other compounds that modulate HSF1 and the SRC and YES1 kinases. If we are unable to maintain patent and other intellectual
property protection for NXP800 and NXP900, and to obtain and maintain patent and other intellectual property protections for our other
current or future product candidates and technology, or if the scope of intellectual property protection obtained or maintained is not
sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability
to commercialize NXP800, NXP900 or any other current or future product candidates or technology may be adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Our success depends in large part on
our ability to obtain and maintain patent and other intellectual property protection in the United States and other countries with respect
to our current or future product candidates, including NXP800 and NXP900, their respective components, formulations, combination therapies,
methods used to manufacture them and methods of treatment and development that are important to our business, as well as successfully
defending these patents against third-party challenges. If we do not adequately protect our intellectual property rights, or if the intellectual
property rights we are able to obtain are insufficiently broad and exclusive, competitors may be able to erode or negate any competitive
advantage we may have, which could harm our business and ability to achieve profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">We intend to rely upon a combination
of patents, patent applications, confidentiality agreements, trade secret protection and license agreements to protect the intellectual
property related to our current or future product candidates and technologies. Any disclosure to or misappropriation by third parties
of our confidential proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, thus
eroding our competitive position in our market. We, or any current or future partners, collaborators, or licensees, may fail to identify
patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent
protection on them. We may be also unable to exclusively license relevant technology and associated intellectual property developed by
others. Therefore, we may miss potential opportunities to establish our patent position.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">If we are unable to secure additional
patent protection or maintain existing or future patent protection with respect to NXP800, NXP900, or any other proprietary products and
technology we develop, our business, financial condition, results of operations, and prospects would be materially harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">We currently hold a license to certain
intellectual property rights relating to NXP800, including its composition of matter and to other compounds that modulate HSF1. In addition,
we hold a license to certain intellectual property relating to NXP900, including its composition of matter and to other compounds that
inhibit the SRC and YES1 kinases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">We have licensed one patent family covering
the composition of matter for NXP800, including two issued U.S. patents covering the composition of matter for NXP800, as well as methods
for using and making NXP800. Additionally, patents have been issued in major markets, including the U.S., the European Union, and Japan.
The statutory expiration for the issued U.S. patents in this family is October&nbsp;2034, without considering any patent extensions that
may or may not be possible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">We have licensed a patent family directed
to additional compounds that modulate HSF1. A patent from this family has been granted in the U.S., and has a statutory expiration of
April&nbsp;2036, without considering any patent extensions that may or may not be possible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><FONT>Risk Factors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">We have also licensed a patent family
directed to deuterated compounds that modulate HSF1. Any U.S. patent that grants from this family would have a statutory expiration of
October&nbsp;2037, without considering any patent extensions or patent disclaimers that may or may not be possible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">We have licensed one patent family covering
the composition of matter for NXP900, which has been granted in the U.S., EU, Japan, China and is pending in the United Kingdom and Canada.
The statutory expiration for patents in this patent family is April&nbsp;2036, without considering any possible patent term extension.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">If the scope of our patent protection,
whether now or in the future, with respect to NXP800, NXP900 or our future product candidates and technology is not sufficiently broad,
we will be unable to prevent others from using our technology or from developing or commercializing technology and products similar or
identical to ours or other competing products and technologies. Any failure to obtain or maintain patent protection, through our own patents
or through in-licensing, with respect to NXP800, NXP900 and our future product candidates would have a material adverse effect on our
business, financial condition, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Even if they are unchallenged, our patent
applications, if issued, and any patents we may own or in-license now or in the future, may not provide us with any meaningful protection
or prevent competitors from designing around our patent claims to circumvent any patents we may own or in-license in the future by developing
similar or alternative technologies or therapeutics in a non-infringing manner. If the patent protection provided by our patent applications
or any patents we may pursue with respect to our current or future product candidates is not sufficiently broad to impede competition,
our ability to successfully commercialize our current or future product candidates could be negatively affected, which would harm our
business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Additionally, we cannot be certain that
the claims in our patent applications covering composition of matter (or other related aspects) of our current or future product candidates
or technology will be considered patentable by the USPTO, or by patent offices in foreign countries, or that the claims in any issued
patents we may own or in-license in the future will be considered patentable by courts in the United States or foreign countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The issuance of a patent does not foreclose
challenges to its inventorship, scope, validity or enforceability. Therefore, our owned and in-licensed patents may be challenged in the
courts or patent offices in the United States and elsewhere. Such challenges may result in loss of exclusivity or freedom to operate or
in patent claims being narrowed, invalidated, or held unenforceable, in whole or in part. Successful patent challenges could limit our
ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent
protection of our technology and products. Given the amount of time required for the development, testing and regulatory review of new
product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized.
As a result, our owned and in-licensed patents may not provide us with sufficient rights to exclude others from commercializing products
similar or identical to ours.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Moreover, we may be subject to a third-party
pre-issuance submission of prior art to the USPTO, or become involved in opposition, derivation, reexamination, inter parties review,
post-grant review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in
any such submission, Patent Trial and Appeal Board trial, proceeding or litigation could reduce the scope of, render unenforceable, or
invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment
to us, or result in our inability to manufacture or commercialize products without infringing third party patent rights. In addition,
if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from
collaborating with us to license, develop or commercialize current or future product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><FONT>Risk Factors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><B><I>If we fail to comply with our
obligations in our current license agreements, or in any future agreements under which we may license intellectual property rights from
third parties or otherwise experience disruptions to our business relationships with our current or future licensors, we could lose license
rights that are important to our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">We are currently party to a license
which grants us certain intellectual property rights relating to our lead product candidate, NXP800, as well as other compounds that modulate
HSF1, and to a license which grants us certain intellectual property rights relating to our second drug candidate, NXP900, as well as
other compounds that inhibit the SRC and YES1 kinases. These agreements impose numerous obligations on us to maintain our licensing rights,
including development, diligence, payment, commercialization, funding, milestone, royalty, sublicensing, insurance, patent prosecution,
enforcement and other obligations. In spite of our efforts, our licensor might conclude that we have materially breached our license agreement
and might therefore terminate the license agreement, thereby removing or limiting our ability to develop and commercialize NXP800 or NXP900
(and other compounds covered by the licenses).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Additionally, in the future, we may
be party to other license or collaboration agreements with third parties to advance our research or allow commercialization of current
or future product candidates. Such future agreements may impose numerous obligations, such as development, diligence, payment, commercialization,
funding, milestone, royalty, sublicensing, insurance, patent prosecution, enforcement and other obligations on us and may require us to
meet development timelines, or to exercise commercially reasonable efforts to develop and commercialize licensed products, in order to
maintain the licenses. In spite of our efforts, our future licensors might conclude that we have materially breached our future license
agreements and might terminate the license agreements, thereby removing or limiting our ability to develop and commercialize products
and technologies covered by these license agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Any termination of these current or
future licenses, or failure of the underlying patents to provide the intended exclusivity, could result in the loss of significant rights
and could harm our ability to commercialize our current or future product candidates, and competitors or other third parties would have
the freedom to seek regulatory approval of, and to market, products identical to ours and we may be required to cease our development
and commercialization of certain of our current or future product candidates. Any of the foregoing could have a material adverse effect
on our competitive position, business, financial conditions, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><B><I>If we are unable to protect the
confidentiality of our trade secrets, our business and competitive position would be harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">In addition to the protection afforded
by patents we may own or in-license in the future, we seek to rely on trade secret protection, confidentiality agreements, and license
agreements to protect proprietary know-how that is not patentable, processes for which patents are difficult to enforce, and any other
elements of our product discovery and development processes that involve proprietary know-how, information, or technology that is not
covered by patents. Although we require all of our employees, consultants, advisors and any third parties who have access to our proprietary
know-how, information, or technology to enter into confidentiality agreements, trade secrets can be difficult to protect and we have limited
control over the protection of trade secrets used by our collaborators and suppliers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">If we are unable to prevent unauthorized
material disclosure of our intellectual property to third parties, we will not be able to establish or maintain a competitive advantage
in our market, which could materially adversely affect our business, financial condition, results of operations and future prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><B><I>Third-party claims of intellectual
property infringement, misappropriation or other violations may be costly and time consuming and may prevent or delay our product discovery
and development efforts.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The intellectual property landscape
around precision medicine is crowded, and third parties may initiate legal proceedings alleging that we are infringing, misappropriating,
or otherwise violating their intellectual property rights; the outcome of which would be uncertain and could have a material adverse effect
on the success of our business. We or any of our future licensors or strategic partners may be party to, exposed to, or threatened with,
future adversarial proceedings or litigation by third parties having patent or other intellectual property rights alleging that our current
or future product candidates and/or proprietary technologies infringe, misappropriate or otherwise violate their intellectual property
rights. Thus, because of the large number of patents issued and patent applications filed in our fields, there may be a risk that third
parties may allege they have patent rights encompassing our current or future product candidates, technologies or methods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><FONT>Risk Factors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Third parties may assert that we are
employing their proprietary technology without authorization. In addition, because some patent applications in the United States may be
maintained in secrecy until the patents are issued, patent applications in the United States and many foreign jurisdictions are typically
not published until 18 months after filing, and publications in the scientific literature often lag behind actual discoveries, we cannot
be certain that others have not filed patent applications covering our current or future product candidates or technology. If any such
patent applications issue as patents, and if such patents have priority over our patent applications or patents we may own or in-license,
we may be required to obtain rights to such patents owned by third parties which may not be available on commercially reasonable terms
or at all, or may only be available on a non-exclusive basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">In the event of a successful claim of infringement, misappropriation
or other violation against us, we may have to pay substantial damages, including treble damages and attorneys&rsquo; fees for willful
infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible
or require substantial time and monetary expenditure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><B><I>Changes to patent law in the United
States and in foreign jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Our success is heavily dependent on
intellectual property, particularly patents. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available
in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard
to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents,
once obtained. Laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents
or to enforce patents that we might obtain in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><B><I>We may be subject to claims challenging
the inventorship or ownership of any intellectual property, including any patents we may own or in-license currently or in the future.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">We may be subject to claims that former
employees, collaborators or other third parties have an interest in any patents we may own or in-license currently or in the future, trade
secrets, or other intellectual property as an inventor or co-inventor. Litigation may be necessary to defend against these and other claims
challenging inventorship of any patents we may own or in-license in the future, trade secrets or other intellectual property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><B><I>We may be subject to claims that
our employees, consultants or independent contractors have wrongfully used or disclosed confidential information or alleged trade secrets
of third parties or competitors or are in breach of non-competition or non-solicitation agreements with our competitors.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">We may be subject to claims that we
or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information or
trade secrets of these third parties or our employees&rsquo; former employers or our consultants&rsquo; or contractors&rsquo; current
or former clients or customers. Litigation or arbitration may be necessary to defend against these claims.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><B><I>If we do not obtain patent term
extension and data exclusivity for any of our current or future product candidates we may develop, our business may be materially harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Depending upon the timing, duration
and specifics of any FDA marketing approval of any of our current or future product candidates we may develop, one or more U.S. patents
we may own or in-license in the future may be eligible for limited patent term extension under the Drug Price Competition and Patent Term
Restoration Act of 1984, or the Hatch-Waxman Amendments. If we are unable to obtain patent term extension or the term of any such extension
is shorter than what we request, our competitors may obtain approval of competing products following expiration of any patents that issue
from our patent applications, and our business, financial condition, results of operations, and prospects could be materially harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><B><I>If our trademarks and trade names
are not adequately protected, then we may not be able to build name recognition in our marks of interest and our business may be adversely
affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Our trademarks or trade names may be
challenged, infringed, diluted, circumvented or declared generic or determined to be infringing on other marks. We intend to rely on both
registration and common law protection for our trademarks. We may not be able to protect our rights to these trademarks and trade names
or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest.
If we are unable to obtain a registered trademark or establish name recognition based on our trademarks and trade names, we may not be
able to compete effectively and our business may be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><FONT>Risk Factors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><B>Risks Related to our Reliance on
Third Parties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><B><I>We plan to rely on third parties
to conduct our preclinical studies and clinical trials. If these third parties do not properly and successfully carry out their contractual
duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our current or future product
candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">We plan to utilize and depend upon independent
investigators and collaborators, such as medical institutions, CROs, CMOs, and strategic partners to conduct and support our preclinical
studies and clinical trials under agreements with us. We rely upon, and plan to continue to rely upon, such third-party entities to execute
our clinical trials and preclinical studies and to monitor and manage data produced by and relating to those studies and trials. However,
in the future we may not be able to establish arrangements with CROs when needed or on terms that are acceptable to us, or at all, which
could negatively affect our development efforts with respect to our drug candidates and materially harm our business, operations and prospects.
As a result of the use of third-party contractors, we will have only limited control over certain aspects of their activities. Nevertheless,
we are responsible for ensuring that each of our studies, including each of our clinical trials, is conducted in accordance with the applicable
protocol, legal and regulatory requirements as well as scientific standards, and our reliance on any third-party entity will not relieve
us of our regulatory responsibilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Based on our present expectations, we
and our third-party contractors will be required to comply with GCP regulations for the clinical development of all of our drug candidates.
If we or any of these third parties fail to comply with applicable GLP or GCP regulations, the clinical data generated in our preclinical
and clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional
clinical trials before approving our marketing applications, which we may not have sufficient cash or other resources to support and which
would delay our ability to generate revenue from future sales of such drug candidate. Any agreements governing our relationships with
CROs or other contractors with whom we currently engage or may engage in the future may provide those outside contractors with certain
rights to terminate a clinical trial under specified circumstances. If such an outside contractor terminates its relationship with us
during the performance of a clinical trial, we would be forced to seek an engagement with a substitute contractor, which we may not be
able to do on a timely basis or on commercially reasonable terms, if at all, and the applicable clinical trial would experience delays
or may not be completed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Large-scale clinical trials require
significant additional financial and management resources and reliance on third-party clinical investigators, CROs, and consultants, which
may cause us to encounter delays that are outside of our control. We may be unable to identify and contract with sufficient investigators,
CROs, or consultants on a timely basis, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">If these third parties do not successfully
carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced, or if the quality or accuracy
of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, legal and regulatory requirements
or for other reasons, our preclinical or clinical trials may be extended, delayed or terminated and we may not be able to complete development
of, obtain regulatory approval for, or successfully commercialize, our current or future product candidates. In addition, we will be unable
to control whether or not they devote sufficient time and resources to our preclinical and clinical programs. These outside contractors
may not assign as great a priority to our programs or pursue them as diligently as we would if we were undertaking such programs ourselves.
As a result, our operations and the commercial prospects for the effected drug candidates would be harmed, our costs could increase and
our ability to generate revenues could be delayed. These contractors may also have relationships with other commercial entities, some
of whom may compete with us. If our contractors assist our competitors to our detriment, our competitive position would be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">If our relationships with any third
parties conducting our studies are terminated, we may be unable to enter into arrangements with alternative third parties on commercially
reasonable terms, or at all. Switching or adding third parties to conduct our studies involves substantial cost and requires extensive
management time and focus. In addition, there is a natural transition period when a new third party commences work. As a result, delays
occur, which can materially impact our ability to meet our desired clinical development timelines. Although we carefully manage our relationships
with third parties conducting our studies, we cannot assure you that we will not encounter similar challenges or delays in the future
or that these delays or challenges will not have a material and adverse effect on our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><FONT>Risk Factors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><B><I>We rely, and expect to continue
to rely, on the third-party manufacturers to manufacture our current or future product candidates. Reliance on third parties increases
the risk that we will not have sufficient quantities of our products or such quantities at an acceptable quality and cost, which could
delay, prevent or impair our development or commercialization efforts.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">We do not currently own any facility
that may be used as our clinical-scale manufacturing and processing facility and must rely on outside vendors to manufacture our current
or future product candidates. We rely on a single CMO for manufacturing the NXP800 drug substance and the NXP800 drug product, which are
manufactured at two different sites of the same CMO. We intend to continue our relationship with this CMO for the supply of NXP800; however,
there can be no assurance that we will be able to retain this relationship on commercially reasonable terms, if at all. If we are unable
to maintain this relationship, we could experience delays in our development efforts as we locate and qualify a new CMO. For the in vitro
and in vivo experiments of NXP900 conducted to date, small, lab-scale, non cGMP material has been used. While we have identified an appropriate
cGMP CMO to manufacture drug substance and drug product for NXP900, there is no assurance that such CMO will be successful in manufacturing
NXP900 drug substance or product. If NXP800, NXP900 or any other drug candidate we may develop or acquire in the future receives regulatory
approval, we will rely on one or more CMOs to manufacture the commercial supply of such drugs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Our anticipated reliance on a limited
number of third-party manufacturers exposes us to a number of risks, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">due to the limited number of potential manufacturers, and because the FDA requires inspection of any manufacturers&rsquo; cGMP compliance as part of our marketing application, we may be unable to identify manufacturers on acceptable terms, if at all;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a new manufacturer would have to be educated in and develop substantially equivalent processes for, the production of our current or future product candidates;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our third-party manufacturers might be unable to timely manufacture our current or future product candidates or produce the quantity and quality required to meet our clinical and commercial needs due to a variety of potential reasons including failure to achieve drug substance or drug product specifications, batch to batch inconsistencies, site or equipment contaminations, failed regulatory inspections, competition for production capacity and availability from other customers;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may not own, or may have to share, the intellectual property rights to any improvements made by our third-party manufacturers in the manufacturing process for our current or future product candidates;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our third-party manufacturers could breach or terminate their agreements with us;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our third-party manufacturers might be unable to formulate and manufacture our drugs in the volume and of the quality required to meet our clinical and commercial needs, if any;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our third-party manufacturers may not perform as contractually agreed or may not remain in the contract manufacturing business for the time required to supply our clinical trials or to successfully produce, store and distribute our products;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">drug manufacturers are subject to ongoing periodic unannounced inspection by the FDA and some state agencies in the United States, as well as foreign regulatory authorities, to ensure strict compliance with cGMP regulations and other regulatory requirements; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"></P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><FONT>Risk Factors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">raw materials and components used in the manufacturing process, particularly those for which we have no other source or supplier, may not be available or may not be suitable or acceptable for use due to material or component defects.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Each of these risks could delay or prevent
the completion of our preclinical or clinical trials or the approval of any of our current or future product candidates by the FDA or
another foreign regulatory authority, result in higher costs or adversely impact commercialization of our current or future product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Although our agreements with our CMOs
require them to perform according to certain cGMP requirements such as those relating to quality control, quality assurance and qualified
personnel, we cannot control the conduct of our CMOs to implement and maintain these standards. If any of our CMOs cannot successfully
manufacture material that conforms to our specifications and the regulatory requirements of the FDA, EMA or other comparable foreign authorities,
we could be prevented from obtaining regulatory approval for our drug candidates unless and until we engage a substitute CMO that can
comply with such requirements, which we may not be able to do. Any such failure by any of our CMOs would significantly impact our ability
to develop, obtain regulatory approval for or market our drug candidates, if approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><B><I>If our third-party manufacturers
use hazardous and biological materials in a manner that causes injury or violates applicable law, we may be liable for damages.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Although we believe that our manufacturers&rsquo;
procedures for using, handling, storing, and disposing of hazardous and biological materials comply with legally prescribed standards,
we cannot completely eliminate the risk of contamination or injury. In the event of an accident, local, city, state or federal authorities
may curtail the use of these materials and interrupt our business operations. Further, we could be held liable for damages or penalized
with fines, and the liability could exceed our resources. We do not have any insurance for liabilities arising from medical or hazardous
materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><B>Risks Related to Managing Growth
and Employee Matters</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><B><I>We are highly dependent on our
key personnel and anticipate hiring new key personnel. If we are not successful in attracting and retaining highly qualified personnel,
we may not be able to successfully implement our business strategy.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Our ability to compete in the highly
competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific
and medical personnel. We are highly dependent on our management, scientific and medical personnel, including our Chairman, Chief Executive
Officer and President, our Chief Scientific and Business Officer and our Chief Development and Operations Officer. While we expect to
engage in an orderly transition process as we integrate newly appointed officers and managers, we face a variety of risks and uncertainties
relating to management transition, including diversion of management attention from business concerns, failure to retain other key personnel
or loss of institutional knowledge.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><B><I>We will need to grow the size
of our organization, and we may experience difficulties in managing this growth.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">As of June&nbsp;30, 2022, we had 10
full-time employees. We also contract for various services through consulting and vendor agreements. We intend to hire new employees to
conduct our research and development activities in the future. Any delay in hiring such new employees could result in delays in our research
and development activities and would harm our business. As our development and commercialization plans and strategies develop, and as
we transition into operating as a public company, we expect to need additional managerial, operational, sales, marketing, financial and
other personnel, as well as additional facilities to expand our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">If we are not able to effectively expand
our organization by hiring new employees and expanding our groups of consultants and contractors, or we are not able to effectively build
out new facilities to accommodate this expansion, we may not be able to successfully implement the tasks necessary to further develop
and commercialize our current or future product candidates and, accordingly, may not achieve our research, development and commercialization
goals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><FONT>Risk Factors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><B><I>We will incur significant increased
costs as a result of operating as a public company, and our management will be required to devote substantial time to compliance activities
and initiatives.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">As a public company, we will incur significant
legal, accounting, and other expenses that we did not incur as a private company. We are now subject to the reporting requirements of
the Securities Exchange Act of 1934, as amended, which requires, among other things, that we file with the SEC, annual, quarterly, and
current reports with respect to our business and financial condition. In addition, the Sarbanes-Oxley Act of 2002 (&ldquo;SOX&rdquo;),
as well as rules&nbsp;subsequently adopted by the SEC and the Nasdaq Capital Market to implement provisions of SOX, impose significant
requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and
changes in corporate governance practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Moreover, these rules&nbsp;and regulations
will increase our legal and financial compliance costs and make some activities more time-consuming and costly. For example, these rules&nbsp;and
regulations make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required
to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result,
it may be more difficult for us to attract and retain qualified persons to serve on our Board of Directors, our Board committees or as
executive officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">SOX requires, among other things, that
we maintain effective internal control over financial reporting and disclosure controls and procedures. As a result, we are required to
periodically perform an evaluation of our internal control over financial reporting to allow management to report on the effectiveness
of those controls, as required by Section&nbsp;404 of SOX. These efforts to comply with Section&nbsp;404 will require the commitment of
significant financial and managerial resources. While we anticipate maintaining the integrity of our internal control over financial reporting
and all other aspects of Section&nbsp;404, we cannot be certain that a material weakness will not be identified when we test the effectiveness
of our control systems in the future. If a material weakness is identified, we could be subject to sanctions or investigations by the
SEC or other regulatory authorities, which would require additional financial and management resources, costly litigation or a loss of
public confidence in our internal control, which could have an adverse effect on the market price of our stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><B><I>Our business and operations would
suffer in the event of computer system failures, cyber-attacks, or deficiencies in our or third parties&rsquo; cybersecurity.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">We are increasingly dependent upon information
technology systems, infrastructure, and data to operate our business. In the ordinary course of business, we may collect, store, and transmit
confidential information, including, but not limited to, information related to our intellectual property and proprietary business information,
personal information, and other confidential information. We have outsourced elements of our operations to third party vendors, who each
have access to our confidential information, which increases our disclosure risk. Although we have implemented internal security and business
continuity measures, our information technology and other internal infrastructure systems may breakdown, incur damage or be interrupted
by system malfunctions, natural disasters, terrorism, war, or telecommunication and electrical failures, as well as by inadvertent or
intentional security breaches by our employees, contractors, consultants, business partners, and/or other third parties, or from cyber-attacks
by malicious third parties, each of which could compromise our system infrastructure or lead to the loss, destruction, alteration, disclosure,
or dissemination of, or damage or unauthorized access to, our data or other assets. Such a security breach may cause loss, damage, or
disclosure of proprietary or confidential information, which could in turn result in significant legal and financial exposure and reputational
damage that could adversely affect our business. Furthermore, the loss or corruption of clinical trial data from future clinical trials
may result in delays in our regulatory approval efforts and could significantly increase our costs to recover or reproduce the data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The costs related to significant security
breaches or disruptions could be material and our insurance policies may not be adequate to compensate us for the potential losses arising
from any such security breach. In addition, such insurance may not be available to us on economically reasonable terms, if at all, may
not cover all claims made against us, and may have high deductibles. Furthermore, if the information technology systems of our third-party
vendors and other contractors and consultants become subject to disruptions or security breaches, we may have insufficient recourse against
such third parties and we may have to expend significant resources to mitigate the impact of such an event, and to develop and implement
protections to prevent future events of this nature from occurring.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><FONT>Risk Factors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"><B>Risks Related to Commercial Activities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><B><I>If any of our current or future
product candidates do not achieve broad market acceptance among physicians, patients, healthcare payors and the medical community, the
revenues from any such current or future product candidate may be limited.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The use of precision medicines as a
potential cancer treatment is a recent development and may not become broadly accepted by physicians, patients, hospitals, cancer treatment
centers, and others in the medical community. We cannot predict whether physicians, patients, hospitals, cancer treatment centers, and
government agencies or third-party payors will determine that our product is safe, therapeutically effective, and cost effective as compared
with competing treatments. If our current or potential future product candidates do not achieve an adequate level of market acceptance,
we may not generate significant product revenues and may not become profitable. Factors influencing acceptance of our current or future
product candidates in the market, include: the clinical indications for which our product candidates are licensed; whether our product
candidates are viewed as a safe and effective treatment; our ability to demonstrate our product&rsquo;s advantages, including cost advantages,
over alternative treatments; the prevalence and severity of any side effects of our products and of other precision medicines; product
labeling or product insert requirements of the FDA or other regulatory authorities and limitations or warnings contained in the labeling;
the timing of market introduction of our product candidates and competitive products; patient willingness to pay out-of-pocket in the
absence of coverage by third-party payors and government authorities; and the effectiveness of our sales and marketing efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">If our current or future product candidates
are licensed but fail to achieve market acceptance among physicians, patients, hospitals, cancer treatment centers or others in the medical
community, we will not be able to generate significant revenue. In addition, although our current or future product candidates may differ
in certain ways from other precision medicine approaches, serious adverse events or deaths in other preclinical or clinical trials involving
precision medicines, even if not ultimately attributable to our current or future products or product candidates, could result in increased
government regulation, unfavorable public perception and publicity, potential regulatory delays in the testing or licensing of our current
or future product candidates, stricter labeling requirements for those product candidates that are licensed, and a decrease in demand
for any such product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><B><I>If product liability lawsuits
are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our current or future product
candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">We face an inherent risk of costly and
time-consuming product liability lawsuits as a result of the planned clinical testing of our current or future product candidates and
will face an even greater risk if we commercialize any products. For example, we may be sued if our current or future product candidates
cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale.
If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit
commercialization of our current or future product candidates. Failure to obtain or retain sufficient product liability insurance at an
acceptable cost may prevent or inhibit the commercialization of products we may develop. Although we have clinical trial insurance, our
insurance policies have various exclusions, and we may be subject to a claim for which we have no coverage. We may have to pay any amounts
awarded by a court or negotiated in a settlement that are not covered by or which exceed our insurance coverage, and we may not have sufficient
capital to pay such amounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><B>Risks Related to Ownership of our
Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><B><I>We do not know whether an active,
liquid and orderly trading market will develop for our Common Stock or what the market price of our Common Stock will be and, as a result,
it may be difficult for you to sell your shares of our Common Stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Prior to the pricing of our initial
public offering on February&nbsp;4, 2022, there was no public trading market for shares of our Common Stock. Although our Common Stock
is listed on the Nasdaq Capital Market, an active trading market for our shares is still developing and may not be sustained in the future.
The lack of an active market for our Common Stock may impair investors&rsquo; ability to sell their shares at the time they wish to sell
them or at a price that they consider reasonable and may reduce the fair market value of their shares. Further, an inactive market may
impair our ability to raise capital by selling shares of our Common Stock and to enter into strategic partnerships or acquire companies
or products using our shares of Common Stock as consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><FONT>Risk Factors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our growth is subject to economic and political conditions.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Our business is affected by global and
local economic and political conditions as well as the state of the financial markets, inflation, recession, financial liquidity, currency
volatility, growth, and policy initiatives. There can be no assurance that global economic conditions and financial markets will not worsen
and that we will not experience any adverse effects that may be material to our consolidated cash flows, results of operations, financial
position or our ability to access capital, such as the adverse effects resulting from a prolonged shutdown in government operations both
in the United States and internationally. Political changes, including war or other conflicts, some of which may be disruptive, could
interfere with our supply chain, our customers and all of our activities in a particular location.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><B><I>We do not intend to pay dividends
on our Common Stock in the foreseeable future, so any returns will be limited to the value of our stock, which may be volatile.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">We plan to retain future earnings for
the development, operation, and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable
future. Any return to stockholders will be limited to the appreciation of their stock, which may never occur. Further, the trading price
of our Common Stock is likely to be highly volatile and may be subject to wide fluctuations in response to various factors, some of which
are beyond our control. Broad market and industry factors may negatively affect the market price of our Common Stock, regardless of our
actual operating performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><B><I>If equity research analysts do
not publish research or reports about our business or if they publish negative evaluations of or downgrade our Common Stock, the price
of our Common Stock could decline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The trading market for our Common Stock
relies in part on the research and reports that equity research analysts publish about us or our business. We do not control these analysts.
We may never obtain research coverage by industry or financial analysts. If no or few analysts publish research reports on the Company
or if analysts publish negative research reports about the Company, our stock price may significantly decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><B><I>The holders of our Common Stock
will suffer, and may in the future suffer, substantial dilution due to the Private Placement and our corporate financing practices.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Assuming the issuance of the Common
Stock issuable upon exercise of the pre-funded warrants and investment options, together with the issuance of Common Stock pursuant to
the Private Placement, the holders of our Common Stock will suffer substantial dilution. Holders of our Common Stock could suffer additional,
substantial dilution in the future due to our corporate financing practices. These additional issuances of shares of Common Stock could
also cause a significant reduction in the market price of our Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><B><I>Raising additional capital may
cause dilution to our existing stockholders, restrict our operations, or require us to relinquish rights to our current or future technologies
or product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">We may seek additional capital through
a combination of public and private equity offerings, debt financings, strategic partnerships and alliances and licensing arrangements.
Any equity or equity-related financing may dilute our stockholders may subject us to restrictive covenants and interest costs. If we obtain
funding through a strategic collaboration or licensing arrangement, we may be required to relinquish our rights to our current product
candidates or any future product candidates that we may develop.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Additional fundraising efforts may divert
our management from their day-to-day activities, which may adversely affect our operations. If we are unable to raise additional capital
as needed or on acceptable terms, we may be required to delay or discontinue any research, development or commercialization programs and
may be unable to expand our operations or otherwise capitalize on our business opportunities. Further, we may be required to seek collaborators
for potential product candidates earlier, or on less favorable terms, than might otherwise be desired, or to relinquish or license our
rights to potential product candidates in markets where we otherwise would seek to pursue development or commercialization. Any of the
above events could significantly harm our business, prospects, financial condition and results of operations and cause the price of our
Common Stock to decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><FONT>Risk Factors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><B><I>Future issuances of our Common
Stock or securities convertible into our Common Stock, or the expiration of lock-up agreements that restrict the issuance of new Common
Stock or the trading of outstanding stock, could cause the market price of our Common Stock to decline and would result in the dilution
of your shareholding.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Future issuances of our Common Stock
or securities convertible into our Common Stock or the trading of outstanding stock, could cause the market price of our Common Stock
to decline. We cannot predict the effect, if any, of the exercise of future issuances of our Common Stock or securities convertible into
our Common Stock on the price of our Common Stock. In all events, future issuances of our Common Stock would result in the dilution of
your shareholding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><B><I>Our principal stockholders and
management own a significant percentage of our stock and will be able to exert significant influence over matters subject to stockholder
approval.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">As of June&nbsp;30, 2022, our executive
officers, directors, and 5% stockholders beneficially owned approximately 70% of our voting stock and anticipate that the same group will
hold a significant portion of our outstanding voting stock for the foreseeable future. These stockholders will have the ability to influence
us through their ownership position. This may prevent or discourage unsolicited acquisition proposals or offers for our Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><B><I>Our failure to meet the continuing
listing requirements of the NASDAQ Capital Market could result in a de-listing of our securities.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">If we fail to satisfy the continuing
listing requirements of NASDAQ, such as the corporate governance, stockholders&rsquo; equity or minimum closing bid price requirements,
NASDAQ may take steps to delist our Common Stock. Such a delisting would likely have a negative effect on the price of our Common Stock
and would impair our stockholders&rsquo; ability to sell or purchase our Common Stock. In the event of a delisting, we would likely take
actions to restore our compliance with NASDAQ&rsquo;s listing requirements, but we can provide no assurance that any such action taken
by us would allow our Common Stock to become listed again, stabilize the market price or improve the liquidity of our securities, prevent
our Common Stock from dropping below the NASDAQ minimum bid price requirement or prevent future non-compliance with NASDAQ&rsquo;s listing
requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><B><I>We are an emerging growth company
and a smaller reporting company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies
and smaller reporting companies will make our Common Stock less attractive to investors.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">We are an emerging growth company, as
defined in the JOBS Act. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various
reporting requirements that are applicable to other public companies that are not emerging growth companies, including: exemption from
the auditor attestation requirements of Section&nbsp;404 of SOX, as amended; being permitted to provide only two years of our audited
financial statements and correspondingly reduced &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results
of Operations&rdquo;; exemption from any Public Company Accounting Oversight Board requirement regarding audit firm rotation or an auditor
report supplement providing additional information about the audit and financial statements; reduced disclosure obligations regarding
executive compensation; and exemption from the nonbinding advisory votes on executive compensation and stockholder approval of any golden
parachute payments not previously approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">We have elected to take advantage of
certain of the reduced reporting obligations. We cannot predict whether investors will find our Common Stock less attractive if we rely
on these exemptions. If some investors find our Common Stock less attractive as a result, there may be a less active trading market for
our Common Stock and our stock price may be reduced or more volatile.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><FONT>Risk Factors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><B><I>Provisions in our certificate
of incorporation, our bylaws, and Delaware law may discourage, delay, or prevent a change in control of our Company or changes in our
management and, as a result, depress the trading price of our stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Provisions of our certificate of incorporation,
our bylaws and Delaware law may deter unsolicited takeovers and/or delay or prevent a change in control of our Company, including transactions
in which our stockholders might otherwise receive a premium for their shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">In addition, the Delaware General Corporation
Law prohibits a publicly held Delaware corporation from engaging in a business combination with an interested stockholder, defined as
a person who owns, or within the last three years has owned, 15% of our voting stock, for a period of three years after the date of the
transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The foregoing provisions and anti-takeover
measures may limit the price that investors might be willing to pay in the future for shares of our Common Stock and may deter potential
acquirers of our Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: 3 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B><A NAME="sp7"></A>Use
of Proceeds</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">We
are not selling any securities under this prospectus and we will not receive any proceeds from the sale of securities by the Selling
Shareholders, although we could receive up to $19,764,147 upon the exercise of all of the Investment Options and $909 upon the exercise
of all of the Pre-Funded Warrants. Any amounts we receive from such exercises, along with approximately $15.9 million in net proceeds
received in the Private Placement will be used for working capital and general corporate purposes. The holders of the Investment Options
and Pre-Funded Warrants are currently not obligated to exercise the Investment Options or Pre-Funded Warrants and we cannot assure you
that the holders of either will choose to exercise all or any exercise the Investment Option or Pre-Funded Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B><A NAME="sp8"></A>Dividend
Policy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">We
have never declared or paid any cash dividends on our capital stock. We currently intend to retain any future earnings to fund the development
and expansion of our business, and therefore we do not anticipate paying cash dividends on our Common Stock in the foreseeable future.
Any future determination to pay dividends will be at the discretion of our board of directors and will depend on our results of operations,
financial condition, capital requirements, contractual restrictions and other factors deemed relevant by our board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>MARKET
PRICE AND DIVIDENDS ON COMMON EQUITY AND RELATED STOCKHOLDER MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">Currently,
our shares of Common Stock are listed on the Nasdaq Capital Market under the symbol &ldquo;NVCT&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">As
of the date of this prospectus, there were 53 holders of record of our shares of Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">We
have not paid any cash dividends on our Common Stock and do not plan to pay any cash dividends on our Common Stock in the foreseeable
future. Our board of directors will determine our future dividend policy on the basis of many factors, including results of operations,
capital requirements, and general business conditions, subject to any restrictions under our credit facility.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B><A NAME="sp21"></A>Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><I>You
should read the following discussion and analysis of our financial condition and results of operations together with our financial
statements and related notes incorporated by reference in this prospectus. Some of the information contained in this discussion and </I></FONT><I>analysis
or set forth elsewhere in this prospectus, including information with respect to our plans and strategy for our business and related
financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those
factors set forth in the &ldquo;Risk Factors&rdquo; section of this prospectus, our actual results could differ materially from the
results described in or implied by the forward-looking statements contained in the following discussion and analysis.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">We
are a biopharmaceutical company focused on the development of novel targeted small molecule therapeutics for the treatment of cancer
in genetically defined patient populations. Our precision medicine approach translates key scientific insights relating to the oncogenic
drivers and pathway addiction of cancer into potent and highly selective anticancer drugs. In addition, we will investigate the relevance
of specific mutations and other DNA alterations as a potential patient selection marker and to identify synthetic lethality targets.
This work could support our use of a tumor agnostic development strategy wherein we enroll patients based on the cancer&rsquo;s genetic
and molecular features without regard to the type or location of the cancer. Since our inception in 2020, we have devoted substantially
all of our efforts and financial resources to organizing and staffing our company, business planning, raising capital, acquiring, discovering
product candidates and securing related intellectual property rights and conducting research and development activities for our programs.
We do not have any products approved for sale and have not generated any revenue from product sales. We may never be able to develop
or commercialize a marketable product. We have not yet successfully completed any pivotal clinical trials, obtained any regulatory approvals,
manufactured a commercial-scale drug, or conducted sales and marketing activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Results
of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">From
our inception on July&nbsp;27, 2020, through June&nbsp;30, 2022, we did not generate any revenue. Our main activities through June&nbsp;30,
2022 have been organizational and capital raising activities and the completion of the in-license agreements for our two drug candidates,
NXP800 and NXP900, our Initial New Drug and Clinical Trial Application for the FDA and Medicines and Healthcare Regulatory Agency, respectively,
and preparation and ongoing execution of the Phase 1a clinical trial for NXP800, which commenced in December&nbsp;2021, and beginning
our IND-enabling studies for NXP900, which commenced in late 2021. Additionally, we completed our initial public offering in February&nbsp;2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Research
and Development Expenses</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Research
and development expenses include costs directly attributable to the conduct of research and development programs, including licensing
fees, cost of salaries, share-based compensation expenses, payroll taxes, and other employee benefits, subcontractors, and materials
and service used for research and development activities, including clinical trials, manufacturing costs, and professional services.
All costs associated with research and development are expensed as incurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Product
candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development,
primarily due to the increased size and duration of later-stage clinical trials. We expect that our research and development expenses
will increase substantially in connection with our ongoing and planned preclinical and clinical development activities in the near term
and in the future. The successful development of our product candidates is highly uncertain. At this time, we cannot accurately estimate
or know the nature, timing and costs of the efforts that will be necessary to complete the preclinical and clinical development of any
of our product candidates and we may never succeed in obtaining regulatory approval for any of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">General
and Administrative Expenses</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">General
and administrative expenses consist primarily of salaries and personnel-related costs, including stock-based compensation, for our personnel
in executive, finance and accounting, and other administrative functions. General and administrative expenses also include legal fees
relating to patent and corporate matters; professional fees paid for accounting, auditing, consulting, and tax services; insurance costs;
travel expenses; and facility costs not otherwise included in research and development expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">We
anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support our continued
research and development activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT>The tables below also appear in our Quarterly Report on Form 10-Q filed with the SEC on August
10, 2022.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">The
following table summarizes our results of operations expenses for the three months ended June&nbsp;30, 2022 and the three months ended
June&nbsp;30, 2021: (in thousands)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Three Months Ended June&nbsp;30</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2022</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2021</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Change</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">OPERATING EXPENSES:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; width: 58%; font: 10pt Times New Roman, Times, Serif; text-align: justify">RESEARCH AND DEVELOPMENT</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: justify">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">2,505</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: justify">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">4,245</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: justify">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,740</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: justify">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">GENERAL AND ADMINISTRATIVE</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,068</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,693</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(625</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">OPERATING LOSS</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,573</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(5,938</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,365</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">FINANCE INCOME</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">NET LOSS</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: justify">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,569</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: justify">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(5,938</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,369</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Research
and Development Expenses</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">The
following table summarizes our research and development expenses for the three months ended June&nbsp;30, 2022 and the three months ended
June&nbsp;30, 2021: (in thousands)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">For&nbsp;the&nbsp;three months ended June&nbsp;30</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Increase/</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2022</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2021</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">(Decrease)</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 58%; font: 10pt Times New Roman, Times, Serif; text-align: justify">Clinical Expense</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: justify">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,144</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: justify">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">31</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: justify">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,113</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Employee Compensation and Benefits</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">844</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">667</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">177</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Manufacturing</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">453</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">39</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">414</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">License Fee</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,500</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,500</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Professional services and other</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">64</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">8</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">56</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Total research and development expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,505</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,245</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,740</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Research
and development expenses decreased by $1.7 million or 41% during the three&nbsp;months ended June&nbsp;30, 2022 compared to the same
period in 2021. The decrease in research and development expense during the three months ended June&nbsp;30, 2022 was primarily driven
by $3.5 million in one-time licensing fees expense and paid during the period in 2021 for compound NXP800 partially offset by $1.1 million
in increased clinical expenses, $0.4 in manufacturing expenses mostly related to the NXP800 program and $0.2 million of additional employee
expenses including $0.3 million in employee stock compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">The
following table summarizes our general and administrative expenses for the three months ended June&nbsp;30, 2022 and the three months ended June 30, 2021: (in
thousands)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">For&nbsp;the&nbsp;three months ended June&nbsp;30</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Increase/</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2022</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2021</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">(Decrease)</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 58%; font: 10pt Times New Roman, Times, Serif; text-align: justify">Professional and consulting services</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: justify">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">319</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: justify">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,257</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: justify">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">(938</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: justify">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Employee Compensation and Benefits</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">281</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">222</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">59</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Insurance and Other</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">468</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">214</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">254</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Total general and administrative expenses</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,068</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,693</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(625</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">General
and administrative expenses decreased by $0.6 million or 37% during the three&nbsp;months ended June&nbsp;30, 2022 compared to the same
period in 2021. The decrease in general and administrative expense during the three months ended June&nbsp;30, 2022 was primarily driven
by the $0.9 million decrease in professional and consulting services related to the private funding round in 2021 which could not be
netted against the proceeds, partially offset by a $0.3 million increase in insurance and other expenses associated with the IPO.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">As
a result of the foregoing, our loss from operations for the three&nbsp;months ended June&nbsp;30, 2022, decreased $2.4 million or 40%,
compared to the same period in 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">The
following table summarizes our results of operations expenses for the six months ended June&nbsp;30, 2022 and the six months ended June&nbsp;30,
2021: (in thousands)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Six Months Ended June&nbsp;30</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2022</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2021</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Change</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">OPERATING EXPENSES:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; width: 58%; font: 10pt Times New Roman, Times, Serif; text-align: justify">RESEARCH AND DEVELOPMENT</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: justify">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">4,310</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: justify">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">4,245</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: justify">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">65</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">GENERAL AND ADMINISTRATIVE</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,208</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,716</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">492</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">OPERATING LOSS</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(6,518</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(5,961</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(557</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">FINANCE INCOME</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">NET LOSS</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: justify">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(6,512</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: justify">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(5,961</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(551</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Research
and Development Expenses</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">The
following table summarizes our research and development expenses for the six months ended June&nbsp;30, 2022 and the six months ended
June&nbsp;30, 2021: (in thousands)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">For&nbsp;the&nbsp;six months ended June&nbsp;30</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Increase/</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2022</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2021</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">(Decrease)</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 58%; font: 10pt Times New Roman, Times, Serif; text-align: justify">Clinical Expense</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: justify">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,588</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: justify">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">31</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: justify">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,557</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Employee Compensation and Benefits</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,311</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">667</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">644</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Manufacturing</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">757</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">39</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">718</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">License Fee</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">400</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,500</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,100</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Professional services and other</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">254</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">8</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">246</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Total research and development expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,310</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,245</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">65</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Research
and development expenses increased by $0.1 million, or 2%, during the six months ended June&nbsp;30, 2022 compared to the same period
in 2021. The increase in research and development expense during the six months ended June&nbsp;30, 2022 was primarily driven by, $1.6
million increase in clinical expenses paid out in connection with our product candidates NXP800 and NXP900, $0.6 million in employee
compensation and benefits including $0.4 million in stock based compensation and $0.7 million in manufacturing expenses mostly associated
with our product NXP800 and $0.2 million in professional services and other expenses associated with the company&rsquo;s drug product
programs, partially offset by a $3.1 million decrease in license fees paid during 2021 to CRT for NXP800 net of fees owed to the UoE
associated with the company&rsquo;s 2022 IPO and the UoE License agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">General
and Administrative Expenses</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">The
following table summarizes our general and administrative expenses for the six months ended June&nbsp;30, 2022 and the six months ended
June&nbsp;30, 2021: (in thousands)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">For&nbsp;the&nbsp;six months ended June&nbsp;30</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Increase/</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2022</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2021</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">(Decrease)</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 58%; font: 10pt Times New Roman, Times, Serif; text-align: justify">Professional and consulting services</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: justify">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,002</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: justify">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,280</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: justify">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">(278</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: justify">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Employee Compensation and Benefits</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">460</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">222</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">238</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Insurance and Other</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">746</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">214</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">532</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Total general and administrative expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,208</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,716</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">492</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">General
and administrative expenses increased by $0.5 million, or 29%, during the six months ended June&nbsp;30, 2022 compared to the same period
in 2021. The increase in general and administrative expenses for the six months ended June&nbsp;30, 2022, was primarily driven by $0.5
million increase in insurance due to insurance associated with the IPO, $0.2 million in employee compensation including $0.3 million
in stock compensation expense offset by a decrease of $0.3 million in professional and consulting fees paid to third-party providers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">As
a result of the foregoing, our loss from operations for the six&nbsp;months ended June&nbsp;30, 2022, increased $0.6 million or 9%, compared
to the same period in 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Liquidity
and Capital Resources</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">As
of June&nbsp;30, 2022, we had $13.6 million of cash and cash equivalents. For the three&nbsp;months ended June&nbsp;30, 2022, and 2021,
we had net losses of $3.5 million and $5.9 million, respectively. For the six&nbsp;months ended June&nbsp;30, 2022, and 2021, we had
net losses of $6.5 million and $6.0 million, respectively. As of June&nbsp;30, 2022, we had an accumulated deficit of $19.4 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">On
February&nbsp;4, 2022, we entered into an underwriting agreement with H.C. Wainwright&nbsp;&amp; Co. (the &ldquo;Underwriter&rdquo;),
as sole book-running manager, in connection with our initial public offering of common stock (the &ldquo;IPO&rdquo;). On February&nbsp;4,
2022, we announced the pricing of our IPO of 3,200,000 shares of common stock for a price of $5.00 per share, less certain underwriting
discounts and commissions.
We will pay UoE 2.5% of the gross amount of each of the Company&rsquo;s future fund raisings up to a cumulative total of $3.0 million,
including this $0.4 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">The
IPO closed on February&nbsp;8, 2022, with gross proceeds of $16.0 million, before deducting underwriting discounts and expenses (for
net proceeds of $12.6 million).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">In
addition, on July&nbsp;29, 2022, we completed a private placement in which we received gross proceeds of $15.9 million before deducting
fees and expenses (for net proceeds of $14.2 million). We believe that the proceeds from our IPO and private placement will enable us
to fund our operating expenses and capital expenditures into the second half of 2024. We have based this estimate on assumptions that
may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. Our future viability in the long term
is dependent on our ability to raise additional capital to finance our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B><I>Funding
Requirements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">We
expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance the preclinical activities
and clinical trials of our current or future product candidates, including payments of milestones and sponsored research commitments
associated with our license agreements for NXP800 and NXP900. In addition, now that we have closed our initial public, we expect to incur
additional costs associated with operating as a public company, including significant legal, accounting, investor relations and other
expenses that we did not incur as a private company. The timing and amount of our operating expenditures will depend largely on our ability
to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">advance
                                            development of our clinical and preclinical programs;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">acquire
                                            additional product candidates;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">manufacture,
                                            or have manufactured on our behalf, our preclinical and clinical drug material and develop
                                            processes for late state and commercial manufacturing;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">seek
                                            regulatory approvals for any current or future product candidates that successfully complete
                                            clinical trials;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">achieve
                                            milestones in accordance with the license agreements for NXP800 and NXP900;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">establish
                                            a sales, marketing, medical affairs and distribution infrastructure to commercialize any
                                            current or future product candidates for which we may obtain marketing approval and intend
                                            to commercialize on our own;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">hire
                                            additional clinical, quality control and scientific personnel;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">expand
                                            our operational, financial and management systems and increase personnel, including personnel
                                            to support our clinical development, manufacturing and commercialization efforts and our
                                            operations as a public company; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">obtain,
                                            maintain, expand and protect our intellectual property portfolio.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">We
anticipate that we will require additional capital as we seek regulatory approval of our product candidates and if we choose to pursue
in-licenses or acquisitions of other product candidates. If we receive regulatory approval for our other future product candidates, we
expect to incur significant commercialization expenses related to product manufacturing, sales, marketing and distribution, depending
on where we choose to commercialize.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 47 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Because
of the numerous risks and uncertainties associated with research, development and commercialization of our product candidates, we are
unable to estimate the exact amount of our working capital requirements. Our future funding requirements will depend on and could increase
significantly as a result of many factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT>&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">the
                                            scope, progress, results and costs of researching and developing our current or future product
                                            candidates, and conducting preclinical and clinical trials;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">the
                                            costs, timing and outcome of regulatory review of our current or future product candidates;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">the
                                            costs, timing and ability to manufacture our current or future product candidates to supply
                                            our clinical and preclinical development efforts and our clinical trials;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">the
                                            costs of future activities, including product sales, medical affairs, marketing, manufacturing
                                            and distribution, for any of our current or future product candidates for which we receive
                                            marketing approval;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">the
                                            costs of manufacturing commercial-grade product and necessary inventory to support commercial
                                            launch;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">the
                                            ability to receive additional non-dilutive funding, including grants from organizations and
                                            foundations;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">the
                                            revenue, if any, received from commercial sale of our products, should any of our current
                                            or future product candidates receive marketing approval;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">the
                                            costs of preparing, filing and prosecuting patent applications, obtaining, maintaining, expanding
                                            and enforcing our intellectual property rights and defending intellectual property- related
                                            claims;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">our
                                            ability to establish and maintain collaborations on favorable terms, if at all; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">the
                                            extent to which we acquire or in-license other product candidates and technologies.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Until
such time, if ever, as we can generate substantial product revenue, we expect to finance our operations through a combination of public
or private equity offerings, debt financings, governmental funding, collaborations, strategic partnerships and alliances or marketing,
distribution or licensing arrangements with third parties. To the extent that we raise additional capital through the sale of equity
or convertible debt securities, your ownership interest may be materially diluted, and the terms of such securities could include liquidation
or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available,
may involve agreements that include restrictive covenants limiting or restricting our ability to take specific actions, such as incurring
additional debt, making capital expenditures or declaring dividends. In addition, debt financing would result in fixed payment obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we raise additional funds through governmental funding, collaborations, strategic partnerships and alliances or marketing, distribution
or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams,
research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional
funds through equity or debt financings or other arrangements when needed, we may be required to delay, limit, reduce or terminate our
research, product development or future commercialization efforts or grant rights to develop and market product candidates that we would
otherwise prefer to develop and market ourselves.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Contractual
obligations and other commitments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">We
enter into contracts in the normal course of business with clinical research organizations, contract manufacturing organizations, and
other third parties for clinical trials, preclinical research studies, and testing and manufacturing services. These contracts are cancelable
by us upon prior written notice. Payments due upon cancellation consist only of payments for services provided or expenses incurred,
including noncancelable obligations of our service providers, up to the date of cancellation. The amount and timing of such payments
are not known.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">We
have also entered into license and collaboration agreements with third parties, which are in the normal course of business. We have not
included future payments under these agreements since obligations under these agreements are contingent upon future events such as our
achievement of specified development, regulatory, and commercial milestones, or royalties on net product sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Pursuant
to the NXP800 License Agreement, we are required to make payments to the ICR for certain development and regulatory milestones. As of
June&nbsp;30, 2022, we were obligated to pay up to $23.0 million in milestone payments to the ICR related to pre-approval milestones,
up to $178 million (in addition to the $23.0 million) in regulatory and commercial sales milestones, and mid-single digit to 10% royalties
on a tiered basis on net sales. Additionally, the Company originally agreed to provide the ICR with up to an additional $0.5 million
in research and development. On March&nbsp;31, 2022, the Company and ICR agreed to research and development support of an additional
$0.4 million ($0.9 million total).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 48 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Pursuant
to the NXP900 License Agreement, we are required to make payments to the UoE for certain development and regulatory milestones. As of
June&nbsp;30, 2022, we were obligated to make up to $46.0 million in milestone payments to the UoE related to pre-approval milestones,
including $0.5 million on the first anniversary of the agreement, up to $279.50 million in regulatory and commercial sales milestones,
mid-single digit to 8% royalties on a tiered basis on net sales and 2.5% of the gross amount of each of the Company&rsquo;s future fund
raising up to a cumulative total of $3.0 million. Additionally, the Company will provide UoE with up to an additional $754,000 in research
and development support.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">We
do not currently have any long-term leases. We rent our office space in Fort Lee, New Jersey based on a one-year agreement signed on
May&nbsp;1, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Critical
Accounting Policies and Significant Judgments and Estimates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Our
financial statements are prepared in accordance with generally accepted accounting principles in the United States, or GAAP. The preparation
of our financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets,
liabilities, costs and expenses. We base our estimates on historical experience, known trends and events and various other factors that
we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values
of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis.
Our actual results may differ from these estimates under different assumptions or conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">While
our significant accounting policies are described in more detail in Note 2 to our financial statements included in our Form 10-K filed with the SEC on March 23, 2022 which is incorporated herein by reference.
The preparation of the Company&rsquo;s financial statements requires management to make estimates and assumptions that impact the reported
amounts of assets, liabilities and expenses in the Company&rsquo;s financial statements and accompanying notes. The most significant
estimates in the Company&rsquo;s financial statements relate to accruals for research and development expenses, valuation of equity awards,
and valuation allowances for deferred tax assets. These estimates and assumptions are based on current facts, future expectations, and
various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about
the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual
results may differ materially and adversely from these estimates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Controls
and Procedures</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Our
financial statements are prepared in accordance with generally accepted accounting principles in the United States. The preparation of
our financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets,
liabilities, costs and expenses. We base our estimates on historical experience, known trends and events and various other factors that
we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values
of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis.
Our actual results may differ from these estimates under different assumptions or conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Off-balance
Sheet Arrangements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">We
did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules&nbsp;and
regulations of the Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Quantitative
and Qualitative Disclosures About Market Risks</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">This
disclosure is not applicable as we are a smaller reporting company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 49 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Emerging
Growth Company and Smaller Reporting Company Status</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">The
Jumpstart Our Business Startups Act of 2012 permits an &ldquo;emerging growth company&rdquo; such as us to take advantage of an extended
transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise
apply to private companies. We have elected to not &ldquo;opt out&rdquo; of this provision and, as a result, we will adopt new or revised
accounting standards at the time private companies adopt the new or revised accounting standard and will do so until such time that we
either (i)&nbsp;irrevocably elect to &ldquo;opt out&rdquo; of such extended transition period or (ii)&nbsp;no longer qualify as an emerging
growth company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">We
are also a &ldquo;smaller reporting company&rdquo; meaning that the market value of our stock held by non-affiliates is less than $700
million and our annual revenue was less than $100 million during the most recently completed fiscal year. We may continue to be a smaller
reporting company after this offering if either (i)&nbsp;the market value of our stock held by non-affiliates is less than $250 million
or (ii)&nbsp;our annual revenue was less than $100 million during the most recently completed fiscal year and the market value of our
stock held by non-affiliates is less than $700 million. If we are a smaller reporting company at the time we cease to be an emerging
growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies.
Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements
in our Annual Report on Form&nbsp;10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure
obligations regarding executive compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 50 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Business&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B><A NAME="sp20"></A>Business</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">We
are a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious unmet medical
needs in oncology. Our development strategy utilizes a precision medicine-based approach that translates key scientific insights relating
to oncogenic drivers, pathway addiction and other cancer-promoting factors into selective and potent anticancer drugs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">A
new generation of approved targeted therapies, such as kinase inhibitors, have transformed the treatment of cancer and demonstrated a
significant benefit to certain patients with genetically defined tumor types. In turn, improved genetic sequencing has led to the discovery
of additional cancer-promoting genetic alterations that were previously unknown, unaddressed, unsuccessfully targeted or overlooked.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">We
believe that these advancements provide the basis for modern development of targeted therapies that will enable the discovery and development
of anticancer treatments based on genetic characterization of tumors rather than tumor histology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Nuvectis
was founded and is led by an experienced management team with extensive drug development expertise. Our three co-founders have significant
drug development knowledge and experience, and a demonstrated track record of success including four past FDA approvals of novel medications
in both oncologic and non-oncologic indications and additional approvals in Europe and Japan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>The
Nuvectis Approach</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Our
mission is to develop a portfolio of innovative product candidates for the treatment of cancer. We rely on our core competencies of target
selection, drug profiling, licensing, and clinical and regulatory execution to build a pipeline of anticancer drugs. We plan to continue
to collaborate with best-in-class technology partners that we believe have the capability to discover selective and potent compounds
with desirable pharmacologic properties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">We
apply our deep understanding of how genetic alterations lead to the development, growth and spread of cancer. This understanding, combined
with our knowledge of the underlying unmet clinical needs, informs and enables our development of an effective clinical and regulatory
strategy. We believe that our combination of clinical development and preclinical research expertise, could improve the potential for
clinical, regulatory, and commercial success.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">With
our focus on precision medicine, we aim to pharmacologically target oncogenic drivers, such as certain kinases that are mutated, overexpressed,
or overactive, in cases where such alterations to the oncogene result in hyperactivation of pro-malignant signaling pathways, and non-oncogenic
addiction targets, such as support genes required for the survival of cancer cells. Our approach could enable the use of biomarker-driven
patient selection, which could prospectively identify patients that are more likely to benefit from our targeted therapy, a type of cancer
treatment that precisely identifies and attacks a specific pathway of cancer cells, thereby potentially increasing the likelihood of
a successful treatment outcome.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Moreover,
we believe that our approach will allow us to potentially improve the time, costs and risks often associated with cancer drug development,
and enable us to improve outcomes for patients with cancer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 51 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Business&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Figure
6: Nuvectis Precision Medicine Pipeline</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2223302d1_s3img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Our
Leadership Team</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Nuvectis
was founded in 2020 and is led by a highly qualified management team comprised of industry veterans with extensive drug development experience,
as well as proven capabilities to raise the capital necessary to support clinical development. Our three co-founders, Ron Bentsur, Enrique
Poradosu, PhD., and Shay Shemesh, have extensive experience and a proven track record of successful drug development including four past
FDA approvals of novel medications in both oncologic and non-oncologic indications and additional approvals in Europe and Japan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Collectively,
the three co-founders of Nuvectis held leadership roles in four FDA approvals and launches of novel medications in both oncologic
and non-oncologic indication, including three NDAs and one BLA, </FONT>as well as two approvals in the EU, and one approval in Japan
(via a Japanese partner). Our co-founders successfully led the approvals and launches of: Auryxia<SUP>&reg;</SUP>, which is used for
the treatment of hyperphosphatemia in patients with dialysis-dependent chronic kidney disease (&ldquo;CKD&rdquo;) and for the
treatment of anemia in patients with non-dialysis-dependent CKD; Jelmyto<SUP>&reg;</SUP>, which is used for the treatment of upper
tract urothelial carcinoma; and Elzonris<SUP>&reg;</SUP>, which is used for the treatment of blastic plasmacytoid dendritic cell
neoplasm. Notably, significant regulatory achievements also include obtaining two Breakthrough Therapy Designations in oncology and
six Orphan Drug Designations (four in the U.S. and two in the EU) and two Fast Track Designations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Our
principals are:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ron
Bentsur (56), Co-Founder, Chairman, Chief Executive Officer and President of Nuvectis</B></FONT><FONT STYLE="font-size: 10pt">, has
over 20 years of senior leadership experience in the biotechnology industry. He served as CEO of UroGen Pharma,&nbsp;Inc. (NASDAQ:
URGN) from August&nbsp;2015 until January&nbsp;2019, and as CEO of Keryx Biopharmaceuticals,&nbsp;Inc. (NASDAQ: KERX, acquired by
Akebia Therapeutics) from May&nbsp;2009 until May&nbsp;2015. At UroGen and Keryx, Mr.&nbsp;Bentsur led the clinical development,
regulatory approvals and the commercial infrastructure buildouts for the US commercial launches of Jelmyto and Auryxia,
respectively. Mr.&nbsp;Bentsur also led the establishment of a successful worldwide partnership for an earlier-stage program at
UroGen and an ex-US development partnership for Auryxia at Keryx. Mr.&nbsp;Bentsur served as CEO of XTL
Biopharmaceuticals,&nbsp;Inc. (NASDAQ: XTLB) from January&nbsp;2006 until April&nbsp;2009 and as Investor Relations and CFO of Keryx
from October&nbsp;2000 until January&nbsp;2006. Mr.&nbsp;Bentsur worked as an investment banker in NYC and Tel Aviv,&nbsp;Israel,
from 1994 until 2000. Mr.&nbsp;Bentsur served as a member of the Board of Directors of Stemline Therapeutics,&nbsp;Inc. from 2009
through the approval and launch of Elzonris<SUP>&reg;</SUP> and through the subsequent acquisition of the company by Menarini in
June&nbsp;2020, and serves on the Board of Directors of Beyond Air,&nbsp;Inc. (NASDAQ: XAIR). Mr.&nbsp;Bentsur holds a BA in
Economics and Business Administration with<FONT STYLE="font-family: Sans-Serif"><B> </B></FONT>distinction
from the Hebrew University of Jerusalem,&nbsp;Israel and an MBA (<I>Magna Cum Laude</I>), from New York University&rsquo;s Stern
School of Business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 52 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Business&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Enrique
Poradosu, PhD (56), Co-Founder, Executive Vice President, Chief Scientific and Business Officer of Nuvectis</B></FONT><FONT STYLE="font-size: 10pt">,
has over 20 years of senior scientific leadership experience in the biotechnology industry. From 2016 until 2020, he served as SVP, Business
and Scientific Strategy at Stemline Therapeutics,&nbsp;Inc. (NASDAQ: STML, acquired by Menarini in June&nbsp;2020). At Stemline Dr.&nbsp;Poradosu
led the licensing and scientific strategy of the company&rsquo;s pipeline, as well as directly leading strategic planning and operational
execution of the early-stage drug development programs. Prior to that, Dr.&nbsp;Poradosu served as VP Business and Scientific Strategy
at Keryx Biopharmaceuticals,&nbsp;Inc. (NASDAQ: KERX, acquired by Akebia Therapeutics), from 2003 until 2016. From 1998 until 2003, Dr.&nbsp;Poradosu
served as a project manager at a private biomedical incubator.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Dr.&nbsp;Poradosu
holds a BSc in Chemistry and Biology with distinction from the Hebrew University of Jerusalem,&nbsp;Israel and a PhD in Biochemistry,
from the Hebrew University of Jerusalem.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shay
Shemesh (39), Co-Founder, Executive Vice President, Chief Development&nbsp;&amp; Operations Officer of Nuvectis</B></FONT><FONT STYLE="font-size: 10pt">,
has over 15 years of multi-disciplinary experience in drug development. From 2015 until 2020, he served as SVP, Clinical and Regulatory
Affairs at Stemline Therapeutics,&nbsp;Inc. (NASDAQ: STML, acquired by Menarini in June&nbsp;2020) where he led multi-disciplinary development
teams in early and late-stage projects. In this role, Mr.&nbsp;Shemesh held responsibilities for the strategic planning and operational
execution of the Elzonris<SUP>&reg;</SUP> clinical program and Biologics License Application, with the FDA and Marketing Authorization
Application with EMA, resulting in the approval of Elzonris&trade; in both regions for the treatment of blastic plasmacytoid dendritic
cell neoplasm, an orphan hematologic malignancy. Prior to that, Mr.&nbsp;Shemesh was a clinical operations lead at Keryx Biopharmaceuticals
(NASDAQ: KERX, acquired by Akebia Therapeutics), where he managed the late-stage clinical trials for Auryxia&trade; for the treatment
of anemia in patients with non- dialysis CKD, which led to the approval of Auryxia in this indication in the US and the EU. Mr.&nbsp;Shemesh
holds a BSc and MSc in Biotechnology from Bar Ilan University in Israel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Michael
Carson (46), Vice President of Finance</B></FONT><FONT STYLE="font-size: 10pt">, has over 20 years of broad experience in corporate finance,
accounting, and operations. He specializes in clinical stage biopharmaceutical and biotechnology companies. From late 2019 until 2021,
he served as Vice President of Finance at XyloCor Theraputics,&nbsp;Inc. where he led the accounting, treasury and finance functions.
During 2019, Mr.&nbsp;Carson consulted for Smiths Medical,&nbsp;Inc., a division of Smiths Group, as Global Controller along with serving
as Vice President of Finance in a consulting role for several other biopharmaceutical and medical device companies. At Smiths Medical,
he led a team responsible for accounting, treasury and foreign currency exposure. From 2015 to 2019 he served as Director of Financial
Planning and Analysis at Neuronetics (NASDAQ: STIM). In this role, Mr.&nbsp;Carson served as the second in command to the Chief Financial
Officer and held responsibilities for strategic planning, financial execution, investor relations, and controllership. In the past, he
has held several finance and accounting positions at Abbott Laboratories (NYSE: ABT) and served as an auditor at Crowe LLP and Deloitte.
Mr.&nbsp;Carson holds a Bachelor of Arts in Business and Economics along with a Bachelor of Science in Mechanical Engineering from Lafayette
College in Pennsylvania. He is a licensed Certified Public Accountant in the Commonwealth of Pennsylvania.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>NXP800
 &mdash; Our Lead Product Candidate</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">We
have licensed exclusive world-wide commercial rights to NXP800, our lead product candidate, which was developed at the world-renowned
Institute for Cancer Research (&ldquo;ICR&rdquo;) in London, England. The ICR is a pioneer in discovery of new anti-cancer agents with
unique mechanisms of action. The ICR&rsquo;s drug discovery unit has discovered several successful product candidates, the most notable
of which is Zytiga, a leading drug for metastatic prostate cancer. Our license agreement with the ICR is subject to certain milestone
and royalty payments. For additional information see section &ldquo;NXP800 License Agreement&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">NXP800
is an inhibitor of the Heat Shock Factor 1 (&ldquo;HSF1&rdquo;) pathway. A large body of work has verified the importance of HSF1 to
tumorigenesis and progression in a variety of malignancies. Cancer cells actively exploit HSF1 to overcome diverse stresses and promote
biological activities crucial for the survival, progression, immune evasion, and metastasis. This utilization of the HSF1 pathway by
the cancer cell in order to overcome stress is also referred to as an HSF1 addiction. It was hypothesized that inhibiting the HSF1 pathway
would substantially impede the survival of cancer cells. This hypothesis led to the discovery of NXP800.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">In
preclinical studies, treatment with NXP800 inhibited tumor growth in human xenografts of ovarian cancer. In addition, we identified a
gene signature related to a mutation in the AT-Rich Interaction Domain (&ldquo;ARID1a&rdquo;) gene that has potential to serve as a biomarker
for patient selection in ovarian and other cancer types. Based on this work, we plan to initially study the potential efficacy of NXP800
in Ovarian Clear Cell Carcinoma (&ldquo;OCCC&rdquo;) and endometrioid ovarian carcinoma, and to investigate the use of ARID1a mutations
as a potential patient selection marker for additional types of cancer. The genetic screening for the ARID1a mutation is a standard part
of the commercially available screening panels being utilized in the clinic for cancer patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 53 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Business&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">A
comprehensive preclinical data package comprised of pharmacology, pharmacokinetic, and toxicological and other safety studies
required as part of an IND Application to the FDA and a CTA to the MHRA </FONT>for the initiation of a first in human (FIH), Phase
1, clinical study of NXP800 were completed by the ICR and by third-party certified labs, supported the approval of the CTA by the
MHRA. In preclinical and toxicology studies no meaningful off-target effects were observed when screened against a broad panel of
kinases, bromodomains, GPCRs, orphan receptors, and nuclear hormone receptors. In December&nbsp;2021, we announced the commencement
of the Phase 1 study for NXP800. The Phase 1 study is comprised of two parts: dose-escalation Phase 1a, initiated in
December&nbsp;2021, followed by an expansion Phase 1b. In the Phase 1a, the safety and tolerability of NXP800 are evaluated in
patients with advanced solid tumors to identify a dose and dosing schedule for the Phase 1b. In June&nbsp;2022 we announced that the
FDA had accepted the IND for NXP800 and the phase 1a study is currently enrolling patients both in the U.S. and U.K. In the Phase
1b, the safety and preliminary anti-tumor activity of NXP800 will be evaluated in biomarker- selected patients, initially in ovarian
clear cell carcinoma and endometrioid carcinoma harboring the ARID1a mutation and possibly cohorts of patients with additional types
of solid tumors. Moreover, additional preclinical studies are being conducted in order to assess the preclinical efficacy of NXP800
in additional solid tumor types.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Clinical
Trial and Regulatory Execution</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Our
clinical development strategy employs a stepwise approach designed to identify signals of activity early in development. In our exploratory
clinical trials, we plan to treat patients whose tumors harbor a specific genetic alteration, the ARID1a mutation. We believe that this
patient enrichment approach improves the likelihood of demonstrating clinical benefit and providing meaningful insight into a product
candidate&rsquo;s therapeutic potential.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>NXP800
Scientific Background Cell Stress and Carcinogenesis</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Living
cells possess different mechanisms that allow them to adapt to stressful factors in their environment. These cellular mechanisms involve
alterations in metabolism, as well as in signal transduction, transcription, translation, protein packaging and/or release. The initial
cellular response against a harmful factor is aimed at defense. If the damaging signals are too severe and cause irreversible injury,
cells activate death signaling pathways. The activation of protective or destructive pathways depends to a large extent on the nature
and duration of the stress, as well as the cell type involved. The final fate of the stressed cell depends on the interplay between these
responses. Carcinogenesis is a complex multi-step process involving metabolic and functional changes enabling transformed cells to survive
and adapt to the tumor microenvironment. Most cancers are associated with various genetic and epigenetic changes leading to the malfunctioning
of critical genes. However, cancer cells also depend on the normal functioning of certain genes. As such, activation of specific cytoprotective
mechanisms can support the survival of transformed cells.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>HSF1
 &mdash; A Guardian of the Proteome</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">One
of the main pro-survival responses, a factor promoting the survival of a cell, that protect cancer cells from stress is the transcription
factor HSF1, which plays a dominant role in the cellular response to the oncogenic stress imposed on the cancer cell, such as proteotoxic
oxidative stress (an imbalance of free radicals and antioxidants resulting from increased metabolic rate of the cancer cell), and acidification
of the microenvironment as well as heavy metals such as iron, all of which are relevant to the etiology of our initial targeted indications.
A large body of work has verified the importance of HSF1 to tumorigenesis and cancer progression.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 54 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Business&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">HSF1
can also be considered as one of the guardians of the cellular proteome, or the pool of proteins within a cell. It has been found
that HSF1 normally regulates a subset of genes involved in the control of cell proliferation, the process that results in an
increase of the number of cells and cell cycle progression, and also extends the survival of transformed cells. Consequently, cancer
cells may become dependent upon, or addicted to, HSF1. Although HSF1 is neither a tumor suppressor nor a typical oncogene, it
affects many aspects of cellular metabolism that are important for the cancer phenotype by modulating signaling pathways associated
with growth and proliferation, apoptosis, glucose metabolism, angiogenesis, cell motility, and </FONT>the response to the
proteotoxic stress in the tumor microenvironment (<I>See </I>Figure 7).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Figure
7: HSF1 addiction in cancer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><IMG SRC="tm2223302d1_s3img002.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">The
                                            HSF1 pathway is utilized by cancer cells to overcome diverse stresses and to promote biological
                                            activities crucial for cancer survival, progression, immune evasion and metastasis.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">It
                                            functions as a master transcription factor regulating protein homeostasis and survival in
                                            response to proteotoxic stresses.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">HSF1
                                            also regulates a distinct gene expression pattern in response to oncogenic stress.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><I>Legend:
HSF1 is actively exploited by cancer cells to overcome diverse stresses and to promote biological activities crucial for cancer survival,
progression, immune evasion and metastasis.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Additionally,
HSF1&rsquo;s activity has been found to modulate signaling pathways that are altered through the expression of mutant oncogenic proteins,
thus affecting the phenotype of cancer cells. This phenomenon has been referred to as non-oncogenic addiction, based on the observation
that cancer cells are more dependent on the chaperoning function of HSPs than normal cells. Thus, the HSF1 pathway is a compelling oncology
target, which led to the discovery of the NXP800 strategy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Discovery
and Optimization of NXP800</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">NXP800
emerged from a phenotypic screen for antagonists of the HSF1-mediated transcriptional response. In phenotypic screens, small molecules
undergo high-throughput screening against intact cells, and discrete phenotypic changes in the cell are measured and quantified. Phenotypic
screens are unbiased and have several advantages over screens using recombinant proteins. Hits from a phenotypic screen will, by definition,
be cell permeable and have cellular activity, potentially reducing optimization cycles and timelines. The ICR screening led to the identification
of the bisamide series, and further optimization of the series led to the identification of NXP800, which was selected as the clinical
drug candidate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Figure
8: NXP800 &mdash; Planned Development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><IMG SRC="tm2223302d1_s3img003.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><I>Source:
Nuvectis Pharma</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 55 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Business&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Beyond
the initial target indications of OCCC and endometrioid ovarian carcinoma, we believe that NXP800 has the potential to demonstrate anti-tumor
activity in several additional tumor types, such as endometrial, breast, lung, gastrointestinal, hepatocellular, esophageal and others.
Preclinical work is currently being conducted to investigate the use of ARID1a mutation as a potential patient selection marker in additional
tumor types. This work could support our use of a tumor-agnostic development strategy (see Figure 6) wherein we enroll patients based
on the cancer&rsquo;s genetic and molecular features without regard to the type or location of the cancer. We expect to provide preclinical
and clinical data updates at key medical conferences in 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>NXP800
Patient Enrichment Strategies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Using
gene expression microarray analysis, we have identified a gene signature that may indicate the sensitivity of specific cancer mutations
to NXP800 and has potential as a biomarker for patient enrichment. Tumor samples from seven different ovarian cancer xenograft model
studies were split into two groups based on their response to NXP800 treatment (4/7 responsive and 3/7 non-responsive), with probes required
to express at least a two-fold differential in the responsive groups. Treatment with NXP800 in the IGROV-1, OVISE, SK-OV-3 and TOV-21G
xenografts showed significant anti-tumor effect (as illustrated in Figure 9 showing data for two of these models). These OCCC and endometrioid
ovarian cancer models all harbor a mutation in ARID1a. ARID1a is frequently mutated in solid tumors and is associated with aberrant cell
cycle and loss of control of proliferation, allowing cancer cells to achieve an advantage, but at the expense of lowered defenses against
oncogenic, cellular and environmental stressors such as oxidative stress (an imbalance of free radicals and antioxidants resulting from
increased metabolic rate of the cancer cell), heavy metals and chemotherapy. The cancer cells compensate for this exposure utilizing
the cell stress response including increased activity of the HSF1 pathway.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Figure
9: Inhibition of OCCC Tumor Growth in Preclinical In Vivo Models Harboring the ARID1a Mutation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><IMG SRC="tm2223302d1_s3img004.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><I>Legend:
NXP800 (CCT361814 in the chart) strongly inhibited tumor growth of SKOV3 and Tov-21G OCCC models in vivo</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Thus,
ARID1a deficiency offers a potential biomarker for a patient enrichment strategy in ovarian and other cancers. ARID1a testing is available
in commonly used and commercially available and academic molecular diagnostic panels.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Mutations
and epigenetic downregulation, the reduction at the cellular level of the magnitude or rate of a physiological response or a
biochemical process, such as the expression of a gene of ARID1a occur in roughly two thirds of all OCCC patients, approximately 40%
of all endometrioid ovarian carcinoma patients, as </FONT>well as in varying percentages in several additional types of cancers.
Consequently, the ARID1a mutation provides the potential as a biomarker for patient enrichment strategies in ovarian and other
cancer types. Based on this data, we plan to initially study the potential efficacy of NXP800 in OCCC and endometrioid ovarian
carcinoma in patients harboring the ARID1a mutation. ARID1a is also frequently mutated in additional solid tumors (<I>see </I>Table
2).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 56 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Business&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">We
hope to become the first company with an approved drug in relapse/refractory OCCC and endometrioid ovarian carcinoma, two unmet medical
needs with no approved therapies. Additionally, given the potentially wider role of ARID1a, we believe that NXP800 has substantial potential
beyond our initial indications, and we plan to explore additional development approaches to broaden the market opportunities in a variety
of solid tumors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Table
2: Prevalence of ARID1a mutation and protein loss in solid tumors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Primary Cancer</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">ARID1a<BR>
 Mutation</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">ARID1a Protein<BR>
 Loss</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 72%; font-size: 10pt">OCCC</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">53.8</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: justify">%</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">64.8</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: justify">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">Endometrioid Ovarian Carcinoma</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">37.6</TD><TD STYLE="font-size: 10pt; text-align: justify">%</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">41.8</TD><TD STYLE="font-size: 10pt; text-align: justify">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">Gastric</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">15.6</TD><TD STYLE="font-size: 10pt; text-align: justify">%</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">25</TD><TD STYLE="font-size: 10pt; text-align: justify">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">Hepatocellular Carcinoma (HCC)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">13.2</TD><TD STYLE="font-size: 10pt; text-align: justify">%</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">27</TD><TD STYLE="font-size: 10pt; text-align: justify">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">Esophageal</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">13.3</TD><TD STYLE="font-size: 10pt; text-align: justify">%</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">11</TD><TD STYLE="font-size: 10pt; text-align: justify">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">Pancreatic Cancer</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5.7</TD><TD STYLE="font-size: 10pt; text-align: justify">%</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6.7</TD><TD STYLE="font-size: 10pt; text-align: justify">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt">Uterine endometrioid carcinoma</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">40</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: justify">%</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">34.9</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: justify">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">N.A.
 &mdash; Data not available</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>OCCC
and Endometrioid Ovarian Carcinoma: Disease Etiology and HSF1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Clinically,
it has been observed that OCCC arises predominantly from ovarian endometriotic cysts, which are characterized by repeated bleeding into
the cyst cavity during the menstrual cycle. The content of an endometriotic cyst, consisting of old blood, contains a markedly high concentration
of free iron. Free iron is a source of reactive oxygen species (&ldquo;ROS&rdquo;) and excess iron is associated with cancer development
through the induction of persistent oxidative stress (an imbalance of free radicals and antioxidants resulting from increased metabolic
rate of the cancer cell) in several organs. Thus, extensive oxidative stress in the endometriotic cyst may contributes to of the development
of OCCC and endometrioid ovarian carcinoma through induction of DNA damage (<I>see </I>Figure 10 below).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Figure
10: Unique microenvironment within endometriotic cysts may lead to ovarian carcinoma</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2223302d1_s3img005.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><I>Legend:
Microenvironment with especially high concentration of free iron, derived from blood accumulated in the cyst, causes oxidative stress
(&ldquo;ROS&rdquo;) and leads to DNA damage. Accumulation of DNA damage over the years eventually leads to development of cancer.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><I>Source:
Nuvectis Pharma</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">In
parallel to the DNA damage, exposure to free iron can also trigger ferroptosis, a newly identified, iron- dependent, regulated cell death
mechanism. As described in Figure 11 below, ovarian cancer cells develop an increased capability to overcome ferroptosis, which in turn
promotes cancer cell survival, with the HSF1 pathway playing a major role in this protective mechanism.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 57 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Business&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>ARID1a
Enrichment Strategy &mdash; Scientific Rationale</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Several
genes were modulated by treatment with NXP800, including known HSF1 target genes such as HSPB1, which is an important pro-survival factor,
a factor promoting the survival of a cell, indicating a direct effect on the HSF1 pathway by NXP800. In addition, treatment with NXP800
resulted in upregulation of CHAC-1, whose unique function is the degradation of GSH, a key metabolite in cancer cell protection from
stress (see Figure 11 below).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">ARID1a
has been identified as a tumor suppressor in a broad array of cancers, in which loss of function mutations and protein loss are associated
with aberrant cell cycle and loss of control of proliferation at the expense of lowered defenses against oncogenic and microenvironment
stress. The cancer cells compensate for this vulnerability in different ways, including by increased activity of the HSF1 pathway. Thus,
by inhibiting the HSF1 pathway and downregulating the GSH levels in cancer cells with the ARID1a mutation, NXP800 tips the balance towards
cancer cell death, with the cancer cell no longer able to tolerate the increased metabolic and other stresses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>ARID1a
and Glutathione Metabolism</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">A
novel relationship was recently established between ARID1a deficiency and glutathione (&ldquo;GSH&rdquo;) metabolism (<I>see </I>Figure
12), showing that reducing antioxidant GSH metabolism is a weakness of ARID1a. Disruption of the SWI/SNF (SWItch/Sucrose Non-Fermentable)
complex, of which ARID1a is a key component, is associated with aberrant cell cycle and loss of control of proliferation, therefore,
cancer cells achieve an advantage at a price of lowering their defenses against insults from free iron (which as discussed previously
is a key stress factor involved in the etiology of OCCC and endometrioid ovarian carcinoma).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Reduction
of the metabolic pathway leading to GSH generation can be partially balanced in cancer cells by an increase in the activity of the HSF1-HSPB1
axis. The discovery of the link between ARID1a deficiency and reduction of the GSH protective pool has important therapeutic implications
for the treatment of ARID1a-deficient tumors, which are susceptible to targeting the HSF1 pathway via synthetically lethality whereby
GSH levels are further reduced through the activation of the main enzyme responsible for GSH degradation (&ldquo;CHAC1&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Figure
11: CHAC1 and HSPB1 are validated NXP800 Biomarkers and are Key Regulators of Ferroptotic Cell Death</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><IMG SRC="tm2223302d1_s3img006.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><I>Legend:
As the levels of the cystine importer, SLC7A11 are reduced in ARID1a mutations, the cancer cells are increasingly dependent on alternative
pathways that are targeted by NXP800 as demonstrated by the validated biomarkers HSPB1 and Chac1</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 58 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Business&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Synthetic
Lethality and ARID1a</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Synthetic
lethality is a clinically validated approach to treating cancer which arises when simultaneous deficiencies in a pair of genes result
in cell death. However, if the deficiency exists in only one gene, the cell survives. The first examples of a molecular targeted therapeutic
exploiting synthetic lethality are the PARP inhibitors, which were first approved in 2016. PARP inhibitors include AstraZeneca and Merck&rsquo;s
Lynparza<SUP>&reg;</SUP>, and Zejula<SUP>&reg;</SUP> from the GlaxoSmithKline unit Tesaro. PARP is a family of proteins involved in essential
cellular processes such as DNA repair, genomic stability, and programmed cell death. The synthetic lethality approach represents a way
to target lost tumor suppressor genes, which have long evaded drug developers as they cannot be drugged directly. The BRCA mutation is
found in approximately 10-15% of the ovarian epithelial cancer, a slightly lower target patient prevalence compared to OCCC and endometrioid
ovarian carcinoma combined. In 2017, prior to their additional approval in the maintenance setting in ovarian cancer and in breast cancer,
global PARP inhibitors revenue in the heavily pretreated, advanced-stage ovarian cancer setting was reported at $461 million. In 2020,
following the label expansion, the global PARP inhibitor market was valued at $2.178 billion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">The
preclinical data establishing the link between ARID1a deficiency and the overactivation of the HSF1 pathway as a compensation mechanism
in cancer cells suggest these cancer cells may be susceptible to a synthetic lethality approach through NXP800&rsquo;s inhibition of
the HSF1 pathway. Synthetic lethality results from the interaction between two genes that cause cell death when both are inactivated,
if only one of the pair genes is inactivated, the cell survives. In cancer cells, a certain genetic lesion which has no apparent effect
on cell viability can create a vulnerability that enables the pharmacological inhibition of a different target, (a synthetic lethality
pair), to kill the cancer cells whereas normal cells (which lack the genetic lesion) are spared the effect of the drug. In cancer cells,
one of these genes can be inactivated epigenetically or via mutation; while the other can be inactivated by a drug.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 59 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Business&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Split-Segment; Name: 4 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Figure
12. ARID1a and NXP800 Driven Synthetic Lethality</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><IMG SRC="tm2223302d1_s4img001.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><I>Source:
Nuvectis Pharma</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Addressing
an Unmet Need in Clear Cell Ovarian Cancer and Endometrioid Ovarian Carcinoma</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">We
plan to initially investigate NXP800 as a treatment for OCCC and endometrioid ovarian carcinoma. NXP800 is precisely targeted for women
with these diseases who have either the ARID1a mutation or ARID1a epigenetic loss.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">OCCC
is highly malignant, difficult to treat, and has a very poor survival rate due to frequent recurrence after surgery and first-line treatment.
The reported response rate to platinum-based chemotherapy (&ldquo;PBC&rdquo;) in patients with relapse/refractory disease is 1%, demonstrating
a clear and dire need for a new treatment option for OCCC. OCCC represents approximately 10% of all ovarian cancer cases in the United
States, with an annual incidence of approximately 2,200 patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Endometrioid
ovarian cancer represents approximately 10% of all diagnosed ovarian cancer cases. If diagnosed at early-stage, endometrioid ovarian
tumors can typically be resected. However, if diagnosed at later stages, these tumors have a substantially worse prognosis. Advanced,
platinum-refractory, endometrioid cancer in the United States represents approximately 30% of the endometrioid ovarian cancer segment.
Notwithstanding the initial PBC response in the endometrioid ovarian subset, the progression-free survival at three years for patients
diagnosed with stage III/IV endometrioid ovarian cancer is a dismal 20% and for stage III and 0% for stage IV.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">OCCC
and endometrioid ovarian carcinoma are subtypes of epithelial ovarian carcinoma with clinical characteristics that are distinct from
those of the most common ovarian carcinoma, high-grade serious ovarian carcinoma. They exhibit a unique biological profile that is markedly
different from those of other histologic types. The incidence of OCCC among ovarian cancer patients is higher in East Asia (approximately
25% in Japan), than in Europe and the United States (approximately 10%) (<I>see </I>Table3 below).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Table
3: Estimated Annual Incidence of ARID1a Mutated Patients in OCCC and Endometrioid Ovarian Carcinoma in Major Markets</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">Indication/Major market</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold">Estimated Annual Incidence</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold">Patients with ARID1a
    mutation or protein loss</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 72%; font-size: 10pt; font-weight: bold">OCCC/US</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">2,175</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">1,410</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: justify">Endometrioid Ovarian Carcinoma/US</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,175</TD><TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">909</TD><TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold">OCCC/EU</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,408</TD><TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,210</TD><TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: justify">Endometrioid Ovarian Carcinoma/EU</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,408</TD><TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,425</TD><TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold">OCCC/Japan</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,500</TD><TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,625</TD><TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: justify; padding-bottom: 1pt">Endometrioid Ovarian Carcinoma/Japan</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">375</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><I>Source:
Nuvectis Pharma</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Business&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">We
believe that we can become the first company with an approved drug in advanced-stage OCCC and endometrioid ovarian carcinoma. Our Phase
1 clinical trial of NXP800 commenced in December&nbsp;2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Market
Potential/Addressable Patient Population in Additional Solid Tumor Types</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Beyond
our initial target indications, we believe that NXP800 has the potential to demonstrate anti-tumor activity in several additional tumor
types, such as gastric, hepatocellular, esophageal, urothelial carcinoma and others.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">ARID1a
mutations are present in a number of other cancers, most notably gastric, hepatocellular, and esophageal cancers. These may be investigated
as secondary indications (<I>see </I>Table4 below).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Table
4: Examples of estimated annual incidence of patients with advanced-stage solid tumors harboring ARID1a mutations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">Indication</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold">Estimated Incidence
    (US)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold">Patients with ARID1a
    protein loss</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 72%; font-size: 10pt; font-weight: bold; text-align: justify">Gastric cancer</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">26,550</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">6,615</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold">Liver</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">34,000</TD><TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">9,070</TD><TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold">Esophageal</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">19,260</TD><TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,120</TD><TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold">Urothelial</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">75,357</TD><TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">25,621</TD><TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: justify">Uterine endometrioid carcinoma</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">66,570</TD><TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">26,628</TD><TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">Pancreatic</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">60,430</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4,230</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><I>Source:
Nuvectis Pharma</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Preclinical
drug discovery and validation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">A
comprehensive preclinical data package for NXP800 has been assembled. Preclinical studies of NXP800 conducted were as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><U>Pharmacology
studies</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">The
in vivo antitumour activity of NXP800 was evaluated in mice bearing human tumor xenografts (in all studies tumor growth inhibition (TGI)
was calculated versus vehicle control (i.e., no active drug) that was administered to a concurrently treated group of mice, p-values
were calculated for the weight-based assessments):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Experiments
in SKOV-3 xenograft models (ovarian cancer model):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">Experiment
                                            1: 10 mice were treated with 35 mg/kg orally once daily for 20 days, resulting in TGI of
                                            75.2% based on tumor volume and 62.7% based on tumor weight (p&lt;0.05); in the same experiment,
                                            10 mice were treated with 70 mg/kg orally once daily on days 0-6, 10,14,19 and 20, resulting
                                            in TGI of 71.7% based on tumor volume and 86.6% based on tumor weight (p&lt;0.05) (10 mice
                                            were treated in the control group).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">Experiment
                                            2: 12 mice were treated with 8.7 mg/kg orally once daily for 33 days, resulting in TGI of
                                            40.5% based on tumor volume and 22.7% based on tumor weight (p&lt;0.05); in the same experiment,
                                            12 mice were treated with 17.5 mg/kg orally once daily resulting in TGI of 45.6% based on
                                            tumor volume and 6.6% based on tumor weight (p&lt;0.05); in the same experiment, 12 mice
                                            were treated with 35 mg/kg orally once daily on days 0-9, 12, 13 17-20, and 26-33 resulting
                                            in TGI of 82.4% based on tumor volume and 72.1% based on tumor weight (p&lt;0.05) (13 mice
                                            were treated in the control group).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 61 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Business&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">Experiment
                                            3: 6 mice were treated with 35 mg/kg on days 0-4, 7-11, 14-18, 21-25, 28-32 and 35-39 resulting
                                            in TGI of 51.5% based on tumor volume (6 mice were treated in the control group). As some
                                            animals were removed from the control group before the end of the experiment, there was no
                                            measurable tumor growth inhibition at the end of the study based on weights.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">Experiment
                                            4: 12 mice were treated with 12.5mg/kg orally twice per day on days 0-8, 12-16, 19-23 and
                                            26-28, resulting in TGI of 40.2% based on tumor volume and 41.3% based on tumor weight (p&lt;0.05);
                                            in the same experiment, 12 mice were treated with 25 mg/kg orally once daily on days 0-8,
                                            12-16, 19-23 and 26-28 resulting in a TGI of 48.7% based on tumor volume and 47.5 based on
                                            tumor weight (p&lt;0.05); In the same experiment, 12 mice were treated with 50 mg/kg once
                                            every other day on days 2, 4, 6, 8, 12, 14, 16, 19, 23, 26,28 resulting in TGI of 65.9% based
                                            on tumor volume and 65.3% based on tumor weight (p&lt;0.05) (12 mice were treated in the
                                            control group).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">Experiment
                                            5: 2 groups of mice each were treated with 35 mg/kg orally once daily on days 0-4, 7-11,
                                            21-25 28-31, 33 and 34 (group 1 &mdash; 10 mice, group 2 &mdash; 6 mice), resulting in TGI
                                            of 58.7% based on tumor volume and 57.1% based on tumor weight (p&lt;0.05) in group 1, and
                                            71.3% based on tumor volume and 69.2% based on tumor weight (p&lt;0.05) in group 2 (10 mice
                                            were treated in the control group).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Experiment
in TOV-21G xenograft model (ovarian cancer model):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">12
                                            mice were treated with 35 mg/kg orally once daily on days 0-4, 7-11, 14-18, 21-25, 28-30
                                            resulting in TGI of 73.3% based on tumor volume and 59.1% based on tumor weight (p&lt;0.05)
                                            (12 mice were treated in the control group).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Experiment
in OVISE xenograft model (ovarian cancer model):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">12
                                            mice were treated with 35 mg/kg orally once daily on days 0-4, 7-11, 14-18, 21-25, 28-32,
                                            35-39, 42-46 and 49-51 resulting in TGI of 50.5% based on tumor volume and 46.9% based on
                                            tumor weigh (p&lt;0.05) (12 mice were treated in the control group).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Experiment
in IGROV-1 xenograft model (ovarian cancer model):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">9
                                            mice were treated with 35 mg/kg orally once daily on days 0-2, 4-6, 8, and 11-14, resulting
                                            in TGI of 51.3% based on tumor volume and 50.7% based on tumor weight (p&lt;0.05) (9 mice
                                            were treated in the control group).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Experiment
in PA-1 xenograft model (ovarian cancer model):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">10
                                            mice were treated with 35 mg/kg orally once a day on days 0-4, 7-10, 14-18, 21-25 and 28-31,
                                            resulting in TGI of 80.6% based on tumor volume and 79.9% based on tumor weight (p&lt;0.05)
                                            (10 mice were treated in the control group).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><U>Experiment
in WM266.4 xenograft model (melanoma model):</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">10
                                            mice were treated with 35 mg/kg orally once daily on days 0-17, resulting in TGI of 66.2%
                                            based on tumor volume and 62.6% based on tumor weight (p&lt;0.05) (10 mice were treated in
                                            the control group).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><U>Experiment
in MCF-7 xenograft model (breast cancer model):</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">12
                                            mice were treated with 35 mg/kg orally once daily on days 0-4, 8-10, 14,16, 20-22, and 27-30,
                                            resulting in TGI of 57.5% based on tumor volume and 60.1% based on tumor weight (p&lt;0.05)
                                            (12 mice were treated in the control group)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><U>Secondary
pharmacodynamics</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">NXP800
has been screened against several panels for secondary pharmacology, and no hits were found in any of the screens at concentrations that
are relevant to the free drug target concentrations of NXP800 associated with efficacy (in mouse models) or toxicity (in rat and dog,
the species used in the GLP-toxicology studies).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 62 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Business&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><U>Safety
pharmacology</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">NXP800
was profiled against the Cerep Safetyscreen 87 at a concentration of 10 &mu;M. Hits (&gt; 50% at </FONT>10 &mu;M) in this
preliminary screen were then assessed across a range of concentrations in an individual cell- based assay for both agonism and
antagonism of the relevant receptors. NXP800 showed no agonism activity with any receptor and antagonist activity with only one
receptor with an IC50 of 2.0 &mu;M. A GLP study was performed to evaluate the effects of NXP800 on cardiovascular parameters and
body temperature in the dog (two groups of two dogs each) following oral administration, and the No Adverse Effect Level (NOEL),
driven by a transient increase in arterial blood pressure, was 3 mg/kg.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><U>Pharmacokinetics</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">The
absorption, distribution, and metabolism properties of NXP800 were characterized, including apparent permeability in Caco-2 cells and
transporter interaction, plasma protein binding and blood-to-plasma partitioning, intrinsic clearance, identification of metabolites
(including a proposed metabolic pathway in human) and inhibition of human CYP isoforms. The excretion of NXP800 was characterized post
IV or oral dose in rats.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><U>Toxicology</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">The
toxicity of NXP800 was initially assessed in healthy mice. Formal toxicology was then performed in rat and dog. In both rat and dog,
non-GLP combined dose range finding and pharmacokinetic (&ldquo;PK&rsquo;&rsquo;) studies were performed prior to the pivotal GLP
28-day repeat dose toxicity studies and included an </FONT>assessment of recovery and toxicokinetics. All pivotal GLP toxicity
studies were conducted at Charles River Laboratories Edinburgh Ltd, UK. The GLP studies were therefore performed in a country that
is a member of the OECD Mutual Acceptance of Data program with the OECD Test Guidelines and Principles of GLP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Rat
and dog were selected as the rodent and non-rodent species for toxicity studies of NXP800 based on similarities to humans with regard
to the proportion of hydrolysis metabolism. Based on initial PK studies, free drug exposure levels could be achieved following oral dosing
at comparable levels to those required to achieve efficacy in mice. In addition, all metabolites found after exposure of human matrices
to NXP800 were also found in matrices of one or both toxicity model species, and therefore their toxicity would be assessed in the toxicology
studies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Continuous
daily dosing was selected as the initial schedule for NXP800 toxicity studies to facilitate flexibility in clinical administration. In
the dog, Cmax-driven emesis limited exposure and the schedule changed to continuous twice daily dosing to increase exposure to NXP800.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Based
on the clinical indication (advanced solid tumors) and route of administration (oral) of NXP800, no carcinogenicity, reproductive toxicity
or local tolerance studies have been performed at this stage of development. Non GLP mutagenicity studies have been performed. The phototoxicity
of NXP800 has also been assessed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>NXP800
Clinical Development Plan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Based
on the compelling preclinical data, in December&nbsp;2021 we announced the commencement of the Phase 1 study for NXP800. The Phase 1
study is comprised of two parts: dose-escalation Phase 1a, initiated in December&nbsp;2021, followed by an expansion Phase 1b. In the
Phase 1a, the safety and tolerability of NXP800 are being evaluated in patients with advanced solid tumors to identify a dose and dosing
schedule for the Phase 1b. The Phase 1a is being conducted in the U.S. and U.K. In the Phase 1b, the safety and preliminary anti-tumor
activity of NXP800 will be evaluated in biomarker-selected patients, initially in ovarian clear cell carcinoma and endometrioid carcinoma
harboring the ARID1a mutation and possibly cohorts of patients with additional types of solid tumors. The endpoints in the Phase 1 study
that will be utilized to inform the primary objective include estimation of the rate and severity of adverse events and dose-limiting
toxicities in the Phase 1a dose escalation stage, and estimation of clinical activity in the Phase 1b expansion stage of the Phase 1
study. Secondary objectives include characterization of the pharmacokinetic and pharmacodynamic profile of NXP800. Once a recommended
dose is established, patients will be enrolled in additional </FONT>cohorts to determine the clinical activity and further characterize
the clinical profile of NXP800. The sample size for the dose escalation portion of the study will be driven by the emerging clinical
data and is expected to be between 20-50 subjects. In the expansion stage of the Phase 1 study, we plan to enroll three cohorts of 12
 &ndash; 15 subjects each. We plan to include OCCC or endometrioid ovarian carcinoma patients with the ARID1a mutation in these cohorts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 63 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Business&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>NXP900
Scientific Background</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">In
August&nbsp;2021 we licensed worldwide commercial rights to NXP900 from the UoE. NXP900 is a preclinical- stage, targeted-therapy,
small molecule drug candidate designed to preferentially inhibit the SRC and YES </FONT>1 kinases. We started the preclinical
IND-enabling (or equivalent) studies for NXP900 in the fourth quarter of 2021. Following the IND-enabling studies, if successfully
completed, we plan to submit an IND with the FDA, or an equivalent submission with a foreign agency, in order to begin a Phase 1
dose- escalation study of NXP900 in solid tumors in the second half of 2022. Subsequently, upon successful completion of the dose-
escalation study, we plan to conduct a clinical trial to investigate NXP900 in solid tumors where the SRC and/or YES1 pathways are
overactivated and implicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>SRC
as an anti-cancer target</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">SRC
is aberrantly activated in many cancer types, including solid tumor cancers such as breast, colon, prostate, pancreatic and ovarian cancers,
while remaining predominantly inactive in non-cancerous cells. Increased SRC activity is generally associated with late-stage cancers,
metastatic potential and resistance to therapies, and correlates with poor clinical prognosis. Signaling pathways activated by SRC include
proliferation, cell growth, cell migration and metastasis, and angiogenesis mediated by Phosphatidylinositide 3 Kinase (PI3K), Mitogen-Activated
Protein Kinase (MAPK), Signal Transducer and Activator of Transcription 3 (Stat3),&nbsp;Interleukin (IL) 8, and Vascular Endothelial
Growth Factor (VEGF) (see Figure 13).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 64 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Business&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Figure
13: Key oncogenic pathways activated by SRC kinase</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><IMG SRC="tm2223302d1_s4img002.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><I>Legend:
Signaling pathways activated by SRC include proliferation, cell growth, cytoskeleton (cell migration and metastasis), and angiogenesis
mediated by Phosphatidylinositide 3 Kinase (PI3K), Mitogen-Activated Protein Kinase (MAPK), Signal Transducer and Activator of Transcription
3 (Stat3),&nbsp;Interleukin (IL) 8, and Vascular Endothelial Growth Factor (VEGF)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">SRC
is a non-receptor tyrosine kinase and a widely studied member of the SRC family kinases (SFKs), which include LYN, FYN, LCK, HCK, FGR,
BLK, FRK and YES. The SRC kinase, product of the first cellular proto-oncogene identified, emerged as a potential therapeutic target
in the early 1980s. Predominantly inactive in non-cancerous cells, SRC is aberrantly activated in many cancer types, including breast,
colon, prostate, pancreatic and ovarian cancers. Increased SRC activity is generally associated with late-stage cancers, metastatic potential
and resistance to treatment, and correlates with poor clinical prognosis. Despite the vast amount of evidence gathered over the years
and the approval of dasatinib and bosutinib, which act as dual SRC/ABL kinase inhibitors to treat chronic myelogenous leukemia and acute
lymphoblastic leukemia, both hematologic (liquid) tumors, to date no SFK inhibitor has been approved for the treatment of </FONT>SRC-active
solid tumor malignancies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Due
to high structural similarities between their active sites, most inhibitors targeting SFK&rsquo;s, including the approved drugs dasatinib
and bosutinib, display equal potency against the nonreceptor tyrosine kinase ABL. While dual inhibition of ABL and SRC can be beneficial
in the treatment of hematologic cancers, this polypharmacological profile is not desirable in the treatment of solid tumors, as several
studies have found that inhibition of ABL leads to immuno suppressive effects. To date no kinase inhibitor has been approved for the
treatment of SRC-active solid tumor malignancies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>NXP900&rsquo;s
Novel Mechanism of Action</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">SRC
pathway activation is regulated by a switch between an inactive and active conformation. The inactive conformation of SRC family kinases
is associated with lack of membrane binding, lack of phosphorylation of the activation loop, and characterized by a &ldquo;closed conformation.&rdquo;
The active &ldquo;open&rdquo; conformation allows for the binding of SRC to signaling partners such as PI3K and FAK, thus enabling full
activation of the pathway via SRC&rsquo;s kinase catalytic activity and the scaffolding property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">NXP900
is a targeted-therapy designed to preferentially inhibit the SRC and YES1 kinases. Unlike the approved and clinical-stage SRC kinase
inhibitors, NXP900 induces and locks SRC in its native inactive conformation (see Figure 14), by inhibiting both the catalytic (enzymatic)
and scaffolding functions, thus preventing phosphorylation and complex formation with its primary partners. NXP900 is highly selective
compared to dasatinib, (see figure 15), an approved multitargeted kinase inhibitor, a property typically associated with an improved
therapeutic window. Moreover, the existing SRC inhibitor drugs only inhibit the catalytic functions of SRC, still enabling it to bind
to its primary partners and remain partially active.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">This
unique mechanism of action, which leads to inactivation of the SRC kinase, has resulted in SRC- pathway inhibition in vitro and in vivo.
In vivo, treatment with NXP900 inhibited primary and metastatic tumor growth in xenograft models of breast cancer and demonstrated on-target
pharmacodynamic effects. Therefore, this novel mode of inhibiting SRC by NXP900 could lead to improved treatment of SRC-associated oncologic
disorders and provides the potential to treat solid tumors for the first time with a SRC inhibitor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 65 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Business&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Gene
amplification of the site containing the YES1 gene has been reported in clinical samples in several tumors including lung, head and
neck, bladder and esophageal cancers. Furthermore, it has been found that YES1 gene amplification is a key mechanism of resistance
to EGFR, Alk and HER2 inhibitors. YES1- dependent oncogenic transformation has also been reported, suggesting that YES1 plays a key
role in these </FONT>solid tumors &mdash; The transforming ability of YES1 has been demonstrated via several experimental methods,
for example down-regulating YES1 by short hairpin RNA (shRNA) significantly inhibited cell growth in several malignancies, including
colon carcinoma, rhabdomyosarcoma, and basal-like breast cancer suggesting YES1 may play a key role in these solid tumors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">NXP900
has been shown to inhibit the YES1 kinase in preclinical models, providing an additional target for pharmacological inhibition by NXP900
of a biologically-relevant target in various cancer types, some of which may rely on both the SRC and YES1 pathways for their advantage.
There are no YES1 inhibitors that are FDA approved or currently in clinical development. We plan to conduct in vivo studies to better
understand the effects of YES1 inhibition in solid tumors driven by YES1 overexpression or gene amplification. We expect to continue
to provide preclinical data updates at key medical conferences in 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Figure
14: Novel mechanism of action compared to other SRC inhibitors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><IMG SRC="tm2223302d1_s4img003.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><I>Legend:
Complete activation of the SRC pathway requires both catalytic activity and scaffolding of its signal transduction partners in its active
conformation (middle image).NXP900 locks SRC in its inactive conformation (left image) by inhibiting both the catalytic activity of SRC
and its ability to bind to its signal transduction partners. Other SRC inhibitors, including dasatinib, only inhibit the catalytic activity
of SRC while locking it in its active conformation (right image) thereby only partially inhibiting the SRC pathway.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 66 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Figure
15: Kinome profiling reveals high selectivity compared with dasatinib</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><IMG SRC="tm2223302d1_s4img004.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Legend:
Kinome-wide activity profile of NXP900 </I></FONT><I><FONT STYLE="font-size: 10pt">- enzymatic inhibition screen was performed by Carna
Biosciences, against 326 wildtype and mutant kinases. Circles identify kinase targets of NXP900 (0.5&mu;M, lilac) and dasatinib (1&mu;M,
deep purple), size represents percent inhibition. Dasatinib data from Remsing Rix et al., Leukemia 23, 477&ndash;485 (2009).</FONT></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>NXP900
preclinical proof of concept &mdash; In Vitro</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NXP900
is active against the catalytic activity of SRC in vitro at low nanomolar concentrations. NXP900 requires concentrations approximately
three orders of magnitude (X1000) greater to inhibit ABL. </FONT><FONT STYLE="font-size: 10pt">In cells, NXP900 reduces SRC binding to
its partner FAK. Notably, the SRC/ABL inhibitor dasatinib (known to bind SRC in its active conformation) induces precisely the opposite
effect. These results provide convincing evidence that NXP900 and dasatinib bind and promote different conformations in SRC whereby NXP900
inhibits both SRC kinase catalytic activity and its scaffolding functions. Further, it has been recently reported that SRC inhibitors
such as dasatinib are allosteric facilitators of SRC conformational activation, and actually enhance SRC-FAK complex formation and increase
FAK autophosphorylation, leading to activation of signaling via SRC, whereas treatment with NXP900 is not expected to lead to such paradoxical
activation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">The
kinase inhibitors approved or in clinical development that target SRC activity are examples of non- selective, promiscuous inhibitors
targeting many kinases in addition to SRC and its most closely related family members, often resulting in undesirable off-target effects.
Preclinically, NXP900 inhibits YES1 and SRC in concentrations of 0.5 and 2.4 nM respectively. In addition, co-crystal structure analysis
reveals that NXP900 induces and stabilizes the native inactive conformation of the SRC kinase domain as shown in Figure 14. The benefits
of targeting the inactive SRC kinase conformation make this a unique property. which could prove advantageous clinically compared to
other SRC inhibitors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 67 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>NXP900
preclinical proof of concept &mdash; In Vivo</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">NXP900
demonstrated antitumor activity in mouse models of triple negative breast cancer (TNBC).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">NXP900
mediated in vivo antitumor activity in murine triple negative breast cancer models, against primary tumors and bone metastases. (Figure
16). In the post-treatment period, mice with an intact immune system were able to control tumor growth beyond the treatment phase, whereas
tumor relapse occurs in immunosuppressed mice as soon as the animals were off treatment. NXP900 was superior compared to dasatinib in
an orthotopic model of TNBC. Moreover, this superiority in tumor growth inhibition and duration of response translated into improved
overall survival of the test mice (Figure 17).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Based
on the preclinical data and novel mechanism of action, we believe that NXP900 represents an important drug candidate for the treatment
of SRC and YES1 associated oncologic disorders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Figure
16: In vivo antitumor activity of NXP900 in murine triple negative breast cancer models, against primary tumors and bone metastases</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><IMG SRC="tm2223302d1_s4img005.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><I>Legend:
(d,e) tumor growth inhibition of a MetBo2 breast cancer model in (d)&nbsp;immunocompetent FVB mice and (e)&nbsp;immunocompromised CD-1
mice treated orally daily for 28 d with NXP900 (40 mg/Kg) or vehicle.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(f)&nbsp;Tumor
volumes at days 28 and 39 in FVB vs. CD1 mice treated with NXP900. (g-i) Metastasis inhibition by NXP900 in a breast cancer bone metastasis
model (40 mg/Kg or vehicle). (g)&nbsp;Percentage bioluminescence imaging </I></FONT><FONT STYLE="font-size: 10pt">(<I>BLI) in left and
right hind legs. Animals were monitored for 63 d. (h)&nbsp;Comparative analysis of % BLI between groups at day 7. (i)&nbsp;Bioluminescence
tomography images of two representative mice from each group at day 7.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 68 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Figure
17: NXP900 inhibited tumor growth in an orthotopic model of triple negative breast cancer (TNBC) in immunocompetent animals demonstrating
a substantial long-term effect after treatment completion and improved survival compared to dasatinib.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><IMG SRC="tm2223302d1_s4img006.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><I>Legend:
A,B) Comparative analysis of tumor volumes vs dasatinib; C) Kaplan-Meier Survival analysis.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Preclinical
Data of NXP900 in Medulloblastoma</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Medulloblastoma
is a rare brain cancer (with an annual incidence of approximately 500 in the U.S.) that affects mostly pediatric patients. While rare,
it is the most common pediatric brain tumor, and by the time of diagnosis, as many as 40% of patients carry metastases and have a poor
prognosis for survival. Metastatic disease and tumor recurrence are responsible for the lack of improvement in survival rates over the
past decades. In addition, survivors frequently face treatment-related adverse effects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Out
of the four identified subtypes, group 4 is the most prevalent biological subtype, comprising approximately 40% of all medulloblastoma
patients. Recent studies have identified aberrant ERBB4-SRC signaling pathway as the hallmark of group 4 patients, indicating the SRC
kinase as a potential therapeutic target in this most common medulloblastoma subgroup.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
a PK study, NXP900 was shown to cross the blood-brain barrier in mice, in concentrations that exceeded the levels required to inhibit
SRC in vitro with NXP900. The efficacy of NXP900 in a preclinical xenograft model of Group 4 Medulloblastoma was presented on June<SUP>&nbsp;1</SUP>2th,
2022 at SIOPE Brain Tumour Group (Figure 18). </FONT><FONT STYLE="font-size: 10pt">This data supports the further exploration of NXP900
in the treatment of group 4 medulloblastoma. We plan to conduct additional preclinical testing of NXP900 to better understand the potential
therapeutic effect of NXP900 in this indication.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Figure
18: NXP900 is highly effective in a preclinical model of group 4 Medulloblastoma</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><IMG SRC="tm2223302d1_s4img007.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><I><U>Legend:
SrcCA/DNp53 tumour cells&nbsp;were cultured in vitro and transduced using lentivirus expressing Luciferase-eGFP, for tumor tracking.
Mice received NXP900 (eCF506) 20mg/kg daily for 28 days via IP in a citric buffer. Tumor response was monitored weekly via bioluminescence
and measured by calliper.</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 69 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Our
Strategy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">We
have a mission-driven strategy to build a global biopharmaceutical company through the identification, licensing, development, and commercialization
of therapeutics to address unmet medical needs in oncology, with an initial focus on OCCC and endometrioid ovarian carcinoma patients.
We intend to leverage our core competencies of target selection, drug profiling and clinical and regulatory execution to build a pipeline
of product candidates targeting cancers driven by genetic alterations. The key elements driving our business strategy include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">establishing
                                            a leadership position in targeted oncology therapeutics, targeting the inhibition of the
                                            HSF1 pathway utilizing the ARID1a mutation as a biomarker;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">advancing
                                            our lead product candidate, NXP800, through clinical development towards regulatory approval
                                            in OCCC, endometrioid cancers and possibly additional indications;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">maximizing
                                            the therapeutic potential for NXP800 by leveraging preclinical data in additional tumor types
                                            harboring the ARID1a mutation, both as a monotherapy and in possibly in combination with
                                            other approved therapies;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">positioning
                                            NXP900 as a differentiated SRC kinase inhibitor with improved therapeutic activity in solid
                                            tumors compared to the existing SRC kinase inhibitors;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">maximizing
                                            the therapeutic potential of NXP900 by generating additional preclinical data to highlight
                                            the benefits of YES1 inhibition;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">deploying
                                            our differentiated and proven business development expertise to further expand our targeted
                                            oncology pipeline for patients with unmet medical needs; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">evaluating
                                            opportunities to accelerate development timelines and enhance the commercial potential of
                                            our programs in collaboration with third parties, including potential ex-U.S. collaboration
                                            opportunities.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Intellectual
Property</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">We
strive to protect the proprietary technologies that we believe are important to our business, including pursuing, obtaining and
maintaining patent protection intended to cover the composition of matter of our current or future product candidates, including
NXP800, their methods of use, related technologies and other inventions that are important to our business. In addition to patent
protection, we also rely on trade </FONT>secrets to protect aspects of our business that are not amenable to, or that we do not
consider appropriate for, patent protection. We also rely on know-how and continuing technological innovation to develop and
maintain our proprietary and intellectual property position.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">As
with other biotechnology companies, our commercial success depends in part upon our ability to: obtain, maintain, enforce, and protect
our patent, intellectual property, and other proprietary rights for our current or future product candidates and other commercially important
technologies, inventions, improvements, and know-how related to our business; defend and enforce our intellectual property, in particular,
any patent rights that we may own or in-license;, prevent others from infringing any patents we may own or in-license; preserve the confidentiality
of our trade secrets; and operate without infringing the valid and enforceable intellectual property and proprietary rights of third
parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Our
ability to maintain and solidify our proprietary and intellectual property position for our current or future product candidates and
technologies depends on our success in obtaining effective patent claims and enforcing those claims if granted. However, our current
patent applications and any patent applications that we may in the future file or license from third parties may not result in the issuance
of patents, and any issued patents we may obtain may not guarantee us the right to practice our technology in relation to the commercialization
of our products. We also cannot predict the breadth of claims that may be allowed or enforced in any patents we may own or in- license
in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 70 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">The
patent positions for biotechnology and pharmaceutical companies like us are generally uncertain and can involve complex legal,
scientific, and factual issues. We cannot predict whether the patent applications we are currently pursuing will issue as patents in
any particular jurisdiction or whether the claims of any </FONT>issued patents will provide sufficient proprietary protection from
competitors. Any issued patents that we may own or in-license in the future may be challenged, invalidated, circumvented, or have
the scope of their claims narrowed. Furthermore, the coverage claimed in a patent application can be significantly reduced before a
patent is issued, and its scope can be reinterpreted and even challenged after issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Moreover,
many jurisdictions permit third parties to challenge issued patents in administrative proceedings, which may result in further
narrowing or even cancellation of patent claims. As a result, we cannot guarantee that any of our current or future product
candidates will be protected or remain protectable by enforceable patents. Moreover, any patents that we hold may be challenged,
circumvented or invalidated by third parties. We cannot be certain of the priority of inventions covered by pending third-party
patent applications. If third parties prepare and file patent applications in the United States that also claim technology or
therapeutics to which we have rights, we may have to participate in interference proceedings in the USPTO to determine priority of
invention, which could result in substantial costs to us, even if the eventual outcome is favorable to us, which is highly
unpredictable. In addition, because of the extensive time required for clinical development and regulatory review of any current or
future product candidate we may develop, it is possible that, before any current or future product candidates can be commercialized, </FONT>any
related patent may expire or remain in force for only a short period following commercialization, thereby limiting the protection
such patent would afford the respective product and any competitive advantage such patent may provide.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">We
have licensed one patent family covering the composition of matter for NXP800, which includes two issued U.S. patents covering the composition
of matter for NXP800, as well as methods of using and making NXP800. Composition of matter patents in this family have also been issued
in other major markets, including Australia, Brazil, China,&nbsp;India,&nbsp;Israel, Mexico, Russia, Singapore, the E.U. and Japan. The
statutory expiration for patents in this family is October&nbsp;2034, without taking into account any possible patent term extension,
where applicable. We have also licensed a patent family directed to additional compounds, structurally distinct from NXP800, that modulate
HSF1. This patent family is granted in the U.S. and has a statutory expiration of April&nbsp;2036. In addition, we have also licensed
a patent family pending in the U.S. and Europe directed to deuterated compounds that modulate HSF1. Any patent that grants from this
family would have a statutory expiration of October&nbsp;2037. We intend to pursue additional patent protection for NXP800 relating to
methods of use and related technologies that we consider important to our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">We
have licensed one patent family covering the composition of matter for NXP900, which includes one U.S. patent covering the composition
of matter for NXP900, as well as patents and patent applications issued/pending in major markets, including the E.U. and Japan. The statutory
expiration for patents in this patent family is April&nbsp;2036, without taking into account any possible patent term extension, where
applicable. We have also licensed a patent family directed to additional compounds targeting the SRC family, filed as a priority application
August&nbsp;2021. Any patent that grants from this family would have a statutory expiration of August&nbsp;2042.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">The
term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries
in which we file, the patent term is 20 years from the earliest date of filing a non- provisional patent application. In the United States,
the term of a patent covering an FDA-approved drug may, in certain cases, be eligible for a patent term extension under the Hatch-Waxman
Act as compensation for the loss of patent term during the FDA regulatory review process. The period of extension may be up to five years,
but cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval. Only one patent applicable
to an approved drug is eligible for extension and only those claims covering the approved drug, a method for using it, or a method for
manufacturing it may be extended. Similar provisions are available in Europe and in certain other jurisdictions to extend the term of
a patent that covers an approved drug. It is possible that issued U.S. patents covering NXP800 and NXP900, may or will be entitled to
patent term extensions. If our current or future product candidates receive FDA approval, we intend to apply for patent term extensions,
if available, to extend the term of patents that cover any approved product candidates. We also intend to seek patent term extensions
in any jurisdictions where they are available; however, there is no guarantee that the applicable authorities, including the FDA, will
agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 71 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">In
addition to patent protection, we also rely on trade secret protection for our proprietary information that is not amenable to, or that
we do not consider appropriate for, patent protection, including certain aspect </FONT>of our manufacturing processes. However, trade
secrets can be difficult to protect. Although we take steps to protect our proprietary information, including restricting access to our
confidential information, as well as entering into non-disclosure and confidentiality agreements with our employees, consultants, independent
contractors, advisors, contract manufacturers, CROs, hospitals, independent treatment centers, suppliers, collaborators and other third
parties, such parties may breach such agreements and disclose our proprietary information including our trade secrets, and we may not
be able to obtain adequate remedies for such breaches. In addition, third parties may independently develop the same or similar proprietary
information or may otherwise gain access to our proprietary information. As a result, we may be unable to meaningfully protect our trade
secrets and proprietary information. For more information regarding the risks related to our intellectual property, please see &ldquo;Risk
Factors &mdash; Risks Related to Our Intellectual Property.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>NXP800
License Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">In
May&nbsp;2021, we entered into a worldwide, exclusive license agreement with the CRT Pioneer Fund (&ldquo;CRT&rdquo;) for NXP800 and
any of its derivatives (collectively, the &ldquo;NXP800 Program&rdquo;). NXP800 is a small molecule product candidate that we believe
can be applied to a broad range of cancers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Prior
to Nuvectis, CRT was the commercial owner of the NXP800 Program which it acquired from the ICR. The ICR is a world-renowned research
institute focused on the discovery and preclinical development of cancer therapeutics.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Pursuant
to the license agreement, we have an obligation to pay success-based milestones and royalties to CRT, as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">pre-approval
                                            milestone payments of up to approximately $26.5 million including an upfront payment of $3.5
                                            million which has already been paid;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">regulatory
                                            approval and commercial sales milestones of up $178 million; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">mid-single
                                            digit to 10% royalties on a tiered basis on net sales.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">In
addition, in connection with the licensing agreement, we intend to provide ICR with approximately $650,000 research and development support
over the next 18 months to conduct additional scientific research and preclinical testing for certain indications that we select in connection
with the NXP800 Program. We own an exclusive license to intellectual property rights developed in the collaboration, to research, develop
and commercialize products resulting from the collaboration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><I>License
Term</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">The
license will remain in effect in each territory subject to the license and will continue until our obligation to pay royalties in
such territory has expired. The royalty term for each licensed product in each country commences with the first commercial sale of
the applicable licensed product in the applicable country and ending on the expiration of the last to expire of any patent specified
by the license (with the key composition of matters patent expiring October&nbsp;2034) or the expiration of any extended exclusivity
period in the </FONT>relevant country. CRT may earlier terminate the license if we, or any of our affiliates or sub-licensees,
challenge or seek to challenge the validity of any of the licensed patents or upon a change of control in which we become controlled
by a Tobacco Party, as such term is defined in the license. Either party may terminate the license upon material breach by the other
party, and upon the appointment of a receiver or upon a winding-up order or similar or equivalent action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>NXP900
License Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">In
August&nbsp;2021, we entered into a worldwide, exclusive license agreement with the UoE for NXP900 and any of its derivatives (collectively,
the &ldquo;NXP900 Program&rdquo;). Discovered at the UoE, NXP900 is a targeted therapy, small molecule SRC and YES1 kinase inhibitor
product candidate that we believe can be applied to a broad range of cancers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Pursuant
to the license agreement, we have an obligation to pay success-based milestones and royalties to the UoE, as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">pre-approval
                                            milestone payments of up to approximately $49.5 million including an upfront payment of $3.5
                                            million which has already been paid;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 72 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">regulatory
                                            approval and commercial sales milestones of up $279.5 million;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">mid-single
                                            digit to 8% royalties on a tiered basis on net sales; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">2.5%
                                            of the gross amount of each Nuvectis fundraising, up to an aggregate total of $3.0 million.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">In
addition, in connection with the licensing agreement, we intend to provide the UoE with up to an additional &pound;580,000 in research
and development support over the next approximately 12 months to conduct additional scientific research and preclinical testing for certain indications
that we select in connection with the NXP900 Program. We own an exclusive license to intellectual property rights developed in the collaboration,
to research, develop and commercialize products resulting from the collaboration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><I>License
Term</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">The
royalty term for each licensed product in each country is the period commencing with first commercial sale of the applicable
licensed product in the applicable country and ending on the expiration of the last to expire of any patent specified by the license
(statutory expiration for the NXP900 patent family is April&nbsp;2036), or the expiration of any extended exclusivity period in the
relevant country. We may terminate the license if we determine that it is not scientifically or commercially viable to research,
develop, or commercialize the licensed products which are the subject of the license agreement. UoE may terminate the agreement if
we: (i)&nbsp;cease to carry on the business regarding the treatment, prevention and/or diagnosis of human diseases; </FONT>(ii)&nbsp;discontinue
the development of the licensed products which are the subject of the license; (iii)&nbsp;dispose of our assets or business in whole
or in material part; (iv)&nbsp;challenge the validity, ownership, or enforceability of the exclusively licensed technology;
(v)&nbsp;contest the secret or substantial nature of certain know-how subject to the license; or (vi)&nbsp;breach certain diligence
obligations or fail to pay any amount due under the license within a specified time frame. The parties may terminate the NXP900
License Agreement immediately by written notice upon material breach by the other party, if such breach (if capable of cure) is not
so cured to the within thirty (30) business days following the notice of breach.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Competition</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Our
industry is intensely competitive and subject to rapid and significant technological changes. We face competition with respect to our
current product candidates, and will face competition with respect to future product candidates, from segments of the pharmaceutical,
biotechnology and other related markets. For example, there are several companies that are developing drugs for various types of ovarian
cancer, including Immunogen Therapeutics and Constellation Pharma. Of note, in May&nbsp;2021 Constellation Pharma (acquired by Morphosys,
June&nbsp;2021), has disclosed patient recruitment commencing in May&nbsp;2021 in a phase 2 expansion cohort for CPI-0209, a small molecule
inhibitor of Enhancer of Zeste Homolog 2 (&ldquo;EZH2&rdquo;) in patients with relapsed urothelial carcinoma, relapsed OCCC, and relapsed
endometrial carcinoma all with known ARID1A mutations. As of the last update posted on clinicaltrials.gov on May&nbsp;18<SUP>th</SUP>,
2022, this study is open for enrollment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">In
the SRC/YES1 space Dasatinib (SPRYCEL<SUP>&reg;</SUP>) and bosutinib (BOSULIF<SUP>&reg;</SUP>) are multikinase inhibitors that also target
Abl and SRC and are approved in Philadelphia chromosome-positive chronic myeloid leukemia (CML) and Philadelphia chromosome-positive
acute lymphoblastic leukemia (ALL), both hematological malignancies. These two compounds have been extensively tested in solid tumors
demonstrating only minor clinical activity. Sarcatinib is an inhibitor of the SRC/ABl family of kinases. It was originally developed
by AstraZeneca for various types of cancer, but discontinued in Phase 2 for lack of sufficient efficacy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Turning
Point Therapeutics (Turning Point) is developing TPX-0022, a MET/SRC/CSF1R inhibitor which is currently being studied in a Phase 1 trial
of patients with advanced or metastatic solid tumors harboring MET genetic alterations. The simultaneous inhibition of MET, SRC and CSF1R
kinases has been reported by Turning Point as a key component of the target product profile, and Turning Point has described the program
as a strategy for the treatment of MET-driven solid tumors, an area that does not overlap with our development strategy. Turning Point
is also developing TPX-0046, a RET kinase inhibitor that can also inhibit other kinases including SRC family members, YES1, ABl, TRK
and JAK2. TPX-0046 is being evaluated in an ongoing Phase 1/2 clinical trial for the treatment of advanced solid tumors with RET gene
alterations, an area that does not overlap with our development strategy. As of the last update posted on clinicaltrials.gov on April&nbsp;8<SUP>th</SUP>,
2022, this study is open for enrollment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 73 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Our
competitors may obtain regulatory approval of their products more rapidly than us, or may obtain patent protection or other intellectual
property rights that limit our ability to develop or commercialize our current or future product candidates. Our competitors may also
develop drugs that are more effective, more convenient, more widely used and less costly, or have a better safety profile than our products;
and these competitors may also be more successful than us in manufacturing and marketing their products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">In
addition, we may need to develop our current or future product candidates in collaboration with diagnostic companies, and we will face
competition from other companies in establishing these collaborations. Our competitors will also compete with us in recruiting and retaining
qualified scientific, management and commercial personnel, establishing clinical trial sites and patient registration for clinical trials,
as well as in acquiring technologies complementary to, or necessary for, our programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Furthermore,
we also face competition more broadly across the market for cost-effective and reimbursable cancer treatments. The most common
methods of treating patients with cancer are surgery, radiation and drug therapy, including chemotherapy, hormone therapy and
targeted drug therapy, or a combination of such methods. There are a variety of available drug therapies marketed for cancer. In
many cases, these drugs are administered in combination to enhance efficacy. While our current or future product candidates, if </FONT>any,
are approved, may compete with these existing drug and other therapies, to the extent they are ultimately used in combination with,
or as an adjunct to, these therapies, our current or future product candidates may not be competitive with them. Some of these drugs
are branded and subject to patent protection, and others are available on a generic basis. Insurers and other third-party payors may
also encourage the use of generic products or specific branded products. We expect that if any of our current or future product
candidates are approved, they will be priced at a significant premium over competitive generic and branded generic products. As a
result, obtaining market acceptance of, and gaining significant share of the market for, any of our current or future product
candidates that we successfully introduce to the market will pose challenges. In addition, many companies are developing new
therapeutics, and we cannot predict what the standard of care will be as our current or future product candidates progress through
clinical development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">The
acquisition or licensing of pharmaceutical products is also very competitive. If we seek to acquire or license products, we will face
substantial competition from a number of more established companies, some of which have acknowledged strategies to license or acquire
products and many of which are bigger than us and have more institutional experience and greater cash flows than we have. These more
established companies may have competitive advantages over us, as may other emerging companies taking similar or different approaches
to product licenses and/or acquisitions. In addition, a number of established research- based pharmaceutical and biotechnology companies
may acquire products in late stages of development to augment their internal product lines, which may provide those companies with an
even greater competitive advantage.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Manufacturing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">We
do not have any manufacturing facilities or personnel. We currently rely, and expect to continue to rely, on a third-party manufacturers
including a single-manufacturer to make the NXP800 drug substance and a single-manufacturer to make the NXP800 drug product. With respect
to NXP900, to date, the drug substance has been manufactured by a non-GMP manufacturer for research purposes at lab scale.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">We
plan to continue to rely on third party manufacturers for the supply of NXP800 and NXP900, for manufacture of future additional product
candidates, for preclinical testing as well as for clinical trials and commercial manufacture if our current or future product candidates
receive marketing approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Commercialization</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Subject
to receiving marketing approvals, we expect to commence commercialization activities by building a focused sales and marketing organization
in the United States to sell our products. We believe that such an organization will be able to address the community of oncologists
who are the key specialists in treating the patient populations for which our current or future product candidates are being developed.
Outside the United States, we expect to enter into distribution and other marketing arrangements with third parties for any of our current
or future product candidates that obtain marketing approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 74 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">We
also plan to build a marketing and sales management organization to create and implement marketing strategies for any products that we
market through our own sales organization and to oversee and support our sales force. The responsibilities of the marketing organization
would include developing educational initiatives with respect to approved products and establishing relationships with researchers and
practitioners in relevant fields of medicine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Government
Regulation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B><I>Government
regulation of drugs in the United States</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">The
FDA and other regulatory authorities at federal, state and local levels, as well as in foreign countries, extensively regulate, among
other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging,
storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring and post-approval reporting
of drugs. We, along with our vendors, contract research organizations and contract manufacturers, will be required to navigate the various
preclinical, clinical, manufacturing and commercial requirements of the FDA, as well as of any other governing regulatory agency of the
countries in which we wish to conduct studies or seek approval of our current or future product candidates. The process of obtaining
regulatory approvals of drugs and ensuring subsequent compliance with appropriate federal, state, local and foreign statutes and regulations
requires the expenditure of substantial time and financial resources.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">In
the United States, the FDA regulates drug products under the Federal Food, Drug, and Cosmetic Act and its subsequent enactments, its
implementing regulations, and other laws. Our product candidates have not been approved by the FDA for marketing in the United States.
If we fail to comply with applicable FDA or other requirements at any time with respect to product development, clinical testing, approval
or any other legal requirements relating to product manufacture, processing, handling, storage, quality control, safety, marketing, advertising,
promotion, packaging, labeling, export, import, distribution, or sale, we may become subject to administrative or judicial sanctions
or other legal consequences. These sanctions or consequences could include, among other things, the FDA&rsquo;s refusal to approve pending
applications, the issuance of clinical holds for ongoing studies, suspension or revocation of approved applications, warning or untitled
letters, product withdrawals or recalls, product seizures, relabeling or repackaging, total or partial suspensions of manufacturing or
distribution, injunctions, fines, civil penalties or criminal prosecution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">The
process required by the FDA before a product candidate is approved as a drug for therapeutic indications in the United States generally
involves the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">completion
                                            of extensive preclinical studies in accordance with applicable regulations, including studies
                                            conducted in accordance with GLP requirements;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">submission
                                            to the FDA of an IND application;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">approval
                                            by an institutional review board (&ldquo;IRB&rdquo;) or independent ethics committee at each
                                            clinical trial site before each trial may be initiated;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">performance
                                            of adequate and well-controlled clinical trials in accordance with applicable FDA regulations
                                            commonly referred to as good clinical practice (&ldquo;GCP&rdquo;) requirements and any additional
                                            requirements for the protection of human research subjects and their health information,
                                            to establish the safety and efficacy of the investigational product for each proposed indication;
                                            submission of a NDA to FDA for marketing approval that includes sufficient evidence to establish
                                            the safety and effectiveness of the proposed drug product for its intended indication, including
                                            from results of nonclinical testing and clinical trials;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">a
                                            decision by the FDA to accept the NDA for review, and initiate a scientific review;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">satisfactory
                                            completion of one or more FDA pre-approval inspections of the manufacturing facility or facilities
                                            where the drug will be produced to assess compliance with current good manufacturing practice
                                            (&ldquo;cGMP&rdquo;) requirements to assure that the facilities, methods and controls are
                                            adequate to preserve the drug&rsquo;s identity, strength, quality, and purity;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">potential
                                            FDA inspection of the clinical trial sites that generated the data supporting the NDA;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">payment
                                            of user fees for FDA review of the NDA</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 75 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">review
                                            of the product candidate by an FDA advisory committee, where appropriate or if applicable;
                                            and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">FDA
                                            review and approval of the NDA.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">The
testing and approval process requires substantial time, effort, and financial resources, and we cannot be certain that any approvals
for our current or future product candidates will be granted on a timely basis, if at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Preclinical
and clinical trials for drugs</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Before
testing any drug in humans, a product candidate must undergo rigorous preclinical testing. Preclinical studies include laboratory
evaluations of drug chemistry, formulation and stability, as well as in vitro and animal studies to assess safety and address use
concerns. The conduct of preclinical studies is subject to federal and state regulations and requirements, including GCP
requirements for safety/toxicology studies. The results of the preclinical studies, together with manufacturing information and
analytical data must be submitted to the FDA as part of an IND application. An IND application is a request for authorization from
the FDA to administer an investigational product to humans and must become effective before clinical </FONT>trials may begin. Some
long-term preclinical testing may continue after the IND is submitted. An IND automatically becomes effective 30 days after receipt
by the FDA unless the FDA raises concerns or questions about any portion of the IND application and imposes a clinical hold. In such
a case, the IND sponsor and the FDA need to resolve any outstanding concerns before the clinical trial can begin. Submission of an
IND application may result in the FDA not allowing clinical trials to commence or not allowing clinical trials to commence on the
terms originally specified in the IND application. A separate submission to an existing IND must also be made for each successive
clinical trial conducted during product development of a product candidate, and the FDA must grant permission, either explicitly or
implicitly by not objecting, before each clinical trial can begin.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">The
clinical stage of development involves the administration of a product candidate to healthy volunteers or patients under the supervision
of qualified investigators, generally physicians not employed by or under the trial sponsor&rsquo;s control, in accordance with GCP requirements,
which include the requirements that all research subjects provide their informed consent for their participation in any clinical trial.
Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures,
subject selection and exclusion criteria and the parameters and criteria to be used in monitoring safety and evaluating efficacy. Each
protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND application. Furthermore, an
IRB representing each institution that is participating in the clinical trial must review and approve the plan for any clinical trial
before it commences at that institution, and the IRB must thereafter conduct a continuing review and reapprove the trial at least annually.
The IRB must review and approve, among other things, the trial protocol and informed consent information to be provided to clinical trial
subjects. An IRB must operate in compliance with FDA regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Information
about certain clinical trials, including details of the protocol and eventually study results, also must be submitted within
specific timeframes to the National Institutes of Health for public dissemination on the ClinicalTrials.gov data registry.
Information related to the product, patient population, phase of investigation, study sites and investigators and other aspects of
the clinical trial is made public as part of the registration of the clinical trial. Sponsors are also obligated to disclose the
results of their clinical trials </FONT>after completion. Disclosure of the results of these trials can be delayed in some cases for
up to two years after the date of completion of the trial. Failure to timely register a covered clinical study or to submit study
results as provided for in the law can give rise to civil monetary penalties and also prevent the non- compliant party from
receiving future grant funds from the federal government. The NIH&rsquo;s Final Rule&nbsp;on ClinicalTrials.gov registration and
reporting requirements became effective in 2017, and both NIH and FDA have signaled the government&rsquo;s willingness to begin
enforcing those requirements against non-compliant clinical trial sponsors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">A
sponsor who wishes to conduct a clinical trial outside of the United States may obtain FDA authorization to conduct the clinical trial
under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor must submit data from the clinical trial to the
FDA in support of an NDA. The FDA may accept a well-designed and well-conducted foreign clinical study not conducted under an IND if
the study was conducted in accordance with GCP requirements, and the FDA is able to validate the data through an onsite inspection if
deemed necessary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 76 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Clinical
development of product candidates to support NDAs are typically conducted in three sequential phases, which may overlap:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt"><U>Phase
                                            1</U>: The investigational product is initially introduced into healthy human volunteers.
                                            These studies are typically designed to test the safety, dosage tolerance, absorption, metabolism,
                                            excretion and distribution of the investigational product in humans, the side effects associated
                                            with increasing doses, and, if possible, to gain early evidence of efficacy. In the case
                                            of some products for severe or life-threatening diseases, such as cancer, especially when
                                            the product may be too inherently toxic to ethically administer to healthy volunteers, the
                                            initial human testing is often conducted in patients.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt"><U>Phase
                                            </U>2: This phase typically involves administration of the investigational product to a limited
                                            patient population with a specified disease or condition to determine optimal dosages, dosage
                                            tolerance and dosing schedule, to identify possible adverse side effects and safety risks,
                                            and to preliminarily evaluate the efficacy of the product candidate for specific targeted
                                            diseases.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 72pt"></TD><TD STYLE="font-size: 10pt; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt"><U>Phase
                                            3</U>: This phase typically involves administration of the investigational product to an
                                            expanded patient population to provide significant evidence of clinical efficacy and to further
                                            test for safety, generally at multiple and often geographically dispersed clinical trial
                                            sites. These clinical trials are intended to provide the primary basis for the overall risk/benefit
                                            ratio of the investigational
product and to enable regulatory decision-making of product approval and physician labeling. These trials may include comparisons with
placebo and/or other comparator treatments. The duration of treatment is often extended to mimic the actual use of a product during marketing.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Post-approval
trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These trials are used to
gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate
the performance of Phase 4 clinical trials as a condition of approval of an NDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Progress
reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse
events, or SAEs, occur. The FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a
finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate
approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the clinical protocol,
GCP, or other IRB requirements or if the drug has been associated with unexpected serious harm to patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Concurrent
with clinical trials, additional animal studies are often completed and additional information about the chemistry and physical characteristics
of the product candidate, including finalization of the process for manufacturing the drug product in commercial quantities in accordance
with cGMP requirements is generated. The manufacturing process must be capable of consistently producing quality batches of the product
candidate and manufacturers must develop, among other things, methods for testing the identity, strength, quality and purity of the final
drug product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate
that the product candidate does not undergo unacceptable deterioration over its shelf life.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Marketing
Approval in the United States</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Assuming
successful completion of the required clinical testing, the results of the preclinical studies and clinical trials, together with detailed
information relating to the product&rsquo;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted
to the FDA as part of an NDA requesting approval to market the product for one or more indications. An NDA is a request for approval
to market a new </FONT>drug for one or more specified indications and must contain proof of the drug&rsquo;s safety and efficacy. Data
may come from company-sponsored clinical trials intended to test the safety and efficacy of a product&rsquo;s use or from a number of
alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient
in quality and quantity to establish the safety and efficacy of the investigational product to the satisfaction of the FDA. Under federal
law, the fee for the submission of an NDA for which clinical data is substantial (for example, for FY2021 this application fee exceeds
$2.8 million), and for which the sponsor of an approved NDA is also subject to an annual program fee, is currently more than $300,000
per program. These fees are typically adjusted annually, but exemptions and waivers may be available under certain circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 77 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">The
FDA performs a preliminary review of the NDA within 60 days of receipt and informs the sponsor by the 74th day after the FDA&rsquo;s
receipt of the submission whether an application is sufficiently complete to permit substantive review. The FDA may request additional
information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information.
The resubmitted application is also subject to review before the FDA accepts it for filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">If
the NDA is filed, the FDA begins an in-depth substantive review of the NDA. The FDA reviews an NDA to determine, among other things,
whether the drug is safe and effective and whether the facility in which it is manufactured, processed, packaged or held meets standards
designed to assure the product&rsquo;s continued safety, quality and purity. Under the goals and policies agreed to by the FDA under
the Prescription Drug User Fee Act, or PDUFA, for original NDAs, the FDA has ten months from the filing date in which to complete its
initial review of a standard application and respond to the applicant, and six months from the filing date for an application with priority
review. For all new molecular entity, or NME, NDAs, the ten </FONT>and six-month time periods run from the filing date; for all other
original applications, the ten and six-month time periods run from the submission date. Despite these review goals, it is not uncommon
for FDA review of an NDA to extend beyond the goal date. The review process may be extended by the FDA for three additional months to
consider new information or in the case of a clarification provided by the applicant to address an outstanding deficiency identified
by the FDA following the original submission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Before
approving an NDA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve
an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate
to assure consistent production of the new drug product within required specifications. Additionally, before approving an NDA, the FDA
may inspect one or more clinical trial sites to assure compliance with GCP and other requirements and the integrity of the clinical data
submitted to the FDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">The
FDA also may require submission of a Risk Evaluation and Mitigation Strategies (&ldquo;REMS&rdquo;) plan to ensure that the benefits
of the drug outweigh its risks and to assure the safe use of the drug product. The REMS plan could include medication guides, physician
communication plans, assessment plans, and/or elements to assure safe use, such as restricted distribution methods, patient registries,
or other risk- minimization tools. The FDA determines the requirement for a REMS, as well as the specific REMS provisions, on a case-by-case
basis. If the FDA concludes a REMS is needed, the sponsor of the NDA must submit a proposed REMS. The FDA will not approve an NDA without
a REMS, if required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">The
FDA may refer any NDA to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other
scientific experts, which reviews, evaluates and provides a recommendation as to whether the application should be approved, and under
what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully
when making decisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Before
approving an NDA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve
an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate
to assure consistent production of the new drug product within required specifications. Additionally, before approving an NDA, the FDA
may inspect one or more clinical trial sites to assure compliance with GCP and other requirements and the integrity of the clinical data
submitted to the FDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">After
evaluating the NDA and all related information, the FDA may issue an approval letter or a complete response letter (&ldquo;CRL&rdquo;).
An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. A CRL
generally contains details on specific conditions that must be met to support approval of the NDA, often requiring additional clinical
or preclinical testing in order for the FDA to reconsider the application. Even with submission of this additional information, the FDA
ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when the conditions identified
in the CRL have been met to the FDA&rsquo;s satisfaction, the FDA may issue an approval letter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 78 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">If
a product receives regulatory approval from the FDA, the approval is limited to the conditions of use (e.g., patient population, indication)
described in the application. Further, depending on the specific risk(s)&nbsp;to be addressed, the FDA may limit the approved indications
for use of the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval
studies, including Phase 4 clinical trials, be conducted to further assess a drug&rsquo;s safety after approval, require testing and
surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution and use restrictions
or other risk management mechanisms under a REMS, which can materially affect the potential market and profitability of the product.
The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs.
After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes, and additional
labeling claims, are subject to further testing requirements and FDA review and approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Orphan
drug designation and exclusivity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Under
the Orphan Drug Act, the FDA may grant orphan designation to a drug intended to treat a rare disease or condition, which is a disease
or condition that affects fewer than 200,000 individuals in the United States, or if it affects more than 200,000 individuals in the
United States, but there is no reasonable expectation that the cost of developing and making the product available in the United States
for the disease or condition will be recovered from sales of the product. Orphan designation must be requested before submitting an NDA.
Orphan designation does not convey any advantage in or shorten the duration of the regulatory review and approval process, though companies
developing orphan products are eligible for certain incentives, including tax credits for qualified clinical testing and waiver of application
fees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">If
a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such
designation, the product is entitled to a seven-year period of marketing exclusivity during which the FDA may not approve any other applications
to market the same therapeutic agent for the same indication, except in limited circumstances. However, competitors may receive approval
of different therapeutic product candidates for the indication for which the orphan product has exclusivity or obtain approval for the
same therapeutic agent for a different indication than that for which the orphan product has exclusivity. Orphan product exclusivity
could block the approval of one of our products for seven years if a competitor obtains approval for the same therapeutic agent for the
same indication before we do, unless we are able to demonstrate that our product is superior. If an orphan designated product receives
marketing approval for an indication broader than what is designated, it may not be entitled to orphan exclusivity. Further, orphan drug
exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially
defective or the manufacturer of the approved product is unable to assure sufficient quantities of the product to meet the needs of patients
with the rare disease or condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Expedited
development and review programs</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">The
FDA is authorized to designate certain products for expedited development or review if they are intended to address an unmet medical
need in the treatment of a serious or life-threatening disease or condition. These programs include fast track designation, breakthrough
therapy designation and priority review designation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">A
new drug is eligible for fast track designation if it is intended to treat a serious or life-threatening disease or condition and demonstrates
the potential to address an unmet medical need for such disease or condition. Fast track designation provides increased opportunities
for sponsor interactions with the FDA during preclinical and clinical development, in addition to the potential for rolling review of
a marketing application once a marketing application is filed, meaning that the agency may review portions of the application before
the sponsor submits the complete application, as well as priority review, discussed below. In addition, a new drug may be eligible for
breakthrough therapy designation if it is intended, alone or in combination with one or more other drugs or biologics, to treat a serious
or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement
over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical
development. Breakthrough therapy designation provides all the features of fast track designation in addition to intensive guidance on
an efficient drug development program beginning as early as Phase 1, and FDA organizational commitment to expedited development, including
involvement of senior managers and experienced review staff in a cross-disciplinary review, where appropriate. Drugs or biologics designated
as breakthrough therapies are also eligible for accelerated approval of their respective marketing applications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 79 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Split-Segment; Name: 5 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Finally, the FDA may designate a product
for priority review if it is a drug or biologic that treats a serious condition and, if approved, would provide a significant improvement
in safety or effectiveness. The FDA determines at the time that the marketing application is submitted, on a case-by-case basis, whether
the proposed drug represents a significant improvement in treatment, prevention or diagnosis of disease when compared with other available
therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination
or substantial reduction of a treatment-limiting drug reaction, documented enhancement of patient compliance that may lead to improvement
in serious outcomes, or evidence of safety and effectiveness in a new subpopulation. A priority review designation is intended to direct
overall attention and resources to the evaluation of such applications, and to shorten the FDA&rsquo;s goal for taking action on a marketing
application from ten months to six months for a new molecular entity NDA from the date of filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Even if a product qualifies for one or
more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the
time period for FDA review or approval will not be shortened. Furthermore, fast track designation, breakthrough therapy designation and
priority review do not change the standards for approval and may not ultimately expedite the development or approval process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><B>Pediatric information and pediatric
exclusivity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Pediatric exclusivity is a type of non-patent
marketing exclusivity available in the United States and, if granted, it provides for the attachment of an additional six months of marketing
protection to the term of any existing regulatory exclusivity or listed patents. This six-month exclusivity may be granted if an NDA
sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the
product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA&rsquo;s
request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within
the statutory time limits, whatever statutory or regulatory periods of exclusivity or patent protection cover the product are extended
by six months. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA cannot approve
another application. The issuance of a written request does not require the sponsor to undertake the described studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><B>Post-approval requirements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Drugs manufactured or distributed pursuant
to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating
to recordkeeping, periodic reporting, product sampling and distribution, reporting of adverse experiences with the product, complying
with promotion and advertising requirements, which include restrictions on promoting products for unapproved uses or patient populations
(known as &ldquo;off-label use&rdquo;) and limitations on industry-sponsored scientific and educational activities. Although physicians
may prescribe legally available products for off- label uses, manufacturers may not market or promote such uses. The FDA and other agencies
actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly
promoted off-label uses may be subject to significant liability, including investigation by federal and state authorities. Prescription
drug promotional materials must be submitted to the FDA in conjunction with their first use or first publication. Further, if there are
any modifications to the drug, including changes in indications, labeling or manufacturing processes or facilities, the applicant may
be required to submit and obtain FDA approval of a new NDA or an NDA supplement, which may require the development of additional data
or preclinical studies and clinical trials. The FDA may also impose a number of post- approval requirements as a condition of approval
of an NDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">In addition, drug manufacturers and their
subcontractors involved in the manufacture and distribution of approved drugs are required to register their establishments with the
FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance
with ongoing regulatory requirements, including cGMP, which impose certain procedural and documentation requirements upon us and our
contract manufacturers. Failure to comply with statutory and regulatory requirements can subject a manufacturer to possible legal or
regulatory action, such as warning letters, suspension of manufacturing, product seizures, injunctions, civil penalties or criminal prosecution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 80 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Once an approval or clearance of a drug
is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems
occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of
unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in
revisions to the approved labeling to add new safety information, requirements for post-market studies or clinical trials to assess new
safety risks, or imposition of distribution or other restrictions under a REMS. Other potential consequences include, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify">restrictions
                                            on the marketing or manufacturing of the product, complete withdrawal of the product from
                                            the market or product recalls;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify">safety
                                            alerts, Dear Healthcare Provider letters, press releases or other communications containing
                                            warnings or other safety information about the product;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify">fines,
                                            warning letters or holds on post-approval clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify">refusal
                                            of the FDA to approve applications or supplements to approved applications, or suspension
                                            or revocation of product approvals;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify">product
                                            seizure or detention, or refusal to permit the import or export of products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify">injunctions
                                            or the imposition of civil or criminal penalties; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify">consent
                                            decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs;
                                            or mandated modification of promotional materials and labeling and issuance of corrective
                                            information.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><B>Other regulatory matters</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Manufacturing, sales, promotion and other
activities of product candidates following product approval, where applicable, or commercialization are also subject to regulation by
numerous regulatory authorities in the United States in addition to the FDA, which may include CMS, other divisions of the Department
of Health and Human Services, the Department of Justice, the Drug Enforcement Administration, the Consumer Product Safety Commission,
the Federal Trade Commission, the Occupational Safety&nbsp;&amp; Health Administration, the Environmental Protection Agency and state
and local governments and governmental agencies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><B>Other healthcare laws</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Healthcare
providers, physicians, and third-party payors will play a primary role in the recommendation and prescription of any products for
which we obtain marketing approval. Our business operations and any current or future arrangements with third-party payors,
healthcare providers and physicians may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations
that may constrain the business or financial arrangements and relationships through which we develop, market, sell and distribute
any drugs for which we obtain marketing approval. In the United States, these laws include, without limitation, state and federal
anti-kickback, false claims, physician transparency, and patient data privacy and security laws and regulations. For a description
of these risks, please see the section entitled &ldquo;Risk Factors.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><B>Insurance coverage and reimbursement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">In the United States and markets in other countries,
patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on
third-party payors to reimburse all or part of the associated healthcare costs. Thus, even if a product candidate is approved, sales
of the product will depend, in part, on the extent to which third-party payors, including government health programs in the United
States such as Medicare and Medicaid, commercial health insurers and managed care organizations, provide coverage, and establish
adequate reimbursement levels for the product. In the United States, the principal decisions about reimbursement for new medicines
are typically made by CMS. CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare and
private payors tend to follow CMS to a substantial degree. No uniform policy of coverage and reimbursement for drug products exists
among third-party payors. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. The
process for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting
the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors are
increasingly challenging the prices charged, examining the medical necessity, and reviewing the cost-effectiveness of medical
products and services and imposing controls to manage costs. Third-party payors may limit coverage to specific products on an
approved list, also known as a formulary, which might not include all of the approved products for a particular indication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 81 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">In order to secure coverage and reimbursement for any
product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate
the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable
regulatory approvals. Additionally, companies may also need to provide discounts to purchasers, private health plans or government
healthcare programs. Nonetheless, product candidates may not be considered medically necessary or cost effective. A decision by a
third-party payor not to cover a product could reduce physician utilization once the product is approved and have a material adverse
effect on sales, our operations and financial condition. Additionally, a third-party payor&rsquo;s decision to provide coverage for
a product does not imply that an adequate reimbursement rate will be approved. Further, one payor&rsquo;s determination to provide
coverage for a product does not assure that other payors will also provide coverage and reimbursement for the product, and the level
of coverage and reimbursement can differ significantly from payor to payor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The containment of healthcare costs has
become a priority of federal, state and foreign governments, and the prices of products have been a focus in this effort. Governments
have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and
requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive
policies in jurisdictions with existing controls and measures, could further limit a company&rsquo;s revenue generated from the sale
of any approved products. Coverage policies and third-party payor reimbursement rates may change at any time. Even if favorable coverage
and reimbursement status is attained for one or more products for which a company or its collaborators receive regulatory approval, less
favorable coverage policies and reimbursement rates may be implemented in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><B>Current and future healthcare reform
legislation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The FDA&rsquo;s and other regulatory
authorities&rsquo; policies may change and additional government regulations may be enacted that could prevent, limit or delay
regulatory approval of our current or future product candidates. For example, in December&nbsp;2016, the 21st Century Cures Act, or
Cures Act, was signed into law. The Cures Act, among other things, was intended to modernize the regulation of drugs and devices and
to spur innovation, but its ultimate implementation is uncertain. Legislative proposals continue to be discussed in the U.S.
Congress as potentially leading to a future &ldquo;Cures 2.0&rdquo; bill that is expected to have bipartisan support. In addition,
in August&nbsp;2017, the FDA Reauthorization Act was signed into law, which reauthorized the FDA&rsquo;s user fee programs and
included additional drug and biological product provisions. The next legislative reauthorization must be completed in 2022, which
has the potential to make further changes to FDA authorities or policies pertaining to biopharmaceutical products. If we are slow or
unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to
maintain regulatory compliance, we may lose any marketing approval that we otherwise may have obtained and we may not achieve or
sustain profitability, which would adversely affect our business, prospects, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">In recent years, there has been heightened
governmental scrutiny over the manner in which biopharmaceutical manufacturers set prices for their marketed products. Such scrutiny
has resulted in several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among
other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce
the cost of drugs under Medicare, and reform government program reimbursement methodologies for pharmaceutical products. Congress and
the executive branch have each indicated that it will continue to seek new legislative and/or administrative measures to control drug
costs, making this area subject to ongoing uncertainty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">At the state level in the United States, legislatures
have also increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including
price or patient reimbursement constraints, discounts, restrictions on certain product access, and marketing cost disclosure and
transparency measures, and in some cases, designed to encourage importation from other countries and bulk purchasing. In
December&nbsp;2020, the U.S. Supreme Court held unanimously that federal law does not preempt the states&rsquo; ability to regulate
pharmaceutical benefit managers, or PBMs, and other members of the healthcare and pharmaceutical supply chain, an important decision
that may lead to further and more aggressive efforts by states in this area.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 82 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">We cannot predict the likelihood, nature
or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United
States or abroad. We expect that additional federal, state, and foreign healthcare reform measures will be adopted in the future, any
of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result
in limited coverage and reimbursement and reduced demand for our products, once approved, or additional pricing pressures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><B>Other U.S. environmental, health and
safety laws and regulations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">We may be subject to numerous environmental,
health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and
disposal of hazardous materials and wastes. From time to time and in the future, our operations may involve the use of hazardous and
flammable materials, including chemicals and biological materials, and may also produce hazardous waste products. Even if we contract
with third parties for the disposal of these materials and waste products, we cannot completely eliminate the risk of contamination or
injury resulting from these materials. In the event of contamination or injury resulting from the use or disposal of our hazardous materials,
we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs
associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">We maintain workers&rsquo; compensation
insurance to cover us for costs and expenses we may incur due to injuries to our employees, but this insurance may not provide adequate
coverage against potential liabilities. However, we do not maintain insurance for environmental liability or toxic tort claims that may
be asserted against us. In addition, we may incur substantial costs in order to comply with current or future environmental, health and
safety laws and regulations. Current or future environmental laws and regulations may impair our research, development or production
efforts. In addition, failure to comply with these laws and regulations may result in substantial fines, penalties or other sanctions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><B><I>Government regulation of drugs outside
of the United States</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">To
market any product outside of the United States, we would need to comply with numerous and varying regulatory requirements of other
countries regarding safety and efficacy and governing, among other things, clinical trials, marketing authorization or
identification of an alternate regulatory pathway, manufacturing, commercial sales and distribution of our products. For instance,
in the European Economic Area (&ldquo;EEA&rdquo;) (comprised of the 28 EU Member States plus Iceland, Liechtenstein and Norway),
medicinal products must be authorized for marketing by using either the centralized authorization procedure or national
authorization procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify">Centralized
                                            procedure: If pursuing marketing authorization of a product candidate for a therapeutic indication
                                            under the centralized procedure, following the opining of the European Medicines Agency&rsquo;s
                                            (&ldquo;EMA&rdquo;) Committee for Medicinal Products for Human Use (&ldquo;CHMP&rdquo;) the
                                            European Commission issues a single marketing authorization valid across the EEA. The centralized
                                            procedure is compulsory for human medicines derived from biotechnology processes or advanced
                                            therapy medicinal products (such as gene therapy, somatic cell therapy and tissue engineered
                                            products), products that contain a new active substance indicated for the treatment of certain
                                            diseases, such as HIV/AIDS, cancer, neurodegenerative disorders, diabetes, autoimmune diseases
                                            and other immune dysfunctions, viral diseases, and officially designated orphan medicines.
                                            For medicines that do not fall within these categories, an applicant has the option of submitting
                                            an application for a centralized marketing authorization to the EMA, as long as the medicine
                                            concerned contains a new active substance not yet authorized in the EEA, is a significant
                                            therapeutic, scientific or technical innovation, or if its authorization would be in the
                                            interest of public health in the EEA. Under the centralized procedure, the maximum timeframe
                                            for the evaluation of an MAA (marketing authorization application) by the EMA is 210 days,
                                            excluding clock stops, when additional written or oral information is to be provided by the
                                            applicant in response to questions asked by the CHMP. Accelerated assessment might be granted
                                            by the CHMP in exceptional cases, when a medicinal product is expected to be of a major public
                                            health interest, particularly from the point of view of therapeutic innovation.
The timeframe for the evaluation of an MAA under the accelerated assessment procedure is 150 days, excluding clock stops.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 83 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify">National
                                            authorization procedures: There are also two other possible routes to authorize products
                                            for therapeutic indications in several countries, which are available for products that fall
                                            outside the scope of the centralized procedure:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify">Decentralized
                                            procedure &mdash; Using the decentralized procedure, an applicant may apply for simultaneous
                                            authorization in more than one EU country of medicinal products that have not yet been authorized
                                            in any EU country and that do not fall within the mandatory scope of the centralized procedure.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 17.65pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify">Mutual
                                            recognition procedure &mdash; In the mutual recognition procedure, a medicine is first authorized
                                            in one EU Member State, in accordance with the national procedures of that country. Following
                                            this, additional marketing authorizations can be sought from other EU countries in a procedure
                                            whereby the countries concerned recognize the validity of the original, national marketing
                                            authorization.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">In the EEA, new products for therapeutic
indications that are authorized for marketing (i.e., reference products) qualify for eight years of data exclusivity and an additional
two years of market exclusivity upon marketing authorization. The data exclusivity period prevents generic or biosimilar applicants from
relying on the preclinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar
marketing authorization in the EU during a period of eight years from the date on which the reference product was first authorized in
the EU. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EU
until ten years have elapsed from the initial authorization of the reference product in the EU. The ten-year market exclusivity period
can be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization holder
obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization,
are held to bring a significant clinical benefit in comparison with existing therapies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The criteria for designating an &ldquo;orphan
medicinal product&rdquo; in the EEA are similar in principle to those in the United States. In the EEA a medicinal product may be
designated as orphan if (1)&nbsp;it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically
debilitating condition; (2)&nbsp;either (a)&nbsp;such condition affects no more than five in 10,000 persons in the EU when the
application is made, or (b)&nbsp;the product, without the benefits derived from orphan status, would not generate sufficient return
in the EU to justify investment; and (3)&nbsp;there exists no satisfactory method of diagnosis, prevention or treatment of such
condition authorized for marketing in the EU, or if such a method exists, the product will be of significant benefit to those
affected by the condition. Orphan medicinal products are eligible for financial incentives such as reduction of fees or fee waivers
and are, upon grant of a marketing authorization, entitled to ten years of market exclusivity for the approved therapeutic
indication. During this ten-year orphan market exclusivity period, no marketing authorization application shall be accepted, and no
marketing authorization shall be granted for a similar medicinal product for the same indication. An orphan product can also obtain
an additional two years of market exclusivity in the EU for pediatric studies. The ten-year market exclusivity may be reduced to six
years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, for
example, if the product is sufficiently profitable not to justify maintenance of market exclusivity. Additionally, marketing
authorization may be granted to a similar product for the same indication at any time if (i)&nbsp;the second applicant can establish
that its product, although similar, is safer, more effective or otherwise clinically superior; (ii)&nbsp;the applicant consents to a
second orphan medicinal product application; or (iii)&nbsp;the applicant cannot supply enough orphan medicinal product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Similar to the United States, the various phases of
non-clinical and clinical research in the European Union are subject to significant regulatory controls. The Clinical Trials
Directive 2001/20/EC, the Directive 2005/28/EC on GCP and the related national implementing provisions of the individual EU Member
States govern the system for the approval of clinical trials in the European Union. Under this system, an applicant must obtain
prior approval from the competent national authority of the EU Member States in which the clinical trial is to be conducted.
Furthermore, the applicant may only start a clinical trial at a specific study site after the competent ethics committee has issued
a favorable opinion. The clinical trial application must be accompanied by, among other documents, an investigational medicinal
product dossier (the Common Technical Document) with supporting information prescribed by Directive 2001/20/ EC, Directive
2005/28/EC, where relevant the implementing national provisions of the individual EU Member States and further detailed in
applicable guidance documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 84 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">In April&nbsp;2014, the European Union adopted a new
Clinical Trials Regulation (EU) No 536/2014, which is set to replace the Clinical Trials Directive 2001/20/EC and will overhaul the
current system of approvals for clinical trials in the European Union. Specifically, the new regulation, which will be directly
applicable in all Member States (meaning that no national implementing legislation in each European Union Member State is required),
aims at simplifying and streamlining the approval of clinical trials in the European Union. For instance, the new Clinical Trials
Regulation provides for a streamlined application procedure via a single entry point and strictly defined deadlines for the
assessment of clinical trial applications. It is expected that the new Clinical Trials Regulation (EU) No 536/2014 will come into
effect following confirmation of full functionality of the Clinical Trials Information System, the centralized European Union portal
and database for clinical trials foreseen by the new Clinical Trials regulation, through an independent audit, which is currently
expected to occur in December&nbsp;2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">In addition, the collection, use, storage, disclosure,
transfer, or other processing of personal data regarding individuals in the EEA, including personal health data, is subject to the
General Data Protection Regulation 2016/679 (&ldquo;GDPR&rdquo;), which became effective on May&nbsp;25, 2018. The GDPR is
wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to
processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing
information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality
of personal data, providing notification of data breaches, and taking certain measures when engaging third-party processors. The
GDPR also imposes strict rules&nbsp;on the transfer of personal data to countries outside the European Union, including the United
States, and permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of
up to &euro;20 million or 4% of annual global revenues, whichever is greater. The GDPR also confers a private right of action on
data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain
compensation for damages resulting from violations of the GDPR. In addition, the GDPR includes restrictions on cross-border data
transfers. Compliance with the GDPR will be a rigorous and time-intensive process that may increase our cost of doing business or
require us to change our business practices, and despite those efforts, there is a risk that we may be subject to fines and
penalties, litigation, and reputational harm in connection with our European activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">There is significant uncertainty related
to the manner in which data protection authorities will seek to enforce compliance with GDPR. Additionally, if we utilize third party
distributors, compliance with such foreign governmental regulations would generally be the responsibility of such distributors, who may
be independent contractors over whom we have limited control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><B><I>Payment and reimbursement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Outside the United States, ensuring coverage
and adequate payment for a product also involves challenges. Pricing of prescription pharmaceuticals is subject to government control
in many countries. Pricing negotiations with government authorities can extend well beyond the receipt of regulatory approval for a product
and may require a clinical trial that compares the cost-effectiveness of a product to other available therapies. The conduct of such
a clinical trial could be expensive and result in delays in commercialization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">In the European Union, pricing and reimbursement
schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price
has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular
product candidate to currently available therapies or so-called health technology assessments, in order to obtain reimbursement or
pricing approval. For example, the European Union provides options for its member states to restrict the range of products for which
their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use.
European Union member states may approve a specific price for a product or it may instead adopt a system of direct or indirect
controls on the profitability of the company placing the product on the market. Other member states allow companies to fix their own
prices for products, but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Recently,
many countries in the European Union have increased the amount of discounts required on pharmaceuticals and these efforts could
continue as countries attempt to manage healthcare expenditures, especially in light of the severe fiscal and debt crises
experienced by many countries in the European Union. The downward pressure on healthcare costs in general, particularly prescription
products, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. Political,
economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after
reimbursement has been obtained. Reference pricing used by various European Union member states, and parallel trade, i.e., arbitrage
between low-priced and high-priced member states, can further reduce prices. There can be no assurance that any country that has
price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements
for any products, if approved in those countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 85 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><B><I>Brexit</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">On June&nbsp;23, 2016, the United Kingdom
(&ldquo;UK&rdquo;) held a referendum in which a majority of voters approved an exit from the EU (&ldquo;Brexit&rdquo;). After nearly
years of negotiation and political and economic uncertainty, the UK&rsquo;s withdrawal from the EU became effective on January&nbsp;31,
2020. There was a transitional period, during which EU laws, including pharmaceutical laws, continued to apply in the UK, however this
ended on December&nbsp;31, 2020. The UK and EU have signed an EU-UK trade and cooperation agreement (EU-UK Trade and Cooperation Agreement),
which became provisionally applicable on January&nbsp;1, 2021 and will become formally applicable once ratified by both the UK and the
EU. This agreement provides details on how some aspects of the UK and EU&rsquo;s relationship regarding medicinal products will operate,
particularly in relation to GMP, however there are still many uncertainties. Many of the regulations that now apply in the UK following
the transition period (including financial laws and regulations, taxes, intellectual property rights, data protection laws, supply chain
logistics, environmental, health and safety laws and regulations, medicine approval and regulations, immigration laws and employment
laws), will likely be amended in future as the UK determines its new approach, which may result in significant divergence from EU regulations.
This lack of clarity on future UK laws and regulations and their interaction with the EU laws and regulations increases our regulatory
burden of operating in and doing business with both the UK and the EU.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The long-term effects of Brexit will depend, in part,
on how the EU-UK Trade and Cooperation Agreement, and any future agreements signed by the UK and the EU, take effect in practice.
Such a withdrawal from the EU is unprecedented, and it is unclear how the restrictions on the UK&rsquo;s access to the European
single market for goods, capital, services and labor within the EU and the wider commercial, legal and regulatory environment, could
impact our current and future operations and clinical activities in the UK.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">We may also face new regulatory costs and
challenges that could have an adverse effect on our operations as a result of Brexit. Since the regulatory framework in the UK covering
quality, safety and efficacy of medicinal products, clinical trials, marketing authorization, commercial sales and distribution of medicinal
products is derived from EU directives and regulations, Brexit could materially impact the future regulatory regime with respect to the
approval of any of our product candidate or future product candidates in the UK. For instance, the UK will now no longer be covered by
the centralized procedure for obtaining EEA- wide marketing and manufacturing authorizations from the EMA for medicinal products and
a separate process for authorization of drug products will be required in the UK. For a period of two years from January&nbsp;1, 2021,
the MHRA may rely on a decision taken by the European Commission on the approval of a new marketing authorization in the centralized
procedure, in order to more quickly grant a UK marketing authorization, however a separate application will still be required. Any delay
in obtaining, or an inability to obtain, any regulatory approvals, as a result of Brexit or otherwise, would delay or prevent us from
commercializing our current or future product candidates in the UK and could restrict our ability to generate revenue from that market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">We expect that, now the transition period
has expired, Brexit could lead to legal uncertainty and potentially divergent national laws and regulations as the UK determines which
EU laws to replicate or replace, including those related to the regulation of medicinal products. Any of these effects of Brexit, and
others we cannot anticipate, could negatively impact our business and results of operations in the UK.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The uncertainty concerning the UK&rsquo;s
legal, political and economic relationship with the EU following Brexit may also be a source of instability in the international markets,
create significant currency fluctuations, and/or otherwise adversely affect trading agreements or similar cross-border co-operation arrangements
(whether economic, tax, fiscal, legal, regulatory or otherwise).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 86 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><B>Employees and Human Capital Management</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">As of June&nbsp;30, 2022, we had 10 full-time
employees. Additionally, we have retained and may retain in the future, a number of expert consultants and vendors that help navigate
us through and execute the different aspects of our business. We consider our relationship with our employees to be good and have not
experienced any work stoppages, slowdowns or other serious labor problems that have materially impeded our business operations. None
of our employees are represented by labor unions or covered by collective bargaining agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Our human capital management objectives
include, as applicable, identifying, recruiting, retaining, incentivizing, and integrating our new and existing employees. The principal
purpose of our equity incentive plan is to attract, retain, and motivate selected employees, consultants, and directors through the granting
of stock-based compensation awards and cash-based bonus awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><B>Facilities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">We believe that our current facilities
are adequate for our current needs and that suitable additional or substitute space at commercially reasonable terms will be available
as needed to accommodate any future expansion of our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><B>Legal proceedings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">From time to time, we may become involved
in legal proceedings arising in the ordinary course of our business, the resolution of which we do not anticipate would have a material
adverse impact on our financial position, results of operations or cash flows. However, there is no certainty that any such future litigation
that may arise would not have a material financial impact on our business. As of the date of this prospectus, we were not a party to
any material legal matters or claims.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 87 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="sp19"></A>Management</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The following table sets forth information
about our directors, executive officers and other senior management as of June&nbsp;30, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><B>Executive Officers and Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The following table sets forth certain
information about our directors and executive officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: #231F20 1pt solid; text-align: justify; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="border-top: #231F20 1pt solid; border-bottom: #231F20 1pt solid; width: 4%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Age</B></FONT></TD>
    <TD STYLE="border-top: #231F20 1pt solid; text-align: justify; width: 2%">&nbsp;</TD>
    <TD STYLE="border-top: #231F20 1pt solid; border-bottom: #231F20 1pt solid; width: 64%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Position</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ron Bentsur</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman, Chief Executive
    Officer and President</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enrique Poradosu</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Vice President,
    Chief Scientific and Business Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shay Shemesh</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Vice President,
    Chief Operations&nbsp;&amp; Development Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kenneth Hoberman</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Matthew Kaplan</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: #231F20 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James F. Oliviero</FONT></TD>
    <TD STYLE="border-bottom: #231F20 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</FONT></TD>
    <TD STYLE="border-bottom: #231F20 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: #231F20 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><B>Executive Officers and Senior Management</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ron
Bentsur (56), Co-Founder, Chairman, Chief Executive Officer and President of Nuvectis</B></FONT>, has over 20 years of senior leadership
experience in the biotechnology industry. He served as CEO of UroGen Pharma,&nbsp;Inc. (NASDAQ: URGN) from August&nbsp;2015 until January&nbsp;2019,
and as CEO of Keryx Biopharmaceuticals,&nbsp;Inc. (NASDAQ: KERX, acquired by Akebia Therapeutics) from May&nbsp;2009 until May&nbsp;2015.
At UroGen and Keryx, Mr.&nbsp;Bentsur led the clinical development, regulatory approvals and the commercial infrastructure buildouts
for the US commercial launches of Jelmyto and Auryxia, respectively. Mr.&nbsp;Bentsur also led the establishment of a successful worldwide
partnership for an earlier-stage program at UroGen and an ex-US development partnership for Auryxia at Keryx. Mr.&nbsp;Bentsur served
as CEO of XTL Biopharmaceuticals,&nbsp;Inc. (NASDAQ: XTLB) from January&nbsp;2006 until April&nbsp;2009 and as Investor Relations and
CFO of Keryx from October&nbsp;2000 until January&nbsp;2006. Mr.&nbsp;Bentsur worked as an investment banker in NYC and Tel Aviv,&nbsp;Israel,
from 1994 until 2000. Mr.&nbsp;Bentsur served as a member of the Board of Directors of Stemline Therapeutics,&nbsp;Inc. from 2009 through
the approval and launch of Elzonris&reg; and through the subsequent acquisition of the company by Menarini in June&nbsp;2020, and serves
on the Board of Directors of Beyond Air,&nbsp;Inc. (NASDAQ: XAIR). Mr.&nbsp;Bentsur holds a BA in Economics and Business Administration
with distinction from the Hebrew University of Jerusalem,&nbsp;Israel and an MBA (<I>Magna Cum Laude</I>), from New York University&rsquo;s
Stern School of Business. Mr.&nbsp;Bentsur has been selected to serve on our Board of Directors based on his years of experience in the
biotechnology industry and extensive management experience.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Enrique
Poradosu, PhD (56), Co-Founder, Executive Vice President, Chief Scientific and Business Officer of Nuvectis</B></FONT>, has over 20 years
of senior scientific leadership experience in the biotechnology industry. From January&nbsp;2016 until December&nbsp;2020, he served
as SVP, Business and Scientific Strategy at Stemline Therapeutics,&nbsp;Inc. (NASDAQ: STML, acquired by Menarini in June&nbsp;2020).
At Stemline Dr.&nbsp;Poradosu led the licensing and scientific strategy of the company&rsquo;s pipeline, as well as directly leading
strategic planning and operational execution of the early-stage drug development programs. Prior to that, Dr.&nbsp;Poradosu served as
VP Business and Scientific Strategy at Keryx Biopharmaceuticals,&nbsp;Inc. (NASDAQ: KERX), acquired by Akebia Therapeutics (NASDAQ: AKBA)),
from 2003 until 2016. From 1998 until 2003, Dr.&nbsp;Poradosu served as a project manager at a private biomedical incubator. Dr.&nbsp;Poradosu
holds a BSc in Chemistry and Biology with distinction from the Hebrew University of Jerusalem,&nbsp;Israel and a PhD in Biochemistry,
from the Hebrew University of Jerusalem.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 88 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shay
Shemesh (39), Co-Founder, Executive Vice President, Chief Development Officer of Nuvectis</B></FONT>, has over 15 years of multi-disciplinary
experience in drug development. From 2015 until 2020, he served as SVP, Clinical and Regulatory Affairs at Stemline Therapeutics,&nbsp;Inc.
(NASDAQ: STML, acquired by Menarini in June&nbsp;2020) where he led multi-disciplinary development teams in early and late-stage projects.
In this role, Mr.&nbsp;Shemesh held responsibilities for the strategic planning and operational execution of the Elzonris<SUP>&reg;</SUP>
Biologics License Application, with the FDA and Marketing Authorization Application with EMA, resulting in the approval of Elzonris&trade;
in both regions for the treatment of blastic plasmacytoid dendritic cell neoplasm, an orphan hematologic malignancy. Prior to that, Mr.&nbsp;Shemesh
was a clinical operations lead at Keryx Biopharmaceuticals (NASDAQ: KERX, acquired by Akebia Therapeutics (NASDAQ: AKBA)), where he managed
the late-stage clinical trials for Auryxia&trade; for the treatment of anemia in patients with non- dialysis CKD, which led to the approval
of Auryxia in this indication in the US and the EU. Mr.&nbsp;Shemesh holds a BSc and MSc in Biotechnology from Bar Ilan University in
Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><B>Non-Employee Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Kenneth
Hoberman (57), Director</B></FONT>, joined our Board of Directors in July&nbsp;2021. Mr.&nbsp;Hoberman has extensive financial, investor
relations, corporate governance, operational, and business development experience including M&amp;A, strategic alliances and partnerships
both domestic and international. Mr.&nbsp;Hoberman has served as the Chief Operating Officer of Stemline Therapeutics,&nbsp;Inc. (&ldquo;Stemline&rdquo;)
since 2013, where he negotiated and closed several licensing agreements and was responsible for multiple vendor contracts. While at Stemline,
he helped lead the company from an early-stage drug development company to a fully integrated commercial entity, including through Stemline&rsquo;s
successful initial public offering. Mr.&nbsp;Hoberman directed all Stemline&rsquo;s functional groups, including manufacturing, commercial,
regulatory, R&amp;D, medical affairs, public and investor relations, HR and finance. Mr.&nbsp;Hoberman also led the M&amp;A transaction
which resulted in the sale of Stemline to the Menarini Group in June&nbsp;2020 for approximately $750 million. He was previously Vice
President of Corporate and Business Development of Keryx Biopharmaceuticals,&nbsp;Inc., where he initiated and executed a Japanese partnership
valued at up to $100 million, and originated, negotiated and closed dozens of licensing and operational contracts, including the licensing
of Auryxia&trade;, which was approved by the FDA in September&nbsp;2014. He is on the Board of Directors of TG Therapeutics,&nbsp;Inc.
(Nasdaq: TGTX). He received a B.S.B.A. in Finance from Boston University and completed post- baccalaureate studies at Columbia University.
Mr.&nbsp;Hoberman has been selected to serve on our Board of Directors based on his extensive experience in the biopharmaceutical industry
and in-depth understanding of our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Matthew
L. Kaplan (54), Director</B></FONT>, joined our Board of Directors in September&nbsp;2021. Mr.&nbsp;Kaplan is an experienced Equity
Analyst with deep knowledge in biotechnology, particularly for analysis and advisement of early-stage companies. With 24 years of
experience as an Equity Analyst, since 2008, he has been a Managing Director and the Head of Healthcare Equity Research at Ladenburg
Thalmann&nbsp;&amp; Co. Prior to joining Ladenburg Thalmann&nbsp;&amp; Co., he was a Partner and the Director of Healthcare Research
with Punk, Ziegel&nbsp;&amp; Company, a Senior Biotechnology Analyst at Evolution Capital, and a Director of The Life Sciences Group
at The Carson Group. Mr.&nbsp;Kaplan has received numerous citations as a top ranked Biotechnology Stock Picker by Thomson Reuters,
The Financial Times, and Forbes. Mr.&nbsp;Kaplan also spent six years as a Research Associate with the Albert Einstein College of
Medicine / Montefiore Hospital Department of Cardiology, where he co-authored numerous articles on gene regulation in the heart.
Mr.&nbsp;Kaplan received his BS in Biology from the University of Michigan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>James
F. Oliviero,&nbsp;III (45), Director</B></FONT>, joined our Board of Directors in July&nbsp;2021. Mr.&nbsp;Oliviero has over twenty
years of operational experience in the biotechnology industry. Since 2015, Mr.&nbsp;Oliviero has served as the President and Chief
Executive Officer of Checkpoint Therapeutics,&nbsp;Inc. (NASDAQ: CKPT), where he has completed over $100 million in private and
public financings for the company to date, while designing and overseeing the company&rsquo;s development programs for its novel
immuno-oncology and targeted therapy, a type of cancer treatment that precisely identifies and attacks a specific pathway of cancer
cells, product candidates being evaluated for the treatment of several solid tumor cancer indications. Prior to Checkpoint, from
May&nbsp;2003 to September&nbsp;2015, Mr.&nbsp;Oliviero served in a variety of leadership capacities at Keryx
Biopharmaceuticals,&nbsp;Inc., which was subsequently acquired by Akebia. His most recent position at Keryx, beginning in
April&nbsp;2009, was as Chief Financial Officer, responsible for all of the finance, accounting, investor relations, corporate
governance and legal matters and was also involved in the clinical and regulatory development of Auryxia<SUP>&reg;</SUP>, which
successfully obtained FDA approval in 2014. From August&nbsp;1999 to May&nbsp;2003, Mr.&nbsp;Oliviero was Director of Finance for
ACCESS Oncology,&nbsp;Inc., a privately held biotechnology company. Mr.&nbsp;Oliviero began his professional career as an investment
banker at Furman Selz LLC in New York City. Mr.&nbsp;Oliviero is a CFA charterholder and holds a B.B.A. in Finance with Highest
Distinction from Emory University&rsquo;s Goizueta Business School. Mr.&nbsp;Oliviero has been selected to serve on our Board of
Directors based on his extensive experience in the biotechnology industry and in-depth understanding of our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 89 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Election of Officers and Family Relationships</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Our executive officers are appointed by,
and serve at the discretion of, our board of directors. There are no family relationships among any of our directors or executive officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Board Composition</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Our bylaws provide that our board of directors
shall consist of between one and nine directors, which number shall be fixed from time to time by resolution of our board of directors.
Currently our board of directors consists of Ron Bentsur, Kenneth Hoberman, James Oliviero, and Matthew Kaplan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Our bylaws also provide that our directors
may be removed with or without cause by the affirmative vote of the holders of at least two-thirds of the votes that all our stockholders
would be entitled to cast in an annual election of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Our current and future executive officers
and significant employees serve at the discretion of our Board. Our Board may also choose to form certain committees, such as a compensation
committee and an audit committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Director Independence</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Our board of directors has determined that
Kenneth Hoberman, Matthew Kaplan and James Oliviero are independent directors. In making this determination, our board of directors applied
the standards set forth in the rules&nbsp;of Nasdaq and in Rule&nbsp;10A-3 under the Exchange Act. Our board of directors considered
all relevant facts and circumstances known to it in evaluating the independence of these directors, including their current and historical
employment, any compensation we have given to them, any transactions we have with them, their beneficial ownership of our capital stock,
their ability to exert control over us, all other material relationships they have had with us and the same facts with respect to their
immediate families.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Although there is no specific policy regarding
diversity in identifying director nominees, the board of directors seek the talents and backgrounds that would be most helpful to us
in selecting director nominees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Board Leadership Structure</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Mr.&nbsp;Ron Bentsur, our Chief Executive
Officer, is also the Chairman of our board of directors. Our corporate governance guidelines provide our board of directors with flexibility
to select the appropriate leadership structure at a particular time based on what our board of directors determines to be in the best
interests of the Company. Our board of directors determined that, at the present time, having our Chief Executive Officer also serve
as the Chairman of our board of directors provides us with optimally effective leadership and is in our best interests and those of our
stockholders. Twenty years of management experience in our industry as well as his extensive understanding of our business, operations,
and strategy make him well qualified to serve as chairman of our board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Board Oversight of Risk</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Risk assessment and oversight are an integral
part of our governance and management processes. Our board of directors encourages management to promote a culture that incorporates
risk management into our corporate strategy and day-to-day business operations. Management discusses strategic and operational risks
at regular management meetings and conducts specific strategic planning and review sessions during the year that include a focused discussion
and analysis of the risks facing us. Throughout the year, senior management reviews these risks with the board of directors at regular
board meetings as part of management presentations that focus on particular business functions, operations or strategies, and presents
the steps taken by management to mitigate or eliminate such risks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 90 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Our board of directors will not have a
standing risk management committee, but will rather administer this oversight function directly through our board of directors as a whole,
as well as through various standing committees of our board of directors that address risks inherent in their respective areas of oversight.
In particular, our board of directors is responsible for monitoring and assessing strategic risk exposure. Our audit committee will coordinate
the board of director&rsquo;s oversight of our internal control over financial reporting, disclosure controls and procedures, related-party
transactions and code of conduct and corporate governance guidelines. Our compensation committee will assess and monitor whether any
of our compensation policies and programs has the potential to encourage excessive risk-taking as well as succession planning as it relates
to our Chief Executive Officer. While each committee will be responsible for evaluating certain risks and overseeing the management of
such risks, our entire board of directors will be regularly informed through committee reports about such risks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Board Committees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has established an audit committee and compensation committee, each of which will operate pursuant to a charter adopted
by our board of directors. Our board of directors may also establish other committees from time to time to assist the management of our
business. The composition and functions of each committee are described below. Members serve on these committees until their resignation
or until otherwise determined by our board of directors. Each committee has adopted a written charter that satisfies the applicable
rules&nbsp;and regulations of the Sarbanes-Oxley Act, the SEC and Nasdaq Listing Rules, which we have posted on our website at </FONT>www.nuvectis.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Audit Committee</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Our audit committee consists of Kenneth
Hoberman, Matthew Kaplan and James Oliviero, with James Oliviero serving as chair. Our board of directors has determined that each member
of the audit committee has sufficient knowledge in financial and auditing matters to serve on the Audit Committee. Our board of directors
has determined James Oliviero qualifies as an &ldquo;audit committee financial expert,&rdquo; as defined under the applicable rules&nbsp;of
the SEC. In making this determination, our board has considered prior experience, business acumen and independence. The audit committee&rsquo;s
responsibilities include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify">evaluating
                                            the performance, independence and qualifications of our independent auditors and determining
                                            whether to retain our existing independent auditors or engage new independent auditors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify">reviewing
                                            and approving the engagement of our independent auditors to perform audit services and any
                                            permissible non-audit services;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify">monitoring
                                            the rotation of partners of our independent auditors on our engagement team as required by
                                            law;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify">prior
                                            to engagement of any independent auditor, and at least annually thereafter, reviewing relationships
                                            that may reasonably be thought to bear on their independence, and assessing and otherwise
                                            taking the appropriate action to oversee the independence of our independent auditor;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify">reviewing
                                            our annual and quarterly financial statements and reports, including the disclosures contained
                                            under the caption &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition
                                            and Results of Operations,&rdquo; and discussing the statements and reports with our independent
                                            auditors and management;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify">reviewing,
                                            with our independent auditors and management, significant issues that arise regarding accounting
                                            principles and financial statement presentation and matters concerning the scope, adequacy
                                            and effectiveness of our financial controls;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify">reviewing
                                            with management and our independent auditors any earnings announcements and other public
                                            announcements regarding material developments;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify">establishing
                                            procedures for the receipt, retention and treatment of complaints received by us regarding
                                            financial controls, accounting or auditing matters and other matters;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 91 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify">preparing
                                            the report that the SEC requires in our annual proxy statement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify">reviewing
                                            and providing oversight of any related-person transactions in accordance with our related-
                                            person transaction policy and reviewing and monitoring compliance with legal and regulatory
                                            responsibilities, including our code of business conduct and ethics;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify">reviewing
                                            our major financial risk exposures, including the guidelines and policies to govern the process
                                            by which risk assessment and risk management are implemented;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify">reviewing
                                            on a periodic basis our investment policy; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify">reviewing
                                            and evaluating on an annual basis the performance of the audit committee and the audit committee
                                            charter.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Compensation Committee</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Our compensation committee consists of
Kenneth Hoberman, Matthew Kaplan and James Oliviero, with Kenneth Hoberman serving as chair. Our board of directors has determined that
each of the members of our compensation committee is a non-employee director, as defined in Rule&nbsp;16b-3 promulgated under the Exchange
Act, and satisfies the Nasdaq independence requirements. The functions of this committee include, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify">reviewing
                                            and approving our philosophy, policies and plans with respect to the compensation of our
                                            chief executive officer;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify">making
                                            recommendations to our board of directors with respect to the compensation of our chief executive
                                            officer and our other executive officers;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify">reviewing
                                            and assessing the independence of compensation advisors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify">overseeing
                                            and administering our equity incentive plans;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify">reviewing
                                            and making recommendations to our board of directors with respect to director compensation;
                                            and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify">preparing
                                            the Compensation Committee reports required by the SEC, including our &ldquo;Compensation
                                            Discussion and Analysis&rdquo; disclosure.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">We believe that the composition and functioning
of our compensation committee complies with all applicable requirements of the Sarbanes-Oxley Act, and all applicable SEC and Nasdaq
rules&nbsp;and regulations. We intend to comply with future requirements to the extent they become applicable to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Nominating and Corporate Governance
Matters</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Our board of directors
does not currently have a nominating and corporate governance committee or other committee performing a similar function, nor do we
have any formal written policies outlining the factors and process relating to the selection of nominees for consideration for
membership on our board of directors by our directors or our stockholders. Our board of directors has adopted resolutions in
accordance with the rules&nbsp;of The Nasdaq Stock Market authorizing a majority of our independent members to recommend qualified
director nominees for consideration by the board of directors. Our board of directors believes that it is appropriate for us to not
have a standing nominating and corporate governance committee because of a number of factors, including the number of independent
members who want to participate in consideration of candidates for membership on our board of directors and in matters that relate
to the corporate governance of our company. Our board of directors consists of four members, three of whom are independent. Our
board of directors considered forming a nominating and corporate governance committee consisting of several of the independent
members of our board of directors. Forming a committee consisting of less than all of the independent members was unattractive
because it would have omitted the other independent members of our board of directors who wanted to participate in considering
qualified candidates for board membership and to have input on corporate governance matters related to our company. Since our board
of directors desired the participation in the nominations process of all of its independent directors, it therefore decided not to
form a nominating and corporate governance committee and instead authorized a majority of the independent members of our board of
directors to make and consider nominations for membership to our board of directors. The independent members of our board of
directors do not have a nominating and corporate governance committee charter, but act pursuant to board of director resolutions as
described above. Each of the members of our board of directors authorized to recommend director nominees is independent within the
meaning of the current &ldquo;independent director&rdquo; standards established by The Nasdaq Stock Market rules. Our board of
directors intends to review this matter periodically, and may in the future elect to designate a formal nominating and corporate
governance committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 92 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Compensation Committee Interlocks and
Insider Participation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">None of our current or former executive
officers serve as a member of the compensation committee. None of our officers serve, or have served during the last completed fiscal
year, on the board of directors or compensation committee, or other committee serving an equivalent function, of any other entity that
has one or more of its executive officers serving as a member of our board of directors or our compensation committee. For a description
of transactions between us and members of our compensation committee and affiliates of such members, please see &ldquo;Certain Relationships
and Related-Party Transactions.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Code of Business Conduct and Ethics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have adopted a written code of business conduct, that applies to our directors, officers and employees, including our principal executive
officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. A copy of
the code is posted on our website at </FONT>www.nuvectis.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Director Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Our directors receive an annual cash retainer
of $40,000, payable in quarterly installments on the last day of each calendar quarter, with prorated payment for any partial quarters.
Each member of the Compensation Committee and Audit Committee also receives an additional $5,000 annual fee for membership on each committee,
with the Chairs of the Audit and Compensation Committees receiving $15,000, payable in quarterly installments on the last day of each
calendar quarter, with prorated payment for any partial quarters. Directors also received (i)&nbsp;an initial equity grant of 29,250
options to purchase our Common Stock, with an exercise price of $3.05 per option and (ii)&nbsp;annual option grants valued at approximately
$150,000. All option grants will vest in 3 years, with 1/3 of the granted options of each grant vesting on the first, second and third
anniversaries of the date of such grant. respectively. The Board has full discretion with respect to the annual grants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 93 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B><A NAME="sp18"></A>Executive Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The following are our employment arrangements
with our executive officers as of the end of our most recently completed fiscal year:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Ron Bentsur</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Annual Base Salary</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Mr.&nbsp;Bentsur&rsquo;s annual base salary
is $575,000 per annum, paid monthly in equal installments, which commenced on the consummation of our initial public offering. On an
annual basis, as of the first of January&nbsp;following the Company&rsquo;s initial public offering, and in any event on each January&nbsp;1
thereafter, the amount of Mr.&nbsp;Bentsur&rsquo;s salary shall be increased by no less than the greater of (1)&nbsp;the amount determined
by the Company&rsquo;s Compensation Committee, or (2)&nbsp;the relevant consumer price index (&ldquo;CPI&rdquo;). Mr.&nbsp;Bentsur did
not receive any cash compensation in 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Annual Bonus</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Mr.&nbsp;Bentsur&rsquo;s annual bonus target
will be 75% of his annual base salary, based on the achievement of corporate goals&nbsp;&amp; objectives, paid no later than March&nbsp;15
following such bonus performance calendar year period. The Board or Compensation Committee shall have the discretion to pay Mr.&nbsp;Bentsur
an annual performance bonus in excess of the target for performance exceeding goals, which bonus may be awarded without proration in
the event of a partial contract year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Equity Awards</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Mr.&nbsp;Bentsur will be eligible for grants
of equity awards under the Company&rsquo;s long-term equity incentive plan. On the Effective Date, the Company shall award the following
to the Mr.&nbsp;Bentsur:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 16.4pt">(i)</TD><TD STYLE="text-align: justify">restricted shares of Common Stock upon the consummation of the earlier
                                            of (a)&nbsp;initial public offering (&ldquo;IPO&rdquo;) raising at least $15 million in gross
                                            proceeds, or (b)&nbsp;capital raising of at least $15 million in a private equity financing,
equal to 1% of the fully-diluted share count immediately preceding such IPO/financing event, which milestone was met on July&nbsp;27,
2021 in connection with the closing of the $15.3 million Preferred A round and Mr.&nbsp;Bentsur was granted 96,759 shares of restricted
stock which will vest and become fully exercisable on January&nbsp;1, 2023; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 16.45pt">(ii)</TD><TD STYLE="text-align: justify">fully vested shares of Common Stock equal to 1% of the then fully
                                            diluted share count of the Company when the Company reaches an average market capitalization
                                            over a 30-day period of $350 million or higher.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Termination Provisions</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In the event that Mr.&nbsp;Bentsur is terminated
without Cause, for Good Reason, Change of Control, Death or Disability, as each such term is defined in Mr.&nbsp;Bentsur&rsquo;s employment
agreement, all unvested shares of restricted stock and options shall be immediately accelerated and become fully vested and unrestricted/
exercisable. Upon termination for Cause, all unvested shares of restricted shock shall expire and terminate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">If Mr.&nbsp;Bentsur resigns for Good Reason or is
terminated due to Death or Disability, Change of Control, or otherwise terminated without Cause, then Mr.&nbsp;Bentsur or his estate
or beneficiaries, in the case of Death or Disability, will receive a one-time payment equal to two years of Mr.&nbsp;Bentsur&rsquo;s
then annual base salary, plus a bonus payment equal to the annual bonus earned in the preceding year (if not already paid), the pro
rata portion of the target bonus earned in the current year, benefits and expense reimbursement due to Mr.&nbsp;Bentsur, payment in
lieu of any accrued but unused vacation time, payment of any unreimbursed expenses, and continued coverage through the longest
applicable limitations period under the Company&rsquo;s directors and officers insurance policies, all such payments to be made
within 60 (sixty) days of the date of termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 94 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Executive Compensation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Notwithstanding the above the Company may
terminate Mr.&nbsp;Bentsur&rsquo;s employment hereunder at any time, immediately, for Cause, upon written notice to Mr.&nbsp;Bentsur.
If Mr.&nbsp;Bentsur&rsquo;s employment is terminated for Cause, he shall be entitled to receive (i)&nbsp;the unpaid portion of his base
salary then in effect accrued through the effective date of the termination of his employment hereunder, and (ii)&nbsp;payment for any
unused vacation days which have accrued through the effective date of the termination of Mr.&nbsp;Bentsur&rsquo;s employment, in each
case to be paid within 30 (thirty) days after such effective date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In the event that a &ldquo;<I>Transaction</I>&rdquo;
(as such term is defined in the Company&rsquo;s Global Equity Incentive Plan, as amended from time to time, or a successor plan) occurs
during Mr.&nbsp;Bentsur&rsquo;s employment, regardless of whether Mr.&nbsp;Bentsur&rsquo;s employment is terminated, Mr.&nbsp;Bentsur
shall receive payment of the termination benefits described above as if his employment had been terminated on the effective date of the
Transaction. Following the Transaction, Mr.&nbsp;Bentsur shall not be entitled to receive such termination benefits upon a future termination
of his employment; provided that he shall remain eligible to receive (i)&nbsp;any accrued benefits upon any such subsequent termination,
and (ii)&nbsp;cash payments, paid in periodic installments in accordance with the Company&rsquo;s usual payroll practices, for a period
of 18 months, equal to the cost the Company would have incurred had Mr.&nbsp;Bentsur continued group medical, dental, vision and/or prescription
drug benefit coverage for himself and/or his eligible dependents under any Company sponsored group health plan covering Mr.&nbsp;Bentsur
and his eligible dependents at the time of the termination of employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Enrique Poradosu</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Annual Base Salary</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Mr.&nbsp;Poradosu&rsquo;s annual base salary
is $400,000 per annum, paid monthly in equal installments, which commenced on the consummation of our initial public offering. On an
annual basis, as of the first January&nbsp;following the Company&rsquo;s initial public offering, and in any event on each January&nbsp;1
thereafter, the amount of Mr.&nbsp;Poradosu&rsquo;s salary shall be increased by no less than the greater of (1)&nbsp;the amount determined
by the Company&rsquo;s Compensation Committee, or (2)&nbsp;the relevant CPI.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In 2021, Mr.&nbsp;Poradosu received cash
compensation of $27,083.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Annual Bonus</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Mr.&nbsp;Poradosu&rsquo;s annual bonus
target shall be 50% of the annual base salary, based on the achievement of corporate goals&nbsp;&amp; objectives, paid no later than
March&nbsp;15 following such bonus performance calendar year period. The Board or Compensation Committee shall have the discretion to
pay Mr.&nbsp;Poradosu an annual performance bonus in excess of the target for performance exceeding goals, which bonus may be awarded
without proration in the event of a partial contract year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Equity Awards</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Mr.&nbsp;Poradosu will be eligible for
grants of equity awards under the Company&rsquo;s long-term equity incentive plan. On the Effective Date, the Company shall award the
following to the Mr.&nbsp;Poradosu:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 16.4pt">(i)</TD><TD STYLE="text-align: justify">restricted shares of Common Stock upon the consummation of the earlier
                                            of (a)&nbsp;IPO raising at least $15 million in gross proceeds, or (b)&nbsp;capital raising
                                            of at least $15 million in a private equity financing, equal to 0.5% of the fully-diluted
                                            share count immediately preceding such IPO/financing event, which milestone was met on July&nbsp;27,
                                            2021 in connection with the closing of the $15.3 million Preferred A round and Mr.&nbsp;Poradosu
                                            was granted 48,399 shares of restricted stock, which will vest and become fully exercisable
                                            on January&nbsp;1, 2023; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 95 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Executive Compensation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 16.45pt">(ii)</TD><TD STYLE="text-align: justify">fully vested shares of Common Stock equal to 0.5% of the then fully
                                            diluted share count of the Company when the Company reaches an average market capitalization
                                            over a 30-day period of $350 million or higher.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Termination Provisions</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In the event that Mr.&nbsp;Poradosu&rsquo;s
is terminated without Cause, for Good Reason, Change of Control, Death or Disability (as such terms are defined in Mr.&nbsp;Poradosu&rsquo;s
employment agreement) all unvested shares of restricted stock and options shall be immediately accelerated and become fully vested and
unrestricted/ exercisable. Upon termination for Cause, all unvested shares of restricted shock shall expire and terminate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">If Mr.&nbsp;Poradosu resigns for Good Reason or is terminated
due to Death or Disability, Change of Control, or otherwise terminated without Cause, Mr.&nbsp;Poradosu or his estate or beneficiaries,
in the case of Death or Disability, will receive a one-time payment equal to two years of Mr.&nbsp;Poradosu&rsquo;s then annual Base
Salary, plus a bonus payment equal to Mr.&nbsp;Poradosu&rsquo;s annual bonus earned in the preceding year if not already paid, the pro
rata portion of the target bonus earned in the current year, benefits and expense reimbursement due to Mr.&nbsp;Poradosu, payment in
lieu of any accrued but unused vacation time, payment of any unreimbursed expenses, and continued coverage through the longest applicable
limitations period under the Company&rsquo;s directors and officers insurance policies, all such payments to be made within 60 (sixty)
days of the date of termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Notwithstanding the above the Company may
terminate Mr.&nbsp;Poradosu&rsquo;s employment hereunder at any time, immediately, for Cause, upon written notice to Mr.&nbsp;Poradosu.
If Mr.&nbsp;Poradosu&rsquo;s employment is terminated for Cause, he shall be entitled to receive (i)&nbsp;the unpaid portion of his base
salary then in effect accrued through the effective date of the termination of his employment hereunder, and (ii)&nbsp;payment for any
unused vacation days which have accrued through the effective date of the termination of his employment, in each case to be paid within
30 (thirty) days after such effective date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In the event that a &ldquo;<I>Transaction</I>&rdquo;
(as such term is defined in the Company&rsquo;s Global Equity Incentive Plan, as amended from time to time, or a successor plan) occurs
during Mr.&nbsp;Poradosu&rsquo;s employment, regardless of whether Mr.&nbsp;Poradosu&rsquo;s employment is terminated, Mr.&nbsp;Poradosu
shall receive payment of the termination benefits described above as if his employment had been terminated on the effective date of the
Transaction. Following the Transaction, Mr.&nbsp;Poradosu shall not be entitled to receive such termination benefits upon a future termination
of his employment; provided that he shall remain eligible to receive (i)&nbsp;any accrued benefits upon any such subsequent termination,
and (ii)&nbsp;cash payments, paid in periodic installments in accordance with the Company&rsquo;s usual payroll practices for a period
of 18 months, equal to the cost the Company would have incurred had Mr.&nbsp;Poradosu continued group medical, dental, vision and/or
prescription drug benefit coverage for himself and/or his eligible dependents under any Company sponsored group health plan covering
Mr.&nbsp;Poradosu and his eligible dependents at the time of the termination of employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Shay Shemesh</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Annual Base Salary</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Mr.&nbsp;Shemesh&rsquo;s annual base salary
is $400,000 per annum, paid monthly in equal installments which commenced on the consummation of our initial public offering . On an
annual basis, as of the first January&nbsp;following the Company&rsquo;s initial public offering, and in any event on each January&nbsp;1
thereafter, the amount of the Mr.&nbsp;Shemesh&rsquo;s Salary shall be increased by no less than the greater of (1)&nbsp;the amount determined
by the Company&rsquo;s Compensation Committee, or (2)&nbsp;the relevant CPI.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In 2021, Mr.&nbsp;Shemesh received cash
compensation of $27,083.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 96 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Executive Compensation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Annual Bonus</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Mr.&nbsp;Shemesh&rsquo;s annual bonus target will be
50% of his annual base salary, based on the achievement of corporate goals&nbsp;&amp; objectives, paid no later than March&nbsp;15
following such bonus performance calendar year period. The Board or Compensation Committee shall have the discretion to pay the
Mr.&nbsp;Shemesh an annual performance bonus in excess of the target for performance exceeding goals, which bonus may be awarded
without proration in the event of a partial contract year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Equity Awards</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Mr.&nbsp;Shemesh will be eligible for grants
of equity awards under the Company&rsquo;s long-term equity incentive plan. On the Effective Date, the Company shall award the following
to the Mr.&nbsp;Shemesh:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 16.4pt">(i)</TD><TD STYLE="text-align: justify">restricted shares of Common Stock upon the consummation of the earlier
                                            of (a)&nbsp;IPO raising at least $15 million in gross proceeds, or (b)&nbsp;capital raising
                                            of at least $15 million in a private equity financing, equal to 0.5% of the fully-diluted
                                            share count immediately preceding such IPO/financing event, which milestone was met on July&nbsp;27,
                                            2021 in connection with the closing of the $15.3 million Preferred A round and Mr.&nbsp;Shemesh
                                            was granted 48,399 shares of restricted stock , which will vest and become fully exercisable
                                            on January&nbsp;1, 2023; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 16.45pt">(ii)</TD><TD STYLE="text-align: justify">fully vested shares of Common Stock equal to 0.5% of the then fully
                                            diluted share count of the Company when the Company reaches an average market capitalization
                                            over a 30-day period of $350 million or higher.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Termination Provisions</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In the event that Mr.&nbsp; Shemesh is
terminated without Cause, for Good Reason, Change of Control, Death or Disability (as such terms are defined in the employment agreement)
all unvested shares of restricted stock and options shall be immediately accelerated and become fully vested and unrestricted/exercisable.
Upon termination for Cause, all unvested shares of restricted shock shall expire and terminate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">If Mr.&nbsp;Shemesh resigns for Good Reason or is
terminated due to Death or Disability, Change of Control, or otherwise terminated without Cause, then Mr.&nbsp;Shemesh or his estate
or beneficiaries, in the case of Death or Disability, will receive a one-time payment equal to two years of Mr.&nbsp;Shemesh&rsquo;s
then annual Base Salary, plus a bonus payment equal to the annual bonus earned in the preceding year if not already paid, the pro
rata portion of the target bonus earned in the current year, plus benefits and expense reimbursement due to Mr.&nbsp;Shemesh,
payment in lieu of any accrued but unused vacation time, payment of any unreimbursed expenses, and continued coverage through the
longest applicable limitations period under the Company&rsquo;s directors and officers insurance policies, all such payments to be
made within 60 (sixty) days of the date of termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Notwithstanding the above the Company may terminate
Mr.&nbsp;Shemesh&rsquo;s employment hereunder at any time, immediately, for Cause, upon written notice to Mr.&nbsp;Shemesh. If
Mr.&nbsp;Shemesh&rsquo;s employment is terminated for Cause, he shall be entitled to receive (i)&nbsp;the unpaid portion of his base
salary then in effect accrued through the effective date of the termination of his employment hereunder, and (ii)&nbsp;payment for
any unused vacation days which have accrued through the effective date of the termination of his employment, in each case to be paid
within 30 (thirty) days after such effective date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In the event that a &ldquo;<I>Transaction</I>&rdquo;
(as such term is defined in the Company&rsquo;s Global Equity Incentive Plan, as amended from time to time, or a successor plan) occurs
during Mr.&nbsp;Shemesh&rsquo;s employment, regardless of whether Mr.&nbsp;Shemesh&rsquo;s employment is terminated, Mr.&nbsp;Shemesh
shall receive payment of the termination benefits described above as if his employment had been terminated on the effective date of the
Transaction. Following the Transaction, Mr.&nbsp;Shemesh shall not be entitled to receive such termination benefits upon a future termination
of his employment; provided that he shall remain eligible to receive (i)&nbsp;any accrued benefits upon any such subsequent termination
and (ii)&nbsp;cash payments, paid in periodic installments in accordance with the Company&rsquo;s usual payroll practices for a period
of 18 months, equal to the cost the Company would have incurred had Mr.&nbsp;Shemesh continued group medical, dental, vision and/or prescription
drug benefit coverage for himself and/or his eligible dependents under any Company sponsored group health plan covering Mr.&nbsp;Shemesh
and his eligible dependents at the time of the termination of employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 97 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Executive Compensation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Employee Benefit and Incentive Plans</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">We do not maintain any deferred compensation,
retirement, pension or profit-sharing plans. Our Board of Directors has adopted an incentive plan, the material terms of which are described
below, allowing for the grant of equity and cash-based awards to our employees and directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Equity Incentive Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><I>2021 Incentive Plan</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On May&nbsp;23, 2021 (the &ldquo;Effective
Date&rdquo;), our Board of Directors (the &ldquo;Board&rdquo;) adopted the Centry Pharma,&nbsp;Inc. Global Equity Incentive Plan (the
 &ldquo;2021 Plan&rdquo;), which will continue in effect for ten years from the Effective Date. The material terms of the 2021 Plan are
described below. The 2021 Plan will be administered by the Board of Directors or a designated committee thereof (as applicable, the &ldquo;Administrator&rdquo;),
as further described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Purpose</I></FONT>.
The purpose of the 2021 Plan is to attract and retain the best available personnel for, to provide incentives to service providers of
the Company (&ldquo;Service Providers&rdquo;), and to promote the Company&rsquo;s business by strengthening the common interest between
such individuals and the Company&rsquo;s stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Awards</I></FONT>.
The Administrator may grant any combination of equity awards eligible under the 2021 Plan (an &ldquo;Award&rdquo;), as discussed below.
The Administrator will determine the details of any such grant, including the timing, the number of shares, the purchase price, time
for forfeiture, the vesting schedule, and any acceleration rights thereto. The Administrator may condition any Award on the attainment
of performance targets or any other factor that the Administrator may deem appropriate. Unless otherwise permitted by</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">the Administrator, no
Participant may sell, assign, transfer, pledge, hypothecate, or otherwise dispose of any Award, except by will or pursuant to the
laws of intestacy. The Company may, at its discretion, impose as a condition of any Award that the Participant grant an individual
designated by the Company an irrevocable proxy to vote all shares subject to the Participant&rsquo;s Award at any general meeting of
the Company&rsquo;s stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Permissible
Awards. </I></FONT>The 2021 Plan authorizes awards in any of the following forms:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify"><B>Restricted
                                            Stock Units</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify">All
                                            Participants granted restricted stock units will be issued a stock certificate registered
                                            in the Participant&rsquo;s name bearing a restrictive legend referring to the terms, conditions,
                                            and restrictions of the grant. The Company will issue RSUs promptly following each vesting
                                            date, provided that Participant is still a Service Provider on the applicable vesting date.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 98 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Executive Compensation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify"><B>Options
                                            and Warrants</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify">Options
                                            and Warrants granted under the 2021 Plan (&ldquo;Options&rdquo; and &ldquo;Warrants&rdquo;,
                                            respectively) will be exercisable pursuant to the terms specified in the relevant Award Agreement.
                                            The Administrator, in its discretion, will determine the vesting schedule and acceleration
                                            of any outstanding Award. Unless otherwise resolved by the Administrator and stated in the
                                            Award Agreement, and subject to the Participant remaining a Service Provider, Options and/or
                                            Warrants vest and become exercisable under the following schedule: (a)&nbsp;thirty-three
                                            and a third percent (33.33%) on each of the first 3 anniversaries of the grant provided that
                                            the Participant continuously remains a Service Provider throughout such vesting dates. Unless
                                            otherwise provided in the relevant Award Agreement, any unexercised Option or Warrant Award,
                                            or portion thereof, will terminate within ten (10)&nbsp;years of the grant date. The Board
                                            of Directors will determine the exercise price of any Option or Warrant, provided that the
                                            price per share may not be less than the share&rsquo;s nominal value or, if required for
                                            favorable tax treatment, not less than 100% of the share&rsquo;s fair market value on the
                                            date of the grant. An Option, Warrant Award, or any part thereof, will be exercisable upon
                                            the Participant&rsquo;s execution and delivery to the Company&rsquo;s principal office of
                                            a &ldquo;Notice of Exercise&rdquo; in such form and substance as may be prescribed by the
                                            Board with full payment for the shares underlying such Option or Warrant, along with any
                                            other document required by the applicable Award Agreement. The Administrator may, in its
                                            reasonable discretion, designate certain periods during which the vesting and/or exercise
                                            of Options and/or sale of the underlying shares may be restricted or prohibited.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Adjustments.
</I></FONT>A Participant&rsquo;s right to purchase shares under the 2021 Plan will be adjusted upon the occurrence of certain events,
as described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify"><B>Mandatory Adjustments. </B>In the event of a nonreciprocal
transaction between the Company and its stockholders that causes the per-share value of our common stock (the &ldquo;Shares&rdquo;) to
change (including, without limitation, any stock dividend, stock split, spin-off, rights offering, or large nonrecurring cash dividend),
the authorization limits under the 2021 Plan shall be adjusted proportionately, and the Administrator shall make such adjustments to
the 2021 Plan and Awards as it deems necessary, in its sole discretion, to prevent dilution or enlargement of rights immediately resulting
from such transaction. Action by the Administrator may include: (i) adjustment of the number and kind of Shares that may be delivered
under the 2021 Plan; (ii)&nbsp;adjustment of the number and kind of shares subject to outstanding Awards; (iii)&nbsp;adjustment of the
exercise price of outstanding Awards or the measure to be used to determine the amount of the benefit payable on an Award; and (iv)&nbsp;any
other adjustments that the Administrator determines to be equitable. Notwithstanding the foregoing, the Administrator may not make any
adjustments to outstanding Options that would constitute a modification or substitution of the stock right under Treas. Reg. Sections
1.409A-1(b)(5)(v)&nbsp;that would be treated as the grant of a new stock right or change in the form of payment for purposes of Code
Section&nbsp;409A. Without limiting the foregoing, in the event of a subdivision of the outstanding Shares (stock-split), a declaration
of a dividend payable in Shares, or a combination or consolidation of the outstanding Shares, the authorization limits under the 2021
Plan will be automatically adjusted proportionately and the shares then subject to each Award shall automatically be adjusted proportionately,
without any change in the aggregate purchase price therefor.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 99 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Split-Segment; Name: 6 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Executive Compensation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify"><B>Discretionary Adjustments. </B>Upon the occurrence or in anticipation of any corporate event or transaction involving the Company
(including, without limitation, any merger, reorganization, recapitalization, combination or exchange of shares, or any transaction, as
described in the 2021 Plan, the Administrator may, in its sole
discretion, provide (i)&nbsp;that Awards will be settled in cash rather than in Shares, (ii)&nbsp;that Awards will become immediately
vested and non-forfeitable and exercisable (in whole or in part) and will expire after a designated period of time to the extent not then
exercised, (iii)&nbsp;that Awards will be assumed by another party to a transaction or otherwise be equitably converted or substituted in
connection with such transaction, (iv)&nbsp;that outstanding Awards may be settled by payment in cash or cash equivalents equal to the
excess of the Fair Market Value of the underlying Shares, as of a specified date associated with the transaction, over the aggregate exercise
or base price of the Award, (v)&nbsp;that performance targets and performance periods for performance-based Awards will be modified, or
(vi)&nbsp;any combination of the foregoing. The Administrator&rsquo;s determination need not be uniform and may be different for different
Participants whether or not such Participants are similarly situated.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify"><B>Effect of a Transaction. </B>Except as otherwise provided in the Award Agreement or any special 2021 Plan document governing an
Award, upon the occurrence of a Transaction, as defined in the 2021 Plan, (i)&nbsp;all outstanding Awards in the nature of rights that
may be exercised shall become fully vested and exercisable, (ii)&nbsp;all time-based vesting requirements on outstanding Awards shall
be deemed to have been met, and (iii)&nbsp;all performance-based vesting requirements on outstanding Awards shall be deemed to have been
met, as of the date of the Transaction.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify"><B>Liquidation. </B>Upon a liquidation of the Company, the Administrator will determine the effect of such liquidation on any outstanding,
unexercised, unvested, or restricted portion of any Award, which may include accelerating or cancelling all or a portion of any such Award.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Cancellation
of Awards</I></FONT>. If the Board of Directors determines in good faith that, in the context of a Transaction or Liquidation,
certain Awards have no monetary value and the holders of such Awards are not entitled to any consideration under the terms of the
Transaction or liquidation, the Board of Directors may terminate the Awards. Further, in connection with a Transaction or
liquidation, the Board of Directors may terminate any Award, effective as of the effective date of the Transaction or Liquidation,
that has an exercise price that is greater than fair market value at the time of such Transaction or Liquidation, without any
consideration to the holder thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Governing
Law</I></FONT>. The 2021 Plan is governed by the laws of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20"><B>Outstanding Equity Awards as of December&nbsp;31,
2021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">Through
December&nbsp;31, 2021 we granted 81,003 warrants to service providers with a weighted average exercise price of $3.05. Of these
warrants, all are fully vested.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">Through December&nbsp;31, 2021 we granted 226,590 options
to service providers with a weighted average exercise price of $3.05. Of these options, none are fully vested.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20"><B>Certain U.S. Federal Income Tax Effects</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">The following discussion is limited to a
summary of the U.S. federal income tax provisions relating to the grant, exercise, vesting and settlement of awards under the 2021 Plan
and the subsequent sale of common stock acquired under the Global Equity Incentive Plan. The tax consequences of awards may vary depending
upon the particular circumstances, and it should be noted that the income tax laws, regulations and interpretations thereof change frequently.
This discussion is intended for general information only and does not purport to be a complete analysis of all of the potential tax effects
of the 2021 Plan. Additional taxes, including state, local, and foreign taxes, may apply and may vary from jurisdiction to jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Non-Qualified
Stock Options. </I></B></FONT>There typically will be no U.S. federal income tax consequences to the optionee or to us upon the grant
of a non-qualified stock option under the Global Equity Incentive Plan. When the optionee exercises a non-qualified option, however, he
or she will recognize ordinary income in an amount equal to the excess of the fair market value of our common stock received upon exercise
of the option at the time of exercise over the exercise price, and we will typically be allowed a corresponding U.S. federal income tax
deduction. Any gain that the optionee realizes when he or she later sells or disposes of the option shares will be short-term or long-term
capital gain, depending on how long the shares were held.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 100 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Executive Compensation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Incentive
Stock Options. </I></B></FONT>There typically will be no U.S. federal income tax consequences to the optionee or to us upon the grant
or exercise of an incentive stock option. If the optionee holds the acquired option shares for the required holding period of at least
two years after the date the option was granted and one year after exercise, the difference between the exercise price and the amount
realized upon sale or disposition of the option shares will be long-term capital gain or loss, and we will not be entitled to a U.S. federal
income tax deduction on such amount. If the optionee disposes of the option shares in a sale, exchange, or other disqualifying disposition
before the required holding period ends, he or she will recognize taxable ordinary income in an amount equal to the excess of the fair
market value of the option shares at the time of exercise (or, if less, the amount realized on the disposition of the shares) over the
exercise price, and we would typically be allowed a U.S. federal income tax deduction equal to such amount. While the exercise of an incentive
stock option does not result in current taxable income, the excess of the fair market value of the option shares at the time of exercise
over the exercise price will be an item of adjustment for purposes of determining the optionee&rsquo;s alternative minimum taxable income.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Stock
Appreciation Rights. </I></B></FONT>A participant receiving a stock appreciation right typically will not recognize income, and we will
not be allowed a tax deduction, at the time the award is granted. When the participant exercises the stock appreciation right, the amount
of cash and the fair market value of any shares of our common stock received will be ordinary income to the participant and we will typically
be allowed a corresponding U.S. federal income tax deduction at that time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Restricted
Stock. </I></B></FONT>Unless a participant makes an election to accelerate recognition of income to the date of grant as described
below, the participant will not recognize income, and we will not be allowed a tax deduction, at the time a restricted stock award
is granted, provided that the award is nontransferable and is subject to a substantial risk of forfeiture. When the restrictions
lapse, the participant will recognize ordinary income equal to the fair market value of our common stock as of that date (less any
amount he or she paid for the stock), and we will typically be allowed a corresponding U.S. federal income tax deduction at that
time, subject to limitations in certain circumstances. If the participant files an election under Code
Section&nbsp;83(b)&nbsp;within 30 days after the date of grant of the restricted stock, he or she will recognize ordinary income as
of the date of grant equal to the fair market value of the stock as of that date (less any amount paid for the stock), and we will
typically be allowed a corresponding U.S. federal income tax deduction, subject to limitations in certain circumstances at that
time. Any future appreciation in the stock will be taxable to the participant at capital gains rates. However, if the stock is later
forfeited, the participant will not be able to recover the tax previously paid pursuant to the Section&nbsp;83(b)&nbsp;election.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Restricted
Stock Units. </I></B></FONT>A participant typically will not recognize income, and we will not be allowed a tax deduction, at the
time a restricted stock unit award is granted. When the participant receives shares of our common stock (or the equivalent value in
cash or other property) in settlement of a restricted stock unit award, a participant will recognize ordinary income equal to the
fair market value of our common stock or other property as of that date (less any amount he or she paid for the stock or property),
and we will typically be allowed a corresponding U.S. federal income tax deduction at that time, subject to limitations in certain
circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Cash-Based
Performance Awards. </I></B></FONT>A participant will not recognize income, and we will not be allowed a tax deduction, at the time a
cash-based performance award is granted (for example, when the performance goals are established). Upon receipt of cash in settlement
of the award, the participant will recognize ordinary income equal to the cash received, and we will typically be allowed a corresponding
U.S. federal income tax deduction at that time, subject to limitations in certain circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Section&nbsp;409A. </I></B></FONT>The
2021 Plan permits the grant of various types of incentive awards, which may or may not be exempt from Code Section&nbsp;409A. If an
award is subject to Section&nbsp;409A, and if the requirements of Section&nbsp;409A are not met, the taxable events as described
above could apply earlier than described, and could result in the imposition of additional taxes and penalties. Restricted stock
awards, and stock options and SARs that comply with the terms of the Global Equity Incentive Plan, are generally exempt from the
application of Section&nbsp;409A. Stock units, other stock-based awards and cash-based awards that are granted in one year and
payable in a later year generally are subject to Section&nbsp;409A unless they are designed to satisfy the short-term deferral
exemption from such law. If not exempt, such awards must be specially designed to meet the requirements of Section&nbsp;409A in
order to avoid early taxation and penalties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Tax
Withholding. </I></B></FONT>We have the right to deduct or withhold, or require a participant to remit to us, an amount sufficient to
satisfy federal, state and local taxes (including employment taxes) required by law to be withheld with respect to any exercise, lapse
of restriction or other taxable event arising as a result of the Global Equity Incentive Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 101 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<B><A NAME="sp17"></A>Principal Stockholders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">The following table sets forth information
with respect to the beneficial ownership of our common stock as of June&nbsp;30, 2022, and as adjusted to reflect the sale of our common
stock offered by us in this offering, for:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD>each of our named executive officers;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD>each of our directors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD>all of our current directors and executive officers as a group; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify">each person, or group of affiliated persons, known by us to be the beneficial owner of more than 5% of our outstanding shares common
stock.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">We have
determined beneficial ownership in accordance with the rules&nbsp;of the SEC, which generally means that a person has beneficial
ownership of a security if he or she possesses sole or shared voting or investment power of that security, including options or
warrants that are currently exercisable or exercisable within 60 days of June&nbsp;30, 2022. Unless otherwise indicated, to our
knowledge, the persons and entities named in the table below have sole voting and sole investment power with respect to all shares
that they beneficially own, subject to community property laws where applicable. The information in the table below does not
necessarily indicate beneficial ownership for any other purpose, including for purposes of Sections 13(d)&nbsp;and 13(g)&nbsp;of the
Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">Unless otherwise indicated, the address
of each beneficial owner listed in the table below is c/o Nuvectis Pharma,&nbsp;Inc., 1 Bridge Plaza, Fort Lee, NJ 07024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 102 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; color: #231F20">Principal Stockholders</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><P STYLE="font: 13pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231F20"><B>Name of Beneficial Owner</B></P></TD><TD STYLE="font-size: 10pt; color: #231F20; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: #231F20; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of <BR> Shares <BR> Beneficially Owned As of June 30, 2022</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: #231F20; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #231F20; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: #231F20; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percentage of <BR> Shares <BR> Beneficially Owned As of June 30, 2022</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: #231F20; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: #231F20; font-weight: bold; text-align: left">5% and Greater Stockholders:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; font-size: 10pt; color: #231F20; text-align: left">Charles Mosseri Marlio</TD><TD STYLE="width: 1%; font-size: 10pt; color: #231F20">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; color: #231F20; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; color: #231F20; text-align: right">1,572,107</TD><TD STYLE="width: 1%; font-size: 10pt; color: #231F20; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; color: #231F20">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; color: #231F20; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; color: #231F20; text-align: right">12.36</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; color: #231F20; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: #231F20; text-align: left">Pontifax VI LP(1)</TD><TD STYLE="font-size: 10pt; color: #231F20">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: #231F20; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #231F20; text-align: right">1,379,360</TD><TD STYLE="font-size: 10pt; color: #231F20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20; text-align: right">10.85</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Thomas P. Peters (Bat Sheva M. Gerald)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">755,200</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5.94</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #231F20; text-align: left">Named Executive Officers and Directors:</TD><TD STYLE="font-size: 10pt; color: #231F20">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: #231F20; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #231F20; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #231F20; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #231F20">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: #231F20; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #231F20; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #231F20; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: #231F20">Ron Bentsur(2)</TD><TD STYLE="font-size: 10pt; color: #231F20">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: #231F20; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #231F20; text-align: right">2,871,555</TD><TD STYLE="font-size: 10pt; color: #231F20; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #231F20">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: #231F20; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #231F20; text-align: right">22.58</TD><TD STYLE="font-size: 10pt; color: #231F20; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: #231F20">Enrique Poradosu(3)</TD><TD STYLE="font-size: 10pt; color: #231F20">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: #231F20; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #231F20; text-align: right">1,209,920</TD><TD STYLE="font-size: 10pt; color: #231F20; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #231F20">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: #231F20; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #231F20; text-align: right">9.51</TD><TD STYLE="font-size: 10pt; color: #231F20; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: #231F20">Shay Shemesh(4)</TD><TD STYLE="font-size: 10pt; color: #231F20">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: #231F20; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #231F20; text-align: right">1,193,036</TD><TD STYLE="font-size: 10pt; color: #231F20; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #231F20">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: #231F20; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #231F20; text-align: right">9.38</TD><TD STYLE="font-size: 10pt; color: #231F20; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: #231F20">Kenneth Hoberman(5)</TD><TD STYLE="font-size: 10pt; color: #231F20">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: #231F20; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #231F20; text-align: right">64,890</TD><TD STYLE="font-size: 10pt; color: #231F20; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #231F20">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: #231F20; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #231F20; text-align: right"><FONT STYLE="font-size: 10pt; color: #231F20">*</FONT></TD><TD STYLE="font-size: 10pt; color: #231F20; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: #231F20">Matthew Kaplan(6)</TD><TD STYLE="font-size: 10pt; color: #231F20">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: #231F20; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #231F20; text-align: right">35,760</TD><TD STYLE="font-size: 10pt; color: #231F20; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #231F20">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: #231F20; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #231F20; text-align: right"><FONT STYLE="font-size: 10pt; color: #231F20">*</FONT></TD><TD STYLE="font-size: 10pt; color: #231F20; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; color: #231F20; text-align: left">James F. Oliviero III(7)</TD><TD STYLE="font-size: 10pt; color: #231F20">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: #231F20; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #231F20; text-align: right">19,578</TD><TD STYLE="font-size: 10pt; color: #231F20; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #231F20">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: #231F20; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #231F20; text-align: right"><FONT STYLE="font-size: 10pt; color: #231F20">*</FONT></TD><TD STYLE="font-size: 10pt; color: #231F20; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: #231F20; font-weight: bold; text-align: left; padding-bottom: 1pt">All executive officers and directors as a group (6 persons)</TD><TD STYLE="font-size: 10pt; color: #231F20; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: #231F20; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: #231F20; font-weight: bold; text-align: right">5,394,739</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: #231F20; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #231F20; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: #231F20; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: #231F20; font-weight: bold; text-align: right">42.42</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: #231F20; font-weight: bold; text-align: left">%</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">* Represents beneficial ownership of less
than 1%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1)</SUP></FONT></TD><TD STYLE="text-align: justify">Pontifax Management 4 GP (2015) Ltd. is the general partner
(the &ldquo;General Partner&rdquo;) of Pontifax VI GP L.P, the general partner of each of, Pontifax VI (Cayman) LP and Pontifax VI (Israel)
LP (which are collectively referred to as &ldquo;Pontifax VI LP&rdquo;). Mr.&nbsp;Tomer Kariv holds approximately 51% of the share capital
of the General Partner; as a result, Mr.&nbsp;Kariv may be deemed to exercise control over Pontifax VI LP. The remaining share capital
is held by Mr.&nbsp;Ran Nussbaum. Mr.&nbsp;Kariv and Mr.&nbsp;Nussbaum disclaim beneficial ownership of all the reported shares and the
inclusion of all shares herein shall not be deemed to be an admission of beneficial ownership of the reported shares except to the extent
of their pecuniary interest therein.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>2)</SUP></FONT></TD><TD STYLE="text-align: justify">This excludes 96,759 shares of restricted stock granted to Mr.&nbsp;Bentsur
on July&nbsp;27, 2021 in connection with the closing of the $15.3 million Preferred A capital raise. These restricted shares vest on
January&nbsp;1, 2023. This also excludes 120,000 shares of restricted stock granted to Mr.&nbsp;Bentsur on April&nbsp;1, 2022 in connection
with his employee agreement. These shares vest over a 3-year period with 1/3 vesting on each anniversary date of the grant.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>3)</SUP></FONT></TD><TD STYLE="text-align: justify">This excludes 48,399 shares of restricted stock granted to Dr.&nbsp;Poradosu
on July&nbsp;27, 2021 in connection with the closing of the $15.3 million Preferred A capital raise. These restricted shares vest on
January&nbsp;1, 2023. This also excludes 60,000 shares of restricted stock granted to Dr.&nbsp;Poradosu on April&nbsp;1, 2022 in connection
with his employee agreement. These shares vest over a 3-year period with 1/3 vesting on each anniversary date of the grant.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>4)</SUP></FONT></TD><TD STYLE="text-align: justify">This excludes 48,399 shares of restricted stock granted to Mr.&nbsp;Shemesh
on July&nbsp;27, 2021 in connection with the closing of the $15.3 million Preferred A capital raise. These restricted shares vest on
January&nbsp;1, 2023. This also excludes 60,000 shares of restricted stock granted to Mr.&nbsp;Shemesh on April&nbsp;1, 2022 in connection
with his employee agreement. These shares vest over a 3-year period with 1/3 vesting on each anniversary date of the grant.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>5)</SUP></FONT></TD><TD STYLE="text-align: justify">Excludes 16,380 shares owned by the Hoberman Descendants Trust,
to which Mr.&nbsp;Hoberman disclaims ownership. On July&nbsp;19, 2021, Mr.&nbsp;Hoberman was granted 29,250 options vesting over a 3-year
period, 1/3 each year, exercisable into common shares of the Company at a price of $3.05. 9,750 shares will be exercisable within 60
days of June&nbsp;30, 2022 and were included in the beneficial ownership calculation. On April&nbsp;1, 2022 Mr.&nbsp;Hoberman was granted
15,000 options vesting over a 3-year period with 1/3 vesting on each anniversary date of the grant, exercisable into common shares of
the Company at a price of $7.02.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>6)</SUP></FONT></TD><TD STYLE="text-align: justify">On September&nbsp;2, 2021, Mr.&nbsp;Kaplan was granted 29,250
options vesting over a 3-year period, 1/3 each year, exercisable into common shares of the Company at a price of $3.05. On April&nbsp;1,
2022 Mr.&nbsp;Kaplan was granted 15,000 options vesting over a 3-year period with 1/3 vesting on each anniversary date of the grant,
exercisable into common shares of the Company at a price of $7.02.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>7)</SUP></FONT></TD><TD STYLE="text-align: justify">On July&nbsp;6, 2021, Mr.&nbsp;Oliviero was granted 29,250 options
vesting over a 3-year period, 1/3 each year, exercisable into common shares of the Company at a price of $3.05. 9,750 shares will be
exercisable within 60 days of June&nbsp;30, 2022 and were included in the beneficial ownership calculation. On April&nbsp;1, 2022 Mr.&nbsp;Oliviero
was granted 15,000 options vesting over a 3-year period with 1/3 vesting on each anniversary date of the grant, exercisable into common
shares of the Company at a price of $7.02.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 103 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: rgb(35,31,32)"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: rgb(35,31,32)"><B><A NAME="sp16"></A>Certain Relationships
and Related-Party Transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">Since inception, we have not been involved
in a transaction or series of similar transactions that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD>the amount involved exceeded or exceeds $120,000; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify">any of our directors or executive officers, any holder of 5% of our capital stock or any member of their immediate family had or will
have a direct or indirect material interest.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20"><B>Policies and Procedures for Transaction
with Related Persons</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">Upon
the consummation of our initial public offering, our board of directors adopted a written related person transaction policy, setting
forth the policies and procedures for the review and approval or ratification of related person transactions. This policy covers,
with certain exceptions set forth in Item 404 of Regulation S-K under the Securities Act, any transaction, arrangement or
relationship, or any series of similar transactions, arrangements or relationships in which we were or are to be a participant,
where the amount involved exceeds $120,000 or 1% of the average of our total assets as of December 31, 2021 and 2020 and a related
person had or will have a direct or indirect material interest, including without limitation purchases of goods or services by or
from the related person or entities in which the related person has a material interest, indebtedness, guarantees of indebtedness
and employment by us of a related person. In reviewing and approving any such transactions, our audit committee is tasked to
consider all relevant facts and circumstances, including but not limited to whether the transaction is on terms comparable to those
that could be obtained in an arm&rsquo;s length transaction with an unrelated third party and the extent of the related
person&rsquo;s interest in the transaction. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 104 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: rgb(35,31,32)"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: rgb(35,31,32)">&nbsp;<B><A NAME="sp14"></A>Description of
Capital Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">The following descriptions are summaries
of the material terms of our amended and restated certificate of incorporation and amended and restated bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">Our authorized capital stock consists of
60,000,000 shares of Common Stock, par value $0.00001 per share, and 5,000,000 shares of preferred stock, par value $0.00001 per share,
all of which shares of preferred stock are undesignated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">As of June&nbsp;30, 2022, 12,717,794 shares
of our Common Stock were outstanding and held of record by 44 stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">Holders of our Common Stock are entitled
to one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. An election
of directors by our stockholders shall be determined by a plurality of the votes cast by the stockholders entitled to vote on the election.
Holders of Common Stock are entitled to receive proportionately any dividends as may be declared by our Board of Directors in its sole
discretion, subject to any preferential dividend rights of outstanding preferred stock, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">In the event of our liquidation or dissolution,
the holders of Common Stock are entitled to receive proportionately all assets available for distribution to stockholders after the payment
of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock. Holders of Common Stock have no
preemptive, subscription, redemption or conversion rights. The rights, preferences and privileges of holders of Common Stock are subject
to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock that we may designate and issue
in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20"><B>Preferred stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">Our board of directors has the authority,
without further action by our stockholders, to issue up to 5,000,000 shares of preferred stock in one or more series and to fix the rights,
preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights,
voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the designation
of, such series, any or all of which may be greater than the rights of Common Stock. The issuance of our preferred stock could adversely
affect the voting power of holders of Common Stock and the likelihood that such holders will receive dividend payments and payments upon
our liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control
of our company or other corporate action. Immediately after consummation of this offering, no shares of preferred stock will be outstanding,
and we have no present plan to issue any shares of preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20"><B>Anti-takeover effects of Delaware law
and certain provisions of our certificate of incorporation and amended and restated bylaws</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">Our certificate of incorporation and bylaws
include a number of provisions that may have the effect of delaying, deferring or preventing another party from acquiring control of
us and encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our board of
directors rather than pursue non-negotiated takeover attempts. These provisions include the items described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 105 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20">Description of Capital Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20"><B><I>Board composition and filling vacancies</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">Our certificate of incorporation provides
for the division of our board of directors into three classes serving staggered three-year terms, with one class being elected each year.
Our certificate of incorporation also provides that directors may be removed only for cause and then only by the affirmative vote of the
holders of two-thirds of the shares then entitled to vote at an election of directors. Furthermore, any vacancy on our board of directors,
however occurring, including a vacancy resulting from an increase in the size of our board, may only be filled by the affirmative vote
of a majority of our directors then in office even if less than a quorum. The classification of directors, together with the limitations
on removal of directors and treatment of vacancies, has the effect of making it more difficult for stockholders to change the composition
of our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20"><B><I>No written consent of stockholders</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">Our certificate of incorporation provides
that all stockholder actions are required to be taken by a vote of the stockholders at an annual or special meeting, and that stockholders
may not take any action by written consent in lieu of a meeting. This limit may lengthen the amount of time required to take stockholder
actions and would prevent the amendment of our bylaws or removal of directors by our stockholders without holding a meeting of stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20"><B><I>Meetings of stockholders</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">Our certificate of incorporation and bylaws
provide that only a majority of the members of our board of directors then in office may call special meetings of stockholders and only
those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders. Our
bylaws limit the business that may be conducted at an annual meeting of stockholders to those matters properly brought before the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20"><B><I>Advance notice requirements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">Our bylaws establish advance notice procedures
with regard to stockholder proposals relating to the nomination of candidates for election as directors or new business to be brought
before meetings of our stockholders. These procedures provide that notice of stockholder proposals must be timely given in writing to
our corporate secretary prior to the meeting at which the action is to be taken. Generally, to be timely, notice must be received at our
principal executive offices not less than 90 days nor more than 120 days prior to the first anniversary date of the annual meeting for
the preceding year. Our bylaws specify the requirements as to form and content of all stockholders&rsquo; notices. These requirements
may preclude stockholders from bringing matters before the stockholders at an annual or special meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20"><B><I>Amendment to certificate of incorporation
and bylaws</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">Any amendment of our certificate of incorporation
must first be approved by a majority of our board of directors, and if required by law or our certificate of incorporation, must thereafter
be approved by two- thirds of the outstanding shares entitled to vote on the amendment and two-thirds of the outstanding shares of each
class entitled to vote thereon as a class. Our bylaws may be amended by the affirmative vote of a majority of the directors then in office,
subject to any limitations set forth in the bylaws; and may also be amended by the affirmative vote of two-thirds of the outstanding shares
entitled to vote on the amendment, or, if our board of directors recommends that the stockholders approve the amendment, by the affirmative
vote of two-thirds of the outstanding shares entitled to vote on the amendment, in each case voting together as a single class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 106 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20">Description of Capital Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20"><B><I>Undesignated preferred stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">Our certificate of incorporation provides
for 5,000,000 authorized shares of preferred stock. The existence of authorized but unissued shares of preferred stock may enable our
board of directors to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. For
example, if in the due exercise of its fiduciary obligations, our board of directors were to determine that a takeover proposal is not
in the best interests of our stockholders, our board of directors could cause shares of preferred stock to be issued without stockholder
approval in one or more private offerings or other transactions that might dilute the voting or other rights of the proposed acquirer
or insurgent stockholder or stockholder group. In this regard, our certificate of incorporation grants our board of directors broad power
to establish the rights and preferences of authorized and unissued shares of preferred stock. The issuance of shares of preferred stock
could decrease the amount of earnings and assets available for distribution to holders of shares of Common Stock. The issuance may also
adversely affect the rights and powers, including voting rights, of these holders and may have the effect of delaying, deterring or preventing
a change in control of us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20"><B><I>Delaware anti-takeover statute</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">We are subject to the provisions of Section&nbsp;203
of the Delaware General Corporation Law. In general, Section&nbsp;203 prohibits a publicly held Delaware corporation from engaging in
a &ldquo;business combination&rdquo; with an &ldquo;interested stockholder&rdquo; for a three-year period following the time that this
stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner. Under Section&nbsp;203,
a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify">before the stockholder became interested, our board of directors approved either the business combination or the transaction which
resulted in the stockholder becoming an interested stockholder;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder
owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of
determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans, in some
instances, but not the outstanding voting stock owned by the interested stockholder; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify">at or after the time the stockholder became interested, the business combination was approved by our board of directors and authorized
at an annual or special meeting of the stockholders by the affirmative vote of a majority of the outstanding voting stock which is not
owned by the interested stockholder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">Section&nbsp;203 defines a business combination
to include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD>any merger or consolidation involving the corporation and the interested stockholder;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify">any sale, transfer, lease, pledge, exchange, mortgage or other disposition involving the interested stockholder of 10% or more of
the assets of the corporation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation
to the interested stockholder; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided
by or through the corporation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">In general, Section&nbsp;203 defines an
interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and
any entity or person affiliated with or controlling or controlled by the entity or person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 107 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20"><B>Choice of forum</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">Our amended and restated bylaws provide
that the Court of Chancery of the State of Delaware will be the exclusive forum for state law claims for (i)&nbsp;any derivative action
or proceeding brought on our behalf, (ii)&nbsp;any action asserting a breach of fiduciary duty by one or more of our directors, officers
or employees, (iii)&nbsp;any action asserting a claim against us arising pursuant to the Delaware General Corporation Law or (iv)&nbsp;any
action asserting a claim against us that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery having
personal jurisdiction over the indispensable parties named as defendants therein (the &ldquo;Delaware Forum Provision&rdquo;); provided,
however, that this forum provision will not apply to any causes of action arising under the Exchange Act or the Securities Act which,
unless we consent in writing to the selection of an alternative forum, are required to be brought exclusively in federal district courts
of the United States of America in accordance with the 2<SUP>nd</SUP> Amended and Restated Articles of Incorporation. In addition, our
amended and restated bylaws will provide that any person or entity purchasing or otherwise acquiring any interest in shares of our Common
Stock is deemed to have notice of and consented to the Delaware Forum Provision. We recognize that the Delaware Forum Provision in our
bylaws may impose additional litigation costs on stockholders in pursuing any such claims, particularly if the stockholders do not reside
in or near the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">Additionally, the Delaware Forum
Provision may limit our stockholders&rsquo; ability to bring a claim in a judicial forum that they find favorable for disputes with
us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees.
The Court of Chancery of the State of Delaware may also reach different judgments or results than would other courts, including
courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments
may be more or less favorable to us than our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20"><B>Stock exchange listing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">Our Common Stock is listed on Nasdaq Capital
Market under the trading symbol &ldquo;NVCT.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20"><B>Transfer agent and registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">The Transfer Agent and Registrar for our
Common Stock is American Stock Transfer&nbsp;&amp; Trust Company, LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 108 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Material U.S. Federal Income Tax Consequences to Non-U.S. Holders&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(35,31,32)"><B><A NAME="sp13"></A>Material
U.S. Federal Income Tax Consequences to Non-U.S. Holders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">The following is a summary of the material
U.S. federal income tax consequences relating to the acquisition, ownership and disposition of our common stock as of the date hereof.
Except where noted, this summary deals only with our common stock that is held as a capital asset (within the meaning of Section&nbsp;1221
of the Internal Revenue Code of 1986, as amended, or the Code, by a &ldquo;non-U.S. holder&rdquo; (as defined below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">For purposes of this summary, a &ldquo;non-U.S.
holder&rdquo; means a beneficial owner of our common stock (other than a partnership or any other entity treated as a partnership for
U.S. federal income tax purposes) that is not for U.S. federal income tax purposes any of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD>an individual citizen or resident of the U.S.;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify">a corporation (or any other entity treated as a corporation for U.S. federal income tax purposes) created or organized in or under
the laws of the United States, any state thereof or the District of Columbia;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD>an estate the income of which is subject to U.S. federal income taxation regardless of its source; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify">a trust if it (1)&nbsp;is subject to the primary supervision of a court within the United States and one or more United States persons
have the authority to control all substantial decisions of the trust or (2)&nbsp;has a valid election in effect
under applicable United States Treasury regulations (&ldquo;Treasury Regulations&rdquo;) to be treated as a United States person.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">This summary is based upon provisions
of the Code and Treasury Regulations, administrative rulings and judicial decisions currently in effect, all as of the date hereof
and all subject to change at any time, possibly with retroactive effect, or to different interpretation by the Internal Revenue
Service (&ldquo;IRS&rdquo;). This summary does not address all aspects of U.S. federal taxes and does not address any foreign,
state, local or other tax considerations that may be relevant to non-U.S. holders in light of their personal circumstances. In
addition, this summary does not represent a detailed description of the U.S. federal income tax consequences applicable to non-U.S.
holders that are subject to special treatment under the U.S. federal income tax laws (including a non-U.S. holder that is a United
States expatriate, &ldquo;controlled foreign corporation,&rdquo; &ldquo;passive foreign investment company,&rdquo; &ldquo;real
estate investment trust,&rdquo; &ldquo;regulated investment company,&rdquo; dealer in securities or currencies, financial
institution, tax-exempt entity, insurance company, person holding our common stock as part of a hedging, integrated, conversion or
constructive sale transaction or a straddle, trader in securities that elects to use a mark-to-market method of accounting, person
liable for the alternative minimum tax, person who acquired our common stock as compensation for services, or a partnership or other
pass-through entity, or partner in a partnership or beneficial owner of a pass-through entity that holds our common stock for U.S.
federal income tax purposes). We cannot provide assurance that a change in law will not alter significantly the tax considerations
that we describe in this summary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">If a partnership (or other entity treated
as a partnership for U.S. federal income tax purposes) holds our common stock, the tax treatment of a partner will generally depend upon
the status of the partner and the activities of the partnership. Non-U.S. holders that are partners of a partnership holding our common
stock should consult their tax advisors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">Non-U.S. holders considering the purchase
of our common stock should consult their own tax advisors concerning the particular U.S. federal income and estate tax consequences of
the ownership of our common stock, as well as the consequences arising under the laws of any other taxing jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20"><B>Distribution on our common stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">As indicated in the &ldquo;Dividend Policy&rdquo;
section of this prospectus, we have never paid cash dividends on any of our capital stock and currently intend to retain our future earnings,
if any, to fund the development and growth of our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">In the event that we do make a distribution,
distributions paid on our common stock will be treated as dividends to the extent paid out of current or accumulated earnings and profits,
as determined under U.S. federal income tax principles. If a distribution exceeds our current and accumulated earnings and profits, the
excess will be treated as a tax-free return of the non-U.S. holder&rsquo;s investment, up to such holder&rsquo;s tax basis in the common
stock. Any remaining excess will be treated as capital gain, subject to the tax treatment described below in &ldquo;Gains on disposition
of our common stock.&rdquo; Dividends paid to a non-U.S. holder of our common stock generally will be subject to U.S. federal withholding
tax at a 30% rate or such lower rate as may be specified by an applicable income tax treaty. However, dividends that are effectively connected
with the conduct of a trade or business by the non-U.S. holder within the United States (and, if required by an applicable income tax
treaty, are attributable to a United States permanent establishment) are not subject to United States federal withholding tax, provided
certain certification and disclosure requirements are satisfied. Instead, such dividends are subject to U.S. federal income tax on a net-income
basis in the same manner as if the non-U.S. holder were a &ldquo;United States person&rdquo; as defined in the Code. Any such effectively
connected dividends received by a foreign corporation may, under certain circumstances, be subject to an additional &ldquo;branch profits
tax&rdquo; at a 30% rate or such lower rate as may be specified by an applicable income tax treaty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 109 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Material U.S. Federal Income Tax Consequences to Non-U.S. Holders&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; color: rgb(35,31,32)"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">A non-U.S. holder who wishes to claim the
benefit of an applicable treaty rate and avoid backup withholding, as discussed below, for dividends will be required (a)&nbsp;to complete
IRS Form&nbsp;W-8BEN or W-8BEN-E (or other applicable form) and certify under penalty of perjury that it is not a &ldquo;United States
person&rdquo; as defined in the Code and is eligible for treaty benefits or (b)&nbsp;if the common stock is held through certain foreign
intermediaries, to satisfy the relevant certification requirements of applicable Treasury Regulations. Special certification and other
requirements apply to certain non-U.S. holders that are pass-through entities rather than corporations or individuals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">A non-U.S. holder eligible for a reduced
rate of United States withholding tax pursuant to an income tax treaty may obtain a refund of any excess amounts withheld by filing an
appropriate claim for refund with the IRS. Dividend distributions to non-U.S. holders would also be subject to the rules&nbsp;concerning
backup withholding and FATCA, as further discussed below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20"><B>Gain on disposition of our common stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">Subject to the discussions below under the
heading &ldquo;Information reporting and backup withholding&rdquo; and &ldquo;FATCA withholding requirements,&rdquo; any gain realized
on the disposition of our common stock by a non-U.S. holder generally will not be subject to U.S. federal income tax unless:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify">the gain is effectively connected with a trade or business of the non-U.S. holder in the United States (and, if required by an applicable
income tax treaty, is attributable to a United States permanent establishment of the non-U.S. holder);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify">the non-U.S. holder is an individual who is present in the United States for 183 days or more in the taxable year of that disposition,
and certain other conditions are met; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#10146;</FONT></TD><TD STYLE="text-align: justify">we are or have been a &ldquo;United States real property holding corporation&rdquo; for U.S. federal income tax purposes at any time
during the shorter of the five-year period ending on the date of the disposition or such non-U.S. holder&rsquo;s holding period for our
common stock and such non-U.S. holder held (at any time during the shorter of the five-year period ending on the date of the disposition
or such non-U.S. holder&rsquo;s holding period) more than 5% of our common stock.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">An individual non-U.S. holder described
in the first bullet point immediately above will be subject to tax on the net gain derived from the sale under regular graduated U.S.
federal income tax rates. If a non-U.S. holder that is a foreign corporation falls under the first bullet point immediately above, it
will be subject to tax on its net gain in the same manner as if it were a &ldquo;United States person&rdquo; as defined in the Code and,
in addition, may, under certain circumstances, be subject to a branch profits tax equal to 30% of its effectively connected earnings and
profits or at such lower rate as may be specified by an applicable income tax treaty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">We believe we have not been and are
not currently a &ldquo;United States real property holding corporation&rdquo; for U.S. federal income tax purposes; however, no
assurance can be given that we are not or will not become one in the future. If, however, we are or become a &ldquo;United States
real property holding corporation,&rdquo; so long as our common stock continues to be regularly traded on an established securities
market, only a non-U.S. holder who holds, or held (at any time during the shorter of the five-year period ending on the date of
disposition or the non-U.S. holder&rsquo;s holding period) more than 5% of our common stock will be subject to U.S. federal income
tax on the disposition of the common stock. No assurance can be given, however, that our common stock will continue to be treated as
regularly traded on an established securities market for applicable U.S. federal income tax purposes. Non-U.S. holders should
consult their own tax advisors about the consequences if we are, or become, a &ldquo;United States real property holding
corporation.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 110 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Material U.S. Federal Income Tax Consequences to Non-U.S. Holders&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; color: rgb(35,31,32)"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20"><B>Information reporting and backup withholding</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">Information returns are required to be filed
with the IRS and reporting the amount of dividends paid to each non-U.S. holder and the tax withheld with respect to such dividends, regardless
of whether withholding was required. Copies of the information returns reporting such dividends and withholding may also be made available
to the tax authorities in the country in which the non-U.S. holder resides under the provisions of an applicable income tax treaty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">A non-U.S. holder will be subject to backup
withholding for dividends paid to it unless it certifies under penalty of perjury that it is not a &ldquo;United States person&rdquo;
as defined in the Code (and the payor does not have actual knowledge or reason to know that the non-U.S. holder is a &ldquo;United States
person&rdquo; as defined in the Code), or it otherwise establishes an exemption.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">Information reporting and, depending on
the circumstances, backup withholding will apply to the proceeds of a sale of our common stock within the United States or conducted through
certain United States- related financial intermediaries, unless the non-U.S. holder certifies under penalty of perjury that it is not
a</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">&ldquo;United States person&rdquo; as defined
in the Code (and the payor does not have actual knowledge or reason to know that the non-U.S. holder is a &ldquo;United States person&rdquo;
as defined in the Code), or it otherwise establishes an exemption.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">Backup withholding is not an additional
tax. Any amounts withheld under the backup withholding rules&nbsp;may be allowed as a refund or a credit against a non-U.S. holder&rsquo;s
U.S. federal income tax liability provided the required information is timely furnished to the IRS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20"><B>FATCA withholding requirements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">Sections 1471 to 1474 of the Code
(such sections, and the Treasury Regulations and administrative guidance issued thereunder, commonly referred to as FATCA) impose a
30% United States withholding tax on certain &ldquo;withholdable payments&rdquo; made to a &ldquo;foreign financial
institution&rdquo; or a &ldquo;nonfinancial foreign entity.&rdquo; &ldquo;Withholdable payments&rdquo; include payments of dividends
and the gross proceeds from a disposition of certain property (such as shares of our common stock), if such disposition occurs after
December&nbsp;31, 2018. In general, if a non-U.S. holder is a &ldquo;foreign financial institution,&rdquo; the 30% withholding tax
will apply to withholdable payments made to it, unless it enters into an agreement with the United States Department of Treasury to
collect and provide substantial information regarding its United States account holders, including certain account holders that are
foreign entities with United States owners, and to withhold 30% on certain &ldquo;passthru payments.&rdquo; If it is a
 &ldquo;non-financial foreign entity,&rdquo; FATCA also generally will impose a withholding tax of 30% on withholdable payments made
to it unless it provides the withholding agent with a certification that it does not have any &ldquo;substantial United States
owners&rdquo; or a certification identifying its direct and indirect substantial United States owners. Intergovernmental agreements
between the United States and a non-U.S. holder&rsquo;s resident country may modify the foregoing requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">Non-U.S. holders should consult their own
tax advisors regarding the impact of FATCA on their ownership and disposition of shares of our common stock and the potential applicability
of any intergovernmental agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 111 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: rgb(35,31,32)"><B>&nbsp;Selling Shareholders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.25in">The Common Stock being offered by the Selling
Shareholders are those previously issued to the Selling Shareholders, and those issuable to the Selling Shareholders upon exercise of
the Investment Options and Pre-Funded Warrants (the &ldquo;Securities&rdquo;). For additional information regarding the issuances of those
Securities, see &ldquo;Private Placement of Shares of Common Stock, Preferred Investment Options, and Pre-Funded Warrants.&rdquo; We are
registering the shares of Common Stock in order to permit the Selling Shareholders to offer the shares for resale from time to time. Except
for the ownership of the shares of Common Stock and the Securities, the Selling Shareholders have not had any material relationship with
us within the past three years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The table below lists the Selling Shareholders
and other information regarding the beneficial ownership of the shares of Common Stock by each of the Selling Shareholders. The second
column lists the number of shares of Common Stock beneficially owned by each Selling Shareholder, based on its ownership of the shares
of Common Stock and Securities, as of August&nbsp;5, 2022, assuming exercise of the Securities held by the Selling Shareholders on that
date, without regard to any limitations on exercises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The third column lists the shares of Common Stock
being offered by this prospectus by the Selling Shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In accordance with the terms of a registration rights
agreement with the Selling Shareholders, this prospectus generally covers the resale of the sum of (i) the number of shares of Common
Stock issued to the Selling Shareholders in the &ldquo;Private Placement of Shares of Common Stock, Preferred Investment Options, and
Pre-Funded Warrants&rdquo; described above and (ii) the maximum number of shares of Common Stock issuable upon exercise of the related
Preferred Investment Options and Pre-Funded Warrants, determined as if the outstanding Preferred Investment Options and Pre-Funded Warrants,
as applicable, were exercised in full as of the trading day immediately preceding the date this registration statement was initially filed
with the SEC, each as of the trading day immediately preceding the applicable date of determination and all subject to adjustment as provided
in the registration right agreement, without regard to any limitations on the exercise of the Preferred Investment Options and Pre-Funded
Warrants, as applicable. The fourth column assumes the sale of all of the shares offered by the Selling Shareholders pursuant to this
prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under the terms of the Securities held by Selling
Shareholders, a Selling Shareholder may not exercise the Securities to the extent such exercise would cause such Selling Shareholder,
together with its affiliates and attribution parties, to beneficially own a number of shares of Common Stock which would exceed 4.99%
or 9.99% of our then outstanding Common Stock following such exercise, excluding for purposes of such determination shares of Common Stock
issuable upon exercise of the Securities which have not been exercised. The number of shares in the second and fourth columns do not reflect
this limitation. The Selling Shareholders may sell all, some or none of their shares in this offering. See &ldquo;Plan of Distribution.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 112 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: justify; border-bottom: Black 1pt solid">Name of Selling<BR> Shareholder</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of shares of<BR> Common Stock Owned <BR> Prior to Offering&nbsp;(1)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Maximum Number of<BR> shares <BR> of Common Stock to be <BR> Sold <BR> Pursuant to this<BR> Prospectus(2)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of shares of<BR> Common Stock<BR> Owned <BR> After Offering (3)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Percentage of Beneficial<BR> Ownership After Offering (3)</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; font: 10pt Times New Roman, Times, Serif; text-align: justify">Charles Mosseri Marlio (4)</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="width: 13%; font: 10pt Times New Roman, Times, Serif; text-align: right">2,299,381</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">727,274</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,572,107</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">12.36</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: justify">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Sabby Volatility Warrant Master Fund,&nbsp;Ltd. (4)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,818,182</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> (5)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,818,182</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">--</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Thomas Peters (4)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">997,626</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">242,426</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">755,200</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5.16</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Omri Minin (4)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">436,692</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">109,092</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">327,600</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.24</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Eyal Carmon (4)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">251,074</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">87,274</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">163,800</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.12</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Ronit Capital SPC &ndash; Ronit Capital Fund I SP (4)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">363,638</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">363,638</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">--</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Relidano Ltd. (4)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">73,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">73,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">--</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Jacques Mosseri Marlio (4)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">72,728</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">72,728</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">--</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Lowenstein Yair Holdings LTD (4)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">72,728</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">72,728</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">--</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Susan Mosseri Marlio (4)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">72,728</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">72,728</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">--</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Yehoshua Abramovich (4)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">50,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">50,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">--</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Gerarad Mosseri-Marlio Trust 1992 Exempt (4)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">43,638</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">43,638</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">--</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Tnuvat Haarava Ltd (4)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">32,728</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">32,728</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">--</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Anne Mosseri-Marlio (4)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">24,242</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">24,242</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">--</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Donald Wright (4)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">18,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">18,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">--</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">David A. Barrett (4)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12,122</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12,122</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">--</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Jacqueline Mosseri Marlio (4)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12,122</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12,122</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">--</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Tsorani Yaron (4)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10,910</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10,910</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">--</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Bar Zorani (4)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6,546</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6,546</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">--</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Michael Vasinkevich (4)(6)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">74,052</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">74,052</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">--</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Noam Rubinstein (4)(6)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">25,406</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">25,406</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">--</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">James Cappuccio (4)(6)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10,971</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10,971</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">--</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Craig Schwabe (4)(6)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,897</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,897</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">--</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Charles Worthman (4)(6)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,155</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,155</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">--</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(1)&nbsp;All of the Securities that are exercisable for the shares
underlying the Securities offered hereby contain certain beneficial ownership limitations, which provide that a holder of the Securities
will not have the right to exercise any portion of its Securities if such holder, together with its affiliates and attribution parties,
would beneficially own in excess of 4.99% or 9.99%, as applicable, of the number of shares of common stock outstanding immediately after
giving effect to such exercise, provided that upon at least 61 days&rsquo; prior notice to us, a holder may increase or decrease such
limitation up to a maximum of 9.99% of the number of shares of common stock outstanding (each such limitation, a &ldquo;Beneficial Ownership
Limitation&rdquo;). Additionally, stockholders may have acquired shares on the open market without the Company&rsquo;s knowledge that
may not be reflected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(2)&nbsp;Represents shares of common stock issued to the selling stockholders
in the private placement and offered hereby</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(3)&nbsp;We do not know when or in what amounts a Selling Stockholder
may offer shares for sale. The Selling Stockholders might not sell any or might sell all of the shares offered by this prospectus. Because
the Selling Stockholders may offer all or some of the shares pursuant to this offering, and because there are currently no agreements,
arrangements or understandings with respect to the sale of any of the shares, we cannot estimate the number of the shares that will be
held by the Selling Stockholders after completion of the offering. However, for purposes of this table, we have assumed that, after completion
of the offering, none of the shares covered by this prospectus will be held by the Selling Stockholders, including common stock issuable
upon exercise of the Warrants issued in the Private Placement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(4)&nbsp;The Selling Stockholder purchased or received the Securities
in the ordinary course of business and, at the time of purchase of the securities that are registered for resale, the selling stockholders
had no agreements or understanding, directly or indirectly with any person to distribute securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(5) Sabby Management, LLC is the investment
manager of Sabby Volatility Warrant Master Fund, Ltd. (&ldquo;Sabby&rdquo;) and shares voting and investment power with respect to
these shares in this capacity. As manager of Sabby Management, LLC, Hal Mintz also shares voting and investment power on behalf of
Sabby. Each of Sabby Management, LLC and Mr. Mintz disclaims beneficial ownership over the securities listed except to the extent of
their pecuniary interest therein. Includes the 909,091 shares underlying the Pre-Funded Warrants that are not presently exercisable
in full as a result of the 4.99% Beneficial Ownership Limitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(6)&nbsp;Each of the Selling Stockholders is associated with Wainwright, a registered
broker dealer and has a registered address of c/o H.C. Wainwright &amp; Co. 430 Park Ave, 3rd Floor, New York, NY 10022, and has sole
voting and dispositive power over the securities held. The number of shares beneficially owned prior to this offering consist of shares
of common stock issuable upon exercise of Placement Agent Investment Options, which were received as compensation for the Private Placement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 113 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Plan of Distribution</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Each Selling Shareholder of the securities and
any of their pledgees, assignees and successors-in-interest may, from time to time, sell any or all of their securities covered hereby
on the Nasdaq Capital Market or any other stock exchange, market or trading facility on which the securities are traded or in private
transactions. These sales may be at fixed or negotiated prices. A Selling Shareholder may use any one or more of the following methods
when selling securities:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&bull; ordinary brokerage transactions and transactions
in which the broker-dealer solicits purchasers;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&bull; block trades in which the broker-dealer
will attempt to sell the securities as agent but may position and resell a portion of the block as principal to facilitate the transaction;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&bull; purchases by a broker-dealer as principal
and resale by the broker-dealer for its account;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&bull; an exchange distribution in accordance with
the rules&nbsp;of the applicable exchange;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&bull; privately negotiated transactions;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&bull; settlement of short sales;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&bull; in transactions through broker-dealers that
agree with the Selling Shareholders to sell a specified number of such securities at a stipulated price per security;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&bull; through the writing or settlement of options
or other hedging transactions, whether through an options exchange or otherwise;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&bull; a combination of any such methods of sale;
or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&bull; any other method permitted pursuant to applicable
law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Selling Shareholders may also sell securities
under Rule&nbsp;144 or any other exemption from registration under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;),
if available, rather than under this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Broker-dealers engaged by the Selling Shareholders
may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts from the Selling Stockholders
(or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser) in amounts to be negotiated, but, except
as set forth in a supplement to this Prospectus, in the case of an agency transaction not in excess of a customary brokerage commission
in compliance with FINRA Rule&nbsp;2121; and in the case of a principal transaction a markup or markdown in compliance with FINRA Rule&nbsp;2121.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In connection with the sale of the securities or
interests therein, the Selling Shareholders may enter into hedging transactions with broker-dealers or other financial institutions, which
may in turn engage in short sales of the securities in the course of hedging the positions they assume. The Selling Shareholders may also
sell securities short and deliver these securities to close out their short positions, or loan or pledge the securities to broker-dealers
that in turn may sell these securities. The Selling Shareholders may also enter into option or other transactions with broker-dealers
or other financial institutions or create one or more derivative securities which require the delivery to such broker-dealer or other
financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution may
resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Selling Shareholders and any broker-dealers
or agents that are involved in selling the securities may be deemed to be &ldquo;underwriters&rdquo; within the meaning of the Securities
Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale
of the securities purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. Each Selling Shareholders
has informed the Company that it does not have any written or oral agreement or understanding, directly or indirectly, with any person
to distribute the securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company is required to pay certain fees and
expenses incurred by the Company incident to the registration of the securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We agreed to keep this prospectus effective until
all of the securities have been sold pursuant to this prospectus or Rule&nbsp;144 under the Securities Act or any other rule&nbsp;of similar
effect. The resale securities will be sold only through registered or licensed brokers or dealers if required under applicable state securities
laws. In addition, in certain states, the resale securities covered hereby may not be sold unless they have been registered or qualified
for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under applicable rules&nbsp;and regulations under
the Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously engage in market making activities
with respect to the Common Stock for the applicable restricted period, as defined in Regulation M, prior to the commencement of the distribution.
In addition, the Selling Stockholders will be subject to applicable provisions of the Exchange Act and the rules&nbsp;and regulations
thereunder, including Regulation M, which may limit the timing of purchases and sales of the Common Stock by the Selling Stockholders
or any other person. We will make copies of this prospectus available to the Selling Stockholders and have informed them of the need to
deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance with Rule&nbsp;172 under
the Securities Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 114 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: rgb(35,31,32)"><B><A NAME="sp12"></A>Legal Matters</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">The validity of the securities offered through
this prospectus has been passed on by Alston&nbsp;&amp; Bird LLP, New York City.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: rgb(35,31,32)"><B><A NAME="sp11"></A>Experts</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">The financial statements incorporated in this Prospectus by reference to the Annual Report on Form 10-K for the year ended December 31,
2021 have been so incorporated in reliance on the report of Kesselman&amp; Kesselman, Certified Public Accountants (Isr.), a member firm
of PricewaterhouseCoopers International Limited, an independent registered public accounting firm, given on the authority of said firm
as experts in auditing and accounting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: rgb(35,31,32)"><B><A NAME="sp10"></A>Where You Can Find More Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have filed with the SEC a registration statement on Form&nbsp;S-1 under the Securities Act with respect to the shares of our Common Stock
offered by this prospectus. This prospectus, which constitutes a part of the registration statement, does not contain all of the information
set forth in the registration statement, some of which is contained in exhibits to the registration statement as permitted by the rules&nbsp;and
regulations of the SEC. For further information with respect to us and our Common Stock, we refer you to the registration statement, including
the exhibits filed as a part of the registration statement. Statements contained in this prospectus concerning the contents of any contract
or any other document are not necessarily complete. If a contract or document has been filed as an exhibit to the registration statement,
please see the copy of the contract or document that has been filed. Each statement in this prospectus relating to a contract or document
filed as an exhibit is qualified in all respects by the filed exhibit. The SEC maintains a website that contains reports, proxy statements
and other information about issuers, like us, that file electronically with the SEC. The address of that website is </FONT>www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also file periodic reports, proxy statements and other information with the SEC. <FONT STYLE="color: #231f20">These periodic reports,
proxy statements and other information will be available for inspection at the website of the SEC referred to above. We also maintain
a website at www.nuvectis.com</FONT></FONT> <FONT STYLE="color: #231f20">where you may access these materials
free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. The information on
or that can be accessed through our website is not a part of this prospectus and the inclusion of our website address in this prospectus
is an inactive textual reference only.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 115 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B><A NAME="sp10a"></A>Incorporation
of Certain Information by Reference</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">The
SEC allows us to &ldquo;incorporate by reference&rdquo; the information we file with them. This means that we can disclose important
information to you by referring you to those documents instead of having to repeat the information in this document. The information
incorporated by reference is considered to be part of this prospectus, and later information that we file with the SEC will automatically
update and supersede this information. We incorporate by reference the documents listed below and any future filings made with the SEC
under Sections&nbsp;13(a), 13(c), 14 or 15(d)&nbsp;of the Securities Exchange Act of 1934, as amended, (1)&nbsp;after the date of the
initial registration statement, as amended, and prior to effectiveness of the registration statement, and (2)&nbsp;after the date of
this prospectus and prior to the termination of this offering. Such information will automatically update and supersede the information
contained in this prospectus and the documents listed below; provided, however, that we are not, unless specifically indicated, incorporating
any information furnished under Item&nbsp;2.02 or Item&nbsp;7.01 of any current report on Form&nbsp;8-K, whether listed below or filed
in the future, or related exhibits furnished pursuant to Item&nbsp;9.01 of Form&nbsp;8-K:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">Our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31,
2021 filed with the SEC on <A HREF="https://www.sec.gov/Archives/edgar/data/1875558/000110465922037110/tm2210237d1_10k.htm">March 23, 2022</A>;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 61.5pt 0pt 112.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Our Quarterly Reports on Form 10-Q filed with the SEC on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1875558/000141057822001377/tmb-20220331x10q.htm">May 12, 2022</A> and <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1875558/000155837022013018/tmb-20220630x10q.htm">August 10, 2022</A>;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 61.5pt 0pt 112.5pt; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">Our Current Reports on Form&nbsp;8-K filed with the SEC on
<A HREF="https://www.sec.gov/Archives/edgar/data/1875558/000110465922011786/tm2134227d1_8k.htm">February 4, 2022</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1875558/000110465922036359/tm229925d1_8k.htm">March 22, 2022</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1875558/000110465922058628/tm2214978d1_8k.htm">May 11, 2022</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1875558/000110465922084332/tm2222131d1_8k.htm">July 29, 2022</A>, and <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1875558/000110465922086454/tm2222617d1_8k.htm">August 5, 2022</A>; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 61.5pt 0pt 112.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">A description of our common stock, which is contained in the
Registration Statement on Form&nbsp;8-A, as filed with the SEC on <A HREF="https://www.sec.gov/Archives/edgar/data/1875558/000110465922011408/tm2134024d2_8a12b.htm">February 3, 2022</A>, and including any amendments or reports filed for
the purpose of updating such description.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">We
will provide to each person, including any beneficial owner, to whom a copy of this prospectus is delivered, a copy of any or all of
the information that we have incorporated by reference into this prospectus. We will provide this information upon written or oral request
at no cost to the requester. You may request this information by contacting our corporate headquarters at the following address: 1 Bridge
Plaza, Suite 275, Fort Lee, NJ 07024, Attn: Vice President of Finance, or by calling (201)&nbsp;614-3150 or at the following email address:
ir@nuvectis.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 116 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Part II&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Information not required in prospectus</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20"><B>Item 13. Other Expense of Issuance and
Distribution</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">The following table sets forth the costs
and expenses, other than certain discounts and commissions, payable by the registrant in connection with the sale of our common
stock being registered. All amounts are estimates except for the Securities and Exchange Commission, or SEC, registration fee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #231f20">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; color: #231f20">Amount</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #231f20">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 86%; color: #231f20; text-align: justify">SEC registration Fee</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #231f20; text-align: justify">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; color: #231f20; text-align: right">3,128.70</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #231f20; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: justify">Legal fees and expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: justify">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">30,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: justify">Accounting fees and expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: justify">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">25,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #231f20">Total</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: justify">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">58,128.70</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20"><B>Item 14. Indemnification of Directors
and Officers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">Section&nbsp;145(a)&nbsp;of the Delaware
General Corporation Law, or DGCL. provides, in general, that a Delaware corporation may indemnify any person who was or is a party, or
is threatened to be made a party, to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative
or investigative (other than an action by or in the right of the corporation) because that person is or was a director, officer, employee
or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another
corporation or other enterprise. The indemnity may include expenses (including attorneys&rsquo; fees), judgments, fines and amounts paid
in settlement actually and reasonably incurred by the person in connection with such action, so long as the person acted in good faith
and in a manner he or she reasonably believed was in or not opposed to the corporation&rsquo;s best interests, and, with respect to any
criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">Section&nbsp;145(b)&nbsp;of the DGCL provides,
in general, that a Delaware corporation may indemnify any person who was or is a party, or is threatened to be made a party, to any threatened,
pending or completed action or suit by or in the right of the corporation to obtain a judgment in its favor because the person is or was
a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer,
employee or agent of another corporation or other enterprise. The indemnity may include expenses (including attorneys&rsquo; fees) actually
and reasonably incurred by the person in connection with the defense or settlement of such action, so long as the person acted in good
faith and in a manner the person reasonably believed was in or not opposed to the corporation&rsquo;s best interests, except that no indemnification
shall be permitted without judicial approval if a court has determined that the person is to be liable to the corporation with respect
to such claim. Section&nbsp;145(c)&nbsp;of the DGCL provides that, if a present or former director or officer has been successful in defense
of any action referred to in Sections 145(a)&nbsp;and (b)&nbsp;of the DGCL, the corporation must indemnify such officer or director against
the expenses (including attorneys&rsquo; fees) he or she actually and reasonably incurred in connection with such action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">Section&nbsp;145(g)&nbsp;of the DGCL provides,
in general, that a corporation may purchase and maintain insurance on behalf of any person who is or was a director, officer, employee
or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another
corporation or other enterprise against any liability asserted against and incurred by such person, in any such capacity, or arising out
of his or her status as such, whether or not the corporation could indemnify the person against such liability under Section&nbsp;145
of the DGCL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 117; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">As permitted by Section&nbsp;102 of the
Delaware General Corporation Law, or the DGCL, we have adopted provisions in our Amended and Restated Certificate of Incorporation that
limit the liability of our directors for monetary damages for breach of their fiduciary duties, except for liability that cannot be eliminated
under the DGCL. Delaware law provides that directors of a corporation will not be personally liable for monetary damages for breach of
their fiduciary duties as directors, except liability for any of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&bull; any breach of their duty of loyalty
to the corporation or the stockholder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&bull; acts or omissions not in good faith
or that involve intentional misconduct or a knowing violation of law;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&bull; unlawful payments of dividends or unlawful
stock repurchases or redemptions as provided in Section&nbsp;174 of the DGCL; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&bull; any transaction from which the director
derived an improper personal benefit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">This limitation of liability does not apply
to liabilities arising under the federal securities laws and does not affect the availability of equitable remedies such as injunctive
relief or rescission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">Our Amended and Restated Certificate of
Incorporation and our Bylaws also provide that we will indemnify our directors and executive officers and may indemnify our other officers
and employees and other agents to the fullest extent permitted by law. We believe that indemnification under our Bylaws covers at least
negligence and gross negligence on the part of indemnified parties. Our Bylaws also permit us to secure insurance on behalf of any officer,
director, employee or other agent for any liability arising out of his or her actions in this capacity, regardless of whether our Bylaws
would permit indemnification. We have secured such insurance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">Insofar as indemnification for liabilities
arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing
provisions or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy
as expressed in the Securities Act and is, therefore, unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20"><B>Item 15. Recent Sales of Unregistered
Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">Since July&nbsp;27, 2020, we have made the
issuances of our unregistered securities described below. Also included is the consideration received by us for such securities and information
relating to the section of the Securities Act, or rule&nbsp;of the SEC, under which exemption from registration was claimed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">During June&nbsp;and July&nbsp;2021, the
Company closed an investment agreement with its founders, directors, and certain new investors to issue 128,520 preferred A shares, at
a price of approximately $119.05 per share, for a total investment amount of approximately $15.3 million, in which $1.73 million were
invested by related parties on the same terms as all other investors. These securities were offered and sold by us in reliance upon the
exemption from the registration requirements provided by Section&nbsp;4(a)(2)&nbsp;of the Securities Act and Rule&nbsp;506(b)&nbsp;of
Regulation D promulgated thereunder in a transaction by an issuer not involving any public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20"><FONT STYLE="color: #231F20">During July 2022, the
Company closed an investment </FONT>for the issuance and sale in a private placement (the &ldquo;Private Placement&rdquo;) of 1,015,598
shares of its common stock, par value $0.00001 (the &ldquo;Common Stock&rdquo;) and pre-funded warrants to purchase up to an aggregate
of 909,091 shares of Common Stock (the &ldquo;Pre-Funded Warrants&rdquo;). The investors in the Private Placement also purchased preferred
investment options to purchase up to an aggregate of 1,924,689 shares of Common Stock, and certain designees of H.C. Wainwright &amp;
Co., the exclusive placement agent for the Private Placement, also received preferred investment options to purchase up to an aggregate
of 115,481 shares of Common Stock (collectively, the &ldquo;Investment Options&rdquo;). The Private Placement included a Securities Purchase
Agreement, a Preferred Investment Option, a Pre-Funded Warrant, and a Registration Rights Agreement among other documents. Gross proceeds
to the Company from the Private Placement are approximately $15.9 million. <FONT STYLE="color: #231F20">These securities were offered
and sold by us in reliance upon the exemption from the registration requirements provided by Section 4(a)(2) of the Securities Act and
Rule 506(b) of Regulation D promulgated thereunder in a transaction by an issuer not involving any public offering.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">&nbsp;</P>

<!-- Field: Page; Sequence: 118 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20"><B><A NAME="sp9"></A>Item 16. Exhibits and Financial Statement Schedules</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">(a)&nbsp;Exhibits. The exhibits to the Registration Statement
are listed in the Exhibit&nbsp;Index below and incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit&nbsp;Index</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 14%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit&nbsp;Number</B></FONT></TD>
    <TD STYLE="width: 86%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #DAEEF3">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="tm2223302d1_ex5-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</FONT></A></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="tm2223302d1_ex5-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Alston&nbsp;&amp; Bird LLP</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1875558/000110465922084332/tm2222131d1_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></A></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1875558/000110465922084332/tm2222131d1_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of Securities Purchase Agreement by and among Nuvectis Pharma,&nbsp;Inc. and the Purchasers, dated July&nbsp;27, 2022. Filed as Exhibit&nbsp;10.1 to the Registrant&rsquo;s Form&nbsp;8-K filed on July&nbsp;29, 2022 File No.&nbsp;001-41264 and incorporated herein by reference.</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #DAEEF3">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1875558/000110465922084332/tm2222131d1_ex10-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</FONT></A></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1875558/000110465922084332/tm2222131d1_ex10-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of Preferred Investment Option filed as Exhibit&nbsp;10.2 to the Registrant&rsquo;s Form&nbsp;8-K filed on July&nbsp;29, 2022 File No.&nbsp;001-41264 and incorporated herein by reference.</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1875558/000110465922084332/tm2222131d1_ex10-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</FONT></A></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1875558/000110465922084332/tm2222131d1_ex10-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of Pre-Funded Stock Warrant filed as Exhibit&nbsp;10.3 to the Registrant&rsquo;s Form&nbsp;8-K filed on July&nbsp;29, 2022 File No.&nbsp;001-41264 and incorporated herein by reference.</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #DAEEF3">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1875558/000110465922084332/tm2222131d1_ex10-4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</FONT></A></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1875558/000110465922084332/tm2222131d1_ex10-4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of Registration Rights Agreement by and among Nuvectis Pharma,&nbsp;Inc. and the Purchasers, dated July&nbsp;27, 2022. Filed as Exhibit&nbsp;10.4 to the Registrant&rsquo;s Form&nbsp;8-K filed on July&nbsp;29, 2022 File No.&nbsp;001-41264 and incorporated herein by reference.</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="tm2223302d1_ex23-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</FONT></A></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="tm2223302d1_ex23-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Kesselman&nbsp;&amp; Kesselman, Certified Public Accountants (Isr.), a member firm of PricewaterhouseCoopers International Limited.</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #DAEEF3">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="tm2223302d1_ex5-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2</FONT></A></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="tm2223302d1_ex5-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Alston&nbsp;&amp; Bird LLP (included in Exhibit&nbsp;5.1)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1</FONT></A></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power of Attorney (included on signature page)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #DAEEF3">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="tm2223302d1_ex-filingfees.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">107.1</FONT></A></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="tm2223302d1_ex-filingfees.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing Fee Table</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20"><B>Item 17. Undertakings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">(b)&nbsp;The undersigned registrant hereby undertakes that,
for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant's annual report pursuant to
Section&nbsp;13(a)&nbsp;or 15(d)&nbsp;of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit
plan's annual report pursuant to Section&nbsp;15(d)&nbsp;of the Securities Exchange Act of 1934) that is incorporated by reference in
the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering
of such securities at that time shall be deemed to be the initial bona fide offering thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)&nbsp;Insofar
as indemnification for liabilities arising under the&nbsp;</FONT>Securities Act of 1933&nbsp;may be permitted to directors, officers and
controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the
opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore,
unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses
incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding)
is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless
in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the
question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication
of such issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 119 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Signatures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">Pursuant to the requirements of the Securities Act of 1933,
the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in
the City of Fort Lee, State of New Jersey, on this   15th day of August, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">Nuvectis Pharma,&nbsp;Inc.</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"> /s/ Ron Bentsur</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">Ron Bentsur</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">Chairman, Chief Executive Officer and President</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B><A NAME="a_001"></A>POWER OF ATTORNEY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">We, the undersigned
directors and/or executive officers of Nuvectis Pharma,&nbsp;Inc., hereby severally constitute and appoint Ron Bentsur, acting singly,
his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her in any and all
capacities, to sign this report and to file the same, with all exhibits thereto and other documents in connection therewith, with the
Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and
every act and thing necessary or appropriate to be done in connection therewith, as fully for all intents and purposes as he or she might
or could do in person, hereby approving, ratifying and confirming all that said attorney-in-fact and agent, or his substitute, may lawfully
do or cause to be done by virtue hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231f20">Pursuant to the requirements of the Securities Act of 1933,
as amended, this registration statement has been signed by the following persons in the capacities held on the dates indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: bottom; width: 30%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signature</B></FONT></TD>
    <TD STYLE="width: 5%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 45%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 4%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 16%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Ron Bentsur</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman,
    Chief Executive Officer and President</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August&nbsp;15, 2022</FONT></TD>
    </TR>
  <TR>
    <TD STYLE="text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ron
    Bentsur</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">(Principal Executive Officer)</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    </TR>
  <TR>
    <TD STYLE="text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    </TR>
  <TR>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Michael Carson</FONT> &nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice
    President of Finance</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August&nbsp;15, 2022</FONT></TD>
    </TR>
  <TR>
    <TD STYLE="text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    Carson</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">(Principal Financial and Accounting Officer)</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    </TR>
  <TR>
    <TD STYLE="text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    </TR>
  <TR>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Kenneth Hoberman</FONT> &nbsp;&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">Director</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August&nbsp;15, 2022</FONT></TD>
    </TR>
  <TR>
    <TD STYLE="text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kenneth
    Hoberman</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    </TR>
  <TR>
    <TD STYLE="text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    </TR>
  <TR>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    James F. Oliviero</FONT> &nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">Director</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August&nbsp;15, 2022</FONT></TD>
    </TR>
  <TR>
    <TD STYLE="text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;James
    F. Oliviero</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    </TR>
  <TR>
    <TD STYLE="text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    </TR>
  <TR>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Matthew L. Kaplan </FONT>&nbsp;&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">Director</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August&nbsp;15, 2022</FONT></TD>
    </TR>
  <TR>
    <TD STYLE="text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Matthew
    L. Kaplan</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 120; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>tm2223302d1_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 5.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: Red"><IMG SRC="tm2223302d1_ex5-1img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left; color: Red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">90 Park Avenue<BR>
New York, NY 10016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">212-210-9400 | Fax: 212-210-9444</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38%; font-size: 10pt; font-weight: bold"><FONT STYLE="font-weight: normal">Matthew W. Mamak</FONT></TD>
    <TD STYLE="width: 26%; font-size: 10pt; font-weight: bold; text-align: center"><FONT STYLE="font-weight: normal">Direct Dial:&nbsp;&nbsp;212-210-1256</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 36%; font-size: 10pt; font-weight: bold; text-align: right"><FONT STYLE="font-weight: normal">Email:&nbsp;&nbsp;matthew.mamak@alston.com</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">August 15, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nuvectis Pharma, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Bridge Plaza Suite 275</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fort Lee, NJ 07024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re:</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration Statement on Form S-1</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are acting as counsel to
Nuvectis Pharma, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;) in connection with the registration statement (the &ldquo;<U>Registration
Statement</U>&rdquo;) on Form S-1 filed today by the Company with the Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;)
to register under the Securities Act of 1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;), 3,964,859 shares of the Company&rsquo;s
common stock, $0.00001 par value per share (the &ldquo;<U>Shares</U>&rdquo;). The Shares are being registered pursuant to a private placement
(the &ldquo;<U>Private Placement</U>&rdquo;) closed July 29, 2022 in which the Company sold 1,015,598 Shares and sold preferred investment
options exercisable for up to 2,040,170 Shares, and sold pre-funded warrants to purchase up to 909,091 Shares<FONT STYLE="background-color: white">.</FONT>&nbsp;This
opinion is furnished to you at your request in accordance with the requirements of Item 601(b)(5) of Regulation S-K promulgated under
the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have examined the Second
Amended and Restated Certificate of Incorporation of the Company, the Amended and Restated Bylaws of the Company, records of proceedings
of the Board of Directors of the Company (the &ldquo;<U>Board of Directors</U>&rdquo;), or committees thereof, and records of proceedings
of the stockholders, deemed by us to be relevant to this opinion letter and the Registration Statement. We also have made such further
legal and factual examinations and investigations as we deemed necessary for purposes of expressing the opinion set forth herein. In our
examination, we have assumed the genuineness of all signatures, the legal capacity of all natural persons, the authenticity of all documents
submitted to us as original documents and the conformity to original documents of all documents submitted to us as certified, conformed,
facsimile, electronic or photostatic copies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As to certain factual matters
relevant to this opinion letter, we have relied conclusively upon originals or copies, certified or otherwise identified to our satisfaction,
of such records, agreements, documents and instruments, including certificates or comparable documents of officers of the Company and
of public officials, as we have deemed appropriate as a basis for the opinion hereinafter set forth. Except to the extent expressly set
forth herein, we have made no independent investigations with regard to matters of fact, and, accordingly, we do not express any opinion
as to matters that might have been disclosed by independent verification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our opinion set forth below
is limited to the General Corporation Law of the State of Delaware, applicable provisions of the Constitution of the State of Delaware
and reported judicial decisions interpreting such General Corporation Law and Constitution that, in our professional judgment, are normally
applicable to transactions of the type contemplated by the Plan, the laws of the State of New York, and the federal law of the United
States, and we do not express any opinion herein concerning any other laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 5pt; font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: left">Alston
    &amp; Bird LLP</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 5pt; font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: right">www.alston.com</TD></TR>
  <TR STYLE="font-size: 8pt; vertical-align: bottom; background-color: White">
    <TD COLSPAN="2" STYLE="font: 8pt Times New Roman, Times, Serif; padding-top: 5pt; text-align: left">Atlanta | Beijing | Brussels | Charlotte | Dallas
    | Fort Worth | London | Los Angeles | New York | Raleigh | San Francisco | Silicon Valley | Washington, D.C.</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">August 15, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This opinion letter is provided
for use in connection with the transactions contemplated by the Registration Statement and may not be used, circulated, quoted or otherwise
relied upon for any other purpose without our express written consent.&nbsp; The only opinion rendered by us consists of those matters
set forth in the sixth paragraph hereof, and no opinion may be implied or inferred beyond the opinion expressly stated.&nbsp; This opinion
letter is rendered as of the date hereof and we make no undertaking and expressly disclaim any duty to supplement or update the opinions
rendered herein, if, after the date hereof, facts or circumstances come to our attention or changes in the law occur which could affect
such opinions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on the foregoing, it
is our opinion that the Shares to be issued under the Private Placement are duly authorized, validly issued, fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We consent to the filing of
this opinion letter as an exhibit to the Registration Statement.&nbsp; In giving such consent, we do not thereby admit that we are within
the category of persons whose consent is required under Section&nbsp;7 of the Securities Act or the rules&nbsp;and regulations of the
Commission thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">ALSTON &amp; BIRD LLP</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: italic 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: italic 10pt Times New Roman, Times, Serif; width: 3%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: italic 10pt Times New Roman, Times, Serif; width: 47%">/s/ Matthew W. Mamak</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Matthew W. Mamak</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Partner&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>tm2223302d1_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 23.1&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;<IMG SRC="image_001.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">We hereby consent to the incorporation by reference in this Registration
Statement on Form S-1 of Nuvectis Pharma, Inc. of our report dated March 23, 2022, relating to the financial statements, which appears
in Nuvectis Pharma, Inc.'s annual report on Form 10-K for the year ended December 31, 2021. We also consent to the reference to us under
the heading &ldquo;Experts&rdquo; in such Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #333333">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #333333">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 2in"><FONT STYLE="font-size: 10pt">Tel-Aviv, Israel&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD>/s/ Kesselman &amp; Kesselman</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">August 15, 2022</FONT></TD>
    <TD>Certified Public Accountants (Isr.)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: -14.2pt">&nbsp;</TD>
    <TD STYLE="padding-right: -14.2pt"><FONT STYLE="font-size: 10pt">A member firm of PricewaterhouseCoopers International Limited</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>Kesselman &amp; Kesselman, 146 Derech Menachem Begin, Tel-Aviv 6492103,
Israel,</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>P.O Box 7187 Tel-Aviv 6107120, Telephone: +972 -3- 7954555, Fax:+972
-3- 7954556, www.pwc.com/il</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>4
<FILENAME>tm2223302d1_ex-filingfees.htm
<DESCRIPTION>EXHIBIT 107
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 107 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Calculation of Filing Fee Table </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form S-1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Form Type)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Nuvectis Pharma, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in its Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Table 1: Newly Registered Securities</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center"><B>&nbsp;</B></TD><TD STYLE="text-align: center; font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD STYLE="text-align: center; font-size: 10pt; border-bottom: Black 1pt solid"><B>Security<BR>
 Type</B></TD><TD STYLE="text-align: center; font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 10pt; text-align: center"><B>Security<BR>
 Class Title</B></TD><TD STYLE="text-align: center; font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Fee<BR> Calculation<BR> Rule</B></TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="text-align: center; font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Amount<BR> Registered</B></TD><TD STYLE="text-align: center; font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Proposed<BR> Maximum<BR> Offering<BR>
    Price Per<BR>
 Unit(4)</B></TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="text-align: center; font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Proposed Maximum<BR> Aggregate<BR>
    Offering Price</B></TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="text-align: center; font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Fee Rate</B></TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="text-align: center; font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Amount of<BR> Registration<BR> Fee</B></TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; width: 10%; font-size: 10pt; text-align: left; text-indent: -9pt; padding-left: 9pt">Fees to be paid</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 8%; font-size: 10pt; text-indent: -9pt; padding-left: 9pt; text-align: center">Equity</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 10%; font-size: 10pt; text-indent: -9pt; padding-left: 9pt; text-align: left">Common Stock, par value $0.00001 per share</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font-size: 10pt; text-align: center">457</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">(c)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 10%; font-size: 10pt">3,964,859 </TD><TD STYLE="width: 1%; font-size: 10pt">(1)</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">8.5125</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">33,750,862.20</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 8%; font-size: 10pt; text-align: right">0.0000927</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 8%; font-size: 10pt; text-align: right">3,128.70</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="4" STYLE="vertical-align: top; font-size: 10pt; text-align: left; text-indent: -9pt; padding-left: 9pt">Total Offering Amounts</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">33,750,862.20</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">3,128.70</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="4" STYLE="vertical-align: top; font-size: 10pt; text-align: left; text-indent: -9pt; padding-left: 9pt">Total Fee Offsets</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">--</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">--</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="4" STYLE="vertical-align: top; font-size: 10pt; text-align: left; text-indent: -9pt; padding-left: 9pt">Net Fee Due</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">33,750,862.20</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">3,128.70</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;Consists of 1,015,598 shares of Common Stock registered for sale by certain of the selling stockholders named in this registration statement, 1,924,869 shares of Common Stock issuable upon the exercise of Preferred Investment Options for $9.65 per share registered for sale by certain of the selling stockholders named in this registration statement, 115,481 shares of Common Stock issuable upon the exercise of Preferred Investment Options for $10.3125 per share registered for sale by certain representatives of H.C. Wainwright &amp; Co., who served as placement agent for the Company&rsquo;s private placement, and 909,091 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants for $0.001 per share registered for sale by certain of the selling stockholders named in this registration statement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Table 2: Fee Offset Claims and Sources </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>N/A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Table 3: Combined Prospectuses </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>N/A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>tm2223302d1_s1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2223302d1_s1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !G +T# 2(  A$! Q$!_\0
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M^SP7.BF2\EA35C#;Q"Z*;A@G8[]=O'K5))+@:1K.G).\$8U"TB5+>Y9Q&K.
MVUR<UZQ<:'I=VDD5Q8P2+*_FN'C!W-_>^M)%H6DP(4CTZU125)"0@ E3D9^A
MIJ:70+'G]QX?M3XEOM,\V[-I;:4;A(_M4F/,X^;.:K:;&VG)X5U@75X]S=&1
M;EWG9]R>6YQM)(XVC'%>J&PM6N'G-O'YSQ^6S[>2O]TU&-,L%6!1:P[;<YB
M0?)VX].II<X6/'Q</'>Z+J5J9(OM&H(IN)+UGFF4D@@IT ]L5[+;W<%QYBP2
MH_EMM;:?NFJ$?AS187:5=*LUE+B1F$*]0<YZ<>M2:;H]OILMY+"6W7<IEDR
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%110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>tm2223302d1_s3img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2223302d1_s3img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M>W0_2D?'7P:6_P"1J\/?7^T(O_BJ#\=?!N<?\)3X>^O]H1?_ !5?G[7,^/\
MXO>'OA=J/AVTUW4?L-QXJU--&TI/L\LGVN[=7=8\HK!,K&YW/A>.N2*J7AWA
MHJ\J]M4MENW:V_<SAXM8Z;Y889-ZO1O9*[^Y:OR/TH7XZ^#,?\C1X?\ QU"'
M_P"*H_X7MX-_Z&KP_P#^#"+_ .*K\_:SO%OBW3? ?AB_UK6;VWTW2]+@>ZN[
MJ=]L<$2#+,Q[  54O#G#Q5Y5W;T7^8H^+F-E)1CADV_-GZ)GXZ^#<?\ (U>'
MO_!A%_\ %4+\=?!G_0T^'_\ P81?_%5^=/B'QKI/A+PE<Z]JFH6NGZ/9VYNI
M[RY<110Q 9WL3T&*P/AO^T!X7^+&LW>FZ1>7\>J6<0N);'4]*N]*NS"3M$Z0
MW443R0D\"5 4)X#9J?\ B'N&4N1U]>UE?[KEQ\6,?*#JK"KE6[UM]Y^F_P#P
MO;P;_P!#3X?_ /!A%_\ %4?\+V\&_P#0T^'_ /P81?\ Q5?GW15?\0YH?\_W
M]R_S,O\ B+V*_P"@=?>S] C\=/!N,_\ "5>'O_!A%_\ %4J_'7P8?^9J\/\
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M .(P8G_GPOO9^@?_  O3P:?^9J\/<?\ 40B_^*I&^.W@T'_D:O#_ /X,(O\
MXJOS@^)GQ*T7X.^ =4\3^([W^S=#T6!KF]NO*DF\B)>K;(U9V^B@FN>MOVH?
M EWXV\4>'(_$$)USP7ID6LZQ9FWF$EK9R1F1)AE,2#:,D1EBN0" 2 <:GA_@
MZ;Y9XBS\TNS??R?W'33\5,QJ0YZ>%NNZNUNE^;2^:/U /QU\&_\ 0U>'O_!A
M%_\ %4#XZ>##_P S3X?_ /!A%_\ %5^45S^W#\-XI-#CM]3U[5)?$6BQ^([&
M/2O"^JZE))ITAVK<NMO;R-&I(Q^\"D=P*])\(>,=+\?^&K+6-%OK;4]+U&,3
M6UU;OOCE4]P?T(Z@@@\T0\/<+-N,,1?O9+3\1XCQ2S*BE*MA.5/O=?F?HM_P
MO;P;_P!#3X?_ /!A%_\ %4?\+V\&_P#0T^'_ /P81?\ Q5?GW16O_$.*'_/]
M_<O\SF_XB]BO^@=?>S] C\=?!K?\S5X?_P#!A%_\51_PO7P8?^9I\/\ _@PB
M_P#BJ_-GQ?\ %WP]X#\8^&?#^K:A]EU;QA<36ND6_D2O]LEBB::1=RJ53$:L
M<N5!Q@9/%-\7?%_P]X$\8:%H&IWLD.L>)4NGTRUCM)IWNQ;1^;-CRT8 JG(!
M(+=%!/%9_P#$/<*DV\1L[;+?MOZ&W_$5L>[?[+NFUOJENUY*SOZ,_2C_ (7K
MX,)_Y&CP_P#^#&+_ .*IW_"]O!O_ $-/A_\ \&$7_P 57YWZ!K47B31+6_MU
MNH[>\B6:-+JTDM)E5AD!XI%62-O5756!X(!JY5_\0YH?\_W]R_S,GXN8R+L\
M.OO9^@G_  O;P;_T-/A__P &$7_Q5'_"]O!O_0T^'_\ P81?_%5^?=%5_P 0
MWH_\_G]R_P R?^(P8G_GPOO9^@2_'7P:7Q_PE'A[CO\ VA%S_P"/4?\ "\_!
MN?\ D:O#O_@QB_\ BJ_*;Q7^VU\./!7C#7-%U+5M7AN/#%Q#:ZQ<IX=U.;3]
M*DE5)(Q<7B0&VB!21#N>4 !N2*[7P/\ %70/B1JFOV>BZ@M]<>%]0_LO4T$,
MD?V6Y\M)-F64!_DD0[D)7YL9R"*PI^'^$J.T,3?T2?Z^AV5?$_-*4.>I@[+>
M[NE9[=/-?>?I-_PO;P;_ -#3X?\ _!A%_P#%4?\ "]O!O_0T^'__  81?_%5
M^?=%:_\ $.*/_/Y_<O\ ,Y/^(O8K_H'7WL_0+_A>G@S_ *&KP_QT_P")A%_\
M50/CIX-Q_P C5X>_\&$7_P 57Y^]ZY?PG\:?"OCWQ[X@\,Z+K=GJ6N>$Q =7
MM;<E_L!FWF-78#9O(C8E =RC&0,C)+PZPZ:BZ[N_)?YFD?%K&RBY1PR:6^KT
MUMKVU=O4_2S_ (7MX-_Z&GP__P"#"+_XJC_A>W@W_H:?#_\ X,(O_BJ_/NBJ
M_P"(;T?^?S^Y?YF7_$8,2M\.OO9^@G_"]O!O_0T^'_\ P81?_%4?\+V\&_\
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MC:DN2&&3;Z)MGZ4?\+V\&_\ 0U>'_P#P81?_ !5#?'7P9C_D:/#_ .&H0_\
MQ5?G'\/OB)HWQ4\)6VN:!>+J&FWFX1R^6\;*R,4='C<*\<B,K*R.H964@@$$
M5M5HO#>BU=5G]R_S)EXNXR$G">'2:\V?H)_PO;P;_P!#3X?_ /!A%_\ %4?\
M+V\&_P#0T^'_ /P81?\ Q5?GW11_Q#>C_P _G]R_S(_XC!B?^?"^]GZ"?\+T
M\&Y_Y&KP]_X,(?\ XJD'QU\&_P#0T^'_ /P80_\ Q5?F1\7_ -H'PO\  N71
M8O$5SJ<=UXDN7L],M=/T>\U2YO9DC:5E2&UAED.$5F)VXPIK/\)?M7> ?'.J
M>'K'3M<DDOO%%Q>6FGVLMA=6]P9K10]S%+')&K6\D:D$I,$;G@&N?_4'!\[I
M_6?>72ROT\_/\3L_XBEF3IJLL)[KOKK;3?6W2S/U(_X7MX-_Z&GP_P#^#"+_
M .*H_P"%[>#?^AI\/_\ @PB_^*K\^Z*W_P"(;T?^?S^Y?YG+_P 1>Q7_ $#K
M[V?H$OQT\&[_ /D:?#W_ (,(O_BJ#\=O!H;_ )&GP_\ 7^T(O_BJ_/VO/?B+
M^U-X#^%'C2'P_KVO+8ZI)'#-(JV=Q-#91S2>5"]S-'&T5LLDGR(9W0.W"Y-1
M/P[PT+<V(M?35+?MN:T?%C'U7R4\+S/?2[T/U&_X7MX-_P"AI\/_ /@PB_\
MBJ/^%[>#?^AI\/\ _@PB_P#BJ_/NBM/^(;T?^?S^Y?YF/_$8,3_SX7WL_1GP
MUXTTGQE#))I.I6&I1PMLD>VN%F"-C."5)P<<UI]%Y_"O OV AGP+K'_7TO\
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M^'__  81?_%5^?=%'_$-Z/\ S^?W+_,7_$8,3_SX7WL_03_A>W@W_H:?#_\
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M2627EDD;G'H'QK^#7BKQ7\3K6;0])U30_#=QX6TFT\#M;?#NZOK[PY=1S/\
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MJYO16T^-W[V1^0,/[+GBC5OA1XHDOO /B*XU?3_@9HEIHXFT><RPZO#Y[>7
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M!8_&31Y='U)-,F>Z32?+LH[B6&3:6^SM&)%E=?D8)AR=O'Z>_P##)OC_ /Z
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MV:)5R\>(V ,8(^0XZ&OTP_X95\='_F"I_P"#"V_^.4?\,J^.O^@*G_@PMO\
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M2_S/YHJ<,YLYM_5Y[_RO_(X.BN\_X9D\;?\ 0*M__!E:_P#QRC_AF3QM_P!
MJW_\&5K_ /'*K^W,N_Y_P_\  E_F1_JSFW_0-/\ \!?^1P=%=Y_PS)XV_P"@
M5;_^#*U_^.4?\,R>-O\ H%6__@RM?_CE']N9=_S_ (?^!+_,/]6<V_Z!I_\
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MRC^W,N_Y_P /_ E_F'^K.;?] T__  %_Y'!T5WG_  S)XV_Z!5O_ .#*U_\
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M>\DOM.N6N)S=PVEFQU".>1Y)%,]P$B>1CY#UK:S_ ,$T/B-8? +X/^'M"O\
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M3LG\]PHHHK$T"BBB@ HHHH **** "BBB@#2T_P#X]%_'^=35#I__ !Z+^/\
M.IJ#,**** "BBB@ HHHH **** )O#O\ Q^7G^\G_ *#6L>E9/AW_ (_+S_>3
M_P!!K6/2JE\7W?D5'8\CHHHKWCQ0HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#MOA?_P @FX_Z['^0HH^%_P#R"KC_
M *['^0HKQ*WQL];#_P -'34445D;!1110 4444 %%%% !1110 4444 %%%%
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M6Z&-ELX;76+NWA@5XXXQ(L<4:()"@9PH9N2:]PJ)1<79@]&XONU]SL%%%%2
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M#XD?$GPC^PK\ 6UO5K76(_"^A^6-0N--TV6^EMT8XDNIDB4OY:_>=P#M Z8
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MMHUV_'_)JUEW,?PI_P %</ 7COPEJ'B31?"OQ!U/POINFZ??3ZQ!:V)M3-J
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MOO%OA][MO$WAJWL]-DU#PM;VWEF2YN7%[]FDC*S1LB6L\\L@8A(V*N%@LO\
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M_P"/1?Q_G4U!F%%%% !1110 4444 %%%% $WAW_C\O/]Y/\ T&M8]*R?#O\
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MJ.HHHKPSV HHHH **** "BBB@ HHHH **** "BBB@ HHHH [;X7_ /(*N/\
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M*\L@2(E84+(&?&!O!Z D3ULN]OGL+F35_*_R/1/^%M:7_P ^OB;_ ,)S4/\
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M)]-\8Z#;:II.H6.J:9>)YMO>6<ZSP3I_>1U)5A[@U\-6W[&/Q6NO"5[';?\
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MM/\ $NL>&V\'66B>"+/PN]I]IM91J-PDBR-(@@=\0Q@%$WE6.]OE '.F)P6
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MB&3Q5I]WH/P\O_#4.H3WMA/8SF3#D6MM8VQNI8CY>_?</YP+D"-RQ8=V)R?
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MHHK$V"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J^K_\
M(,G_ -PU8JOJ_P#R#)_]PT <G1110 4444 %%%% !1110 4444 %:A&X5EUJ
M5429$3Q5&UL#VJS15$E46P]*<D 6K%% #$CQ3Z** "HKW_CV;Z#^=2U%>_\
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M%% !1110 4444 %%%% !1110 57U?_D&3_[AJQ5?5_\ D&3_ .X: .3HHHH
M**** "BBB@ HHHH **** "M2LNM2JB3(****HD**** "BBB@ J*]_P"/9OH/
MYU+45[_Q[-]!_.@#S[XY:T_AKP6FI0_#_6/B5=Z;>0W-MI&E?V:+Q)5;Y;B-
MM0N;:!3'USYH8?P@GBO#?A3^T!\(?^"@GPYO]>\=?"G3]%T%;'3+P'XC)X;O
M/M=K<32-9NT4%[=M"OG(2@N5BR[?NPQ#8^H9U\V!U'5E(%? ?A[_ ()K_&#P
M)\.(O">EWOPUN]/UWPOX7T?6[RZU*]CFTZXT:]EG;[-&MJ1<1SQRE0SO"8V7
M.V0' SA:[3[JWEW?W)&DO@NO1^:_X<^A6^-O[,.BVD=D?%WP&M(/ANKPI;G5
M=)C3PL+AFLW4+NQ:B5F> CY=Y+(<DD5L>+/'OP ?P_J7PDUS6?@]_9>AZ")]
M0\%W]WIOV?3](BC&'EL'.V.T2,#ED$84#M7B/A#_ ()K>(-!GT![B3P8QTKP
M_P"/]-F*-*=]UK^I17-M(,PC(6%'65CR"V%$@)->4^(_^"17Q8UO]E";X.?;
MOAA)ID$VK>(+;Q3->WC:M=:E?Z==VWV.2+[+MC@1[LH;H3.[V\2Q_9U)R+C%
M2TD][?/5K\$N;YV*IQC>+?6_R5E^;T\CZ4TR#]D#Q/X4\&_#NS3]FW4-#U'4
M)KGPGX8A719;2ZO89&2:2QM!E&FCD#JS1*65@P.#FO9)?V?_  '<:U?ZE)X)
M\(MJ.J02VU[=-H]N9KR*6."*6.1]FYU>.VMD96)#+;Q Y"*!\S_M(?L">-?B
M)\<_#VN^$U\#Z98)I>B:;J%_/J-VDMJ-,OOM<>[2Y+>XT_45!R(686DUN7=E
MF;<H3[&INRC=/6[3\UHK_,B,I)JVFB^5]6CEOA1\#O!7P&T*72_ W@_POX,T
MR>19I;/0M*@TZ"1UC6-69(4521&B("1D*BCH!74T45%VW=C"BBBD 4444 %%
M%% !1110 4444 %%%% &EI__ !Z+^/\ .IJAT_\ X]%_'^=34&84444 %%%%
M !1110 4444 3>'?^/R\_P!Y/_0:UCTK)\._\?EY_O)_Z#6L>E5+XON_(J.Q
MY'1117O'BA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% ';?"_\ Y!5Q_P!=C_(44?"__D%7'_78_P A17B5OC9ZV'_A
MHZ:BJ.OZ_8^%]*EOM2O+73[*$CS+BYF6&*/)"C+,0!DD <]2*Y__ (7YX&_Z
M'3PG_P"#>W_^+K(V.NHKD?\ A?G@;_H=/"?_ (-[?_XNC_A?G@;_ *'3PG_X
M-[?_ .+H ZZBN1_X7YX&_P"AT\)_^#>W_P#BZ/\ A?G@;_H=/"?_ (-[?_XN
M@#KJ*Y'_ (7YX&_Z'3PG_P"#>W_^+H_X7YX&_P"AT\)_^#>W_P#BZ .NHKD?
M^%^>!O\ H=/"?_@WM_\ XNC_ (7YX&_Z'3PG_P"#>W_^+H ZZBN1_P"%^>!O
M^AT\)_\ @WM__BZ/^%^>!O\ H=/"?_@WM_\ XN@#KJ*Y'_A?G@;_ *'3PG_X
M-[?_ .+H_P"%^>!O^AT\)_\ @WM__BZ .NHKD?\ A?G@;_H=/"?_ (-[?_XN
MC_A?G@;_ *'3PG_X-[?_ .+H ZZBN1_X7YX&_P"AT\)_^#>W_P#BZ/\ A?G@
M;_H=/"?_ (-[?_XN@#KJ*Y'_ (7YX&_Z'3PG_P"#>W_^+H_X7YX&_P"AT\)_
M^#>W_P#BZ .NJOJ__(,G_P!PUS/_  OSP-_T.GA/_P &]O\ _%U#J?QY\#R:
M?,%\9^%&)0@ :O;\_P#C] !17,_\+K\&_P#0V>&?_!I!_P#%4?\ "Z_!O_0V
M>&?_  :0?_%4 =-17,_\+K\&_P#0V>&?_!I!_P#%4?\ "Z_!O_0V>&?_  :0
M?_%4 =-17,_\+K\&_P#0V>&?_!I!_P#%4?\ "Z_!O_0V>&?_  :0?_%4 =-1
M7,_\+K\&_P#0V>&?_!I!_P#%4?\ "Z_!O_0V>&?_  :0?_%4 =-17,_\+K\&
M_P#0V>&?_!I!_P#%4?\ "Z_!O_0V>&?_  :0?_%4 =-6I7"_\+K\&_\ 0V>&
M?_!I!_\ %5H_\+R\%?\ 0W>%_P#P;0?_ !55$F1U-%<M_P +R\%?]#=X7_\
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M_"Z_!O\ T-GAG_P:0?\ Q5'_  NOP;_T-GAG_P &D'_Q5 '345S/_"Z_!O\
MT-GAG_P:0?\ Q5'_  NOP;_T-GAG_P &D'_Q5 '345S/_"Z_!O\ T-GAG_P:
M0?\ Q5'_  NOP;_T-GAG_P &D'_Q5 '345S/_"Z_!O\ T-GAG_P:0?\ Q5'_
M  NOP;_T-GAG_P &D'_Q5 '345S/_"Z_!O\ T-GAG_P:0?\ Q5'_  NOP;_T
M-GAG_P &D'_Q5 '345S/_"Z_!O\ T-GAG_P:0?\ Q5'_  NOP;_T-GAG_P &
MD'_Q5 '345S/_"Z_!O\ T-GAG_P:0?\ Q5'_  NOP;_T-GAG_P &D'_Q5 '<
M:?\ \>B_C_.IJY&R^.'@M+50?%_A<'G@ZK!Z_P"]4W_"\O!/_0X>%?\ P:P?
M_%T&9U%%<O\ \+R\$_\ 0X>%?_!K!_\ %T?\+R\$_P#0X>%?_!K!_P#%T =1
M17+_ /"\O!/_ $.'A7_P:P?_ !='_"\O!/\ T.'A7_P:P?\ Q= '445R_P#P
MO+P3_P!#AX5_\&L'_P 71_PO+P3_ -#AX5_\&L'_ ,70!U%%<O\ \+R\$_\
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M<OV.75(G51A"MWC=&A*C+5<K<J<-;VWT_#LUZF.JDUTZ6UOM^3TZ7['L&O\
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MHHH TM/_ ./1?Q_G4U0Z?_QZ+^/\ZFH,PHHHH **** "BBB@ HHHH F\._\
M'Y>?[R?^@UK'I63X=_X_+S_>3_T&M8]*J7Q?=^14=CR.BBBO>/&"BBB@0444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ';?"_
M_D%7'_78_P A11\+_P#D%7'_ %V/\A17B5OC9ZV'_AHZ:BBBLC8**** "BBB
M@ HHHH ***,T %%%% !1110 4444 %%%% !1110 57U?_D&3_P"X:L57U?\
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MNOU7]E'X6ZWX+D\-WOPU\ 7GAV7[+YFE3^'K22R?[*H2VS"8RA\E541\?(%
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MTK*_R[G045S^N_%;POX6\4Z?H>I>)-!T[6M6_P"/'3[K4(H;J][?NHF8,_\
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M,QB-QL\UUZ EOE^8G]*O"_[(OPH\$#11HOPQ^'NC_P#".:C/JVDBQ\.V=O\
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M1O&=Y/</?^)K*YTU+_48;FVLH+FVDC:R-L(Y?L%O)E(%DCD#&)XP<5L>!_\
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M%G_@1IG_ ,F5'>^/]8N+.2-? ?BO+J0,W&F?_)==E10!YE_;>O\ _0B^)O\
MP*TW_P"2Z/[;U_\ Z$7Q-_X%:;_\EUZ;10!YE_;>O_\ 0B^)O_ K3?\ Y+H_
MMO7_ /H1?$W_ (%:;_\ )=>FT4 >9?VWK_\ T(OB;_P*TW_Y+H_MO7_^A%\3
M?^!6F_\ R77IM% 'F7]MZ_\ ]"+XF_\  K3?_DNC^V]?_P"A%\3?^!6F_P#R
M77IM% 'F7]MZ_P#]"+XF_P# K3?_ )+H_MO7_P#H1?$W_@5IO_R77IM% 'F7
M]MZ__P!"+XF_\"M-_P#DNKG_  E6N?\ 0A^*/_ G3/\ Y+KT&B@#S[_A*M<_
MZ$/Q1_X$Z9_\ET?\)5KG_0A^*/\ P)TS_P"2Z]!HIW8N5'GW_"5:Y_T(?BC_
M ,"=,_\ DNC_ (2K7/\ H0_%'_@3IG_R77H-%%V'*CS[_A*M<_Z$/Q1_X$Z9
M_P#)='_"5:Y_T(?BC_P)TS_Y+KT&BB[#E1Y]_P )5KG_ $(?BC_P)TS_ .2Z
M9<>)]>FA*CP)XHR?6YTW_P"2Z]$HHNPY4>,>/_#EQ\4?"=WH6N_#GQ+?:;>[
M#)']NL(F#(ZNCHZ7BNCHZJRNC!E90000#6RNM>(%&/\ A!?$W'K=:;_\EUZ=
M12&>9?VWK_\ T(OB;_P*TW_Y+H_MO7_^A%\3?^!6F_\ R77IM% 'F7]MZ_\
M]"+XF_\  K3?_DNC^V]?_P"A%\3?^!6F_P#R77IM% 'F7]MZ_P#]"+XF_P#
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tm2223302d1_s3img002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2223302d1_s3img002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M$V_YQ1M_SBO._P#A%_BQ_P!#M\/_ /PC+S_Y9T?\(Q\6/^AV^'__ (1EY_\
M+2CV<?YE^/\ D'M)?RO\/\ST3;_G%&W_ #BO._\ A%_BQ_T.WP__ /",O/\
MY9T?\(O\6#_S.WP__P#",O/_ ):4>SC_ #+\?\@]I+^5_A_F>B;?\XHV_P"<
M5YW_ ,(O\6/^AV^'_P#X1EY_\LZ/^$8^+!_YG;X?_P#A&7G_ ,M*/9Q_F7X_
MY![27\K_  _S/1-O^<4;?\XKSO\ X1?XL?\ 0[?#_P#\(R\_^6E'_"+_ !8_
MZ';X?_\ A&7G_P LZ/9Q_F7X_P"0>TE_*_P_S/1-O^<4;?\ .*\[_P"$7^+'
M_0[?#_\ \(R\_P#EG1_PB_Q8/_,[?#__ ,(R\_\ EI1[./\ ,OQ_R#VDOY7^
M'^9Z)M_SBC;_ )Q7G?\ PB_Q8_Z';X?_ /A&7G_RSH_X1CXL?]#M\/\ _P (
MR\_^6E'LX_S+\?\ (/:2_E?X?YGHFW_.*-O^<5YW_P (O\6/^AV^'_\ X1EY
M_P#+2C_A%_BQ_P!#M\/_ /PC+S_Y9T>SC_,OQ_R#VDOY7^'^9Z)M_P XHV_Y
MQ7G?_"+_ !8_Z';X?_\ A&7G_P LZ/\ A%_BQ_T.WP__ /",O/\ Y9T>SC_,
MOQ_R#VDOY7^'^9Z)M_SBC;_G%>=_\(O\6/\ H=OA_P#^$9>?_+.@^%_BQ_T.
MWP__ /",O/\ Y:4>SC_,OQ_R#VDOY7^'^9Z)M_SBC;_G%>=_\(O\6/\ H=OA
M_P#^$9>?_+2C_A%_BQ_T.WP__P#",O/_ )9T>SC_ #+\?\@]I+^5_A_F>B;?
M\XHV_P"<5YW_ ,(O\6/^AV^'_P#X1EY_\LZ/^$7^+'_0[?#_ /\ ",O/_EG1
M[./\R_'_ "#VDOY7^'^9Z)M_SBC;_G%>=_\ "+_%C_H=OA__ .$9>?\ RSH_
MX1?XL?\ 0[?#_P#\(R\_^6E'LX_S+\?\@]I+^5_A_F>B;?\ .*-O^<5YW_PB
M_P 6#_S.WP__ /",O/\ Y:4?\(O\6/\ H=OA_P#^$9>?_+.CV<?YE^/^0>TE
M_*_P_P ST3;_ )Q1M_SBO._^$7^+'_0[?#__ ,(R\_\ EG1_PB_Q8_Z';X?_
M /A&7G_RTH]G'^9?C_D'M)?RO\/\ST+&&_G3P:\FO=?^('@7XB^";/7-<\'Z
MUI?B?5IM,GCL?#MS87$.W3[R[5UD>^F7[UJJD%.0YY&*]6)*U,J?*T73ES7T
M)****DL**** "BBB@ HHHH **** "BBB@ HHHH *\D_;@\=>(?AQ^RIXRU;P
MG?\ ]E>)4LQ:Z7?&!)Q87-Q(MO'<>6_R2>6THD"-\K% &^4D5ZTS;17C7_!0
M#YOV2O$W_76P/7&/]/MZ<;7U$]CRV+X=Z?X=33=-U+QM\1+[4KHFWBN;SQ]J
ML%QJTR1EY'6."YBBW;59RL,:( K%451@4/%,O@GP'9M<ZY\0/$FC6\=S]C:6
M^^)NL6Z+/M#^46>^ W[2&V]<'.*Y;]J?X:ZWX]^-WP'N=)FU6QM]$\2ZE=WN
MIZ?';R/IT3Z%J$".RSQ21[7DDCCY0_ZS(Z5Y'K/PXU/X4?&V[\2ZCI?Q2O18
M:KK,5EXMT%;:^U6-;NWT=#'+IB6;K)!.UJ<W,40,/V0(QQ*TA]N-*"2M$\R4
MI-WYCWKQ-XC^'?@N>UBUCXG:QI$M] EU;)>_%/5H&N(7)"2(&OQN1BK ,.#M
M/I70GP!IK:JUB/$WCPWL<2SO;CX@ZYYJQL64.5^VY"DJP!Z94^E>7?L^?"SQ
M.GC'2[[4[C7O"/V#P%X9T]K/3HK:"SNY;:?56EMF$D4S)L26 $0R@QB; <G#
M#:\ _ :R\"?MM>._%>GZ5>1KXR\/:>U]JDLLLWVZ\BN;L"/+N?*5(A%MCCQ&
M@887DDU[.#^R9NI-;2.N@\+Z#<^(9])C\7>-)-6M8$N9K)?B+K9N(8G9E61H
M_MNX*61P&(P2K#L:LW7P]TVP">?XD\?0B1BB&3X@:ZN]@"2!F]Y. 3] ?2OE
M3P+\,?C%-^U9'\<KS1/#.DZ=K>J:GHEG9"SNV\0VFDW2Q6MC]K_>&$0&?3["
MZ=53?"+F8AOFD#4_$/@;QA\09O@KKQMOC9?:QX,\;Q7GB/\ MA'\FUO)M"U2
MUFE@AQEK9;R6VCS'FV6.Y(B(5I\1[&"UY0YJG\Q]:6_@O1Y] 75$\5>-VTQ[
M?[6MXOQ#UPP-"5W"4/\ ;=NS;SNSC'.:L1?#C3YF<+XA^($GE/Y;A?B!KORM
MC.T_Z;P<5\N^!D_:)?P9=:?KMSKSQK\/T\4V&HK&@N9]:DT6.W?1IQQO(O\
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M ()-1_\ D>E]=H?S+[Q>QG_*SZ(W_P"U1O\ >OG?_AZI\!_^AY;_ ,$FH_\
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MPY_X5TW_  L'X;1>!-7CU;5-3B@T26(W[I<VK2)>7%TC'4)59)Y58;%<.?\
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M/\(=,\4:;I)\7-=-JKV,<5_9Z3?7>DP27RH]G'<7\4+6EL\ZR1F-)I49Q(F
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M:Z0& ]Q$\B_DQJOK53HS'ZO3,<_!7XY,?^/WX5$=/N:ATZ'O_P#7XH7X*?'
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M2:;JU]$D:">:5H6O07$,7FQQW*13;3YB/O?=-+=<_G^>GX?B*5];?+[OSO\
M@?,/@?\ X*7>-_AWHNJ:_P"*)/\ A*K"S\,V5WY4Z1Z?8V-Q/XAU6Q:]O+FW
MMI)(+6."V@\R012!%B+;"2Q/U!X%_:3UKXN?L>:E\0-#T_PJ=<_LZ^EL(K#Q
M1#J^BW4L!D6.2+4+>)M\#E P8P"0!L/$K J,7P__ ,$[/#?@JVN#X?\ &7Q$
M\.ZE)IL&F0:EIVHV\5S:+#J-WJ".H,!CD)EO)59)DDB>,*K1GDGNO@O^S#H7
MP3^&.K^&+>\U76AXBN[N_P!8U#4#"MWJES<_ZZ9Q;QQ0H2,#$42* !A14R3=
M*45OK9_/3\"[KG4EM[MUZ)7_ !_KO\V?#3_@I/X\C_9XL->OO .F^++KP/X%
MTKQ9\0[^V\1BV>&.ZMFN!]A@^QA;FX-O&T\D3?9HTWA$DDZU] _'C]IN3X::
M7X&M_#>AP^*?%'Q*U$:;X=L+J_.FVLKBUFO'EN+@12M%$D$$C$K%(V=H"$FO
M-X?^"5OA>W\%6_AU?'_Q/&CW&@6WA;7[9+S3XU\6Z7;;UMK:]*68*^7%(T/F
M6Q@E>(XD>0\UZY\;OV:](^-?A?P_9KJ6L>%=3\(W\>IZ!K&B- E[HLZ1/!NB
M$\4L+ PRR1LDL3HRN05Z$;5)1;;CM?YF=&+BE&>KLTWTO96?WGB\7_!4.WT#
M2]8D\6^";KP[=>']+UY[Z%-2%VC:KI#P^=I\#B)?-$T5Q%+!+A6=2P,2,I%<
MY>_\%B] \._'F/P;K6G^"=':QUW3?"NKVDWCNV_X2*#4[Q(,FUTHPB2ZLXI;
MB.-[@R1O\LC+"50FN_\ %W_!+;X:^//AWX1\/ZU<>)]4;PIXQ'CN35)[V,WV
MN:F79YFO&$01XIBV'BC2-=JHJ!%4 =;)^QGI]I\7+[Q-I/C;X@^'=-UK5HM=
MU;PUI>HP6^E:K?1K&HGD;R#=H'$4?F10W$<4NS]Y&^Y]TT[*2Y]NMNKNG?RZ
MKKLO,<NMOEZ/;Y[?>_(\PTW_ (**^-/$&G:>VF_"[09KWQ?XUU+P5X1M9_&,
MD3:E-ITU^MY=7C#3V%I;K'82.IC^T.Q<*57[QN>._P#@H5XP\'Z?XDNA\(F?
M_A6?A^U\0?$*UG\4P+=:(LR22FWL1%#+'?2I#"\IWR6ZE&CPV]BB]IJ_[ _A
MF\^&>C>']/\ $/B[0[[PSXJO_&&C:_8S6IU/2K^]N+N:<Q^;;R6[QD7MQ%LE
MA<>6X!RPWUA^*O\ @FAX;\6V4UK-X\^*4=GKVD1:'XMB.LPW#>-[6-I&5;^6
M:"256Q+*A:U>W/EOY>=BHJDK=._4O3F\O+??_(Y>7_@I-XNU+QY]AT7X3V6I
M^'[_ ,9R> ](U.7Q7]FFO-0^P?;8IY;<VC>39E RR2"225"IVPRUS_C/_@L=
MIWA#PKX16\T/P/X=\5:[%K4NH6?BWX@VV@:79'2K]["XAM[Z6!C=323HWDIY
M,89 6D,.,5[MIW[$OA+1]3T^XMKO6H1IGC63QU;Q":(1K>/9O9F''EY^SB.0
MD+G?N ^?'%8*_P#!/+0=!33[CPMXU^('@O7M/N-8D_MK2+BQ:\N8-4OY+^YM
M)%N+66!HA/)F,^4)8PHVR EBR3T2?E?[O_DOP)7?K^&[_2WS-37OVV]%C_9"
M\-?%K0=+N]<M?&T6E+H&FF5;>2[N=3FA@M89),,L0\V= [X8* Q ; !\'TO]
MN#XL:5\=/$6A^(?#J_VU:^-7T33?#6EZW;/I[B/PA)J@A-X^G^?-#-/'N5]D
M,J,ZYRB&%_J+XB?LV:%\3_@=;^ M4O->DT^SCM#::B^HO/JMM<6DD<MM=BYF
MWL]PDL4<F^3?N9?F# D'@OAO_P $]/#W@3XDVWB^]\8>//%7B6+Q.?%<]]K%
MS9%KR\.D/I.'2"UBC6+[.Y(2-4 < C"_(;7+S3?1WMUMJK?D[LJ#2C[V]OQ/
M//B/_P %?/#/A#PE%KECI>DS:/J%GX?6QU36?$<6CZ:FHZO%/<):W5Q)&RVT
M<%M")I9<.P$J*L3,0#/\._\ @J#=_'+3_"-G\/O"?@[Q;XD\0>(M3\-7WV7Q
MP)=!L9K&U6[DFAU&"SF-S"\+H4(@1MSA65"&V]1X#_X);?#GX5?"S5_"_AJ\
M\4:+)J'BZ7QO9ZS;W<+:CH>I.-L;6K-$T0BBBS"D4L<B>62KAP3GN_"G[)UC
MH'B7PEK6I^+?''BK7/"-Y?W\6H:U?0RR7LMY!]GD\Q(X4BBC5,;(K9(8U.3M
MY.9T=_O7X:>>M^W0SG?W>7T?G:Z^71_>CP+0O^"QNF_\(7\0O$>N>&_#VEZ;
MX&LC<R6$/C& Z[83&[CM8K;5;"YAMY-/>1I499 9X H<M*,*&]7_ &(OV[M'
M_;$NO%FEPS>")->\&O:M?-X0\70^*='EAND=H7BO8XH26S%*KQO$C*R?Q*RL
M:&L_\$T?"?C76[R\\7>+/B%XV']G3Z7HZ:SJ,$DGAN&6XBN2;:YC@CN9)%F@
M@9)+J:=T\I=I&6SZG\%/@M=_".VU!M1\=>./'VH:DT9DOO$=S;LT:QJ51(H+
M6"WMHA@G<4A5G."[,0""/PZ[V_&Y4M_=[_AH?)GQ0_X*H^)_$WPP^.4/@OP[
MX1T?Q+\/_#NM7]G%?>+D&NZ3)9-L$NH:1+:"6$2)NG@,?VF&4*JR20^8#79^
M/?\ @I#XD^"VF^+KSQ5X$\.QZ+\-O#^DZAXEU1/%Q3?>:BA$%O:K)91QNGGX
M5YII+=41P^TX*#LO%_\ P3?\,_$K5M8F\5>,/B'XIT_4-+U72-/T_4]0MI4\
M/PZE&T=U]FG%N+IR48J@N9YUC& @4 "MJ/\ 83\+W_A3Q9I>NZQXH\32>--/
MTNQU*^O;BWANM^G _9;J,VT,*QSJ^V3<JA=Z*0J@8*U]FEULK_C?YE2DG)*V
MEW?T?+;\F>$K_P %I='G\!ZM/;V'PWU+7-#UFQTW4+[2/B"-2\&:9!=P3S0W
M=UK5O9.T"9MI86#VGRS&-3\CB2ND\0?\%4GT3QA\/])_X1/PE:MXTTJRU03:
MEX^M+2VU(W-P\/V?1KL1/9:G,@3S"AN+<E)(=N6<HOJO_#'6I/X7DMY/C5\:
M)O$#7L-Y'XA.IV"W,(CC>,0BS6S&FM$4D;<KV;;VVNQ,B(Z\EJ7_  2\\(WO
MPQM?!,/C3XD6/@V2UDM==T2+4+22Q\3B2ZENYGN(Y;9Q!))--*7DL?LK$.%R
M%2,):M?YK[K?YDZ6^7XWW^XY&[_X+#>#[']IJX\"NG@[^S[?Q7_PA)'_  FE
MK_PE$FI;O+$B:+L\PV9F(B\[S@^3N\KRQOKMOV'/V_6_;+UO6K?^PO#FB_V9
M;1W1M+3Q4E_J^F%W9?LNJ:>\$%Q8W0"@E0LT7W@LS%>>JT7]B[3/"_Q+O-:T
M7QI\0=%T'4-6;7;OPGI^HPVVCW&H.<R7!981> .QW/"MR(';):(DG)\%_P!C
M#3?A)\5?^$RO/&/CKQQKEKI,F@:7/XDN[6YDTC3Y)DF>W26*WBFGR\469+N2
M>7]V/WG+;II_"N?>VOK;_/\ #[G,[MOEVNK>E_\ (X_XG_M]ZE\(?VDO#/@[
M7?"7ANST3Q9XDC\,:;<'QI;MX@N9GB+K=KI21,/LF< LUR)5R"80",\-X3_X
M*SZA#\.M*\<>-/AG_P (UX*U[2-?U/3KNQ\0_P!IWTC:1YC2QR6_V:)466.)
MFB82L21AT3@GO;[_ ()D>$[OXK?\)0OBSQY;QKXPB\<PZ1#/8+8Q:DKEG8O]
MD-S+$^YP8IIY%0.?*$6%*ZT?_!.7X?3_  K\)^";Z37M6\/^$;35[&&WN[F+
M_3H=3CECN%G*1J3A9GV%-A! R3BIC?V>N_\ P%\M_D4_XO\ =T_-W^]6,;]G
M3]H#XG>/_P!L3Q/X5\=:#IOA+3['P5I.MV>DV&J)JT/FW-W?(TIN3;02^9LA
MC1XR"BM&2C,#N/TMM&>:\:^ W['%G\#/BAJWC";QQX\\;>(-6T:ST%Y_$=Q9
MR""SM9)I(41;:V@ (,[@L<L^ 6+-EC[,/O<U6EK+^OZ0MY-^GY*_XW/._C1_
MR4[X1_\ 8U3_ /ICU:O1'ZUYW\:/^2G?"/\ [&J?_P!,>K5Z(_6MI;1]/U9E
M#>7K^B'4445B;!1110 4C' I:;OVKEN* *]W>):1%GSM52S'^Z!U)KY_^+_[
M05QXCLIE\-W7]EZ7=0;H]6<C[5>#M]DA8'"'G]^XQCE0WRFNX_:<\<?\(_X.
MM=(M_FOO%-VNE1;>3%&ZL9I3_="1!SN((W;01ALCYQ^,7C.Q3Q3+=6?[^UQ%
M#;A#PRJ@ V]M@QUQSZU\GQ)G$L-3]G2>K/I.'\I6)J\U1>ZCG=6\;7GA2YMF
MBUCQ!'>+(9DN?MTDD@/;>79O,'J&!&":^@OA%^V%8W6D+:^*$EMKV/"Q7EM:
MO+!?+S\^$W&-NF5;C)&"><?)'C[Q5)-<MMTZZ:YM $>$ YB9C_RTP"8Q@-R1
MVQRS(KX'AWQRNJZG-8-+%!?VC['1)5F1B<D;&'<8.00".,C!&?E<OJY[0@\?
M"E*5-;WO9=#Z7,9<.5*T<OJ5HPJ/;5:^G<_3?PGXWTSQOH4.HZ3=PZA97 W1
M36[B1)!WPP.#@@@^X-;8DQ'G:WRC/2O@7]G[XFWGA3XMZ(EG)]ECU;4H;34(
MHW*IJ/F$1[Y$Z%QGA^HQC..*^\HY&6T^]O(CZX^\<5]QD.=PS*C[2._4^.SS
M)YY;B/8SZ[#KJX\I%9ACGOCC@UYW\<?VIOA_^S-X/F\0>/O%NB^%=+246R2Z
MA<+$UQ,>1#$GWI92.1&@+GL*\G_X*2_\%(-%_8!^$<&L75G'K_BC6+L6>AZ!
M'<^1-?.-Q>9R [K;1KM+R+&V"R #<X _'/X9_"/XW?\ !8O]I?S-6UI]8U#2
MX'N;[7[^,?V5X-MIW.VVM8(R!ERA"QJ2[B,&60;68=N*QRIS]E35Y/H>YP_P
M?4QN'GF6+G[+#PWDUN^T>[/M#X^?\'!6O?$7XLVO@O\ 9T^'+>,+W4MPT_4M
M6M[E[C4=@S(UOID2K,\:J<EYI8MA!+1C -<W\./^"5/[57[?=]/K_P"T9\8/
M$W@6VF.;3P]97:23>63EBUM:2K8Q;25"EA<.1G?M.,_?'[&/_!.GX9?L.>&$
ML_!N@P-K4\4<&I^);U8Y=6U@;@S"68*#Y9;D1)MC4_=05] &)+?#+QDX-:0H
MU):UG=^1Q8[.<+1;HY732CMS2UD_T7R/D+]EW_@AY^SW^S+:"8^"['QUXBV8
MFUOQ9#'JES,<[MPC91;Q-DGYHHD., EL9KZA\->#M!\$Z3]CT?2].TVTCY,-
MC:1P)D?[* #/'TKG_CQ^T7X6_9T\'76N>*-6M=/MX8RT<3R 3W;C)\N),Y=C
MV _&OD^\_:[^,_[92S6_PPT!?AWX6SN_X2'6@LMS<CT@BVNO0@DA7'4;U;@<
MF*S3#X=^SC[TNRW./!Y=C<=^\FWR]V[(^U_$OC?1_!FAS:EK&J6.EZ;9C,]S
M>3K## #_ 'V8X'XD5Y;J_P#P47^">A3M')\1?#L[*<9M9_M(/T,8;-?/6C_\
M$U['QCJ=KJ?Q2\9>+/B)J"(VR.ZOFBM(,D$A$#%T&1]U7"GN!@5Z-HO["GPE
MT*'RU\"Z#=+C!^TVPN,CWWYKR:F:XR;O"$8KSO?\#UZ>29=3_CUI2?\ =22^
M]G70?\%0/@;<R>6OCJS4DX^>VG0'\2@KKO!?[:/PK^(6JQZ?H_CWPO=:A<$"
M.T^WQI<2GT6)B';\ :\R/[%WPC?&WX:^!TP<Y&B6X/YA*YCQ;_P3@^#_ (JL
MWB7PG;Z66.5?3YY;78W/(",%[]P1[4HYICXZRC%KYIE2RG*Y?#*<7YV:^9]:
M/=PWUR=K*S;.,*"2.>G>N'^)'[+'PW^,MI<?\)1X&\&Z^UTA1I-3T.UNW;(Q
MG,L;&OD]/V4?BU\ +B.7X5_%75)]-LQMBT/Q)_I-N .0GF8;"GH B+_O5TGP
MO_X*IMX>\:VO@[XP>$[OP!XAGD\E+YB'TJ1@/O\ F%OD4GIRRC'+UW4,^IM\
MF(CRO\/O.&MP]7C%U,'/G2[:/[CSWXT?\&[7PQU7Q#<ZQ\,/%GBCX2ZA<.9/
MLFFR>?IP?!(*J2MQ%\W($=PJKGY0.,>(2^*?VW_^"59O+?6/M'QA^'.G(TJ:
MG>/-KL,"'G#S[_[3A*@$L94DB0'AV' _6S0-9M?$EE'=6\\-U;SH'CEA?<C@
M@$$$<$?I5F_L8YG9FWN0 0"WR@^U>H\.JD?:4G;L1@>(JM"U'&4U5ALXR2NO
M1[KU1\-_LB_\%X/A#\<]/TVS\:W"_##Q!?-$D:ZE<>?I-XS< PW^T1;=P('G
MB)CQ@'-?=%EK$=Q<LRK+A5/.S ;IT/?^G?%?FS_P4P_X(KZ#XZ\*ZEXP^$.G
MV>AZU:6TUQJ7A2* _8/%75BD*@A;>XPS %5\MSA6"_ZQ?EG_ ()O_P#!5GQA
M^Q'?6WAGQI'K&O?#=9(=-.F7X\K4/!7EE4E\L,H9HHAN#V[ME=@$9&WRVX/[
M1GAI*EB]GM(^Q_U)P6=8*>8<-R;<-9TGK)+JT^J_$_=6+45FB+K')M'L/\:\
M*_:8_:O7X-75];VT<+2:;#]IN[B>"2:*W!.X(0H'.TJ2<C&X ;CR/7M"\21Z
MYID=Q:SVMQ;RH'CEA.Z.12 <JP)!!SD$<$=">M?%W[8_POTWQCX_\4_VM<7.
MLZ;=2)-_9\$TBP(5CC7]_LY9/-W?Q  @ \UMFF)]G348/XG;35Z]N[/SC#TK
M.?/;1-ZZ+YOH>C^$/V_;#Q5X0W_V;'_:B,-T;/*\<L)+*DL9"EBS,K+L<J1M
M;+\ 'T/X-_M@>%?B9X6TV>XU+3[#5K\M&MHTZJEQ*KE&6!WP).@8 '.U@?7'
MYJ:E!?\ @OP3KA^'.LV]M<7:#1X;.YGQ)9",3%HA(6+,Q\P8+ D;7SU+#R_X
M!Z_XQT&+7YO%<U_IVC+!]F1+R?:;JX_=A9D;!R$1=OF<YR,%@,CDP>.]E@:F
M)Q=91G%V4&K/^FK&&+J.>9T,!A:$I4ZJYG5CK%:*^JTM>Y^[4-ZLD:LJMT';
MFEDNEVG@MZ@=J^-/&7[77BG1UTW7/MD>EV=O'#)+926J"V /+K-*ZE\@G:2L
MD> %PIY->_? #X\P?&[2+JZCLUT^[L91'<6XG$GWE#*ZDX.P@D D ED?"X7)
M[<#F=/%+W=_S].YKBL'*C*SMZ7U^:-;XS_L^^$?V@[*TL_%6BV^HKIKF6TN1
M)+;7EBS8#&WN(626(L!ABC#</E.02*\ZA_X)G_"980K:7XM) Z_\)WKW/_DY
M^M>_+\P[?G64WB^S;4[RRBNK6>\T_;]HMHYE,T 8!E+KG*Y7)&>H4D5TSP=&
MH[U8)OO8YXUIQ7NMH\8'_!-#X2#EM*\6?AX[U_\ ^3*BN/\ @FY\'X9-O]E>
M+R<9_P"1[UWZ?\_M='\;_P!L/1?@;*+6XTW5/$&K",W,]CI<UK&;*+@!YYKJ
M>&WBR3A0TH9RK[%8(Q'%ZI^W+?2>#)-<C\!Z@-L)F31_[9LGU?;[B.1[3NI*
MBZ+D?=5B,5Q5*.6TW:<8_@>C1P>.JI2BI-/U/$/VTOAK\$?V3AX=M9-+UN;4
M/%%^;:-=1^).O6B06Z)NEF3%VSR-S&B1QC<[2#E55R,'PG8?!OQIH7G:/X!^
M(NL:ELFF1+?QYX@CMUBC4L996GN(Y53 ."(7YXR:^'/B;J>M?'?]J3QIXOU'
M6"LNM:S)?:(-1B>7[+%#=3H+4^=&&26WRH1612@W !26S:\0_%+XI^%#'X<U
M077B[0[6#-E//;-?:9;@MO\ -R1\LB'*X?C'9EK?)\#E&-<FZM.G)7]V26J7
M5/S#BR>.R.K0H+!U*WM$FY1O:[Z65]NK/TC_ &9_V;?@[^T3H%U<)H6N0W5I
MY3DZ;\3=<U&TFAD#>7*DPN8R>4=6#(K CI@@GU2/_@FK\)&4?\2KQ9_X7>O?
M_)E?"G_!$+]K?Q1KO[16L?#ZS\.V=UX/^S7MQ_;$+.&LH8[V:>!78DJ<M=2K
M@8ZJ>S9_66RP+5,'S-HP#ZCUK/#X'"3I_#%[VT-\XP];!XCV<I-)I-*^JNKV
M9XGX?_X)T?"7P[K%O?0^';Z^N+602PQZQK^HZQ;1R#E9/L]W/+"74X*L4)1@
M&4@@&O:]+L6M/]9LSC&5R2>_4\_A_P#J%O:M/48KLP^&I45:G%+T/&E4E+=B
MT445TDA1110 4444 ><?!;_DIWQ>_P"QK@_],>E5Z*IX->=?!;_DIWQ>_P"Q
MK@_],>E5Z*O0UI6^)>B_)&.'^'YO\V.HHHK,V/A/]O\ ^(OBCX"?M;W/CWP_
MX@U)+CP[\)-8NK?29H+232XV&HV$37$P,0G,:>:LSA9E_P"/5 "%+A_6OV8?
MB/XLTG]ISQO\-=:\?3?$_3-%\-Z1XAMM;N[*RM[VTFO)+M'M9/L4,,#1E;=)
M8_D$@63YF<8:NZ^*WB/X7?\ "^_!&A>*-'TW6O']];WTGAW=X:EU6ZL+8JD-
MW+YZ0R"S@821QO)(\<;;U0DD@5UGPJ^!_@OX#Z!-I/@?P?X7\&:7<2F>2ST/
M2H-/MY)#U<QPJJECZXS2I_ D_/YW;_*_Z$\MI-][/TT2^=TOQ/BWX,_M3_$F
M]\>V6OWWQ1_X2&WU/XRZW\.CX,.F:='#;Z?#/>"*1'BA6Z^U01Q1RLS2F-H%
M.Z,N?-,/[/\ \9?BY\5]!^#ND:W\:?$6AW'Q4\'ZEXQO?$"Z-H:M9S6AM$CT
M^S1[(Q!"EP\\IF260B)MCQKG;]2? ;]B'X<_L\^*]9\1:)X=TNX\5ZYJ6I:C
M<^(;O3[5M6Q?7<EU+;"Y2)9/LZR2$+&2< #)8\UTGB[]F?X<?$#P!IWA+7O
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M>X3S%3.6;9'N8G>20237R-KWQ6OXO'-SXHBN(['49+IKX,DFQ$DSPN,YVD
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MCP]?+(82M2Q=&4JK^%K:WWGU^._M_&YKEU;*:T885*,:B>][V?3K<\9OH_\
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M7%H\EL(M0A0LH8VIF'S+ZBK>J?MI?!#X@^&+[5M2O#J$/@O4[&5+74O"M_\
MVC%>3[OL,UE9RVPN9WE^?R);:-_,PWELV#14O*,+_9:?JE*_YZ$R34IO9RO\
MG;]#YG^!?[)47CW]HSP3-J?PQNX?A'9:GXLU7PAHFN^'GCL_#UL\>B_9!)9S
M(!9A[N*]G@MY51XQC"(4POG\_P"SY\1M1\!:78_#GP7XR\+_ +05EHWB*'XD
M>+I]*N-,@\2S2Z?=1VX&HR*L6H-)>-;26YBDD^S(A!\H#8?N[]G?]LO0/C_\
M.O&WBR&WFTOP_P"#=:OM*DN)XY_-EBM41Y)7@>))H7&YE:%D+J8R#SP.1O\
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M\%;[KBE=R:?5)?<K:_GZGR[I?[.VJ:7\3_BCI>F^$_B-=P^)-)\0PZWXAM_
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M4HJ$%%=#XO$XB6(J2K5'=R=QU%%%68A1110 4444 %%%% 'G'P8&?B9\7?\
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M:_U*7ZLKV<G4U6OZW2_.)T^A?L,^*-*T:Z@DOO#IEF^,8^(89)I>+ .A\O\
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M  E]CI_B'2?'HTBPT+6_B9KEUJ-[X81A%&!X?%A/#.DEN/-_M.6X+B4YEN$
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M<CXL78_]P=5-2_:&^/.M6S0WOP%^$-Y">J3?%6ZD!_!M"(JO]:<L3NJR^_\
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MFB@ HHS10 449HH *,49HH **** "CK1FB@ HHHH **** /.?C1_R4[X1_\
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M=9\D?O@@V"3(?'\0Z5SD?C#P[\/OV;;#QOXFM+24?V5:7=W*T,7FWMU.D81
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MC;:>W5A<3'9&P&.=I;=C_9-=7_P3A^!<WP*_99\,Z??6[0:OJ-O_ &GJA?\
MUCW$S,YW_P"TJLJ_\ 'I66%A.KCHPZ)7?D^A[F(:P^6U*K^*HU%>=M6_T/6_
M&WP\TWXE>'YM,UC3XKZQF8,\+G'S Y# @@AAV(((KYC_ &J/AAX0^ OAN1=#
MT,Z?=W.G74=W=6S&:^N8R(]JEW;S7!9"P(;Y72,<9S7U]9!A"<G[K$&N _:
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M6-:F[.+NCXO_ &!_CAJ'B_P!)X.\6;[7QYX)<Z7J5G<2?Z08X]JQS.#RV58
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MX_\ !>N:'X;D>/5]1T_6[:YM=*9!N=9Y4<I$5')#D8'6MJDDY<\=O^'^[?\
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MU)_PUI\4!_S;K\1/^_=Y_P#(E??5&*^5CP-ERV1Z*SC$)6N? T7[6WQ.W?\
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ME'[ON_N_X(<U3LOO_P" >D[QZBC>/45YM_PS%X9_Z"'Q"_\ "]UW_P"3*/\
MAF+PS_T$/B%_X7NN_P#R91^[[O[O^"'-4[+[_P#@'I.\>HHWCU%>;?\ #,7A
MG_H(?$+_ ,+W7?\ Y,H_X9B\,_\ 00^(7_A>Z[_\F4?N^[^[_@AS5.R^_P#X
M!Z3O'J*-X]1^=>;?\,Q>&?\ H(?$+_PO==_^3*!^S#X9/_,0^(7_ (7NN_\
MR91^[[O[O^"'-4[+[_\ @#OC.V?B;\(_^QKN/_3'JM>C$\]:X'P_^S=X9\/^
M*--UA'\47E]HTSSV9U+Q1J>HQ02/%)"SB*XN'CW>7+(N2N0'.,5WADV<4JE2
2%DHW>GZ_,*:G%MSMJ_T7D?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>tm2223302d1_s3img003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2223302d1_s3img003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M3P_X6TV29;9+S6-1AL8'E9698P\K*I8JK$+G.%)[&N-_X;Y^!O\ T6;X3_\
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M ..UZY10!Y'_ ,-]? W/_)9?A/\ ^%?I_P#\=H_X;Y^!O_19OA/_ .%?I_\
M\=KURB@#R/\ X;Y^!N/^2S?"?_PK]/\ _CM"_M\_ X_\UF^$_P#X5^G_ /QV
MO7** /(_^&^_@<?^:R?"C_PK]/\ _CM'_#?/P-Q_R6;X3_\ A7Z?_P#':]<H
MH \C_P"&^_@;_P!%D^$__A7Z?_\ ':/^&^_@;_T63X3_ /A7Z?\ _':]<HH
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M_P =H'[?7P-/_-9?A/\ ^%?I_P#\=KURB@H\C_X;Z^!N/^2S?"?_ ,*_3_\
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M]%D^%'_A7Z?_ /':!^WS\#C_ ,UE^%'_ (5^G_\ QVO7** /(_\ AOKX&_\
M19?A/_X5^G__ !VC_AOOX&_]%D^$_P#X5^G_ /QVO7*@%\I^ZR'\: N>5?\
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ML\2C_FX7XZ_^!6B?_*NO?** / _^&*_$G_1PGQV_\"M$_P#E72_\,5^) /\
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MD_Z.$^.G_@3H?_RLJC_P]F_9W_Z*EX>_\B?_ !-'_#V;]G?_ **EX>_\B?\
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M_P#[:?\ LE73BF]3Y^C1YJRI3/)#^SM= ?\ )R7QV_[[T?\ ^55 _9WN2/\
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M=8__ ")1[*0?\1SX;_EG_P" K_,_%ZBOVA_XAPO@W_T-WQ-_\#K'_P"1*/\
MB'"^#?\ T-WQ-_\  ZQ_^1*/92#_ (CGPW_+/_P%?YGXO45^T/\ Q#A?!O\
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M^7&Y_P"_9JE**1M[:FE\2/3/ ?\ R*EC_P!<A6N/O&LKP9 ]IX:LXY$:-TC
M96&"*U1]XUQ2W/EY_$Q:**,TB0HHHH **** "BB@T -!Y]J,YZT@;%<CXL^,
MWASP)X]\.^&]6U2WL-7\5&<:7!*=OVQH0K2(K=-P#@A>I ..AIE0A*;Y8*[\
MO([&BD5MRYI<TB0HHHH **** "BBB@ HHHH **** "N%^-?[1_@?]GC3[.Z\
M:>*-'\.QZC(T5J+R;:]P4&Y]B#+,%&"Q PHY)%=U7A?Q\^#OCRX^._A[XB>
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MOR?UO_@GWJ,'AN/7M/\ %6AIHMQH7]O6ZZO%-9WTL:6\,\T9AA6X59%6YML
MR?/]IBV[LG$/Q'_X)_ZUX TGQ=J,?B[PAJ-AX1^U&8AKN&6Z%K-%;3F)6@V_
M+<RK"-SKO96*;E!8:<TTKV/G:7AUP34G&$<54O+1;;WM;X>Y^LW_  _A_9Q_
MZ&G6/_!#=_\ Q%'_  _A_9Q_Z&G6/_!#=_\ Q%?D%X=_8@\2:_H$6K/K'A?2
M]->UAO9;B[NI@MI#)IS:CN<)$S?+!Y60H8[KF  $,2.QTO\ X)C>+D@\0)JF
MJZ#;:AIK-!9V<,TDC71%_P#8S=,WEA8[8>7=N2Q$NVU?]UWH_>/H%;PYX)I/
MEEBYWT[=?^W?^&/U+_X?P?LXY_Y&C6/_  07?_Q%!_X+O_LXY_Y&C6/_  07
M?_Q%?E4O_!-O7GT[3VC\9>#9[O6)H!IL"_;Q'=V[V1U!YS(]LNSR[4K*R,-^
MTD8W%%?A_C5^R7K'P0\%-KUYKGA76K'^UWT8-H]W)=9E6,N2S>4$CX!&R1EE
M[^7MYIMS2NT:X/PSX+Q5:-&CBYN4M$N__DI^QO\ P_@_9Q_Z&C6/_!#=_P#Q
M%'_#^#]G'_H:-8_\$-W_ /$5^#E%9^V9]-_Q /(O^?M3[U_\B?O'_P /X/V<
M?^AHUC_P0W?_ ,13_P#A^_\ LY;?^1HUC_P17?\ \17X,T4O;,?_ ! /(O\
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MWKBG44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC^UWH7A__A#M/\96&O>"_$GC1H8+33-0L)9D2ZEWA;8W<*O:^9F-N/-S@ID
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MR/V9P?\ D?KK_P )[4O_ )'H_P"'Y/[- '_(_P!U[?\ %/ZE_P#(]?CKX?\
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M#^T!_P!$G\6_^ X_QK^C/R:/)J?9Q.__ (CWGO\ SZI_<_\ Y(_G,_X=@_M
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MI0Y=#\T\0?$#%\18KDUC0@_=C^K\_P B11@44#@44'YT%%%% !1110 4444
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MAZYJEYH/Q1UW01X@LM4TW55MM*M)6N;:_P!3NM0E1&E5_+*M=,BL 2 H/)H
M]#\%_P#!0/X?>/?B5=>'=.O-0:&Q\+IXPGUF>R:WTI;%Q"PVS2;2[;+B)SL5
ME4-@L&^4=G!^U)\/[CX47OCE?%.FKX4T^X-I>:BY9([.82K"8Y00&1A(RJ0P
M!&X=N:\^\7_L Z)K.FQV.C>(M<\+VMK\/&^'=@=.D"3V%IOB9)HY#\PD40JO
MN">0>:S/!?\ P3DT7P5^S'XB^&$/B"Z_LWQ#KZ^()+F.SBA-M+]JM[HQI&OR
M!-\&!GD*YY)&2 =SI?[=/PCUJ"]DM?'FBR+IL4LUW\[*UNL4\=O*&4@$,DLL
M2NN-R^:A( 8$UM6_;G^'&E?&NS\"G7O,U>9-3-RZ0M]FTYM/BBEN4GE. C*D
M\;=^O49&>!\7?\$Q-"\7VFO12>*=8M_[=O/$-X7AABWV\NKWMC>L5W @^3)8
MQA01\RLP/:LR[_X):PZGX@U;69/B7XHM?$&ORZ])>:CIT$-I,/[6M;*&7R2H
M)B,;6$+HP.<,RG.0P .W\5_\%'?AGH-Y#!9ZM<:U)<Z9JVJ(+*WPL:Z;&CW$
M4CRE$AEQ(N!*5'(+% 03TD?[;OPOM/MT=_XTT.PO--T^34[RUFN4\VUBCMUN
M9@=I96>*%E=T0LRJRL1A@3XWH'_!)G1?"OA*ZTNQ\9ZA;KJ$&OVUPR:= B-%
MK-G:6URJH,!2K6<;HW)^9@Q8G?4GC?\ X)*^&_'>A:CI%YXT\0+H]PFJ7%E9
MK!;XL;[4=-;3KBYW;=\B^6[LD;' >1LEAM"@'OFA_M.> _$GP\U[Q78^)M.N
M/#OAA)I-6OE8^7IZPPK/(TF1D 0LLF<<HRL,A@3DW/[;/PGL?#?]KR^/O#J:
M>MX]@TIN1E)DC\UU9?O#;%^\)(P(R')VD-7&>/?V,)%_9^^.'AO0M8CFU;XL
M://90M? Q6]G/_85OI,6YD#-LQ;1R,0I8;VP#@"L'5?^"9%GJWB/6/$P\>>(
MH?&?B*YNGU'6/LEHWG6UQ80V#P"#R_*4B"WA(<#/F*6(*GRZ /2?&W[;GPY\
M)Z+XFN+;Q%8:W=>%-+EU>[M-.N86=X8H5G94ED=(-_E/&V&E4!9$8D*<UR6@
M?\%+/AOKVM36_P!JU"TM[&^O+"^O;N&."WL7M+:*YF=BS[WC"R@;HU< HS-M
M3:[<-J/_  1V\(P0:W:Z+XFUS0=.UCP<_@Q[>TBC0W%L;%+*-[HJ +IXHT#(
MSKO#=7*@*.ETK_@F1H-KXQEO+OQ%J.H:1/+JDLNF2VT863^T=-BT^Y4R#G:4
MA5@,<$D9(H ]2UC]L+X9^']:;3[[QIHUI>I?RZ8\,LI4QSQ&)90V1PJ-/"K.
M?D5I%4D,<50_:?\ VQ/"W[*MKX9?Q#'JEP?$^II81+80)*UI$659+R8,Z[;:
M(R1>8XW%?,7Y3FO&-:_X(]^$_$OA?P?I^I>)M:U"X\/V-W8:I=7-O#,WB!+N
M]^VW,DJNI42O-O\ FPP"R,-I(4KVG[3O_!-CP;^U_P#$2;7/'=]K6HPQ>'WT
M/2K&UOI[&+2VD=WFN089$,KR?N@4DW)B!<J<DT ;_P :OV__ (:_ KQU8^']
M7UY9M2FU 6%_%:*)CHW^A3WIFNN1LC$%NS$+N<;X_DPVX;VO?MG?"WPOIMY>
MWOC71XK33O)^U3*[2);B6V6Z1F*@@+]G=)2W14=22 17EVB_\$TXK'QOI.JW
MWCS6=8M;7Q%;>+-1L;NPMRFJZG'H[:3+,S@;U66$AFCR5#;L<-@<KJ__  1F
M\'W/P L_AW9^+/$UIHT5QJ,UUY@CN1?"YMTM8=Z."IDM+:&WB@D()01%L%FW
M* ?0-O\ M?\ PQNO%=YH:^-M!&IV*3O<1/<A!$(84GF^<X7Y(760X/"'=TYJ
MBO[<7PC.D6=]_P + \.QV]_/);1&2YV,KQB,R;T.&C5!+$69PJJ)HR2 ZD^7
MW?\ P2N\-ZUIK6.H>)-8GLIKK5I[F.*)(C*NHZ$FBS(&Y*[8D\Q3S\QP<@4W
MXP_\$Q8?V@[K1KWQI\0-=UK5-,M+K2Y)FTRQC@EL+AK=GMU@$6T$-;JP=_,Y
MDDR&78J 'IT'[9?@C5OCUIGPZTG5%UGQ!J3:A&YLBDD%@]DL;3QS/N!W#S N
M$#;65E;:17.>$/\ @H?X/\4_&?7O![Z?KVGIX;N-1MK_ %JZ6T_LVU:QR9VF
MV7#SVL> 2DMS#%'(!\C-E<P?"S]@&Q^$_P 9='\36/BK5)=+\/WVN7^FZ-+:
MP^7;/J\BS70,P D8"4,4!Z*V#G&:YOXI_P#!*_1/CAXOU"\\6>-O%&LZ1,FK
MI864D5J+K3AJ4$T$T8OO+-Q)!&EQ)Y4+N4CQ&,,L:* #K?'O_!1CX=>#]*AO
MK'4)O$EO-!J<S'3&AS:FPT]M0E2;SY(O*+P+E"^%.]&)5#O&MIO[<G@77?BO
MX5\$Z=?R:AXA\5><%AMO*E337CLQ>,EPP? ;RRO$9<@NN<!@:\V\9?\ !+#3
MOB+-KE]KGCC6]0UWQ+9:A8:A?_8H(E>*ZT9](0)$@"KY<+E^^Y\YPI"CHOA3
M_P $\-/^$OQ4\-Z_8^+-5FTWPSJ5]J]MI,MM#L:ZO;,6UPS2@;RIQYBK_"68
M9(Q@ UO&'[=5GX!^*NM>&-;\"^--+L_#FFG7-2\13S:2-)L],\R5/MS$7QN/
M*S#)\H@,HVY,8!!KIO&/[:/PO^'\MQ'K/C/2=.DM)YK:=9BP\J2&W@NI0>.-
MEO<P2L>BI(&/ .,_XX?L=Z3\=-7\<7&I:E?6L/CGP6?!5U';(@:W@,EPYF1B
M#\^;@\$$?*.#7FVH_P#!+VR\0Q^(&U7QQK&H7WB2'6HKNY-C!%@ZEHUCI+E5
M3 'EQV*.H[ER"3C- 'J\_P"VS\)[7PJVM/X\\.KIBWTFFF87(.+B.+SG3;][
MY82)2<8$9#YV?-3=4_;:^%.C:SJ&GW'C72?MFDO#'<QQ[Y=KRQQRQ(I12'9X
MY4=57)*DL!A6(\VO/^":EBFOZMK&E^--;T?6M2U2>^2YBM()5@BN-*MM,G@V
M2*RG,=JDBMU5_P"\N5:'4/\ @EEX3N/A7XJ\(PZI<-I?B/4M,U"%;RSCN#IY
ML-.MK"%4;A]P2V5_,1D<,QPV,@@'TQX=\16/BW1+74M-NH;VQO8EFM[B%MT<
MR, RLI[@@@U?KE_@S\-S\(/A;H?ADZSK/B+^P[..S_M/5KC[1?7NQ0OF328&
MYSCDUU% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %!Z44C_=H ^<?^"D/[><G_!/WX/Z1XL7PNOBPZMK,>D_93J/V'RM\
M,\OF;_*DSCR<8V_Q=>.?BX_\'-=P1_R1:'_PK#_\AUZ=_P ''O\ R9WX0Z?\
MCE!_Z17M?C#45)N+T/Z2\*_#W(\ZR3ZYF%+FGS-7YI+16MHFD?JA_P 1-EQ_
MT1:+_P *P_\ R'1_Q$V7'_1%HO\ PK#_ /(=?E?14>VD?IG_ !!OA3_H'?\
MX'/_ #/U0_XB;+C_ *(M%_X5A_\ D.C_ (B;+C_HBT7_ (5A_P#D.OROHH]M
M(/\ B#?"G_0._P#P.?\ F?JA_P 1-EQ_T1:+_P *P_\ R'1_Q$V7'_1%HO\
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M2PT^:6UW4MUZWTV9]U?\1-EQ_P!$6A_\*P__ "'1_P 1-EQ_T1:+_P *P_\
MR'7Y7T5A[9]#[#_B#?"G_0.__ Y_YGZH?\1-EQ_T1:+_ ,*P_P#R'1_Q$V7'
M_1%HO_"L/_R'7Y7T4_;2#_B#?"G_ $#O_P #G_F?JA_Q$V7'_1%HO_"L/_R'
M1_Q$V7'_ $1>+_PK#_\ (=?E?11[:0O^(-\*?] [_P# Y_YGZH#_ (.;+C_H
MBT7_ (5A_P#D.OF;_@H__P %4I?^"A'A'PWI<G@>/PG_ ,(_>278E76/MWG[
MTV;<>3%MQC.<GZ5\D44>V9Z&4^%O#F7XJ&,PM"TX.Z?-)_@VT?HY_P $A_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM<\_LO\ Q$_[%K4?_2:2O1#]RN'_ &D/#MYXO^ /C?2=/@:YOM2T&]M;6)2
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M>(/^@.I_X"_\C[<Q1BOB/_B(&_9__P"?KQ5_X)W_ ,:/^(@']G_'_'YXH_\
M!,__ ,50'^HW$'_0'4_\!?\ D?;F*-O^[^5?$8_X.!?V?R?^/KQ5_P""=O\
MXJ@_\' /[/\ _P _GBG_ ,$[_P#Q5 ?ZC<0?] =3_P !?^1]N;?]W\J-O^[^
M5?$9_P"#@']G_P#Y^_%7_@G;_P"*H/\ P<"?L_C_ )>O%/\ X)V_QH#_ %'X
M@_Z ZG_@+_R/MWRO\YI/)]Z^(O\ B(&_9_\ ^?OQ3_X)W_QI!_P<"?L_EO\
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MZ_BUXH\2^(;K3=.OM34:7XQT3PW++XB9IM-AOC;2:?N>64-Y>1=#!+,I=,@
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M1110 4444 )N^6O.OVM>/V7OB,/^I9U'_P!)I*]$Z&LCQEX4LO'/AC4M%U.
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M*_?C_AR+^S+_ -$VG_\ "BU3_P"2*#_P1$_9E_Z)O<?^%%JG_P D4>Q8?\3
M9&]Z%3[H_P#R1^ ]%?OQ_P .1/V9?^B;W'_A1:G_ /)%'_#D3]F7_HF]Q_X4
M6I__ "15>QD+_B/V1_\ /BI]T?\ Y(_ >BOWX_X<B?LR_P#1-[C_ ,*+4_\
MY(H_X<B?LR_]$WN/_"BU/_Y(H]C(?_$P62?\^:GW1_\ DC\!Z*_?C_AR+^S+
M_P!$VG_\*+5/_DBC_AR)^S+_ -$WN/\ PHM4_P#DBCV,@_XF R-[T*GW1_\
MDC\!Z*_?C_AR)^S+_P!$WN/_  HM4_\ DBC_ (<B_LR_]$VG_P#"BU3_ .2*
M/8R#_B8#(UM0J?='_P"2/P'HK]^/^'(O[,O_ $3:?_PHM4_^2*/^'(O[,O\
MT3:?_P *+5/_ )(H]C(/^)@,D_Y\5/NC_P#)'X#T5^_'_#D3]F7_ *)O<?\
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M3'XN?^$[_P#;* /8**\?_P"&N6_Z)A\7?_"=_P#ME*O[7#,?^28_%S_PG?\
M[90!Z_17D/\ PUO_ -4Q^+G_ (3O_P!LIK?M<$'_ ))C\7/_  G?_ME 'KDL
M*S8W=O>I*\?_ .&N6_Z)A\7?_"=_^V4?\-<M_P!$P^+O_A.__;* /8**\?\
M^&N6_P"B8?%W_P )W_[91_PURW_1,/B[_P"$[_\ ;* /8**\@'[7!)_Y)C\7
M/_"=_P#ME#?M<$?\TQ^+G_A._P#VR@#U^BO'_P#AKEO^B8?%W_PG?_ME'_#7
M+?\ 1,/B[_X3O_VR@#UZ2,2IM/0TV&U6#[N?SKR/_AKEO^B8?%W_ ,)W_P"V
M4[_AKG_JF/Q>_P#"=_\ ME 'KU%>0?\ #7#?]$Q^+G_A._\ VR@_M<$'_DF/
MQ<_\)W_[90!Z_17C_P#PURW_ $3#XN_^$[_]LIP_:X)'_),?BY_X3O\ ]LH
M]>HKR#_AKAO^B8_%S_PG?_ME)_PURW_1,/B[_P"$[_\ ;* /8**\?_X:Y;_H
MF'Q=_P#"=_\ ME'_  URW_1,/B[_ .$[_P#;* /8**\?_P"&N6_Z)A\7?_"=
M_P#ME'_#7+?]$P^+O_A._P#VR@#V"BO'_P#AKEO^B8?%W_PG?_ME'_#7+?\
M1,/B[_X3O_VR@#V"BO'_ /AKEO\ HF'Q=_\ "=_^V4?\-<M_T3#XN_\ A.__
M &R@#V"BO(!^UPQ'_),?BY_X3O\ ]LI/^&N6_P"B8?%W_P )W_[90![!17C_
M /PURW_1,/B[_P"$[_\ ;*/^&N6_Z)A\7?\ PG?_ +90![!17C__  URW_1,
M/B[_ .$[_P#;*/\ AKEO^B8?%W_PG?\ [90![!17C_\ PURW_1,/B[_X3O\
M]LH_X:Y;_HF'Q=_\)W_[90![!17C_P#PURW_ $3#XN_^$[_]LH_X:Y;_ *)A
M\7?_  G?_ME 'L%%>/\ _#7+?]$P^+O_ (3O_P!LH_X:Y;_HF'Q=_P#"=_\
MME 'L%%>/_\ #7+?]$P^+O\ X3O_ -LH_P"&N6_Z)A\7?_"=_P#ME 'L%%>/
M_P##7+?]$P^+O_A._P#VRE'[7!)_Y)C\7/\ PG?_ +90!Z_17D'_  UPW_1,
M?BY_X3O_ -LI/^&N6_Z)A\7?_"=_^V4 >P45X_\ \-<M_P!$P^+O_A.__;*/
M^&N6_P"B8?%W_P )W_[90![!17C_ /PURW_1,/B[_P"$[_\ ;*/^&N6_Z)A\
M7?\ PG?_ +90![!17C__  URW_1,/B[_ .$[_P#;*/\ AKEO^B8?%W_PG?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
B**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>tm2223302d1_s3img004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2223302d1_s3img004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
M  $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $" Q$$!2$Q!A)!
M40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y
M.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4
ME9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/D
MY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]YO&7B2S\&>%=1UC4+A;3
M3])MI+RZG8X$,,:EW8^P4$_A7YW_ /!)?_@M;XR_;J_:3OO!GC[P1I'@?3_$
M'AZ?Q1X(FA:83:S9PWLEL^XR.P9AY;_="_ZF0XVXKTG_ (+[?M,77P+_ ."?
MNN>&=%#2^,/C!=P^!-%A1L,[7N4G;U \@2J#V>2/UKX _;'N_C)_P3YNOV3?
MBKXK^"6C_#SPQ\ ;J#P?/?Z/XNBUJXURPN(%2:*6-(8S&6BANR&)8>9<GN02
M M3]W%.115'0M;L_$^AV>I6%Q'>6.H0)<VT\3;DGC=0R.I[@@@CZU>H ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH 13A:0/@T$8C/TKYU\2^+/B7;?MQ:386QUK_A!&BMQ.BV(.FM
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M '[7WQ1U#3=+T76/A+XJ:^O/"-SK=SJUO:WENL%\D32QV6R6R"*[\(N6+[@
MT()Q3'RO<^KR,T 8%>#_ +.OQ\\8^+/'C>$_%'A>2SOHK.[U1K]B80+?[?-;
MVZ-!LRCLD889;#)A@<DJ/=HV+1@L-I(Y'I0)JPZBBB@04444 %%%% !1110
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M<PK;S1'(4HMT^S(RK]0W@;75^+_PON;'31I-OH>D7L.M>1(TEK%"T,")9J[
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MSN2\>R1W4-!?6TBB54)5CD C%?0;_=JD-W3LQ:^0/V.O^4LG[97_ %S\$?\
MIIN*^OZ^0/V.O^4LG[97_7/P1_Z:;B@1]?,NZD\M?2G44 (J[:4C<*** "@+
MBBB@!-@I/+7TIU% !2;!2T4 )L%&P4M% ";!0J[:6B@!&7=2@;1110 4444
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M^0/V.O\ E+)^V5_US\$?^FFXH ^OZ*** "BBB@ HHHH **** "BBB@ HHHH
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MR")W3/&?E<\$5O4Q'C__  4%_P"3$/C5_P!B%KO_ *;YZWOV3?\ DUOX;_\
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MY#_8ZT[]GUOC#!+\-=2\5ZUJ%A87,&C"\&L7&BZ19NZM-'I\MPGV2.-V5/\
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M\8$82"4,?WA/)7[OOQW%N28AN&&[BI** "BBB@ HHHH **** "BBB@ HHHH
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MH+_R8A\:O^Q"UW_TWSUO?LF_\FM_#?\ [%;2_P#TDBK!_P""@O\ R8A\:O\
ML0M=_P#3?/6]^R;_ ,FM_#?_ +%;2_\ TDBH ]"HHHH **** "BBB@ HHHH
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M?M'_ /A$Q_\ R50!^G5%?F+_ ,16?P#_ .B:?M'_ /A$Q_\ R51_Q%9_ /\
MZ)I^T?\ ^$3'_P#)5 'Z=45^8O\ Q%9_ /\ Z)I^T?\ ^$3'_P#)5'_$5G\
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MQ_\ R51_Q%9_ /\ Z)I^T?\ ^$3'_P#)5 'Z=45^8O\ Q%9_ /\ Z)I^T?\
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MA'8ZE-H5OJ3&4RO)/'8:@?.3YF BN$VC&X#)P/TT^"W[%GPC_9SE\SP'\,_
M_@^XYW7&DZ+;VMQ*3R2\JH'<GN68D]Z /S=_X*6?\'"7AG]FC]N+X2^"_!'A
MN^^*>E:N+>YN[[P]XPFL8+MKB>6U2V2)(FAN2C;)0WF;7.(R5&37VP?BO^TY
M\9$V>&_ACX)^$NFS?=U+QSK+:SJD2GHW]EZ:?()[X.HKZ8/;N_C+^R[;_%GX
MM^"_%4UOX1DD\(3-*HU3P\NH7$P99$VK,9D,:KYA=?E;:XW<]*]AS0!\Y^%_
MV+_%_B&Y\_XE_''XE>,&?@V&@O'X/TN(=?D%@%O>I_CNW[>^>L^'G[!7P=^%
M?C/_ (2;1_AWX97Q7G)\07EFM_K+_6^N-]P>IZR=S7L%% #438H [# KD? O
MPE_X0;Q1XAU3_A(-=U3_ (22\%]/;7@M1#!((HH1Y?E0H^!'#&N&9ONYZDD]
M>6VCFD5PU #J*** "BHWN4C;#-@CV-.5ED0-V/(H =131(#09%5"<].30 YC
MBFMTS6#X=^)_A_Q;?7-MI>M:5J-Q9L%N(K6Z29X"?[X4G;^-;#W,;J5#<^E"
MU5T$HN+LQ[W"HP5I%RW8FGJ:\I^*<_A0?&7P1'J[:#_:UQ-.MDEV8_M$I6,L
M!&&^8X8@\="1WKTR*[CBCYD4 #')K.-1-M=C:IAYPC&37Q*_XVT*'C7Q?:^"
M=!FU*^^T+;6X)=H;>2X9%[G;&K-@=SC JSX8UV'Q-H\-];BX6&X&Y!-;O ^/
M=' 8?B*\_P#VJOC1X7^$'P-\0:MXBUBUTW3_ +%) )')8O(Z[4157+,Q8@8
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MVW^6<R&$AF^4!7SUKLH/^"9<DT88_M$?M/9Z8'C=,?\ I-5WXG?!#X@7%O\
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M#OB+4KFUU3Q$MUI+:?>WSS0;+>XG5E5BS10[0' =!'AE4\4 >&?\/X?V</\
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MJON4'VS1Y=-B.V%?]T5)5 %%%%  1N%-\NG44 (J[12T44 -=-U+M^7%+10
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M6T?E11CRXU+8+!I"7.YVXQZ9110 4444 %%%% !1110 4444 %%%% !1110
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DH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>tm2223302d1_s3img005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2223302d1_s3img005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M>_#I'V/X&?"*)L#Y_P#A$+!G/U8Q$G\30!] G_@I'^SO_P!%Z^#'_A;:;_\
M'J/^'DG[._\ T7KX,?\ A;:;_P#'J\2?]A3X'C_FC/PG_P#"0T__ .,T)^PK
M\$=W_)&OA-_X2&G_ /QFDV![;_P\D_9W_P"B]?!C_P +;3?_ (]1_P /)/V=
M_P#HO/P7_P#"VTW_ ./5XI_PPI\#_P#HC/PF_P#"0T__ .,T?\,*? __ *(S
M\)__  D-/_\ C-3=@>U_\/)/V>/^B]?!?_PM],_^/4?\/)/V=_\ HO/P7_\
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MX'YY^#/PH_'PAI__ ,9I?^&%_@@__-&OA2?^Y1T__P",T78'M9_X*1_L[_\
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M*W5E*%N+=@0>)(USU&00: /6J*A6]C9]JN#].GY]*FH **** "BBB@ HHHH
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M[]H#X4VML4N(KB*&+QWI;*/E:*4>5;ZFO]Y7$4^"2&E(VM].?LM_M?\ @/\
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M1(]Q+E"VW:VT#  KO?CI\ ?#'[2'@^+0?%^GOJ>F0:C:ZM'&EU);,MS;3I/
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MIX(_:*\:^'_%&N0:WI_BWPI%/;Z1K^A:W>:-JEC!.,30">UEC9HWYRC97EL
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MBL0YQ2:3;;3=NB9^A=%1I(2,_G@YQ3U;-?BSW/VWIJ+110>E(844V,[DYIU
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MBU6]M-/:"WM[#2[;[3?ZI=SRK!;VMO'D;Y9)9$502!\V20%I >D45\K>"/\
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MA^(.L?#"^U^3PW;^--,>UU +<1S/"TL^G0NUY;VWF1.#-(F%7:Q 4YH\#?\
M!55_BG\4=5B\+?"/Q]XE^'?A_P 4/X3U/Q5ITUK<O:W:2^3)(VF1R&]^S)(0
M#+Y8PNYB,#-0!]?,<"D4EATI2,MV_#I10 BMFEI PI:  G I%;-+0!B@ W?Y
MQ1110 BKMI:"0OM2!LT +1110 C#(H5=M*6Q0&S0 BH4%+110 V1=R'KTKE?
M^"6D_P!CC^/FCX5%T7XM:J8TQSB\LM.U-C^+WS'\:ZIV^4@=<<5XK_P3X\63
M6?\ P4C_ &D?#*\6LVIV^KL!T\S^P?#<6<=.@JX[ ?=E%%%, /2O@KX88/\
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MCZYKFFK<^<;:?3+= DEP\>V-S+*T9*$[L'!C_:)_X)M?&?XZ_&N:W;PE\+M
MU9]?^VZ;\</#6H2Z)XETG3OM"2&.6Q@C7[5=^2C1;I)60[\Y7)-?I?NV,P]*
M?2;LQ)W5QENGEP*N6;'&YNK>Y_PI]%%0,15VTM%% !1110 T$[J=110 U^M)
MLVK3Z1_NT "G(I:;%]VG4 !&X4 ;1110 4444 )M^;-?/W[ G_*7+]HO_KG;
M?^F?PY7T%7S[^P)_RER_:+_ZYVW_ *9_#E7'8#] J***8 >E?!'PR_Y2=_M8
M?]=?"?\ Z9EK[W/2O@CX9?\ *3O]K#_KKX3_ /3,M 'N]-.[?[4ZAC@5F 4
M8I%;<.F*6@ HHHH *;@^9[4@S@?X4\=*  C--<$]*&8@TZ@ '2BBB@ HHHH
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M=N_:3@#Y/]H57_:J_P"".7BSX(^"-1\2>'[AM<L])A>YN;=]OF^4H)8J1C)
M'3'/-?L(MK''.TBHH=_O,!RWU-0:SI46MZ7=6DZ))!<QM&Z.,JP(P<BO/>7T
M7%Z:GV-#CK,Z=2G:7NQM>/1^?J?%7_!#SX8:?;?LG7'B&:SAFN?$&KS2"22,
M'='&J1 #VW*_XDU]=V?PLT'3O%":S!IMM#J,:E5F1 "H(P0/3O7._LK_ +/E
MA^R_\$M)\$Z7(9;+2#+Y;M]X[Y7?G_OJO1^@KIH4O94U#L?/YIF-3%8J=>[]
MYL8@^7\:?3=_-.K4\O7J%%%-*Y:@ #9<^U.HIH?)H \T_;+^*T_P2_94^(?B
MBTC=]0TCP_>3:?&H.9[PQ,MM&N.[SM&@]VKW+]AOX$+^RY^R'\,OAO\ ()O!
M/A?3](G*-N$DT-O&DK@]PT@<].]?+G[5&G77QM_:3^!/P?LTDDM/$7B7_A,/
M$V!OC&CZ(8KK9*,<)+?R:='Z-EP>"<??$$#0O_#MQU[YJX[ 34444P"FLH?L
M/Q%.HH ^"O"-C=_LW?\ !0;XD?#V[A,/AGXJ(WQ(\)38.QKLM'#K=H&X&Y9V
MMKH*!G_3I"20 %]S4Y0'/! (/L>]8O\ P4W_ &>_$'Q)^">G^,? ,+3_ !,^
M$^IKXJ\.6X^]K'EHZW6E%ASMO+9Y8,<C>\3$$K5/X/\ Q:T+XZ_"C0_&'AJ]
M&H:'XBLTO;2:,_,%8<J1U$B,&5E/*LC*1D$4 ?(OPQ_X*">(?A?HGQIU+7/A
M_P#%GQMX6\ >/M>BU/Q!IRV4T&E6,4H9([>.:ZCGG2"/)D$28C7[I8[E'MWB
MW]MAF^($_ACP'\//&?Q.OM/TNQUO4Y]%:QM[73K:[#M K2WEQ#NN)(T:18DS
ME2I8KN&/ ==^&W[2WA/2/BW\.?#GPY\&:AX<^+7B;Q!<6'B^Z\3K GABSOY'
M!ENK(1-).2K%HQ"Q.6 D5-I)Y[]H/_@GEK7PO^,,_B+0/@3X6_:*TCQ#H>D:
M.\%]XD30-1\.W&GV2V2R[YPT4EO-%%"Q4'>C[OE8<4 >Z:Q_P5$\*/)\,;#P
MSX2\>^+?$7Q@T_4[OP_I%E:VL,L%QITB1W=K>O-.J6K1$R;V)*J87Y)VB2GK
M?[:.B_%?0O =SJ=I\3O &MP?%JW\$:AHMG<6:31ZNMK)/]DO721XIM/>*1')
MA<ELQ%<<@<Q\+OV(_&'@+]H_]FO7/^$;\(:)HOPW\.^*+?7;?P]*8M-TJ[U)
MX)8X[>.9VF=2XE#2?Q-ERJ!]HAUS]CKQ]J7CJ.]CTB 6O_#1]K\1 YOHAC18
M]$@M&N"-Q.[SHV'E??[XQBE= =)\0/\ @K'I/@;X9>+?B);?"_XGZ_\ "WP=
M?7.EW7BO3X+ VUU<071MI)(()+E9Y+83YB,^P+O!&-H)'2>/_P#@H9'H'QX^
M(/PX\)_##XD^/M>^&%M9W^NR::FGP6L-M<P>?&4EN+N,R2E00(@NYF1\9 W'
MX/\ CY\2/$GPT_X)X?%#X*>#M2^%'BCP-;:IJ>B:;K__  DDD.O&6YU>20Z*
M^CM!YTFHB6=HPXD$1C ?J-I^\/@M^SKXG\#?MO\ [2_C34;"%- ^)-OX:@T*
M<7*%KAK'3YX+C<@.],2.,;@,Y!'&:8'JOP(_:)\,_M"? #0/B5H-ZP\+>(],
M75K>>[C\IX82NYA*N2%9,,K8)&5;!(KP6R_X*W>$Y?AKI?Q,N_!?CS3O@MK5
M_#IUCXYFCM/L<KRW!MXIY+7S_M<5J\H*"9HNZ_+A@3TO[ W[+>N_"C_@FCX+
M^%'CB#^S-=L_#,VBZI%;SI/]F:3S%.UT)5B ^002*^/OA=_P2D\8_#_1M%^#
M\WP%^#FNV^@SQ)<?%K6M1>ZT[5M/CF\TJ-'C9;K[88BL7+^7OCW>9C!*T ^J
MO$/_  5 M+"^^*DFD?"SXF^(=%^"6I7.F^+M5M(].2*V-O$LTCVT<EVLMR%1
MM[ (I"#)Y95;F_VLOVU(_#?PD^)GCWX:ZMXPOM?MO@E:^-]#A86W]BP6UQ->
M&UOUAF8$W("EY=X(,,4:JCOP?#_@=KGQNU?Q]^UOX&^&7@#PUKND>-/BIK.F
M/XFU3Q"+*/PG<3Z?:1R7%Q;>4\EQ"(S&R+"6<LK H <UZQXR_P""=?BR'X3^
M+O >B3V5U:7'[.VG_"W3-2NI!"EUJ=K_ &@@WIDLBL)8&+<J/,89)4T: <GX
M$_;;^*$W[:_P_M(_"WCWQ;=^*O@#9:_)X5@O=.M;=-1.K2(^ISNUPMK$)(E4
M*58OB:)-@.X)[GI__!43PCXD^&?@75=!\,>-M<\5_$?5=2T'2?"$-O;1ZK%>
MZ<TB7Z7#/,L$,=NT69)3*0%=2,[L'A_V,/V?_BGHW[3W@KX@>._!=OX.@TGX
M(VW@&]LDUF#47BU"TUB5U :/&Y9;9(YL@84R^6264FO']=_X)<>/9_AOX3\0
MZAX'\->.==^''COQGK@\$ZGJRVT'BG3-9O&=/*NT+)!<H$AD02#9DE7*D470
M'H7[<7[?6I:_^S1XST[08O&'PO\ B9X!\6^$[+7M,NYH4N[6WU#4[8(\4]O+
M)%-;SQ><FY7&2&5E!S7IWA/]LGPG\-/B=\0;2XOOB3KEU=?%/2/ DL&H/;36
M>E7]_:6GDK9 .K1V($B,^[,F]I2%;(KYZU[_ ()V>._'O[,7BV72O@M\/OA3
MXB\5^)/#-S:>&-*U-+K4;*PTW5(;B=K_ %#>+>5F"2/''"H" X+,S<=K\2/V
M)OB>]_\ &'Q-HNB:;?:O_P +AT+XG>%M,N-3C@7Q'!IMK9*UJ91N%L\I@F16
MD  ;86PI+ T ]F^.G_!2SP1^S_XT^*6B:QI7BRYN_A'X3MO&.K/9P0/'=VD\
MC11Q0;IE+2!ERP<( "2&)XKG+W_@I_)!\5]%\ _\*7^*L?C'QMH[ZYX2L+B7
M2HEUJT10TCRRB]9+-E'S%93D+MP-S!*^=?BY^QE^T'^U)K?[2/B[7/AWI7@V
M^^+7PPL/#.@Z*GB:UOVM;J"XD+0SSC:F\J?,W*/+ =5W,02?I7Q3^R_XNU;_
M (*.?!?XA0:7;MX3\'>!=3T/5;EKN-3;W<Y@,<8CSO8'8W*@@<=*- /6OV4?
MVH-%_:T^&$_B/2+34]*GTW5;S0=7TK441;K2-1M)3%<6\AC9T8JXR&1BI5E(
M/.!Z97SM_P $W_@!XH_9Z\"?$NR\56,5C<^)/B9XB\26*I<)-YME>7AE@D)0
MD*60@E3R.A&17T34 0WME%?6DL,T<4T4R%'CD0,DBD8(8'J#W%?(OQK_ ."-
M'PP^)E_=ZAH<^J^#-0NY&E:.Q=9K ,>>(7&0,YX1D SP*^P",BF[ :]++LVQ
M>!GSX:=F>;F&4X7&PY,5!2/R7\9?\$:/B1X1^*&AZ3I6IZ7KFEZI</YFJ6Z2
M0+I4<;)F6=6X5LO\B*[,Y!' S7ZF_#'PE-X&\ Z1HDVK:CK\VDVB6[W]ZRO<
MW>Q<;Y"H )P.3U]23DGXLTS]K[XJ:=^V9JMOXL\2-X-\!P^.E\+Z1;R>$EU7
MPUKMG)(+>&--6M'>:SU1YF12EV8X@SA F0<<E\(OVT?C)X<_9[^%WQL\3>-]
M,\6Z1X]\?CP/<^#H=#M[5(8)M8N-/CN8;F-?.>ZC\I7VDE'4.I16(D/H9SQ%
MBLSA"&)M[O5+<\_)>&\)EDYU,-S+FZ7N?HTLJF38/O@;BN.0/7%$MPD$;L\D
M:K&"7). @'4GTZ&OSK_96_;_ /C!\<=9\!?$">#77\)^//$BZ-/H">&+6V\/
MZ7:27<MHLT.J/-]IENH2H>3<"CLDD:Q)D/7H>D_%GXKZU\-=-^*FI_%7X>6O
MA7QI<7MDG@G7-%AM8((#]I6WM[.ZW>;<:CB$;HY"T<G[Y1&A49\!*Q]$?6FN
M_%GPKX5?35U3Q-X?TPZRK/IPN]1A@^WJJ;V,.YAY@"?,2N<#GI6Y'=1S!=KA
M@_*D?Q?3UK\?OBQ)JM])JOQ*O)_"E^=$_9*T3Q#8Z%>^$=-N=*M/.BNXVMHH
M7B*QPB93+M4 %7$)S&JJ/JGP=\>?BG\<M1^(NMZ#\1/!_P +?#?P5U*TT>;3
M-5TJW.FZP$TZSO[FYU"Y?#VMN5NQ%']G\L1B(LQDH>P'VU*^Q,G@#J?2FB4&
M/K^->'?ML?%SQ5X/A^&OA7P9K%AX8UKXI>*U\.+XBO+1;J/1(EL+R]DD2)SY
M<D\BV9BB1\J7DR5;;M/QEK__  4<^,_PI^)GB[X5WFNMXRUJ7XFP^!M,\2:9
MX;MGOM/LET9+V2>*S!2&:\9N,.P179\1E1Y5+E _3Y9E";BWR]0W8_CTIRN&
M;'?Z5^>UQ^VE\<+/0-%\(>?>:?XDD^*6D>#E\2>)_#UG;7=[I^HV%S.SSZ=!
M)Y<=Q;R1Y&TQK*B0$*OF2+71?$#]I;XM?!CP?K'@"Z\4:IXP\8?\+,A\%6?B
MS2_"EI)J:V,OAR/73(+ -':R7"@R0*2%3!#F,E"C-JX'W0'S2EL5\R?\$[?V
MA?B)\7-3^(WAOXA6-VTO@34[:UTS6;_3[?2]1UBWGMQ-_I=E!(Z0SQMN4[0B
MNK(RHHR*^F'^]4 /IC!L_C^E/I&;:O\ ];- 'S)KW_!2_34USX@GPU\./B+X
MS\+_  DU*;2O&/B#3(;-;?3KB!%>XCMX9;A)[MH4.Z011Y QM#$C.S\0OVY;
M[P[XA\36_ACX2_$CQOIG@N.&YUG6+0V-A8F*2T2Z'V,W=S$]Y(L4B[D1 -Q"
M[BQ"UX[IOPI_:._91\;_ !0\*?#7P?X;\5:!\7_&6J>*]-\;2:Y#9-X#FU';
MYS7EA,C->"%P)(UAW>9MVL%R*XGXS_L2_%7QS\<OB%IVO?"_1?C-;^*(%;P[
MX^\2^-7L=(\/1#3XH?L[:*B/MD6>.67=%$%E-Q\TD8#,N@'O_B+_ (*8Z*/B
M[X0\!^"O _CGX@^*O'G@BW^(.BP6*V=I!)IL\A53--<W$:PLH49# C,D:C+$
MBI--_P""EGASQ!\-? VJZ)X2\;:[XH^(.JZAH&E^$K>.V74TO].>:._2=WF6
MWBA@:)B\QD(PR$ Y%>;_ +'G[(/Q%^'O[7WPD\;>(O#D6DZ-X4_9YT[X=ZF9
M-1MYW@UBWOHG>(+&[%T:-"XD'R\XR"2*Q/"_[&WQ<^"?AWP=X^\.>'=)U[QO
M\-O&WC?5D\)W6KQV@\1:5KE_+(ODWF'CAN0@@=1( O$BL5.*6@'L%Q_P4IT;
M2K-=.U'P+\0-/^)#^)5\)0>"9(;4ZC?7IM!>[X)1/]E>V%N6D,YE"A5^;!(!
MC\5?\%-O#OPQ\ _$K4/&_@SQUX2U[X2V%CJ>OZ!=1VMQ<2VEY,88+FTE@G>&
MXB,BLI.]64QN"H. WC/[0_['GQJ_;'\/^'?B9X^\)^$=1U_P7X@N-6T3X3W&
MJ1/:_P!ES6 M;BPFU14"->O(//21MT,<@5"VPEA@ZC^P!XZ^)7[)/QDBT[X'
M?#KX0>(?'.FZ=IFB>&]/U<7^K%+>_2>9[[4 XM@&"[HXHU^5>6<NV*8'W;\"
M_B=J_P 7_!TFKZSX%\4?#VX^V2QQZ9KQM?M;PC:T<Q6WFE5-P)#1LVZ-D92.
M-U=M3(R77G=]X\''K[<4^HEN 4444@"F3G9'GIV)]*?7AG[;/CO6]4\,:-\*
M/ ^I-IGQ*^,5VV@:+<PY,VC66W=J.K!1@XM+8EU.5S+) H)+@4 ;_P#P35T?
M4/CA\;?BK\=KY<Z/J]\G@?P021MDT72YY5N;I<?\_&HO=D$]8K> \#&?M2N/
M^"?PAT7X$_"+PQX,\.V_V70O"FF6^E6$04#;# BHN< 98A02<<G)ZFNPK0 H
MHHH **** (;NW^TQ;??//KVKX'UGPD/^">W[7TOAV&REM_@]\<M7:ZT"6)B;
M7PQXGE#2W5@X(PD%^1Y\&&P+@7"!?WB5]_5Y]^T[^SKX7_:K^!?B3P%XPL7O
M-!\26H@N##)Y5Q;LK!XYX9!RDT3JLD;#[KHIH \]'[P9%/KQ#]G'XKZYX0\6
MWOP9^)U[+)\3?"*.UMJ,MHUO!XUTM&'D:G;,<(\FQHUN8T)\J?=QL9"?;ZG4
M HHHJ0/+C^Q5\)C\:A\1F^&_@0^.Q<?:QK_]AV_]H^<1M\WSMN[S< #S,[L
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M^9"#@#(!^4Y!R >#W'OWJ&K 2T444@"BBD=MHH 6B@'(H)P* "BD5MU ;+4
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M.T5[?2;?<T<P'&S? 7P[/^T,GQ/,-Q_PED?AU_"ZR_:&\G["]TMT5\OIN\U
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M]!N+_P"#OP;\>^)]/5@(-:\3Q#PCHUT""08WNP;R5#C[\-I(H[GD"M_X>_\
M!/+XH?&[^T&_:#^*(N=&U0[?^$+^':S:)I4<1#;XI]0)&H7.X$ E)+=2%8%#
MNPIR@9/Q3_;4T^TU]/"_POT.\^-'Q"EOET]M!\.W*FVTES]Z34KX;H;"-1U\
MT[R2H5&SQU'PV_X)LZ]\2OB'<>,OV@/$&F_$*1+B&Z\/^"+2!H_"WA)XV#J=
MC$-J4X95/VBZ0;2#LACS\OTA\"OV;_ O[,?PYT[PC\/_  QI/A/PWI6?LVGZ
M; (8D).68XY9B>2S$L>Y-=Q5 0P6RQ*ORQAU7!*K_*IJ** "BBB@ HHS1F@
MHHHH **** "BBB@ HHHH \]^-?[3?@G]GC6/!NG^,-:_LF\^(&MQ>'= C^QW
M%Q]OOY 2D.8D81Y /S2%4'=J] %%%3'5-^=OP3_47VK>5_Q?^0ZBBBJ&4]1T
MF#5XI(;A%ECD0QR1L R.IZ@@C!KRSQ'^P/\ !'Q7KTVJ:A\(_AG=ZQ(I4ZA+
MX6L)+M<C Q*T);CMSQ110!XA\4/^"*_AKXA/MTOXX?M)?#^UZBT\(>,HM*MU
M.<Y"+;$9[?2F^#O^"+>D^#T _P"&BOVK-4P ,ZAX^2<G_P EA110!T?_  Z>
MTD?\UN_:+_\ "Q3_ .1Z7_AU#I7_ $6[]HK_ ,+%/_D>BB@!/^'3VD_]%N_:
M+_\ "Q3_ .1Z/^'3VDC_ )K=^T7_ .%BG_R/110 ?\.GM)_Z+?\ M&?^%BG_
M ,CT?\.H-*_Z+=^T7_X6*?\ R/110 G_  Z>TG_HMW[17_A8I_\ (]*/^"3^
ME+_S6[]HO_PL4_\ D>BB@ /_  2?THG_ )+=^T7_ .%BG_R/1_PZ>TG_ *+?
M^T9_X6*?_(]%% !_PZ>TG_HMW[1?_A8I_P#(]>??&K]CWX9_L[ZQX-T_QA^T
M1^T5I%Y\0-;B\.Z!&/$LMQ]OOY 3'#F*T81Y /S2%4'=J**G=I>:7WNQ+T3?
MDW]R/0/^'4&DX_Y+?^T8OT\8I_\ (]./_!*'2C_S6[]HK_PL4_\ D>BBJ*#_
M (=0:5MQ_P +N_:+_P#"Q3_Y'H'_  2@TI?^:W?M%?\ A8I_\CT44 -'_!)_
M2L?\EO\ VC&^OC%/_D>G?\.H=+_Z+=^T5_X6*?\ R/110!S/Q7_X)[>"_@A\
M--=\8>*/CY^T5I?AWPS8S:EJ5Y_PE1G^S6\2EI'V1VK.V "<*I)[ UY_\/?@
M]\$/BE\1O!?A/0?VF/VB[_Q!\0O#8\7>'[3^W;F+^T-+.<7&][)4CZ'Y)&5^
M/NT44J<4Y-/^M)/_ -M03TI\ZW_X,5^K/9'_ ."4.D]?^%W?M%_^%BG_ ,CU
MP'P,_8^^&/[2-SXLA\&_M$?M&:Q)X&UZX\,ZV/\ A)9;?[%J$&/-A_>VB;]N
M1\Z;D/9C113A%-N_:_SNE^3']CF\[?@_\CT#_AU!I7_1;OVB_P#PL4_^1ZX#
MXU_L@?#3]GC5O!NG>,/VB/VBM)O/B!K<7AW0(_\ A)9;C[??R F.',5HPCR
M?FD*H.[445.[2\TOO=B'HGZ-_<CO7_X)/:2R?\EN_:,&X8R/&*9'_DO7#^+O
M^"%^D^+9M_\ PT[^V)IN6#;;#XC)"HQVQ]E/%%%44>@_"?\ X),_#_P%$B^)
M/$OQ ^+D:DY3XAZA;:^LBD8VL)+<94=0.QKV'X:?LE?"_P""\C/X.^'?@?PG
M*SF3S-&T&TL'W'J<Q1KS110!Z## (1QSGJ3U-2444 %%%% !1110 4444 -
MYKSKXW_M4> _V<=>\&Z9XRUS^Q[[X@:NN@Z!%]BN+C[?>M]V+,4;B/.?O2%5
M]Z**(ZSC%]6E\FPZ/T;^Y$_Q+_:=\$_!S7X]+\1ZPVGW\L"W*QBSGFS&690<
CHC#JK<9SQ1117S];-*T9N*2T?]=3W*.6TI4U)MZK^NA__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>tm2223302d1_s3img006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2223302d1_s3img006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6T";(K>&-0B(H[*J@ #VH U**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KP*Q_X*>_ #5/#
M%]K%O\4_"MUIFF7:6%Q/%*[JMT[R1K; !<M.3%)^Z4%]J[MNT@U[[FOSO\9?
M\$9_$&J?L#_"WX::;XF\+#QG\*_&>H^,+.[U"PN9-&U1KNZU)W@N(X98I\&'
M42-Z.'$D61P30!].>*?^"EGP#\&^'-!UG4/BSX*CTKQ/IT^KZ9=Q:@L\-W90
ML5EN0T>X")'!0NV%#@KG=Q5F3_@H5\%WL?$$R_$7P_Y?A>WT6ZU5][XL8M8,
M8TQW.WI<^;'LQUWC.*_-+X\_\$U?C9^QEX&TGPU\)[>^\::QXL^$>J^ ?%NJ
MVO@:UFTN^>>_O+U%M8H;ZW^PW)EOYU\R:)X"A#NSNI6NXU7_ ((8?%[5)M5D
MT?X@>"]#TCXB^'/AY9^+M)U'1IKN[@NO"XLBD=M<QS+&J.ULQ+F-B>%  .\
M'UMX+_X*F^!CJ/Q+3QW?:9X"A\!_$*]\"6/GWS7DVOFUL+*^DN8X4B#J EYA
ME <((P2_SX#HO^"P'P.O_P!I6Z^'%OXPM6;3_!*>/+KQ 65="BTZ14EC;[43
MM.Z!O.W#]V$XW[SM'@/QW_X(R?$CXA^-/%6J:'X[\%_8/%GQ%U[Q=>Z%XBT>
MZU+1[FVU/2=,L(VFMHYX5FN[1K"62+S"8O\ 22"O6N)OO^#?;QQJ/A;3=%'Q
M'\-0:;=_!*Q^$^N%M(GEF6YT^X-W:7]J1,@V&YCMS)%("2B2*&RX=0#[J/\
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MI<RRK++<ZW?S/=79=T^1BCRF(%?EVQ*%^4"@#Z(HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHIKOL7-
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M:?BOX_USXL>%/#&E>";RW^'-Q?6 O(_"L%FQ.H2QB&V$5T4W/O!C:%S]Y *
M/VP\3?$G0_"OB?0]#O=:T>QUSQ,\J:3I]U>1Q7.J&&/S9A!&6#2F.,%VV [5
M&3Q6\DH9>J^_-?GEJ/[%NJ>!OV[?V+?'=UHWB+Q%XLT/0]2T/QGX@CDNKZRT
MY8?#+P1Y))AMDFNFD.["^=(X)W'&/%O^"?'BC]IS4/\ @K-I^J^,[/XT:7\.
M/%%AXD36=&U?3]>ET30[N&\?[&C7-Z[V;.T(1TDL8X+=E944.XE  /UZSFBH
MX?\ 4K_NBI* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M70W$9_B7\Z3[7'G&[YB,CWK\C)?^"E/[2MOI\EYG33"EF=5P-*M@GEHTBLH
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M\C/1LCMCH:D6X5AQ_*OR-N?^"DG[2>DZ<UQ,]F\-M+:VDLC:;:DJUWGRBV'
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M.M_#_P 3O!>@^-M#M+Q-0@L]5MA/%#<(&595!Z-M=UXZJ[ Y!Q0!^<7[!?\
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M/OFMK=9+B%6<")?E; ##IZ@UA_%W]G72OB[!9K<ZEXJT;[&7*/H&MW6D-(6
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MW_#O'5_@$9KSX&_$#5O \7F-*OAO5B=6\.R$G<4$+L)80QSS%(,9SBLG6/\
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M'"]E?3-;L\DH0LLMJD>#M*Y&1AUQYN*QWL9<B5V=6'POM=6[(_2+1?CIX/\
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MSPUI6AV_B.'3M)T'2K:[ACM;>;1Y"$NVN(S)FXE#Y+AN5C=7_5OP=^SKX/\
MA_\ %?Q1XXT;0[#3?%?C6*SAUS4H8RLVI):1M';A^<?NT9@, <'G-<3\3O\
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M]JMW!M(!YYR.U49?#EM-.7:"-F.,L0"3BO#S3!8ZO)/#5N2WE<J/*FEMO?\
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MXT9;<>*M<N;C47@U>4>>XCDMX=5OH53#EO,5MZE<&GK/_!OM-JWPQ\)^&_\
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M\2],U!O''AGQ=X6U*Z'A#RM:U*'7IC*+B\OC>-]HN+8GRU;REC,2JHC1MSD
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M_P"&],&MW&IZAI-]8VEY8FY2U6ZLY)H46^A-Q)%")+4RJ9)8TSN=0?,O'/\
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M "BBB@ HHHH *1C@4M-E.%H SO$/B"S\,Z9-?7UU%9VEJIDFFF<)'&HZDDD
M"O/KO]IBWU!6_P"$?\-^)/$29PLT5NMI _NKW#1[A[H&'O7F/_!3SX=ZY\1/
M@S90:7>?8;2UU:UO+VZ8MY=F(G#QSR!<EHD8988QDJ6^4$CYX\>_L(?%;X@3
M>,[B'QGIE[;^++^YNK*Z-W/'%Y$USHLBGRD!0#RK&ZPJ,0?-09PQQYM6M/GY
M(NQM3IIKFW/LFU_:*\2),/M7P[UB.'NT&I6<LBC_ '#(O\Z\;_92\>Z7\&/V
MP?B1X*BT_4]#T;XDSIXVT2/4+*2U5M1=!%J=JC$;&.88+@;&(;SYB/NFN2U7
M]FOXC^"_BWXHU;P3=:?:VVM>&M.TFUEEU-XUCN;>Y9YFBM3%)#;AX'**5! <
M!F1A7G'Q4^'_ ,5?$FC^$?!7C^&^\4^,]>?Q -,U;1+NWCCTH.\#64K.H@D1
MXD52TJH>0W/.*B-6<=5*Y?L[Z-6/TTMIQ<0(XZ,,T]ES7S-H*?'7]G/P]:6<
MEOI/QHT"QA5?M"W2:1XFB55QAA)BSO' YWF2VSCD9Y/4> /V_OASXN\?V?@W
M4+_4O!?C>Z3,/ASQ382:1?W&,9$ E CN<$XS;O(ON00:]-.Z3.;8]P*AZYWX
MH1C_ (0C4N/F^S/V]JN>'O%VG^*],%[IMU;WMH9)(A-#(LD9:-S&XW D95U9
M3Z$$5!XXM9=5\)W]O FZ6>!E09P&)![U2DD]2:D6XM(9I^F0ZOX;MX9HTECD
MMPC*Z!E8%0#D&O@CPA^Q;HW@G]MGXD>$O#^I>*OA;X@U.)?%WA'6] O?*M=0
MLWVI=V;VC;K>5;:[.XHR!O+N8@#A>/T#T#-KI$$;KAHXU5N> 0/6O&?VV?"&
MH6OA'1/B-X>LY-2\1?"S4&UZWL8L>9JEFT317]F#W:2V=R@/'G10YIJM9^Z=
M&#Q=?#K]W)KNNC]4SR_3_P!H7X^?LSZ_+9?$WP5!\1O"4:GR/%7@NV8W<6T9
M'VG3\EQD;\F(D#:H ;>2ON7P3_:N\"_M%Z0T_@_Q-INL>62L\ D,=Y:..J2V
M[;9(V!XPZCOZ5V7@3QAH_P 5/!6EZ]HMU#J&CZ[90W]E=1'*7$$B!T<?52#^
M8[5X]^U7^P!\-?CW'-XDU73KW0_$^EPO-;>(_#\CV6L6A"?>22(;I#@<!@V.
MPS6MXST>AZ'M\-B7^]CR2[Q6C]5_E8]9D^)^A1^/&\,_VM8_\)$EDFIMIQG'
MVE;5G:,3;,YV%U*YQC(/-=8C<>OOZU^0?Q(^)_QO'QC\"^*?!NB^-?B??>"Y
MY_L&KZGX(NM!N9K69=LUE<DXAN(F558/MC9756P2"#^I/PS\=W'B_P"&NDZW
MJ6DW^@7NH6D<TVG707SK.1ERT38)&5)(R#@XHJ4>1)WW-\VR-X&%.:DFI+OJ
MFG;5;KYG;TV1-XKFQXZ0(6V1JB@$EGP #T.>F.G/3D4Y_&@5E'EIN;E06Y;(
MR,#K_P#6K+E:Z'A/3<\9^*MS:?!K]N?X<Z]!Y=JGQ.BO/!VJ*,+]NNH+:6_L
M)"!U:.."^0'KB?'9<?1$9WKS7A?[07P0@^/WCCX7Z[-JEQILOPS\5+XIMX[>
M(-]N865S:F!R>BE;IFR.>,>]>G6WC+RX]I5&;:7/S<[1_%]/>EROL"BSIL*3
M3JYEO&REA^[3#<#)ZG..*T-&\0)J$K1LC1RX!VGZ9_J*?*^H:FM137/RU7FO
M!'&6P>/:D!8.17CG[=GQTU+]G?\ 9D\5>(-#MOMWB4VJ:=H%H%W-=ZG=2+;6
MD8'?,TD>?;)/ KM?%_Q;\/\ @2!FUK7-)TF/&2]]=QVX'_?6*^/?B/\ MR^%
MOCS_ ,%,?AC\(],#:QHWA.SE\>WFMV-W:W&G23^5-:6EN["3(97DFD(VD[TA
MP#DE<O;03LVOO1O'"UFN91=O0^L/V6OA0OP._9^\(^$MWF3:!I-M:7,N<F>X
M6,>=(3W+R%V)[EC7H59]G?+<P_*.F#SZ5?5L@>]:J2:NC#5;BT444 %07,7G
M'&.HJ>BEON!P'Q$_9I\ _%R0-XH\'>&_$#+T;4=-AN2OT+J37RA^SC^P3\)]
M<_;<^/BW'PY\(7&A^';O0[#3+:32X6ALYCIL=Q.$0KA=WGQL<=21Z5]U/*(A
M7@_[$BCQ#J/Q8\59W+XJ^(&JF%LYW1V'DZ4I^G^@$CV8#M6#PM)N[BON1V0S
M#%05H5))>K/4_ _PF\.?#6R^R^'M#TG1+8]8K&SCMT/X( *B^)GQ-TGX0>$K
MK5M5N+>SL[;H9'6,.Q^ZH).,DUK>+/$UKX5T.\U"]FCM[2QB:>>65PD<2*,L
MS,2 J@ DDD  9/%?&/P=_:BO?^"G7PRNO'/ASP+XD\&6GP_\4AM%'B.%7E\0
M!;-@TXMXW4>28[L&-Q*23M8<#%9XB+ITFZ>YE&4JDU[1WN:'B+_@H9XZU_Q7
M]@\*Z#X+?*B2.WN-4-S=NI0/NV1NO&TA@1Q@@YP:[3X&_M]7'B33+R?QAIND
M65O8D+)J.C7?VRW1O[CKDLK<C RQ.<<$C/RSXZN?#NJ:-XB\/>(_$EM86NM:
MA-?W:V>B#3+JUE?3_L16(^84C4 [_N%NQ)R37?\ @+P1IG[35CJNGVJV>OS7
M6F:=I,=S::,(K/35LY99([@[I''F;IFP=XV@*%'&*\".-K*:?,Y/M8]:6$I\
MGO*WG<][\1_M;?$?QKIVWX:_ _Q9J<DP'D:AXLNH/#>GJ,_?>-V>\QCD#[."
M?45YUX2\ ?&VU_:\TOQ-XUTKPNR>+_"UUI%\OAA+F;3](ELKA)[$7$L[;G=Q
M<WJ[UC0=!@]:^Q]+L?LEK&IP2J 'ZXIM[,+:+>7VA<LQ] *^EE35:GROJ>)&
M;@^9=#\P/VTOV'=1\>_$SQ5K<^M?%'P+;^.EL(_%$?AJ(2QZDMD-L#17*(98
M#L^5@'\MN,QDUPNK_"'P[JOQ_P#$_B\>,O&MBOB72[S3+S2;?2T@6Y-S8M9&
M2Y*1*;ED1MZM*&DW*N7.*_4?0O$FI>/-?CN+';;Z' [ S.-TEZ1QA1_"@/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1/[/7AW]HWX2:MX3\16SS:?J4:[98F\NXL9D8/%<P/UCFBD"R(XZ,BGFN/\
MV6?CUJFK:KJ/PY\<26MO\2/!<4;:AY2^7#KUDY*P:M;KDD13%6#IR8IEDC)(
M"._K*]M3E/;$TJ&,<1K]-HQ67XDTO99AE4[5.6"CH*W$E60G!^[P?:E9 _6F
M4Y-GQ=XB_9)\8S^'O#*1ZQ!K$VA:;]G>TO;H0P--OC8;'6!LKA#_ *^.4'/3
MH1TWPC_98O/"T&LSZY=6=U?ZE"L,36T,<?V=/L4,!19!$)5^:-ON,HPV0HZ5
M]02:1:RMN,*Y_G1_8UKC_4K^9K>6(DU8OVTGN?./_"C/$TV@^"[3_A)#;CP_
M;K%/Y,2A]PLI("5=U?>&=E)#*N!R#FO+KG]C#QT=*L].BU+259=&-A<ZC+</
M)+*PLI+?:%,1*Y=E8LDBKQDQD\U]4_&+XDZ7\((M :\L9[A?$&O6>@0>2 ?*
MFN7VH[Y(^0'KC)Z5V%KHMK<0*YA4EN3UI+$33%[:2V/D?XC_ +&NJ+K&A2>%
M+RUCC@>>2\>ZEC@-O*SVC++!'' 4&!;D%4$1.XDO\S9]R^!GPYN?!.K>(-[M
M-'J6K/J,697D,:/#$I4E^<[T<XZ<UZ6-"M?^>*_K5F&UCMEPBA?I2=:<H\L@
ME4<E9@YPE?)?[=OQ3\2:4M[I>DZU=Z#;6-DUU(]J_E373;6(&\<JN0!D8Y/)
MKZU(R*\O_:!_9?T/]H'1(8=2DO+2[MF)@O+20)+%NZ@Y!#+[$=J\#/,+B,1A
MG##2Y9'I9'B\/A\4JF)C>/W_ #L?A1_PM#1_C+HLNH:YX?T>R\0$:4M]=^*]
M5E%CITUW;75U(]Q=,K'RO+MT\HJ27,\8S]X5FZ-XJ\$ZK9:%KFE>"_#,-K):
MVDU[!+J 34=2:>]FLR-+18\72(\+2%L@%&4CDU^DGQ%_X)!?$*.68>&_B?HT
MUK+M @U;1G#%1D ,\<I#8!X^4=>E>=^%/^":/Q,@^,'_  A-W\3O!>FZO:Z8
MNM)%8Z'<.%MY)WB+H2Z+N\Q6W '(RI_BKXV63XMR:5)_^!+_ #/U&CGN"]G?
MZVDK;<K_ ,BQ^PA\5_%GAS3]6GM=0U30;?P_XAN]'71+S4Q>V\D4)4*S@DJK
M,&SB/[I(K]/O"VJMK.B6MRRLGGPI)M(^[N4''ZU\V? #_@FKIOPKU"VU3Q%X
MDU'Q9JEO()@K1+:69?L3$"Q.#_>8]J^H;6T%LBKCH,5]-D. Q>'YOK$O==K*
M]['Y_P 29A@\3./U75J]Y6M<L#I1117TQ\P%%%-D<*I[8&: .'_:*^+VF_ '
MX,^)/&6K3+#8^'=/GO6#'_7,J$I$H[L[[44#DLX Y-<;^S+I.G_LP?LN^#=-
M\5ZKI^E7MII<<VJW-]=1PB2_F_?W;$L<9:>25NO>N9_:/TJ+]I[X[>'?AM(K
M7&@>"Y[;QKXEP"%D>*1O[,LF'?S+B-YV7KMM%'_+0&OG+XN^.-9^+=AXSO[;
MP=/<>*;"80V$EWYUQ:QRFX:%(YE:.':0JJ^+=YAME0E@.6X,=C'0CHKLZL+1
M55^\[(]+_;F^,OP_^.WB'X1^#[GQ9I.M>!?$7C1+/Q38Z?J:.MY"+&[DM8;D
M(V[[,]XEL'R0K94-PV*^OM%TZULM*AAM88(8T151(T"JJ@84*!C    ],5^8
M]CXMA;Q6LK_#K4VT/7FL++P]#) ]O>O?3F\#+<;E(6#?:N"^/D0(Q5A(,?5G
M_!/#XU:UXX^&MS9:U8?85T 1*T^Z;R@[!R\ $Z(ZM'M&X#>@WKAS7-@\?.J[
M5$D:XG"*FDX.Y]!>(?A=X;\53K-JGA_1=2F485[JQBF9?H64FKVB^%M-\-VJ
MV^GV-I8VZ](K>%8D'X* *\E\9_M__#'P/J3VESXA:XGB.V06=C/<+&?=D0K^
MM;WPJ_:U\!_&:\-KH.O1W%\!N^R3026T^/9)%4G\*ZHU\.Y\J:N<_LZO+=IV
M/30N!7GGQ(GN/%7BNU\-VLK1V[H9]2D0X982<! >Q;!_ &N^:?;'G-<-\-;<
M:MXR\6:@V=QU 6H]ECC7^K&O1IV6IYV(;=H+J=?H^DP:38QPV\4<4,(V(B#
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M32)M0U*_L]/L;==TMQ<SK#%$/5G8@ ?6O#_B1^VGI?BBTO-!^$EWI?Q#\<3
M0V\.FSBZT[3&; \^^N8LQPQ(#N*EQ(^ J*Q.*J_"K]G6X^->O_\ "P?B_H6G
MWVO7TBR:+X<O_+U&U\%VR@;8XP<QM=MG=-.HSDA%;8@S[YIGAVUT:TCM[6&*
MWMXAA(HD"(G7H!C'6@#@?V=?@-_PISPU?-?ZI-XB\3:_<G4=<UJ:)8I=2N2
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MO4IU(SCS1V.*47%V84445H2%%%% !1110 4444 %%%% !1110 4444 %%%%
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M5,E PX)4GDH2"5)Z@BNJA&3ERU'J9SE%QO36GXG5P;-*T]%;;''"NT#. H'
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ML,_$1M=T_2;_ ,.?#VPT[3OB7/XZB\6Q:G++K0MSJ<EXMND/V10KNC>2V9B
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M2+ZC'UKR7_AB#P3_ -!#XF?^')\1_P#R=2_\,0^"O^@C\3?_  Y7B/\ ^3J
M/65D1#][\,T[[4GK7D?_  Q!X*_Z"'Q,_P##E>(__DZC_AB#P3_T$/B9_P"'
M)\1__)U 'K@G4]_UH^U)ZUY*/V(?!(_YB'Q-_P##E>(__DZF_P##$'@G_H(?
M$S_PY/B/_P"3J /5-2ECEM6^;&>]? 7QF_9Z\9_"[Q)XGU_^R;37-8U'4;N\
MM_%ZM<7.H&UEF#)8-$D;+$L:#RU?]XJ[%81[R37U1#^QCX/TR[@N(+[XCF:W
ME61!+\0_$$T993D;D>]9&7(&58$$9!!%9_Q?O=0U[4I--C\22>'801&J0/Y,
M[#IG?][Z8(KR,UE%03E<[L#S.=D? .O:E//:3-/HNGZMXLO+R%K35[S[7!>>
M&K=)=P@MPEJ1*ZJ!EF$7FL7#C!&/5?AI^ROXC^(J>$AX;MKW2(] UO4;\:G?
MO=0R6\4^J0W<$L;.FZ::.VCDM\-\I%P_S8RI\=U'XF>/7UJU74O&.LZ<^INC
MQW%Y?30^7&UU<1EH2]\L4BJL4>XRO"R&8':0RU]B?LN>(M;/PU\+ZW<^+KU[
MS5=.M[FZT^^G>Y"3/&K.@\TL_#$@$$\ <GJ?&P\HPFI2U5ST*UVG%'U=IL/V
M>V"MUP ?Y5:"XJGHMTUWI\4SC:SH&(_"KE?71E=71X3T844450@HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1Q$+<#[(,S*Y(;G&00.0<6M'_8H^*"^"+NS_ .$,TZUO!IL>G64IOH\VZO\
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M%:*.!@=&M^43!1?N=!C@=J<W[)_PYDNQ<'P-X2-PLRW0D;2+<LLP  <'9PP
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3 **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>tm2223302d1_s4img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2223302d1_s4img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %; U(# 2(  A$! Q$!_\0
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M^$:\-_\ 0N>'_P#P2:7_ /(M;5%'/5_Y_P"(_P#!];_Y<'LJ?_/NE_X)I?\
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MN/!LM_;-\6-6T=?"EA:-;ZIH7PM?QS>^&AHUHNHV!M;2.P=KNW@>J.K> O\
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M .1:VJ*VYZO_ #_Q'_@^M_\ +C+V5/\ Y]TO_!-+_P"5F+_PC7AO_H7/#_\
MX)-+_P#D6C_A&O#?_0N>'_\ P2:7_P#(M;5%'/5_Y_XC_P 'UO\ Y<'LJ?\
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M?>SU2E[SGF-+F<O><O\ D4+WF^9R6KTDY;ON[_K&1-KAY)-I1RJHXI-I1?\
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MCX5T'7?$=K'JUQ!I7VFXM[2YFFB7YA^'?[,WP-^'_P#P18^"_P"VAX4\-O\
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M *"OB+_PJ/$G_P MJFHHY(?RP_\ !5'_ .4A[2K_ ,_JO_@ZO_\ +R'RIO\
MH*^(O_"H\2?_ "VI#'-C_D*^(NW_ #-/B3U_["W_ -;UXJ>E'4?4?SI<D5KR
M0TU_ATNFO_/D/:5?^?U7_P '5_\ Y>>^_!F2:3P>XGN;NZ,7B+Q+#'+>WEU?
MS+%'JLZQQ?:;V>>X,<:92-'D8(F%7A>?6J\D^"W_ ")]S_V,_B;_ -.LU>MU
M^2YTDLWS*R27URK9)))?PM$HJ,5N]%&*NWHKG[1D+<LERJ3;;>!P[;DW)MN,
M[MRDY2;\Y2;=E=L****\P]8**** "BBB@ HHHH **** "BBB@ HHHH ****
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MT_\ Y_+;_O\ )_\ %5]G_P!@:%_T!=)_\%UG_P#&:/[ T+_H"Z3_ ."ZS_\
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M_P#0?@O_  3B_P#,^3_M%O\ \]X?^_J?_%4?:+?_ )[P_P#?U/\ XJOK#_A
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M?_GO#_W]3_XJOJ__ (0+P1Q_Q2N@<]/^)9:\\$_\\_0&E_X0'P3_ -"KH/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<?M:_P#1'_@GCCG=XKZGM_Q^]?;W'K1_Q+WXF?\ 0!D__A^P/_RD7^OG#O\
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M_%)I_A[Q_P")/$OP\U:ZN[+Q%I_AS[787.D?'WQQ_9W\3?!N'Q!XDN;FTO\
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MZB4HJ#H;WP@\&_L]7'PQD\9?$#6]&N/$ND>+/&4NLV&H_$[2O#.LV%OX<L/
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MC&$4N2$[^OZ_X T33OA1X#A\&3_LR>)?%N@_M#?%W2=.U+5/C=^S]INO>,/
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M237/A#<:-IOQFTCQ'\1/#-MX%\!^'!H_A35/!-UIMM\/;0?!/P%\-/#GQ?\
MAYX)\6KI-YK7BKPEX)\(:CXKTZ:YO-<T!]<MM9NK[@/A[XW_ &?K70;7P_\
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M!P_#B"4*,L5/"_594ZRE"C&MS^TH5Z7*U.I345&W,FF[O1JQ_EX_\*D^+?\
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M^&K?P?=.?A]XHD:]\-VC.UMIU^TOA5CJ#V[22F'4;[[1JT8N+E4OPMS.)/\
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M$(9=#"*-=47-8ZC/EFZ>&PT:-=JI":GS0I56VJLW.NYR2=6;G^5/]@:!_P!
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M,\2^&/&W_"NI=!TSN?A?^P3^TUK<WPIF_: \#?%#6_'&N7W[ 6J?&KXE3?M
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MI\8_V0_V3WM_C/\ %KXQW>N>&_ ?B6W\5?$CXJ0ZO\5?$OA3X.>'O$EU\/\
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M?./&W['7PA^''@F/QOJ7[0VEZW?6'P@\1?%*\\':5:^%-8O[K7M-N-/M]!\
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M7XST;6?LWPQ\.VY\%#Q-\>X_%>C>"K^UU2WL9?AMX6TS4]2UJ\9-=TW!>%W
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M.0W#AY/,MK63<3;Q/%_0&39ODV,H?6\+4R[/<-.453Q&"S+"XS#)TW/G@JV
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ME'64:+J^Y*HHIN%-N+J-<D)<[@I?/W[=GAOPY;ZW\$UB\.Z#&&N?'V[9HNF
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M ()Q_P#!/7XD_M__ !T\(>!=*$/A#X1#Q3I&E?$KXK^(KFVT?PQH]O=.9_\
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MM\E*-N:3^*I4D^:I5J3=W.K5J5:LVVYU)-B  # Z#_#'^??-+117*=04444
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M'/VA_@-\(/"=SH>LW.A> OCSX_6^TSPQXZ\':[8:=J^DZ=\2M:75=*T2Z?Q
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M^V/%VC:QX:DN/ OC.?6-9OM#U7PMK6H:#9>(/$6O?#5/#7C77-3UR7(\&_\
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MU?AAXI_X-7O^"8/B+7+O5-(LOC'X-L+EMT7A_0?B#//IEEEY),02ZW9ZKJ+
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M&5C#87%C)JD-Y+\2?B)'#)IT=Q8VQOUE;P&!]C:YU/38ENF(BE?4[ QM*EW
MSZ,/_!(WPC<QQRV_PB25);)]1A8?$3XBKYUC'$UQ)=Q(_@)7D@2W1KDNH(6V
M(GSY)20_I-<_\%#OV*[KPI-X>G_:%^ 5W?GP=I/@J'Q'=_M6? -M2ET+0_$?
M@;Q!HFBZG!;W$%I?:/HA^'/AW3M);R;?7[?2Y]1TRZUR[TY-'M-)CO/^"AO[
M&#^*O&'BFQ_:)^ R2^,;^]EN;'4?VN/@I=6VB:1K.LOJ'B'0?#RVFJV!L;.^
MTTQ>'+&=_M-YINCH\=O,TLGG+XR\'O#22J)3XCIRBYJFY>.7&DH5(JI!4[<O
MB)&5/FI2G4;J)^]3=+DC.<9GKOQ<\4HN#_M:4HRC#G4?#G*HSIN5.3J;\%N-
M3DJ*%*T&DU)5>:4(2@_SJ\,_\$PO!'AS7;#4[?X&?#_Q7]BTX^*[G0O'?BOX
MRZYHEWX<MM/FU7^V)8/#UAX.N[?24L8VU";4)K^?3[FRB*M$T3OO_:'X>_MG
M?M@? 'X=:5\*?AY\$OV%OAM\-+C1%-AX/T[X5?$;2- U;0KQ[F W<NG2:G';
M:I8ZC*EWYMS)#);7UPUY+F1Y)V/@&M?\%(/V.M??5M3N_P!H#]G/3-?NOA;X
MF^'&ES:'^UC\'8M'LG\3^(-<N9KZ]L=5U_5K^\TBV\'ZM_PB$.@0:I9QVT"S
M7-E=6T3V-C8V_"O[?7["+>./!VH:Q^TU^SS8>&_!_P .X?!MG)K7[4GP8UC5
M[>>UU35M=EU#3+FP-U DUQ=ZYJ<&F:?<:0D=G'<1VPUS3Q&+V$PW@_X0X3%4
M<YQ&00S'-,OI8B>#QV;^).;<3YE@)RPDU4ADV+SSCG,X9?/$RE2PM2OE>!R[
M%UZ+K4JN-J44J%7#%>*'BGCX_4O]8,<L+7JTH3IT^"J.786I"5>"]IC</A.%
M<+[54J2JUN3$U\12IS]BXTU*524/9I/V\OVWK-Y9_"D'[,_PWN)$GW'X>_\
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M'_(YH?\ 7G&?^HTO)_D?-\6ZY%BO^ON#_P#4J'?^O3<_+K]I33/V*-2_:1^
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MK9^9)47A85(XZK"M1HW5#GERJ:K3BH4[2INFW*HIVBIOD56;FGRI_0WC./\
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MN_PY>_'JZN/"7Q#\-_M9VW@KQ!?Q?$'5O'/AOQ'^U;X(O/!^HQ:]HMY\1/\
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M@2,2R1>'O'VD7.F^+[./P':6GA[QK'/=RZ/I.M^(-"O-%UK0M7OM.G\_M/\
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MG_GU]>?KS7W;11_KC#_H6R_\+?\ [U#_ %$_ZFK_ /")?_-1\)?VOIHX%S(
M,  6EX!@=!C[+CC^@]!2_P!KZ;_S\R=_^72[[]?^76ONRBC_ %QA_P!"V7_A
M:O\ YD#_ %$_ZFK_ /"*/_S4?"?]KZ;_ ,_,G;_ETN^W3_EUH_M?31TN)/\
MP$N^W3_EU[5]V44?ZXP_Z%LO_"W_ .]0_P!1/^IJ_P#PBC_\U'PE_:^F]?M$
MA([FTNR?KDVN<\]:7^U]-_Y^)/\ P$N_?_IU]S^9K[LHH_UQA_T+9?\ A;_]
MZA_J'_U-7_X11_\ FH^$O[7TW_GXDSTS]DN\\<CG[+GKS]:/[7TW_GXD]?\
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M\!+O_P"1:5=8TX,I\YR%93G[)?>O.?\ 1L9&3C'HO![_ '711_KC'_H6R_\
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M7<#XQ_%S!EFR?^%G>.\?ZUSQC7A@ = >!D+SC-?KGAIX75_$FAF:HYU0R?\
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M57^7BWQQ^*Z9W_&[XIKM?RVW?%;QJ,28+;#GQ%P^ 3M/S8!., TK?&_XLH9
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M125KY/77,N:/^UTM8W:4E>@KIM-)JZ=GKH[?ZA?VBW_Y[P_]_4_^*H^T6_\
MSWA_[^I_\57^7D?CA\65)!^-GQ44JXC;/Q5\; K(>D9SXA&'.#\GWNN!FMW6
M/B9\>] L_#U_K?Q7^+VFV7BS3GU?PY/<_%7QB%UC3$O;G37N[81^)7<(M_:7
M-L8YEAF+Q$B+849Q_1?QD90C+C3 QE4<E3B\CQBE-QBYR4(O,%*;C!<\E%2M
M'WG:.HEXD4FFUD]=J-N9_7*7NW?*KVH-*\O=5VKO1:Z'^GA]HM_^>\/_ ']3
M_P"*I#<6_P#S\0CGG]Z@./;GJ3@=C@G!!Q7^7F_QP^+42B1_C9\543"MN;XJ
M^-P"K*70C/B'YO,524 SN&2N0*W_ !'\2/CYX1U^^\+>)OBO\7]'\1:<EG)J
M&D7'Q6\8275K'J&GV>IV3R"U\2SQE;C3[^SNT,;OB.=0^UU=%;^B]C.90?&N
M!4Y1E.,/[$QBG*$'!5)1B\PNXP<X*4DFHN<%)Q<HW/\ B)%)IM916LFDW]<H
MZ.2;BOX#U:C)I;M1DU>SM_I*_%WXY?#+X(>''\2?$/Q)::7#(9(])TFWVWVO
MZ_>*&?[#H6C6[M=ZA=$(6D9(UM[6-9+B\N(+=)94^%3I_P"T/^W#(DOB*YU#
M]GO]F2[>.2+0K6>SD^(/Q+TLEB'OYY%D@%C=QD'9+%)X0AWKC3_B!Y<5]I_\
M(NDZS\8?B9<:]>V'C;QKXKF\%^%[W7M?U+6/B5>C_A'_  M8ZGI]M/-/JGB7
MQ+;Q10OKNJ:386.DVUR]_JVOZEIEAI>GWNKWUM;R>AZ4_P"U[KWA[3_%FC^)
M/VA=3\/ZM=P6.DZA;>/O';_VI)/<FRAET^R/B)=1O--%TC6K:O;6<FC6TT4D
M<][$\3JGI83Z/5/)J+G2XORB&<*I&']H9AE4YPP+JPE5H1P&!JYA"E3Q=2G"
M=6&)QGUFM",75PU"FDJZ\O%\8U<TK<E? 8O^RN1R> P6(=*>,Y6HU/KV,A2=
M:>%4FH2PN%^KTZCER8BM44O9/_1P^%?PK^&OP8\+P>$/AQH&F>'='C*S73Q3
M&[U76K[8$DU7Q!K5Y+<:IKNJ2HJQO?ZI=W,ZPI%;0M%:006\7I7VBW[SP_\
M?Q/_ (KW_6O\SB^U/]JS3-072[[QG\=([^34_$^D10Q?$SQE>)/JG@OPWI'B
M_P 66-M<V/B:YL[J70/"^OZ+KVHM;SRQ0Z;J=G,CL)<UYTWQP^+:EED^-GQ5
M0I&LC!_BKXV4K&1D2,#X@7:G( 8@#'&<8%>=+Z-&-QU2IB'Q]@L;5JOVM6O_
M &3C<34J.H_XDZBS2K*7.[VE)V=K1M91CZ4/$##X2G3H4\AJ8>E2BJ=.C#$4
M*5.$8))1A3CAH1BDK:126M]6VW_J&?:+?_GO#_W]3_XJC[1;_P#/>'_OZG_Q
M5?YAV@_$WX\>)KB]M?#WQ:^+FJW&F^']=\57L%M\5_& :#P[X9TZ?5M?U8B;
MQ-$)+;2]-MKB[N%@\V=HXF$$,T@\MG2?$KX^0Z9<ZS=?%;XP6.F6EOI=W)<:
MA\5/&6GN]CK%Q=66EZA96=]XD@OM3TZ\N[&]MDU+3+>\LEDMI5FN(F1L0_HP
MXE2=-\;Y>IKD3@\EQ:FG4O[-.#S'GO/EER>[[UFUHFS1>(U-I263U^5W?-];
MI6M'XG?V%O=^UKHW9ZZ'^G?]HM_^>\/_ ']3_P"*H^T6_P#SWA_[^I_\57^7
MDOQP^+3G ^-GQ48^69<#XJ^-B?*7[TG_ ",1)C7^*3 0=R#FNGU+Q[^T/HVD
MQZYK'Q+^-6D:7-XDU'P<LVI_$OQQ83CQ3I.F:7K.I:'+IUWXABU.WOK/2-;T
MF_D6XLHXS#?6XCD9S(BN7T7\7"48SXVP$)3?+",LEQD93D^:RA%YBG-OEEI&
M+^&6ONM$KQ(I--K)Z[44W)K%TFDE;5M4&DM5O;=6W5_]&G]I^?XG'X(>,A\%
MKK4HO'IN/"'DS>'%TZZ\30^$_P#A./#1^),OA:VU"WO8KCQ3'\-?^$ND\,PV
MUG>:K)KJZ>FB6ESK#6$+_ _CS]I#]JWP3KOBSX3?LX_#W_A*=#\!_"_X<_'3
MPUXI^-7PY_:$^(7Q"F^'OC#XM:3\+4^!OB7PJ?%NE?%?7?C7KR^$_CWXS\"_
M$3Q-=6OA[3/"OASP!I_Q8MH+63QK\5K?^&R/XU?%^8,8OC1\6)0K%&,?Q2\;
MN%9<@J=GB A2,=#@C'-(WQC^,"B24?&#XMB1HDC>5?B9XW$CQPM,\,;R#7A(
MT<37$[PQDE8WGE==IED)?_$KN._Z+/!+UR+&^7_4Q\P_XB31_P"A17?IC*-O
M_3)_;9JOQD_X*B6=M<>'=-\">!O$D>J7G[3%_JNI^/?@O\8?"'B>RMK*[GU/
MX$_"SP9JGP3\6>+/"-KJ\W@_5;*27XJ:YXEM/"NH:QH]UX1A\5)XS1M6DUO$
M/QY_X*CZ)X?UE/#_ ,'O@X9;SQ--I7AOQ!XK^#GQ]U>S^&?@_2O%'Q@\/V>O
M>.O#W@#XI^/OB-\<M2\5VOAGX.;!\/\ 1?!%]X:M_B'K/CC6-.UGPWH5\EA]
M=?\ !.K4=1U;]AO]EO4M6O[_ %;4K[X/>%KB]U+5+VYU#4+VX>!B]Q=WMY+/
M=7,[9W/+/-)(YQECBOM.OYAS/!2RW,\RRV515I9=F&-P#K1BX1K/!XO$X5U8
MPDY2@JCP[FH.4G%347)N+;_1\-6^L8?#XA1Y%7H4:Z@VI.*K4J=51;22;C[3
ME;LKM7LKF+X?FUNXT'0KCQ)::;:>(I]'TR;7[31;F_N]&M-;ELH'U6WTF[U7
M3](U.ZTVWOFGBL;G4M*TS4)[18I+K3K.X::VBVJ**XC8**** "BBB@ HIKY(
MP#C) _,X[>O0GL,FOFGXQAYO%VC6[76HQ01^'+V;RK75=2T^(RG4[-3*Z6%W
M:B5PI*B20.54D+A2P/HY7@'F>,AA%65#FI5JCJNG*HE[&"G;EC*#;E>U^9);
MN^QYF;YDLIP,\;*BZZA4HT_9QJ1IMNM4Y%+GE&:2CNURMO96W/IBBOR0^.7[
M5?[,/[,EUH%C^T'\?_"WP@O?%.GZEJOART\;>._$FF7.L:;HTD46JW]A%%>7
M#S6FGRS117EPP2.!I8][ LN[TSP5\1_AK\2)8HOA[\0[?QTMUX/\(?$"QO/"
MOC/Q!KFD:GX'\?1:C+X+\5:1KNG:G/HNLZ-XEATK4+C3+O2]0O5EAMWED$:2
M1&3Z%<)TG.5-9O1=2%N:"PLN:-[VO'ZUS+1-ZI+0^6?&TE"-1Y-B%3E?EJ2Q
M4%3E:U^6?U3DE:^MI.UU>US](Z*_.VX\7^"[?X@6GPHG\8RQ?$O4/"%U\0++
MP,_BOQ&/$EUX)L=5.AW7BF/3_P"TR[:-;:N1ILUV6")>8C /?7TG4O#_ (@F
MUNVT+Q2VNW/AG7KCPIXDAT7QQJ6JR^'O%-G8:9JEYX9UV.PUNX?1_$-GINLZ
M1J%UHFH"WU2VL]5TZYGMDAO;=Y*7"$&[+-J3=W&RPLF[Q5Y)+ZW>ZOJK72U:
M2)_UY2U>4UDK*5_K=.W+)M1EKA5[LG&2C+X6TTG)II??=%?#_P#94F\1^=XA
M$C#*QG7O$@<CU"?VEN('<@8&#GH:3^RW*EA/X@*KDLPU_P 2%5VD*VYAJ6!A
MB <G@D#J15?ZG+_H:0_\(Y]=O^8KK87^O=/_ *%=7_PLI?\ S.?<-%?G5X_\
M:>!OA3X:D\9?$GQL_@CPI#J&CZ7)XA\1>+?$-AI2ZEX@U2VT31+)KE]2*?:-
M3U:\M-.LTP?-NYXH\Y8 =F^G;"P>ZUU2LC1MGQ%XBPLB_>0G^U" P/4$YH_U
M/C=I9K!M6;2P<[I.Z3:^M-V;32=K-IK=-)_Z]1LF\IJ\K;47]<I-2<;72?U:
MUU=75[KF5U9IO[BHK\QI/C+\&XM1^+VD2?%?25U7]G^ST&^^-VF+X[UN2^^%
M=EXI\./XO\-W'C:UCU5YM%CUOPM')KVF&="USI:M.@( KSWP-^U]^RE\2Q>G
MP'^T7X1\1R6%WX3LKNTM?'GB:TU**;QYKEKX9\&.NE:G=V&IS6?B?Q%>6NA:
M1J5M:2Z==:I,ED+L7!91F^$Z2DHO-Z*DW)13PLKMP?+)+_:]XR]V2W3TM=-%
M_P"NLVI2CDN)<8\O,UB8V2G%2@Y-8-J*G%J46[<T6I)N+3?Z]T5^2?@_]JK]
MF/Q_\1YOA!X-^/\ X5U[XGQ:QXI\/1^"+7Q[XCMM=O\ Q#X'N-2MO&>@Z+#?
MWMG!XAUOPO-HVL?VYI6@3ZC?:=#I&K74]NEMIM]-![+X8\2>%/&S:\/!WB]O
M%7_"*^*-6\#^)#X>\::SJZ:'XQT&*QEUOPSJ;V>L3)::WH\>HV1U+3G;[39M
M=0I<)'(S*KCPE3FKPS:E+64=,+)ZQ3<E_O>Z2;:[:[:BEQNX?'D^(AI&7OXJ
M$?=F[1EKA%[LGI%[/5)W32_0>BOAU=-+L52YUYF'55\0>(RR_,%^91J9(^8A
M>0/F(7J0*4Z8R@,UQKX&"V6\0>(P"JG#-G^TQ\H/#-T!ZD5?^IR_Z&D/_".I
M^7UJY'^O=/\ Z%=7_P +*7_S.?<-%?!%G=Z-J6K:SX?L-?NK_7O#QTY/$&BV
M7B_6KK5]"?5[&/4]*36=/AUF2ZTR34],EBU&PCO8H9+O3Y8;VW66WEBE;&OO
M%O@S3O$0\'WWC)H/%1D\-I)X;_X2_7I]=M1XQ?Q1%X1GU#2[;59KO3;/Q/+X
M(\90:%?ZC%:6.JS^%/$,%E<32Z-?)"O]4(V3_M6E9NR?U2=NJ5O]JNVVFDDG
M=IK=-*O]>8WLLIK/3FTQ=.]M'>WU7:S3YFU'56>JO^B%%?#XTN4ML\WQ!O*J
MP4:]XDW%3]U@O]IGY6S@$#:2.#TIK::53S&N=?6/<4WGQ!XC";AU7<=3V[AW
M&<CG.,&G_J<MO[4A?3;!SZ[?\Q76S_&U[.T_Z]T_^A75_P#"RD__ '7/N*BO
MAX:8Q57%QKY1FV*X\0>(RK/G&U6_M/:S9XV@D]..:&TMU#,T_B!51@KLVO\
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MY^SZ5\-?AIKGC'5_$6N.^K7EG8:!X4^$W@F_N+**SLI8="\,-JB7>L2S:A>
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M]\^GK^%>#9K=->J:_.QV*49?#*,O\,HR_P#292%HI,CIG_.<?SXI:"@HHHH
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M[K#>#O$[-+X/M[4_$.'5?#H\+3V"^)]8O%\$0>'Y_&L/B=?%=JT[:[)J]QX
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M<81M']ADX!Z8SD8)(ZGU4?\ U^IPQ-.KYW_9E^/]O^T9X#\0^+D\(ZOX+O\
MPG\1/$OPUUS2M42_^S76K^'+#0=6_MKP]<ZII6AZC?>'=4TKQ+I4UI<WNCZ?
M=17RZEIT]N9+ S2_1%>]3G"I!3@^:,KV>O1M-:I.Z::=UNMW>YXLX2IR=.:Y
M91=I*Z=G9/=.2::<6FF[IKT10/\ 61_[R_\ H:44#_61_P"\O_H:45/A?JOU
M(>Q]1_#7_DG7@'_L2O"O_IBL**/AK_R3KP#_ -B5X5_],5A17X[C_P#?\=_V
M'8W_ -3,8?N^!_W' _\ 8%@O_4/"':T445R'4%%%% !1110 4444 %%%% !1
M110 4444 %%%)D9QS_\ KQC\\_H: #(]?SXZG Z^IX'KVS7FGQ?^,WPF_9_^
M'OB+XL?&[XB^#OA7\-_"=F]]X@\:>.=>T_P[H&G1(C/'"U[J,\*7%_=LGD:;
MI=H)]3U2\>*QTVTNKR:&!_!_C)^UQX3\+W_Q#^%7P<DT7XN_M-^'/A/\6/B!
MX8^$.F:FCB_U_P"&&B_#'6?^$-\2:G8FY/A[Q)KVG_&+P+K?AS0+J./6?%'A
MR77=5T&"ZM?#FKS67X^^'_V6/V@OV_\ XSZ/\=?VCO%WB"T_9O\ !'BG7?'6
MDV?Q.T+2]'^'M_IC^%/"WA/6OA[X9_9Q^(G@J'Q'X4\'ZEX-U3XX_#[XI>+/
M&?C.^M/B%X<\;V.K/;/JW@S2?LH _P#:#_X*>_&;]JGXJM^R5^PKX+U/S/%?
MBKP596_B.X\5?$WX _M(:[X(\&:SXV\4?M$ZW;>%/&_P0^W_ +.O@OP_JGP!
M^*W[$?B_Q7\39_#'Q=^$O[4?C_X37GB;X?\ A/P+X^^%OC#XC>I?"S_@G]^R
MO^R'\'C^T5_P44N_ ^N:RGBK5/&7Q \6_$*V3Q9X"^'/B+XK^*[!]1G^)'C?
M3/"FA:+XBTN+7[;PWX@UGXE>/_#VC>%_!_Q$U7QWK^DZOX=\+>+5L+?[&^(&
MK?LJ_L.?"3XK?%[X3_"KP]\4OBQ^RI\$M-U+Q5:>$;O0M<^/M_X'\9>%OA-X
M+?Q!\3/B#J4MQXIUAO%/@+]FOX2:AXW\9^,M2U;7=<\$? KPAJM\VK0>$?#4
M2?D9!\.OVP?^"L_[1?AWXH>)M!\%^'?V4O!-AXUD^%'B3Q=X>\,_$KX;>'O%
MMWIWB#X5?$GPMINE>%O&WA:3]HWX6_%7PT-72#QX/$VA:I90>(/"GBKP)+X&
MU+PUJT&M 'T9^T7_ ,%H/"?B#XF_"3]E;]B/PA\3?BQJ/QUF_L1?CQ\$O!<7
MC:+X8_#32_C+\!_@Y\4OB]\,?"EUH6L:7\1(/A%X?^*OQ1UAKGPIH7Q=U3X8
M_%S]GK6/"/QU^ FC_"R_UOXC^'NH_P"">O\ P3K_ &M_A?\ $_X9?M6_M3?%
M:SM?CO:ZA\8O#7Q<\!Z'\0O&7Q4\)^.OAOXU\&^%-/\ "-Q>:SXH*>7\2_"/
MCWPC96EEX\MM^J^./@9H'PWTGXJ+K?Q,\.7&M:?^EOPY^%GP'_8H^&CWNHZZ
M1>R)H=WXT^)WC>[BU#Q[\3O&NC?#_P $_#!O%&IF&*(:GXX\2>#_ (<^"]'U
MR?0M/AU/Q,WA_3K_ %]]6U9+O5+CY"^+W[4/Q"^+GVK0O"!U?X6?#>9C%-+#
M,UA\2O%UJ^8WCOKRW<GP1H]RF=]IITK>)KF*0I/?:.=\4GT60<+YKQ%5Y<'2
M]GA8RY:^/KJ4,+1V;BI)<U>JD[JC04YWMSRI1;D?/9]Q/E7#U'GQM;GQ$XN5
M#!47&>*K;I/DO:C3OO6K<E-:\JJR]T^K?C=^U]X8^'][J7@CX<VEM\1_B79M
M):ZE;0WCP>"_ ]T0%#^-O$5NDR/J=NS-/_PA6@M=^);D1)'J?_"-V5W#K"_G
M#XAU?Q7XZU[_ (2SXB^)+OQEXF'FBUN+J&.ST;0+>4EA8>%O#L#/I^A6,(VQ
MB2/[5JM[Y:SZMJ>H7A:YDRM.TVQT>S@T[3;2VL-/M5806EI&L,$0=B\A"*/F
M>25GEFF?,LLC-+*[R22$WBP]<_3MVR:_>>'^$\JX=@I8:G]9QTHVK9A7A%UY
M-JTHT(I.&%I/^2E[\XV]M6J-N*_ N(N+\VXBJ2A5J?5<!&5Z6 P\IJC9/W98
MB?NRQ51*S<JJ5.#O[.C!)2:#(/S=^A)'4DY'WB<X Y'7DG!S4-U=6MI;37EY
M<V]K9VT;SW-W=3Q6]K;P1*6EFGGF=(8HHU!9WDD154%B>,&?3+76_%&O0>$/
M!&@ZAXP\7705XM$TH($LHR5"WVOZE,4L-!TQ"RM)>:C-$"O$,<K?+7H_[06H
M? /_ ()P_ 2^_:H_;#N)/BKXHL]6TSP[\+/@MX5M+:]L_%GQ4UN&XD\)?#[X
M?>'=7>VA\9^-;MK#4-4G\6>*VBT7PGHFDZIXKATS0+7P_?:M,^(^+<GX9P\Z
MN88B+Q$:4ZT,'3J4U5]G",INK7G.2IX3#QC&4IXC$RA%0A.4(56C3A3@CB#C
M''X7 Y1@<36EC,7A\%0G##8C$2Q.+Q5>EAL/@\!AL/2JXG,<=B,17HT,/A,'
M2K5:M>K3I74YQB]/X/\ [/?Q&^./V75XQ?\ PW^%TWER#QGJ>FF+Q9XMM74.
MI\ ^'M3A!LM+N(F4P^-/$=HMK/$Z7'AW1M7MWCU.'[K@\6?LA?L@:)-X7U[X
MJ?!7X+116MQK6M7/Q)^*'@[PKK^JQV=E%=:CX@\2ZMXPUVQU/46BM)(+R]U.
M_E:"WMI4EW0V[I7\-W[5'_!2;]N7]M;4=1?XH_&#Q-\%/A7?2SKIO[.7[.?C
M/Q%\/?"]KH]PDD7]E_$OXH>&+G0OB1\6M2D@E$&LVTFM^'/AY<N)((/!EW"B
MWUQ^>&E?"?X6:&3)I'PU^'NG3-.MS+>V_@SPZNHW-U$S2K>WFI/ILE_>WPE8
MRF\O+F>[:5FG>9I78M_$O''TD\'FF,JX?"X7&YE@J-62IT<+6IX#+$XR:4U/
M$PGBL?-*]L34P]*FW=T*5*#4G_M9X*_LC?$_%9)@\XXQXHX6\-\9CZ%.K/ 9
MA@LQXMXNITZL(S5/'X;)L1@LCR2K[R]KED<YQ^)HW=/&5GB:56E#_3[^'GQO
M^"_Q;:Y'PJ^+WPO^)ILX;>XNQ\/OB!X3\:&UM[I&EM9[D>&]6U+R(KF/,D$L
MNU)XQOC9@"1ZB2!C/?@<$Y_*O\K.[^%'PNO;BVO)_AOX&CU*QF6XL-7L_"^C
M:9KNE7<;K+'>:/K^EV=GKFCWD,@$D-]IFH6EY#(GF).C@&OTS_9+_P""IW[=
M'[%NKZ7'H'Q/\5_M/?!*SFB_MS]GO]H7QAJ?C/7DT=!MGB^#OQX\4W6H_$+P
M?KT$2Q_V/H?C_6O'/@"X>)=-BL_",%P^K6WSF3>,W#V85Z>&S+"8S)95)*$<
M37J4<9@5*3LO;5L/&E6P\+N-ZE3#5*45=SE""YU[GB?^R^\:>#,GQ>=\#<2<
M,^*=+ T*N)KY'EF#S3AKBNI1HTI5*G]F99G-?&Y;G-=1IU'3P."SK"8_$-0I
M86CBL34C0G_H,@@\C/X@CW[@4M?-_P"R=^U7\&?VS_@9X/\ V@?@5XAEUSP/
MXM6]M)[/4;5M+\4^#O%6BW4FF^*? ?CG0)G:\\-^-/"6KP3Z5KNCW99HY8HK
MRSGO=*O;#4+KZ0K]?C*,XQG&49QG%2A*+4HRC)*491E%RC*,HRC*,HR<91E&
M46TTW_FK6HUL/6K8?$4JN'Q&'JU</B,/7I5*%>A7H5:E"O0KT*U.E6HUZ%>C
M6HUJ-:E2JT:U&K2JTZ=2G4IP****HS"BBB@ HHHH Y_Q,P73(&/1=>\*L<=<
M#Q1HY-?QQ-_P;>?M@EG(^-?[->"\A7.J?% G:[NPS_Q;CJ PR.<DDEC@9_L:
M\5?\@F/_ +#?A?\ ]2;2*Z.OO>$/$+B;@.ABGPYB,%0_M6<5C/KF7T,?S?4Y
M?N/9^WJT_9./UFMS./-S\RO;E5_ S3(LNSO$)8^%:?U:G3='V5>="SK*JI\W
M)&7-=4XVNO=UMOI_&%_Q#>_MA?\ 1:_V:O\ P9_%#_YW!IO_ !#=_M@G_FM7
M[-([\:G\4<9]<'X<$<#@8 /8EN<_V?T5]C_Q,+XF_P#0?DW_ (C^!_\ FGU]
M+Z6/-_U$X=_Y\8S_ ,+Z_P#\K/XP!_P;=_MA#/\ Q>K]FG//_,3^*/&3DG_D
MG(P3QR.>!G/)*_\ $-Y^V",G_A=7[-70X_XF?Q1[DDC_ ))P<9SG)W9( QUS
M_9]37Z=^O..N#D']#QCG.#0_I"^)O_0?DO\ XCV!_P#FG^NV]S_4/AW_ )\8
MO_POK_\ RL_C#_XAO/VP,_\ ):_V:?ER% U+XH#'?&/^%<Y'&,$'(7 &0!C\
MT?VMOV*]#_8V\17_ ,.O'?[5/P(^*?QPT^T^U7'[/7[.]A\2/BS\8-/5X[66
MU7QI90>#]!\"_""#4H+V&XTG4_C?X]^&6CZQ;F9](U&_,,H3]N?^"K?_  5H
M\=>-/'7CS]C7]BWQSJO@+P]X UC4/!7[2W[3/A.>&W\3OXJM8DBUSX'_  "U
MDI,FDZ_H,DS:=\3_ (JVJ/=>#=5CN?"'A!HO%]IJ>IZ'^ _AKPMH/@_2O[%\
M-:7!I6GM=76I72QR3W-YJNKWTIFU+7==U6^FN=5\0^(M7N&>YU?Q%KM[J&M:
MM=227.I7MU/([G]Q\.LZ\8.+\+1SK.<YRK),AK^_A53X9R^IFF9TE*SK8:G6
MQ2H83"2<9JGC,3&K.M:4\+AJD(JO+\YXJK\(Y%6J9?E^"Q.8YE3NJW/F>(A@
M\'-Q3Y*TZ=-U:^(CS1<J%%PC"ZC6K1E>FO!?#/P\\;:SIT5]KNB6G@^YD6%U
MT;4M:T_6=4@W)N<7L_AO^T]"1HBPA4Z=K6J122+<$2+&D+7'0'X3ZV2/]/TD
M GG+7?'/&,6N.IR,#AOF.3@#WI1CMR1UY[GOGDGIR<GKD]*?7[K3KXB$(QG6
M=:<4E*K.G2A*I);SE&C&G2BV[NT(1BKV2LC\VGF6)E*4E[*FFVU"$&XP711<
MYRF[=Y2;;U?8^6XO"&M:?XKL=*\8Z5K.A^"KW,=Y\4/"NAW_ ,4-)\.2-+;I
M!-XC^'_@\2?&6[L! ]PUS+\._AQ\1-3MI[>*-=&NK29M1M?UV_9T_P""+GCS
M]K?X=6?Q7_9L_;(_8R^,?@*[E6RFUGP9XJ^)EY/H6KBV@N[CPUXOT*?X;V_B
M+P1XNT^"Y@_MCP;XQTK0_%.BR2+!JVCV4^81\5$$GCC(QG X/_UP>ARIP,@$
M*:M^ ?%OQ1^!/Q1M_C[^S9X_O?@S\=;&"TM+CQ;ID#7GAKXB:-8RK-;^!_C=
MX.22WT[XG^!9BIB2TU8KXA\.;SJ/@S7=!U.,32?#\6T_$/ZM6Q?!G$&7QQ5.
M$IK)\XR3+:]+$<J;5+"9G&IAZU"K)>[3CCJ5;#SGRQEB,.Y*I'Z+(\ZR/VT*
M'$&75G1FXP>/P&+Q-.=*]DYU\&U5A4IIN\GAIPJ12E)4JB5G^H)_X-O/VP&&
M#\:OV:<'H/[3^*&"?Q^'!YQGH.!US@Y4?\&W?[8!))^-7[-)SR#_ &G\4.,]
MP/\ A7'?KUR,<,3DG^A;_@F?_P %$_"/_!0+X0:MJ]SHEO\ #CX^_"J^L/"W
MQ^^#AU 7[^$O$%[;27&C^*O"UW*4N=<^%_Q"M+6ZU?P%XBEBCFF@@U#1=22#
M7=#U:VB_2<=.N<9&3UX.#G\17\L8KQ\\5L%B<1@L9B,KPV+PM:IA\3AJ_#F"
MIUJ%>C.5.K2JPEB%*,X3BTT[IKE:<HRA*7[11X*X7Q-&EB*$<36H5Z<*M*K3
MS&M.G4IU(J<)PDJ=G&2::V=[II2C*,?XPC_P;>?MA8X^-?[-0[#_ (FGQ1[\
M=_AR<X!.._OBD'_!MW^V"/\ FM7[-..>/[2^*''.0./ASSVYX((R.H"_V?T9
M_P _E_B*P_XF%\3?^@_)?_$>P'3_ +F37_4/AS_GQB__  NK?_*S^,3_ (AP
M/VQO+\G_ (7?^S=Y)D\TPG5_BF83+M">9Y7_  KK8)"BJAEP7*@+D #$?_$-
M[^V .1\;/V:L$GG^T_BAS@<?\TY[$<=0!@ $X-?V>-(B(\DC+&D:LSN[!45$
M&7=F) 5% )9B0  22 *^#?BM^V0T_B>3X1?LS>&O^%S?%B5FMKK4;+,_@+PA
MN9HGO=8U>":&VOY+0JTDEO!=VNG1^7B\U:V4[3VX#QS\6<RJRI8/%9)/V<74
MQ%:ID.74,+AJ2UE7Q>)J8J%##THVO*=2=Y-*,*=6HXP.''<*<)9=2C5Q4<9%
MU)*G1HPQN)K8G$U7\-'#8>G2E6KU9.UH4X62?-.=*"E-?RR?%C_@A1\?/@7X
M8N/%'Q$_:1_9FT+3YH[B&RTZVU7XI7.N>([B&,SOINC:/#\.TFU*;A'N';R]
M-TZ$F_U>\T_3X9KR'*^"O_!!S]L/XU^'?^$OLO$OPD\#>&[M+>30]0\=W?C?
M3KCQ-!*K.;[1M*L/!VHZBVDQJ$:#5M0BT^QU421W7AZ35](>+59?ZM?A-^QN
M'\2P_%[]I;Q"WQF^+=QY-Q!:ZMBY\&>$#',+FVL=(TIXH;.^&FR[9+.-[*UT
M6QNE%Y9Z5)JD0UN?[MVG.<Y&1Q].^?R..!T&..>S'_2"XUPE#ZI@\QRG,L<Y
M1>(S59!A</@(..CH8#"NO&KB8[J6-QLJ?/:^'PT(.,WRX+@?"8JL\5B\-B,N
MP?*U0RUXR5?&S3VK8[%*,J="3C9QP>#53V;?[_$SFG%?QB?\0WG[8)Z_&K]F
MGG&<ZG\4#G'3/_%N!G&>N.PQ@#%'_$-Y^V#V^-7[-/XZE\4#CH./^+<#KU/O
MQTP5_L^HKQO^)A?$W_H/R;_Q'\#_ /-1['^H?#O_ #XQG_A?7_\ E9_&"/\
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M/?X<$]>>#Z#/ K^S^BC_ (F%\3?^@_)?_$>P/_S2'^HG#O\ SXQG_A?6]?\
MGWZ>EM#^,'_B&[_; SD?&K]FG.,9.I?%#U![?#@'' R,]"1GH0G_ !#=?M@
M8'QI_9IS_P!A/XH#Z8Q\-_E.,C.#@$\8)!_L_HH_XF%\3?\ H/R;_P 1_ __
M #4'^H?#O_/C%_\ A=6_^5['\8DO_!N#^V-*YDE^-_[-LLA W23:M\4Y'<(@
M10\DGPY9R%150?-\J(JJ JXKYE_:R_X([_$#]B3X/:G\</VD/VJ?V8? _@JW
MU.Q\,:':077Q6UKQG\0O'6L07T_AWX;_  O\%Z?\.'USQ_\ $7Q'%INHW&C>
M%= MI[PZ?INL:_?G3_#NAZYK.G?W<^)?$>@>#?#WB#Q?XJU>PT#PQX6T/5?$
MGB37M5N$M-,T30-"L;C4]8U?4;N4B.UT_3M/M;B\NYY"L<,$$LKG )K_ #FO
MVS_VQ/&__!0_]I/5/VE?&YU*Q^'_ (:_X23P?^R=\--2!BMOA-\'=4O;6*[\
M43Z8&DMH?BQ\;$T?2O$WQ'U]A/J5CH\7AOX;V&H-X=\*AM4^3XQ^ECX@\'Y1
M+,*^+R7$8FM-X?+L%'(<#!XK%<G/:<EB6Z6&H0M5Q-6,7*,.2G33K5J?+_1/
MT9?H=S^DIXCT>#<GGC,GR'+,-#.>->*IUJV)I</Y"L3##+ZOAYPITL;GF;8E
MRR_(LOK5J5&OBEB<9C*E/+<KQLJWJ6I?\%3?V\_%/P%^&'[/O@;Q?)^R/\*/
MAYX'T/P?#8_"?4+>Y^/7BV'3+:))M1\:_%[_ $R'P-<W%Q&;BW\._!]=/N=&
M66:QO?B)XKB(:+\_]3\)Z3K^JWNO^*CJOC;Q%J<[7>K>)/'?B#7/&FO:M=NZ
MN;G4M4\2:CJ-U>3M(HE:29R2^'.YP"O3#H/IT]/;J>GU/U/6EK_.GB?Q!XMX
MMS+'YEF^<8GGS#&8K&5<)@*E7+\NIU<7B*^)JQHX/"UJ<?9^TKU.7V]7%3MR
M\U1M:?\ 2CX3?14\!/!?)\ORO@WPYX>K8W X:AAZG%/$^78#BKB[,*E&E3IO
M%8O/,[P&.G0JU'3Y_89/@LDP-#F]GA\.J<(RGQLG@#P7,NU_"NA*"#GRM.MX
M) <8^66 12IN!(*J^ .,D$U]%? C]I#]J7]E*^AU+]F/]H_XH_"6&W:>5O!-
MQK+?$3X0:@\T8C==7^$_C\Z]X3DWQJ8?[1TJVTCQ!:1.[Z5K6FW7E7$7D]!Z
M'_\ 5^O:O$R_B+/LJK1KY?G&986I&2E^[QF(=.35M*E&K5K8>K%VUC5H5$UH
M[(^\XR\&?"3Q!RZME7&?AIP-Q#@ZM*5+_;>%\EIXRA&2DG+!9K@,NRO.,!5C
MS.5.M@<VPLX349I2<4G_ %\_\$W?^"ZG@W]I?QCX9_9S_:X\,>&?V??VD_%>
MH)HOPV\3^'=0OIOV>_VA-6EB$MMH?@#5O$5W<Z]\-_BE=,EU';_!OQ[J.KW6
MMK%;M\._'_Q%O)M1TW1/Z#@P)QGD=1@\?_KZ@=QD]J_RW=?T+3?$FD7NB:Q
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MX5O=*T2TBGGCM[&**9HZG\&?L]?L_P#PVOX]5^&_P$^!WPZU6'Q+K7C2'5/
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M\-?^2=> ?^Q*\*_^F*PHH^&O_).O /\ V)7A7_TQ6%%?CN/_ -_QW_8=C?\
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M,@^G'X<_X_I2T45\X?1A36!(P#CG\^#Q^>*=10!\O?M*_L6?LL?M@Z%!X?\
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MXVY9QPF:9WB\'&<6DXR^IN4)7G"4)N4Y?CY_P@__  78[_'C_@FB>2>?@O\
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M%'PU_P"2=> ?^Q*\*_\ IBL**_'<?_O^._[#L;_ZF8P_=\#_ +C@?^P+!?\
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MID1]*\*Z;)I?@_0%1$T70+)O,DD^W<<Y_P CIP/;C/UI:*ZS8**** "BBB@
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M70-<^$?PMN/C#X^TC6O/LK5]-OM%\%6L\L33H+75=45=/TNXO!-#/)\XQL&
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M!(F>2>;P]\!?AK:F7P7\$?!]H\OV>PL/"MI_;LEI!;#5?$.I3*\C 'S0-/\
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M]FUG]GTRQC2!!;Q[<T>"_P!M@>)-0\8CX7_M0_\ "4ZMX]\/?%+5->_X4_\
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M\0>&M:TGQ%X?U>V2]TG7-#U"TU?2-4LY-WE76GZG837%E>6\@!*3V\TL;;2
MQP37^87-##<0S6]Q%#/;W$3PW%O<1I-;SQ.NUXIX)5>*:)U.UXY$9&!(*D$U
M])_L??MJ_M._\$_O$\.O?LV^)HM7^'EQ??;/&?[,OCS5M1E^$'C*U=P;P>&'
M_P!-N?A-XM>)<Z;XC\*V[:5'=)"FN>'M4TU[FTE^_P"&?&G#8NM3PO$N"IY<
MZDE!9G@G5G@XR=DGBL+5=2OAX7UE5H5,13IIMSI\L7)?QSXY_LN,[X?RW'<1
M>!7%&-XQA@Z53$U>!>*H8#"<2UZ5*$JDZ?#^?8%8/*,XQ:A%^RR[-<'DV+Q<
ME[/#8UUZE*C/_1ZHKXI_82_;O^"'_!03X+Q_%_X,WFJZ=>:)JY\'?%/X9>*[
M4:;X]^$/Q'M=*T_5=3\#^,+ %[>>6.RU2QU+1/$6C3W_ (9\5:)=V>M:#J=Y
M:SN(?M:OW2G4IUJ<*M*<*E*K"%2E4ISC.G4IU(J<*E.<'*,X3A*,HRC)QE&2
M:;3/\E\9@\7E^+Q>7YAA,3@,?@,3B,%CL#C</6PF,P6,PE:KAL5A,7A<13HX
MC#8K#8BA6H8C#UZ-*M1K4JE*I3C.#05\U?%XD>,](P<9\,W?X_\ $UL^OMSS
MWZ8KZ5KYL^+HSXSTG_L6+O\ ].MH/ZU]-PK_ ,CBG_V"XW_TQ$^/XP_Y$=:V
M_P!9P7_J1(\.UWQSX(\+7$-GXI\:^#O#%W<VQO+:S\2^*M T&ZN;-9'@:Z@M
MM7U"RGN+43QR0O/%&\0EC>,.)$*UT-C>V>I6=IJ6G7EIJ.FZC:VVH:;J.GW,
M%[I^H:?>PI<V5]87MK)+;7EE>6TD5U:W=O+)!<V\T<T+O&ZL?@C]O/\ 9Z\'
M_&>V_9SU;4?@UH/Q.U_0/VI_@#!K.HW?@ZU\2ZII/PKM_$NN:AXN@U"Y>SN;
MBU\%PM=?;-<BF9=+0S>==+E@:^*_C2G[:'@74/B0GPUU3XU>%/@[IG[9>O?"
M+PYHO@;PCXSU33?AG^RWX(_8S^'>J_!0_";P%\,=%NO%S>!]2_:.NM3\,:[X
MI\*:=JJ2&*+PGXA?2_ >DZ]J.B_=U<95H59J=&4Z:DHPE351R;E3=6\FX\B@
MOAE)7M+>R23_ #2CA*=:G3<<0H5)<[G&JX*"Y:GLXQBXR]HY2^)*:5UI&[E%
MK]U&( )/ 49)Z8'.23D848RV<# SG -)'(DL:2Q2)+'(BO'+&ZR1R(P#*Z.A
M9&1E(*LK,K##*<$5_/C\0O%W_!0OQ9\1? _@"\M/VA[=?$7AG3_AW\5UTKPA
MX@\-^#]6\->-_P!DSXP:A?\ C3P]+X3L[_X8>!-6M_C1I?@32+_4=1^(GBSX
M@:!XLU)[!1X>\,7EI+=7/@5X:_;$U#PM\+='T_XB?MA^$O FC?%G]BCX-V^D
M:SI'B;P]J]C\$O$O[%7@^Z_:2UW5&\9^%K'Q,E_HGQTEU32X?'>HP!_A]XCT
M"6+P_=;=6O9+J7F+Y^6.%KR3;2T:U7L[WO"RLIKF?-O&22=KFKRY*/-+%X=-
MI2Y5)S7+:?53O=N#Y8J.J:DVF^4_H%J*26.,H'ECC,CB*(2.J&68J76&+<1Y
MDS*CN(DW,T:N57".R_SU^'_B)_P4\N/%7A2TU^Y^,&DWFE>$X+3P=:?\*J\8
M:SI'Q T?1M8^-^B>--8^)-U8'1_ ^C>-Y=-T'X8ZC::AXUU'2O$DDVHZ7J_P
MYT'Q9#K>M0VVS;>$OVLKWQ_^R*_Q9\3_ +6GB?P3X/\ C?\ L)?&KQCKWV7Q
M;-J6@^+OB3\$?VVO GQFTC5K;PAX??49OAWH7Q"M?V?K+Q?X7?3KK1?AS8^/
MM1U;7FT?P[J=_J^G$LQ;2Y<-7UG&#YHRC;GE"+;M"35N:4F^5J,8QD])IQ3R
M[E=I8K#_  3E:$G-OEA4E96E%-MQ@EKK*4HKWJ;4OW\);G!Z],#Z GN<=^.>
M01G)QF#6]&\J2X.LZ.+>";[-//\ VK8BV@N1>1Z:;6:7[1Y<4YU&2/3! \@E
M&H2)9A&N76,_CI^U;X\_X*.> OCU\4]*^!?AKQEXR^%6G#P)\2/">J6&DPZG
M:WT'Q?T>V^ 7BKX6Z(4M9-I^!&O6%M^TQ# 96>>YU348F#V9G5/B7QI\!_VJ
M-8/Q&TKQ@/VE=0\:>(/!_@'P1X>USP_X<\53^#=4UGP)_P %1O OB;Q#X\_L
M;3/#\GA"SU^P^&?V/XIZ'JWB3[%_;_A\ZSJMBVLV=AK,5B5LPG!R4<+7DXR<
M6^5J,FI<J<&H2YE*VEE:S7O63;*67QG"$YXO#TU4C&<8J:G42:C)J<7.#@XJ
M3YE>_NNT7HE_3A>7UGIMM+?:G>VFG6< !N+O4+J"RM+<,RJ#-<W3Q6\0WNJ!
MI)%#,RJ/F(!AN-4TRVO8M-NM6TRUU&X>.*VT^?4+*WU"XDG6X:"."RFG6ZF>
M9+2]DACBB9Y5M+ED!%O+L_(_XX_#?XT_%'_@G]^VE\#/'>F_%CXD:C'\>/B[
M\,?AM-KMOJU[\3_&?P*A^)GA^\\$ZM#K5G;0:QXH:U\/:KJ=KI'C:-&NK_3M
M%M;N2XN)K26=OE[QU\(?VK=1^+OQI^ >N?#_ .(GBCQSIW@W]F_X0?LJ_M>V
MVE:C)X-TJ7P=\5_''Q!\(?M*>)?%%HWV73O&/P*\ JNE>/O#5W/#-\2_$ATG
MPC*E[H?CS7K^Q4L?->S<<-5:J0C-)J?-&<I3C*FUR-1=H>Y*32DY134.92:I
MX&$U.^+I1=.<XN_+:5.,<.U63E4CS).N_:02YXQIS<54<7&/[[ZKX\\#:"(6
MU[QQX+T);B^U/2[8ZWXL\/:2+C4]$N$L];TZ ZAJ5MYVH:+>2Q6>L649:YTV
MYD2"]A@FD1&U_P"V]$_M.ST/^V](.N:C9-J6GZ*-5T\ZQJ&FKLW:A8Z6+C[?
M=V #INOK6":U4O&3(-XS^!6@?LJ?%;XF7/[%_P *3\'O W@WQ/\  W]FK_@H
MU\*_CUXF_:/^$/BSXX?#;7OC9K'Q[_X)[WVK_%_PEXIN]7\.CQ'XC_:9NK/Q
MQ\=?AIX_U+6[W6-7\-7'Q%T'6M*@\4^&/&NG>&/*/&O['GQP^'_[37A#PQ\-
M=(^-?BGQGX \&?##P#\*?'-SX.:3P#XA\-^%?V>?BKX,N/B[KW[0K79;X7S>
M$?'7B/2;*3X$0ZE8:/XH9] U2[\->*&T:'7-%RCF.(:<_JK<%5A1]U5E*[A"
M<E9TTY651JZ2BI0:YY.4>719?AV^3Z[&-14JM6S]FURPG4A"7,JMHQERQD[R
MG+V=2$E%)23_ *//^$Q\(?V5J>NCQAX3_L+1;MM/UK71XET0Z-HU_');P2V&
MKZK]N^P:;?)/=VL+V=[<07*S75M&8]\\:MKMJ.GJ; -J%BC:JH;2\WEKG4P;
M<7BMI@,H.H*UI_I?^A^<&MAYX/DYD/\ -9X)^$EO8ZQ\.O&\W[(GQYTK]DKP
M#KW[#.F_M/\ P;U#X0>+IM>\?_%CX>? #_@IAX/^)_Q$A^"\1O/$GQFT3PI\
M7?C=^P7J/B[Q9X:TOQ'IWBN[^&__  E.F_\ "36GP^O+]?J2\\.?M5?#?]BW
M]C+1_ ?@_P"(^B_$+PSX8_:6OWT2#P\/%'C3X9^']1\ ?%C7/V>_#.O877FT
MGQ'X4T74OAWX-^Q->S2#7=,'AZ>>Y=)(FJEF56;J<^%J15/9I3_>)<K52'-"
M/[N?,X0;7-STYJ45'95,OIPY%'%0;J3Y6Y.FE3]R;M-QJSY9Q<(RFE[BIUJ7
M+)S<XK]LY+NV@FMK:>[MHKF]:5+*WFN(8KB\:W02W M8)'66Z:WA/FW @CD,
M40\R0(AWBM!J^E7%U+8V^K:7<W\,MS!+80:A9S7L4UDEG+>Q26D<S7$<MG%J
M.GR7<;QA[>._L))DB2\M3-^$]S\*?VL_&WQ@^'_A7Q5XT_:AC\/?"[QUXSU[
MP=\7T-W;>.+.U\>_\$XOA?XKUW3CXX&BB%M$C_:9U_Q;X:LK5K?%KJ6C7/PZ
M$ABM[NV/@'A.Z_; UK7?A?\ &?XQ>'/VK/AW\1[OX;_'N^.J_!WX.>(XKIOB
M]X\_9;_X)U^(O"7A;QQI6@>&=0FTSPAX@^/6F?$W1+R?5+./1XKKPSXAT#Q/
MK.E>&_#^K76GO^TIM*7U6JDWHFI*Z3497]SW6I/3I)--.+>@LM5G_ME!M1N[
M--\SNX6BZB;C**]ZWO4W=-221_2[:ZA87A=;._L;PQ2SP2K:WEM<O#-:R>5<
M0RK!+(8YK:7]S<1/B2&7Y)%1\K5F66.)5:62.)6DBB4R2)$'EFD6**)6<J#+
M-(ZQ1("7DD=4C5G95/\ -;IGA_\ ;>L->\4_$[QBW[1GPT^,6J_!GQ+I$LGP
MV^'/C?QA\.[;Q%:?M)^$=8^)%C9^#_ YTN)!>^!M0\02Z!XMT34V\>3^'+G4
M_$?PSTOX@>(]&@\+7OU[\0H/CA\5_P#@GW\!=;\=Z=^TCHOCCP=^VQ^S=XG\
M62>&I/'=U\7]<^"?PY_;V\,IJ/Q&FT31_!6@_%74O##_  )LQ\1-*T'Q3\/]
M/^*5IH>G:-J/CSP]/XRLM52YT682<*C>&J\T*4ZJ34ES*,H)1:]GS1DU)OEM
M)WBU%2W4SR]0=/\ VJE*,ZD*4I1M+E<H5)7C:HE4BG34>9-7=2+ERJRE^R%I
M=VM[ EU9W5M>VTWF>5<VEQ%=6THBE:%_*G@>2)_+ECDAE"NQ2:.2)L/&X!=7
M=M9QI+=W5K9Q27-G9QRW=Q#;1R7NHWMOIVFV<<D[HCW>HZA=VNG6%LI,UY?W
M5K:6R2W$\4,G\[WA/2/V^/@9\'=-\)?#P_'-_#VN_#R7QIX[@UKPYXBUG4/A
M1/J'[;'Q'TSQE9?"73?#NEMXIT_6'^$%WH6M+X4\*PZUXJG\-:C>>,?#^G7]
M\MI$_P!@>+O#_P"TI\3_ /@GK\,-&\0ZIXSOOC==_MD?L7:OH/B[4?AAJ2>,
MM"^'?@S_ (*E? +Q1X,^)OBSX>:]<ZEK-V? 7P5\/:?X_P#'=[XZ@T/4;S1_
M#^M>)OB!X?\ !;OK>C:1,<QE*C5FL+652E1G5Y)*24I0FH\J:IN5FG=24)/1
MI1=DV3R]0G!/%T)0GB(T>>+3E&,E.7M)0YVE;D=X\VL6I)V:1^I^I^(_#VB0
MWUUK?B+0-&M=+2SDU.XU?6M+TN#34U!I5TY]1FO[NWCL5U!K>X6Q:Z,*WA@G
M6V,K0R;<S6?'W@/PV+-_$GCOP1X>CU*V%_ICZ_XN\.Z,NHV+$A;W3VU+4[87
MUFQ!"7=H9K<L JR$=?P.^.7P&^.&F_'CXU^)/CJGQ@^/GAU-:_8WUK3OC!\/
M_P!G7PUXP\(Z9%X;\$?M.Z=<:=XG_9ET32;^V^.7A70M8U[2M,\4GP=:W7C'
MP3>^*M \2&WE6VME$_PH_9$^*OQR^(?P7O/$WPQT+X!^$O!O['6D^&[;1OB/
M\ -%^*?AFZ"_M+_&J_TO1]*\/?%R_P#&=S\)_$>L^![C0_%5]X'_ .$@U'Q-
MX4TKQ#I.BZE,(M.M(HI^OXB4W".&:DY\BC)S=DI2O*4DE"UDK-37,WH[*SKZ
MA05.-2>,3CR.<I04;-NG&:A!2G[1R<I.+O1BTDGR+=?T'K<V[2I +FW:>2W%
MY' L\1GDM&8(+M848R-:%WCC6X53#YKK'O+E0UA#EX^_S+SZ_.G;MZ5^>,'P
MP\>^!OVYOCM\4/AEX3U?Q$?'/[+7@&UTZ[^(7BGQ+:_#<^*M'^*%[;1>"-#U
MQ;#5K+PO:Z+X8@BU&/0=$TQI,W<]]=+(+E9H_OO0I-8FTO2IO$5G8:=KTMM;
MR:O8:5>3:CIEG?L(S<6]A?W%M9SWEM%)N6*XFM;>210&:)22*[8595(U%*#@
MXSE%;N+49**:=DKN]^76VJ4I6;//JTU#D<:BJ*=.G/HI1<XRE*+CS2=HM<JD
MVN9_9BFD?6_PU_Y)UX!_[$KPK_Z8K"BCX:_\DZ\ _P#8E>%?_3%845^28_\
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MKG/%7_()C_[#?A?_ -2;2*Z.MY_[O0_Z^8G\\.80_P!YK_\ 7K#?EB HHHK
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M&D:O\:?V$/CSXLOTV 7-Y:ZM:_M4_!*&YN"7>:*#5?">G1+"@ARTQ$7[$44
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MF^%7Q:TU[>.Z-[\-OB!X4\;0)#(JE7G;PYJNHFW(SM=+@1R1N/+D575E'KM
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MO]MKXU364Z:=I[?"+X*Z!J;12?9KZ\L--UKQMXRLX)2WE>9I<^J^%S<1(C2
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MA'UCO_S%?!G?K_S-5'_"%>//^A'U?_P:^"__ )JJ^N:*/]<,?_T"8'[L7_\
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MHZYSQ5_R"8_^PWX7_P#4FTBNCK>?^[T/^OF)_/#F$/\ >:__ %ZPWY8@***
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MA/XM&6.:&VD@O/@_XVN/#?Q1TR9+FXAM3#JGA"SF%T_V8IYX:-?O:OF/X_\
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MRNMB,PQ]7#\8<48&A/$UHYKAXSE2PF#PN&A:C"U*A3BTW'F?[??\/^?VW/\
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MG]H7]G:U\&?LMZ%'X\^%NG>%/"T.LV_Q.L+J;2_"B^?>?$+XN7EA<:G\%?\
MA4VMS/;OH>M^$KN%U^*./#^G_8M)CL)QHZE\<%G_ !5BX*53C_&8:3BWRSK8
M6RE]?^I\CYL1"JI4Z=L5B.>C"$*4Z?L:N*3JU*?J\4^$/T?.'\95P^"^A[PU
MGE.G5I1]KA,JSM2E1EPDN)OK*=')L5@ITL;BI/A_)XX?,\3B<5F6%QSS/ 9
MXX+ XW*_X?\ O[;._9_9/P;W[0VW_A%+[=M.<-@:OG:<?>Q@<9(R,H?^"_\
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M?\2A?1?_ .C$^'/_ (9:_P#\^C]OO^'_ #^VY_T!_@[_ .$G?_\ RVH_X?\
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M?&__ (E.=_\ S<?>7_#SG]M[_HMU[_X(]!_^0*/^'G/[;W_1;KW_ ,$>@_\
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MJ5S';/+*8$0R2,_N'_#SC]M[M\;;X8&,-H>@Y^I']GXSQG(/(-?!N3Z']/\
M&C)]#^G^->='/<YBE%9QF2BDE%+'8A**2LHI*I%**2LDDDEHDEH?%_\ $4O$
MQ))>(7&UDK)?ZTYWHELE;'))):)65ET/O+_AYS^V]_T6Z]_\$>@__(%'_#SG
M]M[_ *+=>_\ @CT'_P"0*^#<GT/Z?XT9/H?T_P :?]O9S_T.,R_\+\3_ /+0
M_P"(I>)G_1P^-_\ Q*<[_P#FX^\O^'G/[;W_ $6Z]_\ !'H/_P @4?\ #SG]
MM[_HMU[_ ."/0?\ Y KX-R?0_I_C1D^A_3_&C^WLY_Z'&9?^%^)_^6A_Q%+Q
M,_Z.'QO_ .)3G?\ \W'ZT?LO?\%#/VOO'O[2/P'\$>+/B[>:MX8\7_%GP1X<
M\0Z6VCZ+$E_H^JZ[9VM]:-+#9)+&+BWDDC9XW5P&RI! -?U?!3CKC)Z>W '3
MH0!GCC-?PW_L8 G]KW]F,X_YKG\-O3/'B:QYX)XRP%?W)YS_ "K]=\-\;B\;
ME^:5,9BL1BYT\?1A3EB*U2O*$'@U)Q@ZDI.,7+WG%-)O5IO4_P!!_H:\1\0\
M2<)\;8CB'/<WSVOA>*,LH8:OG&8XS,JN'H3X=]M.C1J8RM6G2I3K?O94X.,9
M5/?:<M3F?%/@SPCXXTV31O&OA3PUXQT>0.)-)\4Z%I>OZ;()%*2+)8ZM:WEJ
MPD7:C[H3N4$-D<5^;?Q+_P""+W_!-OXDZK=^);?]FSP_\(_&M]=2WMQX\_9W
MU[Q5^S]XR:[F \R8ZU\)M:\*R.=ZI*JS1RHLJ!PN<Y_4JBOT<_L8_&^?_@FK
M^UE\*VDNOV3?^"K_ .U?X)@AC%OI7@3]IG1?AW^UW\/;*TC!6&S\SQ_HFD?$
ME8XHQ' LL'Q#BF$*EED2X/GU5U#Q7_P6Y^$.G:CIWC?]GO\ 8/\ ^"@'@L65
MQI-W'\+/B7XY_9*^*'BO3[FPGAN9-2\$_%W1?C)\([G[:7>WOM+_ .$^T6PE
MBFCM0K037-Y:?LU10!_ )^V=^S#\./"NI^(_B+X0_9"_;K_X)EZX([K7O&_P
MR^+'[-?B?]I_]@FYUBZNIY;V?PA\=/V+-1_: USX)27\TD4L]U;^#M0\'K-+
M<SP?#V9@\R_D%I'QZ^'6HW8TYO$&@ZE<[XQ'?_#[Q'I?Q:\/W4<R+)!?>=X
M;5?%GA.RNT#BV3XK^"OAGK1DBN+.[T2TO[6ZLX?]7;YN<=2W!/0# YQDYQTP
M,9/) R37RI^T!^PO^QE^U8)G_:3_ &5/V?/CCJ$UC+IT?B#XF?"7P1XK\6Z=
M;30+;,-$\8:IHLWBG0)U@BBBAO=$UC3[VW2-!!/'Y:8^ XB\->%^(JM3%U<-
M5R['U6Y5,9EDX8>5:;NW/$8:=.IA*\V_BJ.E2K3;O.K.3YG_ &+X*_3I\?\
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M#YMFOU"4HISRNMRPY(P&+9(XZ>G&#R?4D]1VP#Z"I***^X/Y0"BBB@ HHHH
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MR#_@W"TG_HZ/6>3GCP#IO')['4R.."N>XZXK^GFBC_B%W O_ $(X?^%N8?\
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M_P +<Q_^; _XG_\ I;?]'9Q'_B+\&?\ T.G\PW_$.'I/_1T6K_\ AO\ 3?\
MY:4?\0X>D_\ 1T6K_P#AO]-_^6E?T\T4?\0NX%_Z$<?_  MS'_YL#_B?_P"E
MM_T=G$?^(OP9_P#0Z?S#?\0X>D_]'1:O_P"&_P!-_P#EI7UC^Q)_P1CL/V./
MVBO"GQ]M_CIJ7CF7PQHOB[2%\.7/A.RTF*\'BG0KG1&G:^AOIY(VM!<?: HC
M(D*B,D EJ_<BBNG!^'/!N Q>&QV$R>-+%8.O3Q.'J_7,?/V=:E+GISY9XJ<)
M<LM;2BXOJF>'Q/\ 3;^DYQCPYGO"?$?B97S'(.)<IQV1YU@)<.<)T%C<KS*@
M\/C<*Z^%R&CB:*K47R>TP]:E6A\5.I&23.;\5'_B4Q]<_P!M^%^.X_XJ?1^O
M88R"<G..:Z2JES;07"1P3Q)+%Y]O-Y;C*^;:3QW=O)C/#17$,4JG^^BYR!BK
M=?=.:=*G"SO"=:3?1JHZ=K=;KV;O?NK=;?R=&#56K.ZM.-**76]-5;WZ6?M%
M:W9WZ >:_+_]HO\ X)7?!S]I+XQ>+/C/XK\=_$#1-?\ &$7AZ+4--T*31ETJ
M'_A'/#>D^&+5K9;O3Y[A3-9:1;S3AY6'GO(5PA"C]0**\[,,LP&:T8X?,<+3
MQ="%2-6-.KS<JJ1C*,9^Y.F[J,Y+635F]+V:^=XLX+X6XYRZCE/%V28//LMP
M^,IYA1P>.]O[*GC:-&O0IXB/U?%82?M(4<37IJ]1QY:DKP;LX_BC_P .._V>
MO^BG_%;_ +^^'?\ Y54?\.._V>O^BG_%;_O[X=_^55?M=17C_P"IO"__ $)<
M']U?_P":C\]_XEU\$?\ HV_#_P#YE/\ Y]'XH_\ #CO]GK_HI_Q6_P"_OAW_
M .55'_#CO]GK_HI_Q6_[^^'?_E57[744?ZF\+_\ 0EP?W5__ )J#_B77P1_Z
M-OP__P"93_Y]'XH_\.._V>O^BG_%;_O[X=_^55'_  X[_9Z_Z*?\5O\ O[X=
M_P#E57[744?ZF\+_ /0EP?W5_P#YJ#_B77P1_P"C;\/_ /F4_P#GT?BC_P .
M._V>O^BG_%;_ +^^'?\ Y54?\.._V>O^BG_%;_O[X=_^55?M=11_J;PO_P!"
M7!_=7_\ FH/^)=?!'_HV_#__ )E/_GT?BC_PX[_9Z_Z*?\5O^_OAW_Y54?\
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MGK_HI_Q6_P"_OAW_ .55?M=11_J;PO\ ]"7!_=7_ /FH/^)=?!'_ *-OP_\
M^93_ .?1^*/_  X[_9Z_Z*?\5O\ O[X=_P#E51_PX[_9Z_Z*?\5O^_OAW_Y5
M5^UU%'^IO"__ $)<']U?_P":@_XEU\$?^C;\/_\ F4_^?1^1WPL_X(^? [X3
M?$OP#\3]$^(GQ*U#6/A[XNT'QCI=CJ,FA'3[R^T#4(=1MK6\$&FQS_9II80D
MWE.C[&)5@<5^MZ@@<C'/^%.HKULNRG+LIIU*66X2E@Z=:HJM6%+GM.I&'LU)
M\]2H[J'NZ-+NF]3[SA'@3A#@+"XW!<'9!@>'\)F.)IXS&T,#]8Y,3BJ6'^JT
MZ]3ZSB\7+GAA_P!RN6<(\F\6_>"BBBO0/K0HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
..**** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>tm2223302d1_s4img002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2223302d1_s4img002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M8J8N!T _"G;O8TKH!:***8!1110 4444 %%%% !1110 4444 %%%% !1110
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MBG\!==D9_$6D^-O&<S_?D\0>.=9O_-_WE>ZVG\JYOXW_ /!)?]G_ ."_P/\
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M3U)_$5C#J6OSZE+%#;"T\R=H?LO[LB;SD^SJ)B"6"2DX(*XK]ES_ ,&UGPK
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M_C%_P3_^$_BC7M/\92:MKGAZ"\NVM?&FKVD+.^3\D45RJ(.G"J![5]U?M>7
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MOX/S?\>D7Q2U'T-K\,O$39_.S%5+W_@K9X- _P!"^&G[1&K*1PUK\*M:P?\
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M7H0U*/7+G2H'UO5-"6/4["6VD673]0;3YYG&TB.W^T!4$TA5,R(I*N2@V/\
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MYX#_ &I?!YT'Q]X8TGQ-IN[?$MY #+:-_?AE&)(7X'S1LK<=:^1_'O@C6O\
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MQ7W2O*USU*<H.TCLHXBG67-3=T.HHHJ#8**** "BBB@ HHHH **** "BBB@
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M3P^,Q/\ R3_Q-_X*[G_XW64,PRR$N:,XIB]I#N>*YQ7Z-?\ !ON?^*[\8?\
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M444 %%%% !1110 4444 %%%9OB'Q#9^&=)FOKZZALK.U0R33RN$CB0#EF)X
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ME3<E</9OHS^DWX=>.+7XC>"=*UVQW_8]7M(KN'=C(5T# 'D\C.#[@UO5Y?\
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M[.>U?KHG(Z5\R_L._L%K^S1<7&NZU<6NI>)+J%84$,1\JP0\L$<X+,> 6P.
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M.,@\;E]\ @\$*>*]H5MRU\+4I3IS=.HK-=#VZ=2,X\T=AU%%%26-?I7X[_\
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MT[^UAIY;QYXPTS]GOP[.P/\ 8?@>5-5\1%."/-U69?)A(/7R(&R/XQR*Y?\
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M"_X1.-5ET_4_#KQB.;P]J$$A2YLY4VJ59) ?O(A965BHW8KW4BOA_P#:J?\
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M W,C#]&%?I7YZD5^>G[3_ABX\$_M7>+(9(G2TUU8=6LR?NON14E(_P"V@(_
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M411>(;O1HKJWD;HJR&16D@;K\V[9[K6?=:#%%X:^W)-*98YTMYHW51M<JY/
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M&'RY_M'[TRR1LNZ3AQM!^V_'G_!MCJD6O2#P_P"-;*YLL_(;O? X'^Z(G_\
M0S6,/^#;;QIC_D;M#_\  F7_ .,5^E5^+\HQ"C*4W%Q\K[^J/GEEN*@VE$^"
MOB;\9[WXF?"/P=IFKZI>:CJ?AR[O8E28'99V1M]/BMHH^ JJ/L\ORKZ;CRQ)
MX%FVU^F?_$-IXS"_\C=H/_@3+_\ &*[7X+?\&W5M::RL_C7Q@LEO"X;[-8HT
MJR@'."2D>/\ Q[W'K4>-,HH4[4Y-];6(_LK$SEJCY&_X)*?L6ZE^U9^T1I]Q
M-'+;^'=*\R6[N5.UM@ 5BIQC.'"C_:<=E;']!&CZ=%I&F6MK;QB.WM8EBC4?
MPJH  _(5P_[.G[,'A+]EWP6-$\)Z;%9P,=TTI5?-N&[;B !@9.   ,G &37H
M@2OR?B#.IYEBO;/1+1+R/J\OP:P].W5[BDX6OYQO^"K@S^W=X^_["=U_Z4RU
M_1PYPE?SC?\ !5Y@O[=_CW/7^T[H]1_S\RU]!X?22S*\OY6<.?7]@K=SQKX2
M?"35OC9XR.@:'Y#:HUG<W<,,I8?:/(A>9T!"D!O+C<@L57Y3EAUKUG]FK]D7
M1_C5IVJ-)K_VYK?5=-TFVN-+O[>R@+7<,[LVV_\ (>=HC"JF*$;V);;D8:O&
MOAS\1]5^$_BZ+7M!NWL=5MX)[>&X1B'@$L3Q,R,,%7"N<,#D'![5U^G_ +4N
MI6.LZ]>'P]X-N/\ A(-4@UJ:";3-UM;W<(E"2Q1!@J_Z^3*8*?-PH  'ZGF$
ML7*36'FDM.MGYGS-'DM[RU/.KNW^S7L\!/S6\C1-D$$$'H0<$'V/(SS7U9_P
M12;_ (V"^$SZJ?\ T9%7RMK.NS^(-9O-0O9S<WNH3O<W$SGYI9'8LS'W))-?
M4W_!%%A_P\$\*<@\'@'_ *:1UEQ!/_A(JJ3UY?\ (O!?[Q&W<^K_ /@O9^PC
MK/B3QG;_ !/\.6[7T5T5M[^)2-R2!0J@?41Y'JV\=2H/Y22Q-;SLCJR.A(96
M!!4]P0>0:_JQU[P]9^*]'FLK^TMKRSNEVS07$0DCE4]F4\'M7Q?^TS_P0F^%
M?QVUJ;4M+FNO"M]<.7<6\?FQ$GT&5;_OIFQV '%?G/#'&BP=)87%1O!;-;H]
MW,<GE5FZE+=GY'_LY^ OA_X@^"FN:QXVD2S^Q>+-*L;>Y,;;'\^PU0^1<2HP
M>*U:2*!YGC#2!(2$&X@CRGXF:!?^&OB+KVG:K86NE:E8ZA/;W5G:HJP6LBR%
M61 I(V@C ()R!U/6OTJ\3?\ !MUXB@N)(-)\<:;/8,XD5;B:2)F(R%8HL)&0
M">YZFND^'?\ P;;QW]V)_&'CR21]REDMHWGW@=1N81D<<=37T]'C#+J56=9U
M)24NEGI^)YCRO$2BH*-FNI^6OPR^&>L?%KQ?:Z)HMF]W>73 <#Y4!(&3WZD<
M#D]!S7[G^#OV6&_9&_X)8Z]X5N O]I/9?:KT!MVV0O$NTGU 49QQN+8XKU?]
MES_@G#\,OV3;>"3P[HL4^J0X*WURH:1#ZJ , _[7+>K&N^_:8^'-]\6/@;X@
M\.:;):PWVKVWE0O<,5B5@ZM\Q4,<?+V!KX;B+BF>958QBN6G%W\WZGN9?EGL
M(N4OB9_.J.*VO!/C_4_A[<7DVF3+#-?0QP/(4RR!+F"Y0J>Q$MO&<^@([U[W
M^R;_ ,$V_$?[8OBOX@)X7N+./PKX'U<Z'#XBNKB1;/7KJ,NMQ]D @)>.-E \
MSHVY<9YQ[2__  0$\>1KD^)?#1'3BYFX_P#)>OK)<1X#E5*I+U5CU>;0^/\
MQI^TIXH\=0:JEU)I\"ZLS^:MI:+ D,;"Q'DQJO"1J-.M0JCH(R/XFSD>+/B[
MK7C;PCI^B:@UO)9:<D**RQ;991$KI'O;/S%4D* XZ*G]VO>_V'_^"8'B7]N3
M]GO3OB'HFHZ5I%CJ-Y>6:VMY>NTJM;7,ENQ)6#&"T;$>V*]>?_@@-X\6//\
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M4L3C95*3T]+$4]V_,:(<=Z7R?]HT\'(HKQ34:J[?_P!5.HHH **** "BBB@
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M(0/*RQHJHDDCNS#"1.0&("GJPN*=).+7,GT?3S0'>61S;+U/N>]35\G^/_\
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%HHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>tm2223302d1_s4img003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2223302d1_s4img003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M 'X1_P"A \2?^!D-?ES11_Q#O)?Y'_X%+_,/]:,P_G7W+_(_4;_A_P!^$?\
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M>SXQ^X3@!0!\H_N_+^7'I0!^6O\ P<__ /(G_"'_ *_-3_\ 0+>OR%K]>O\
M@Y__ .1/^$/_ %^:G_Z!;U^0M?6Y7_N\?G^9_:O@[?\ U4HV[S_]+9]-6'_!
M)[XHZEKWPDLXYO#?V?XS6+7NAWYN)_LML5M3=>3<L(2T<OE#("JX/.&."0[P
M1_P2A^)/Q)T?1=6T74O!M]H.HRZE#?ZLE],MGX;>QSYRWQ, :(G;\FQ7W @]
M#7U]^S-_P5M^%O@#QM\,?#OB;63=>"-#^'^DPO?'3;IV\-^(+2.>*3:@C+N)
M(93$SQJRG"<XW$>;_!G]L;X#_"KX*Z[\,;[Q#J^J6'QPO-5O/&6NV<%[%'X6
M\S<+-8H#&K3$?*9=BL&R1EUPHRK5\3&<E&.U[:;ZVU[:7_IG@?ZS<7/FC*A)
M-6U5-M.+Y^9]+.*4;*^K2_F/!/"/_!,'Q/XTL_ )M?'7PY34/BE;W4_A?3YY
M]12?55MR=V&^Q&*-FQ\HE=,[AT.0,SQ/_P $T/B+X1^&UUKEU)H']K:?HD/B
M2\\+I<2G7+73993$ETT?E",KN7E5E9U!!*C->N_$'_@H'X9^"?PK^ </P[C\
M(^-O&WPOTW4[-]7O[#5$_L>:27;'+!&SPQ2>9&2X\R.3:0N0IR*Z?P7_ ,%)
M?#O@?X!ZAK6M>)M#\>?$/5/ T7A2.+^P+^PUJW8W!;RKFY:1[.:WA4LRRQA9
MI"RAE&,T_:XBW,N]O/2]M/N.V6=<6Q4*T*<I*4K).&NDI+HO=ARVUE9W\CP'
MXC?\$P/B7\.DL82=!UK5IM<LO#=]IFFW$LEUHNH7D"3P0W&^-(QE)4^>-Y$!
MR"P(Q7)_M+?L8>)OV8-'TO4M4U+P_KVEZI?7VDK>Z--/+%;WMG+Y5Q;2>=#$
MPD1NA *, 2K,.:^UO'/_  5$^&?@[QAJGBO0-6D\22^.OB'HOBJ\TQ+"XM[C
M0[*ULX(YTD:1%BDG\R-@HB=U( 8L,[:\&_;\_:<\$^.?@5H?@;P;K\7BK_BM
M-=\7W=]#97-I':1W<[M;P%;B.-FD"2$OM!12 %9^M*-?$MJ\=WK]RO\ +?[C
MKR#/N)J^-H4L;1:IRO=N#7V6VV^G+))1_F3Z[GR)1117J'ZT%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!]"?\ !*3_ )2*_";_ +#J_P#HMZ_I
M*'W5^E?S:_\ !*3_ )2*_";_ +#J_P#HMZ_I*_A7Z5\WG'\6/H?R7X]_\CFA
M_P!>U_Z4S*BG_P"*SGC\SE;.)MGF'C+R#.W&.W7/;H,<Z]9<;M_PETZ[FV_9
M(SLW/@'?)SC&S\0=W'(QBM2O'/PLR+Y/^*LTT[>D$_S;%.W_ %?\1.X?@.<<
M]!6N>E9.H#_BK--X7_47')"9'^KZ$_/_ -\\>O:M9ONT ?@C^WC_ ,GF_$[_
M +&2\_\ 1K5[1_P3I^$?@'XJ?L[_ !4MO&UGIT37U[I>DZ=K,MJCW&C7-RTJ
M0R)(1N1?.\K> 0".O%>+?MX?\GF_$[_L9+S_ -&M7%:!\7/$7ACX=:YX3L=1
M-OH/B2:WN-1M1!&WVAX&+1'>5+KM))^5AGOFOZ7^HUL9DM&A1ERMJGKLTDXM
MV^2_ST/QWV\:&/E5DKI.6F^K32OY79]F_M4_L4^&/ ^G6NI>(--_LNS^'/PZ
MTJ?6;#P\+>RNM9U*:XEMMYF,3K]]27E:-V( XYKR[PU^RAHOA7]O#X>^$[6^
MO+KPUXPM;/5[-[RVM;JZM[>XMVD$<T<T4EN[J00=T14C!VCMYOJO[;_Q0U_Q
M1'K&H>*/[0OET@:"_P!KTZTN(+JR#%A#/"\1BG&XDYE5FSSFN?'[1WC3_A<\
M/Q";7IG\86TJS1:A)!$_DLJ[%"Q%3$%5> @3:!@ #%<&7Y+FU*E*E5JIWC);
MNUWMHUT=W??6UK(ZL9C\#4?-3IM;=NB2WOY6L?56E_\ !._X?>)[GPC8R:CX
MPCU[QUI>NZE'<)<6D=C926,KA 8%M@61AC*JR8QP<8 ;X]_9;\ _$OX?^$[:
MWT^]T+Q18?!Q/%YN].%M!8WLL/WOM$0A,DLLFYLR^8I&U>&SQ\YZ?^VS\3M*
MU70[V'Q-LN?#=M>6>FO_ &=:'[-%=DM<+@Q8;>2>6R1_"15&#]K7X@6[0%/$
M&#;^&F\(1_Z#;?+I9ZVW^K_\?_UG^U6$LASER4E66EVM7O>5NFUN56VT9O',
MLOU]QV=KZ+5>XWUWNI:^9]E?'O\ 9[^&WPP^%7CZWUS0;K5H[?QCHMA%J.EV
M.FZ;J=M%/I]O(RI)%:"*.,%F)58AO. QRQ>F_"W]A;P;\-_B%X?T'Q%&WBNT
MA^(UYHJQ26UG"L\2::UU"TTHMS<2 <!H3-Y1/.T<Y^5_^'@OQ:DGU&27Q-:7
M7]K7EOJ%VEUH6G7$<T\$210R;'@*@HL:8P!@H&^]S6+I_P"V/\3-+N;6:'Q5
M=B>SUZ7Q-%,UO \@U"1#'),69"S;D)4HQ*8/W:YX\-YPJ?LU52[ZO?E4=--+
M.[TWOY#GFF!;C)0>GDO[U^NM[K1]CUKX>_LE> ?%EIX)O-6D\6V@^+7B2^T?
M0H;"^M770XX)!$LER6@'VAC*Z_*@AP@)SG KG?VROV9/"'[+GA#P;8V\GB#4
M_%WB'31?7MR]_#_9UL4E>)Q'$( [!BA*DRC:!SNSQQ?AS]LGXC>$4O%TS7+6
MQ2[O9=1"PZ19*+&YD0QR36P\G_179206M_+/-<K\0_C#XD^*MEH=OX@U)M1B
M\-Z>NF::&AC0V]NK%@A*J"_+$[G)8YZU[>%RO,XXJ,ZU7]VGJDWKH[+9;72>
MNMKLXZV,P<J<^2'O.]G9:-M-O?JKVTT.9HHHKZP\,**** "BBB@ HHHH ***
M* "BBB@ HHHH **** /V0_X(G_\ )CUA_P!A>^_]#6OK;/*U\D_\$3_^3'K#
M_L+WW_H:U];=UK^6>)/^1KB/\<OS/V;)_P#<J7^%&5X)F%SX-TF3S/-$EE"P
M?S#)OS&ISN(!;/J0,^@K7K)\&NTOA+2V9VD9K.$EV9V+G8.27 <Y]6 ;U -:
MU>*>D9&@ILU36_EV[KU3G8J[O]&@&<@Y;TRV#QCH :^>/^"LG_)L=O\ ]ANW
M_P#1<M?0^@#_ (FVM?='^FKT"<_Z-!UV\G_@?S=/X=M?/'_!63_DV.W_ .PW
M;_\ HN6O8X?_ .1E1_Q(\;B'_D6UO\+/SK\&^''\8^+]+TF.1(9-4O(K19'/
MRH9'" GV&:]Z'PB\%^*OCKXD^&-CX=_L^;2K:ZAL=<:^G-W+=6L3.7F1W,/E
MN48;4C4@$$-Z_.MO</:7"2Q,T<D;!T93@J1R"*]-U7]J[7=3?5;Q=)\.VOB#
M7;,V.HZY;VTBWUU$PVOD&0PHSCAF2)6/K7[9FF'Q52470=M&M[6D[6D^Z6NG
MX.^GXUEM?#TU^^5]4]KW2O=+LWI9_B>M^$/V8OAW<C2UN'U2=;SX=7/B2XEN
M(6003!_DN%$<WS%?F'E8VX5268L<<K9?L)76JNU_8ZMJFI>'_P"P;/74FLM$
M,^HS"Z=DCA6U6;!<%'+$2D!5)R:Y/2_VN/$&E^'[6Q72_#\LEIX>G\+K>/#/
M]H:QE.=IQ*(]R_PMLSSSNHB_:Z\0OI%OI=UIN@ZAH\>AVV@3:?/#-Y-Y!;N9
M(GD*2J_F*Q)W(RCGI7BQP>=TYRE"IN^MGI=O1=[6MLNYZSQ64S@HU(;);)IW
MM%:OM=.^YN?$[]C>/X,^"/$&K>(/$LT,VCZS_8UK;6NF>:;YVMDN(I"SS)Y:
ME7&X88K@XW=*H?!/]ERQ^*O@+2]<OO%$^C_VQXD7PW;01:7]K_?/$)%D9O.3
M"\X/!(Z\]*Y?QA\?=4\8^ KOPW)IN@Z?I=UK1USR]/LOLP@E\D0B-%5MBQA0
M.-NXGDL<FI? 7[1>M_#KPGI.CV5MI<EKHWB"/Q)"T\4C2/<H@0(Q#@&/ Z
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M&#O)(('%4O#G[9WBKPOIFFV<%GH3V^FW%]<;'@D/VD7FX31R8E!V?.<;=K#
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MSQ[-V_B-T.[;MYQG((J/P)\/]8^)NO\ ]EZ%8RZC?_9Y[L01D*WE01/-*_)
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MBWNVA=%=2ZCCH>&& PPP S@<[6QX]\?ZQ\4?%][KVO7\VIZOJ+^9<7$N 7(
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M"B4.5(R#GFNVM6S2,N2C!.R6_?KK=?DOT.6C2RY^]6DU>3V[=-&K_>R3Q/\
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ME/'?_13/"W_@NG_QH_M##_S!_P 17X6_Z"U_X#+_ "/S)HK]-O\ B&4\=_\
M13/"W_@NG_QH_P"(93QW_P!%,\+?^"Z?_&C^T,/_ #!_Q%;A;_H+7_@,O\C\
MR:*_3;_B&4\=_P#13/"W_@NG_P :/^(93QW_ -%,\+?^"Z?_ !H_M##_ ,P?
M\17X6_Z"U_X#+_(_,FBOTV_XAE/'?_13/"W_ (+I_P#&C_B&4\=_]%,\+?\
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MA^5XO(,?.M.<(.S;ZKOZGP#17W]_PX%\8?\ 0_\ AW_P"FH_X<"^,/\ H?\
MP[_X!35Z'^O.2_\ /]?=+_(YO]7<P_Y]O[U_F? -%??W_#@7QA_T/_AW_P
MIJ/^' OC#_H?_#O_ (!34?Z\Y+_S_7W2_P @_P!7<P_Y]O[U_F? -%??W_#@
M7QA_T/\ X=_\ IJ/^' OC#_H?_#O_@%-1_KSDO\ S_7W2_R#_5W,/^?;^]?Y
MGP#17W]_PX%\8?\ 0_\ AW_P"FH_X<"^,/\ H?\ P[_X!34?Z\9+_P _U]TO
M\@_U=S#_ )]O[U_F? -%??W_  X%\8?]#_X=_P# *:C_ (<"^,/^A_\ #O\
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MYG/K0!<HHHH *,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444
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M.91,SY1>2X"AO][ SUP.E;% &5HD!CU36&:-D$EXK F,KY@^SPC())W=",@
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M%NKF]U3Q,T_BH^([S3-;;4_,%S*[>(K;SM/-FL<44)-XA D::Q$K[Z_5R)2
MHZ^M.^]1CBCF?+R]-?Q_RV0G'WN?J.HHHH*"BBB@ HHHH **** "BBB@ HHH
MH **** ,Q!_Q5L_R_P#+G'\W[SGYY./[GY?-SSQBM.LF.)CXQG<H0ILXUW>6
MV"=\G&[.T]>F,C//45K4 9.HO_Q5>FC*[O(N, LF3_J^@(W'\"!ZYXK6K)U"
MX\OQ1I\>[&Z&=MOF ;L>7_#M).,]01C/0YXUJ "BBB@ HHHH **** "BBB@
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M'.L:URIQ>KT=#C_1H.NT CZ-D]#G!4#8K)T&X,^IZTN\GRKU5P9 VS_1X3C
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M'VZ!N49ZXI0<"L>:TE+JDE?TV_,7LX\G)TU_&U_OLAPX%%%%!84444 %%%%
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MFQL$CZ\9ZFG!*XSZ/H.HHH)Q0 44FX4N<T %%&<TFX4 +1110 4444 %%%%
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MS2^*K;PY?>%[DQ0IXA;4E>TLPL[(7B:*]DMI"4('E";(;C'T3\//B%HOQ:\
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M:0NW&VRA&/*6+'[M?X%)5?H"0.@)K6H RM$G,FJ:PK2,XCO%4 R%O+'V>$X
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MM.TZ'QM9W5W/'%>P"&+9;V%HL<<,44 BD?>DDA*N@;]*%'[P_P"?6OA+QO\
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M4,3J?E=XX?G(_-1]5KU>"ZU95G"_NM;'!Q-&FZ?,EJF>R*VY<TM Z45^HGQ
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M(OV-O$'BO]C;]FCX:ZQ^SOX[TG5/"/QI@7X@F^\&216^MV3RSDWDLJ*3/:)
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MXM'WS^% X[5\5?\ #UGQ9_T;W\7O_!;;_P#R11_P]9\6?]&]_%[_ ,%MO_\
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M-_A/;?OKCQEK]OK>KQB4H8-%TF:&]N)&V\[)+A;*U(Z-]L()QFO>J "BBB@
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M:)_L>[QP?)?!RW'RG^[\WY<^E&BD_P!CVF>3Y*9.6Y^4?WOF_/GUH N4444
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M#))TR"@96&&4E2"?:*S?$OA72_&6CR:?K&FV.JV$I!>VO+=)X7QR,HP(/Y4
M7+.\AOK9)H)8YH9!N22-@RN/4$<&IJ\"\$_\$\O@M8Z%!?:/\/=!\+W>K(E[
M>7'A:1M#:]N'5&>=WTYH5DD8J,R#[P[X.*DMO^">W@O2]4:\TOQ3\<=-N&8D
MA?BWXGNK<*>J+;W%_+ B],;(QMP I R* />:JZIJ]KH5A)=7US;V=K"-TDT\
M@CC0>I8X KP?2/\ @G]X,N_$U_?:EXB^-FIW$-T HNOBMXJCM)5\F,\VR:@M
MJX!)Y6(#(Y!92QVK7_@GM\%4U^TU2^^&OACQ%JNGG=:7WB&W.MW5HQ4*6CEO
M#*Z,0.64@G+$DEFR -U?_@H%\+([R6R\.^(I/B)JT,S6SZ?X(LIO$D\,PZI,
M;-9([<CN9WC4=R*S?^$J^.WQU=8])\.Z3\%?#LRHS:AK\\.M>)""7W+'8V[-
M96[8$9622ZGP68-!\OS>WZ+H5GX9TJ"QTZSM;&QM4$<-O;1+%%"H[*J@ #V
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M44Z:A%0CLCQ92<GS2W%HHHS6A(5&G^L;_/K4E1K]]O\ /K0!)111F@ HHHH
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M]QXJT[[N?)GX+H&/^KZ C<?^ G []16M0 4444 %%%% #6X% &*;G(KP*_\
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M&*:8J][>RV;QR1YB!,(%N^YB WS#"G)QZ1_PW5X<'Q.&@_\ "/\ BYM&.O\
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MM8V#-AIJME20+]R -I+<^3V; 'J"3QC:=:B@#)%UK7_/AI?;/_$P?@^7D_\
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A%Q<27M_,H629LJH  X1,D(IP,@=2,G)K6HH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>tm2223302d1_s4img004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2223302d1_s4img004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
M   !  $       #_VP!#  (! 0(! 0(" @(" @(" P4# P,# P8$! ,%!P8'
M!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_VP!# 0(" @,#
M P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# S_P  1" &1 R0# 2(  A$! Q$!_\0 'P   04! 0$!
M 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0   %] 0(#
M  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*%A<8&1HE)B<H
M*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:!'=@B*7<A068A0,\D@#DUHV=Y'?VL<T,BS0S*'CD1@RNI&001P01WK-\<^
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MX4444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MA+U[GS_)M1.,+YYQ@QRD8&Y3AL88'<37\UI-.RV/$C4A4CR5%KT?^9!^TO\
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MGPW=IK*I)/=7-M,@=622<F2-9%8,RKM!R,C@8_EE@G\L9*\@@C)P >E?OO\
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MJ]3QGYN/4\5X//I^J_MQ:]9W]O<7FD?#VR >$2+LFNYP&#28!R<YPN2-JY.
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ME_>6AZE11169L%%%% !1110!_,#_ ,'JW_*4WP#_ -DJT[_T[ZQ11_P>K?\
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M_MQ27_P^U;6KBVDFAL_$FG)>6\J\^3J5IA@WH,QI%^*U'V#T,/44ZSIRV?\
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MK<77V>>XGNOL[["B23S--(0=N[EW<X+$#=CL,;1HHYF]R5%+8****"@HHHH
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M6N>!(]6\$Q:3XD9G20VLL_EK>0D?/&DG2.3!!&\$<$$<Y'CNI_$W0_@UJ?\
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MB": ?:K_ "!_9D>%^=N -[!A@#!&[<!T%.^!W[-^B?!2U\R!I-1U5P?,OIP
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M*2"5L81V,1=0>JL,=#C[+@7$4Z686J.W,K+U/T+PUQ=&CFO+6=E*+2]3\YU
M1<#'R^@I'AS\Z?+(O((XS^52LFT?XTR\G%K!D<L>@'K7[A4A%0;1_1LHPY&M
M$C]7/^"!_P#P4O\ AWX4\ ^'_@;XL^&,5]X@N;V[;1M9L[:TN&U'S))+AH[@
M3NA1EW$(4)##:NU6!+?4_P#P6E_9O\(_M-_L8W8T;P[_ ,(7XS\+SC5]+BO]
M#-B^IJB'S;1)4'EDLK*1RWS(J\9)'X">$[;5+:[L_P"R?._M?ST:R$+%9#,6
M&S:1SNW$8QSG&*_J"^/WCO2_V>OAMX5F\4>';S7OMD$4-YJ&N^)'CTVSN B
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MJH5DSR,M[5^P'PH\/^/O@-9M>>&;C2_B#X3N)-\L-G<'S 0>6C3G9(5(R@)
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MY<DC^)L!1P,DDM\[B<R5+%3J8!NG![).Q\EB,VDL7.>5MTZ;V2=M#XQ\*_\
M!)SX'_##QK?7\=EKFM6+S*=/MM;O4DEL@.AE,85-V1D@YQR #P:_0KX,P?%3
MQAX"TE= U;1?#_AZR@CM;$00P.ABC5511F-\ * O X/TJ3]G']F7PE\0O MG
MKFL6]Y>7TQ9;JV:4K"CX'R@A58X]00.:]]\&^!]+^'^B+I^CVOV.S$C2"/S'
MDPS=>6)/X9Q7GUL;B<3+FKS<NUW<\S,,TQ&*:]O)RMW+^F13P:= MS(LUPL:
MB611M#MCD@=LFK5%%8GEA1110 4444 %%%% '\P/_!ZM_P I3? /_9*M._\
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MCCOXU:2V#D$!D=>03UVL.W.<5%^R;XV7Q9\+UM6NVO)]'F:T+MG)C!(3J/\
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M&>!P2<UH03+<)\I],@C!&1GD'D'!'!JIJ'B*UTJYM8;F0PRWDGE0*5)\QNF
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MR\,Z-YJP1R3*\LMQ(>B111JTDC=\*IP 2< $U^?WC#_@ZE^$>E:^]MH?P_\
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M@,K]>O[WOGM7(^-/V<=6U&_:\\/_ ! \4:/<, '2>X>ZADQZC>A_')Q7.?\
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M7*@MU^8X&XUZI2$X->I+$7P\,,HQ2C>S2L]>[*E4;5F+1116) 4444 %%%%
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ME:V+C5Y+>>*2TO-H98VDW+*HSRO;//.!Z<D#@ K:1KR:I'#]H9H=1L@QD3!
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MVKO$'A3X?6'C"?PJOB#PM=;#/<Z/,1/:*S %FBDQTSSDJ,]2*[KX2_'7PO\
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M!^A%3U\V_L\?$?PO\,=&O5T^Z\5ZN;QU;[,;.-TC '!0*!C//5NXXXKJ;O\
M:IO-3N7BTKPGK4,>,BZOK=E51QDF->HZ@?./7VI25G8N.(A:[9ZSKOB/3_#%
ME]IU*^L["WW;?-N9EBCSR<;F(&< _E63\-/B=I?Q8\./JFD-,]JL[P'S%"ME
M>^ 3P001GG!'%?.WQ3M/"^L>);?6/$,?BSXA:U<(JPZ;!;M9V=D!MRA.!@<G
M[N22ISUS79_LZ6=S/XP=M'\/P^"-+7]_<VC63S-?)MV;#,VS#!R&! /"XY&:
M+:#C4;E;H>^4444C8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MWM[B21MNQ9HY)(P0>I=D&#GUQ_.#/D.1G.#4>,FOU/\ XAW@W2Y>>7-W_P"
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M2:;IY:9U7&2[EL$_<R2#DGVK0\(:1XX_:NNFOKR6ZT_0D_=++.RQ[QC. B
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MJ>36C7F?[-WB[^U/ ,-G%"NW32\87S,2,NXX(4]OJ1@$5Z'+J4-N6\R00JI
M+2?(I)Z8)X/X4 6:*@L]0@OXRT,T4RJVTLCA@#Z<=ZGH **C>94=5++N;[H)
MY;OQ4E &+XM\,_\ "26"A7DANK5O-MY8Y#&RM@@C<O(# D'Z]#BK>A0S6VGJ
MDTEQ,5Z-/L\W'^T4^4GW';&><DWZ* "N1\8?"FWU_4(]4TV[NM#UR'++=V;;
M%G[[)DZ2(3C(// YXKKJ#0!YGH7QS_L+XC6G@GQ;"MCX@O(C-97D97[#J:9P
M-A)W+)D$%".H!!^8 =#\4/A%H?Q@T+[#K%KO\M@\4\;;)H#ZH^,CZ=#7R=_P
M66T'XPZAX1\%W'P?^'Z>-[W[1=6^J2)*OG6$3"%H]L98%LLC'>/N&,#^.OJK
MX"P^(HO@CX/7Q?;+8^*O[$L_[9MDF6=;:\\A//C$BY#A9-RA@3D#.3G-;2BE
M",XO5] ]C-0YY--/;773NOU/-_@#_P $Y/A1^S?\5]7\;:!X3TA?%&I7$DL.
MI-9QBXL8Y(T1XHV  &YA(2X <B5E)*\5[QC//6DQN/M2[=H^E14J2F^:;NRZ
ME6=1WFVWYG"_$GP1>ZSXRT?6!;KKFEZ78WEO-HDC($N9YGM_*N )/W9>-(YD
M^;'RW#X/56\A\0?LI^-+K]I.Z\;6.M-9Z+IT6B-;>'UO7DL]6^R+,)8I2=I#
M1EU>)V!!?:6 QE?IK'%-V\=:(U&MCFE1C)W?>YP_@WX<77A;XU^+=<$UU)IN
MO:?IR1+->R7!2XBEO6F"JY/EIMFAPJX7K@#%=R.5HVTH&*AZFJ5E9'\P/_!Z
MM_RE-\ _]DJT[_T[ZQ11_P 'JW_*4WP#_P!DJT[_ -.^L44#/Z?J*** "BBB
M@  Q7+_$*^\36<4(\,VFG7ERS$2"^W)%&,'#%PP/48PJL>1T%=0,T$9K.I'F
M5D[>@T['SGXI_:;\8?#>01>(F\*R7<@"_8]&@FN+BWD.?W;LTFP,-I)Z]NQ&
M;VE:=<>)[A?$'C2UTG3TFNFET^/7;W[2WV<H<QK:J%0ME^.2WRKQSFN.^,FN
MZU\6_BCH\>CZ#>^&=856,BZDL;7J)PNXHK/&A.!MPQW#DXQBO<? ?P!T+P<J
M7%Q#_;&K;B[WUX/,D9CCH"2%' Q7AX>%:K6G";O&+Z_\-J=]1PC336C?8\%^
M*7C6/0O&4-KX5U:XT]GM"]Q+8:>EK)*H)XC7;N5.%R6ZE>.*Y.Q^*GC;Q6T%
MK9W>K7 U/=%$MWJ,C^?'P&9T4A0I#>G)8=J^K_'7P+\.>/XKG[19K;W%VJ12
MW%MB.21$SA">XY(__557X??LS>"?A=XOO_$&BZ(MMK6J00VUS<O<2S;TA&(P
MJ.Q1,?["KGO64LGKRJ-\]H]D:+'4U!+EN_,YCX;?LEV>DWR:EXDN%U;4DD$J
M1Q_+;1$*1TP">2>OH*]>'DZ=9X55BAA3 55X10.@ ]!V%4O$WB_3?!EA]JU2
M^@LX>@+MRY]%4<L?8 FOG+]J_P"*.H>)OLPT/5+Q/#DT(BN1'')$TTH9LKM8
M*6!!CZ5WU:E'!4G[-:]NK.6$:F(FE)GJ'C;]K/PIX0@189+S5KN4/L@MH&!R
MH!Y+ 8'(YYKRWQ;^VUJ?CFVBT_PWHL^EM?N8#>7$H,G)4#R@._S?>YQGC!P:
MX;PC\(K2QL_[9UF/4;&TOU\M;=B7OM0(Y8 =ADGVYKT'X7?"'^T/C["NH6?D
MPZ+;Q726H4;;;<9"D;>O"Q]>NT5Y$<9C:\U%^ZI::;KYG=]7H4KMZV.@^&ND
M6O[//Q1TVPU:\W2^*K$*DTC#/VD-ED8\GG"X/ RQ':O>L[C7C?[8'PEO/B/X
M7L[C2;6>?5-/\XQ-!]]#Y321MZG$T<7 _O'UKT;X9W>HWWP]T675X)+;5&LH
MC=Q/]Y)=H#9_'->W@^:%25'EM%:I^IY]:THJ=]>IT%% XJO?W\>GV_F2+,R]
M,10O*W_?*@G]*](YRQ6#XO\ "IUU8VBCMF;*K.)/D:>-3N">8 6 SG_OHTRP
M\>0ZUK$UG8VUW<RV\8>1RGE11%N@8MA@>#QM)P,XZ9U(8+IKHM+=*8PQ*1Q0
M[ 5/0,26)(XY&WOQZ ',:7;3^$WB"VOASP_9LA0F64RS.0>[?(#VZL3SGVKH
M)=7M;@)'YMQ-]H ,?DH^U\8.5=1TY'.['O67K6MZ%X=E9C<:;;7X_=B9X3.Z
MM_M;3N)X/5@:V-%U%-5LX[A"TA9%RY@>%7R,Y56YP?Q[<G%)=@*\6D^6?-CM
MIGER8]MW=.PVMRQ'+CVZ#IZ8J0:K-'>K;S?V?!)(ORK]J+.3@XPA5<C(/<=#
M5JX6YEC7RI((6_BWQF0'Z<K4-GI31:BUQ,MB\[+M,L=MLD([ L6)QUI@%M:3
M7ELK7CXD(R8XF**IY[@Y)P<'G''2K$=O'91<;L*O+.Y8X&3RQ.>YZFI%3;*W
MS,0<8!Q@?3O3)HH2%DD6,^7E@SC[GJ<GI0 Z*9)T5HV#*PR&4Y!_&O%-,\47
M'P^_:,OM+NC:V-CJ1>Y6=UW";S<R  \='W#US[5[);ZQ!=LRP,9R@.3&I*D^
M@;[N?;->$_MT_#&\\9>%['5+*3R[O3W9(F!VA1P_SG/()3@\8S[U$DVM-RH:
MNQ[I:W,UQ<':MJT&2#(DQ9L]OEVXZ8[\>]3BXP$W1R*7'W=N['L2,COZUXQ\
M./C?=^$M$TNS\?6<EG<7EN!::O$A,=Q$1G#,/F4@;22/[P)QU/K6C*T>EJT5
MY)J4))DBD#*QD0C@;NC<]\C\J<9+H3UL2S>)-/MI=DE]91OC.UIU!QZXS['\
MJ@3QQHLDFQ=8TLL>BB[CS^6:TF"SQ8D7Y7&&5AG@]CVJK_PC>G9/^@6?S=?W
M"\_I5 6K>=;J%)$.Y9%#*?4'D5)6>_A?39"-VGV+8.1F!.#Z]*?_ ,(_89'^
M@V?R]/W*\?I0!=HJM<6*S0*BL\.S[AB.W9CIQT./0@CVJGH^EZC82?Z5JC7R
M_P"U;I&3]2OX=J -6BLVR-])?.TDMNMN"?W7V5DD7(R!OWE6QD9(&,@UGZKX
MNO?#SL]]I$[68ZSVD@F"<9)92%(4#.3STH AUKX2:+K_ ([M?$5U#+)J5G L
M$>)2(_E?>C%1_$I)P??G.!CJ*Y/2/$FH:[\2YH['5O#-YX;M]-4S00.TFIQ7
MC2':S$.4$!C!P"N[<#R1P.LH"U@HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@!IX&*_+G_@XM_X)K>*/VF/#FD_%WP9_P 3#4? >DRVFK:4
M%)FN+)9&F\V# ^9HR\A93U7E>1@_J,3NQ2;0>O0]:[,OQU3!XB.(I?%$[\KS
M*K@,3#%4?BBS^.":++Y_B8]&&W'YTB6S33+&BLTCL$54&XECT''<_P"'K7]6
M_P ;O^"<WP-_:,U&2^\9?"_P?K6H32F:6^.GK#=SN>I>:/;(W_ F-1?#+_@F
M_P# ?X.:<UOX=^$_@;3U=BQG.E1370) '$\@:4=!C#<'D<G-?I$_$A.E94O?
M]=#]A_XBY3]C;V#Y_56_*Y\$?\&\?["_C[X/^#M?\7:I<1^'3XH$"B,PI)="
MV5'*#D$ EI&/L,=Z_2'6?V:?#^O:7<1W'VR;4+O'G:C),7N9.F02>,8&,5W'
MASPU8>$M)CL=-M8;.SA^Y%$N *EU*^CTS3KBXDR5MXVE8+U(49./RK\NQU9X
MJM*O7U<MS\CS3-*N.Q4L54^)GBFC?L4V,%Q,UYJ\[JW[J)+:$0JL SA.IQG)
MSZ^M>S^']!MO#.D0V-G$L-M;KM11VKS,?M9Z==W*PZ?X6\9ZI,SE MK8QL![
MDF0 ?SJ]>>(?$?BFPM[W4YD\"Z+UF2216OI^OR!B,(2!T W9Z9KSL/&A!-T4
M<,Y3?Q%[X\?$^;X9>$I+RRO-'2^C 9;2]4L]RI8+\@#J>,DG@_A7R;J>J:Y^
MTQ\0+YMR-=7"B)[6"'RT50%(#MW QZY]37LWC+0M-NO#DEY;V>I0V3."\]X@
M?4=3<EL!,GA6*]2!T.:A^#G@BX^(NMWE@-/7P_H>DDPSB+Y;J[<L>';KV8>@
MQ[UY.+C/$U5#[/;H=%-QIQOU/)=5^'L5AXBT32[)EFGU*\^R7%TJ ;BH^8)_
ML#IGW%?4WQ@^&L.H_ ;4-"M(_P!W;PI(G)W'RY%D8@]=QPWXFMB;X.:#)JVB
MWBV8@DT$N;01G"J6*DENY/R#G/<UU1.5KT,-E_LXRBW\6AC5K\[3//?V9/%E
MUXN^$>GG4)/.OK'=9SR$8,AC.T,1[X_2O0SS2**=7H4XN,5%N]C"3N[D<LRP
M1L[L%502S$X  [FL.\^)NAV6I1V9U".:ZFP$B@1YV;IV0'UKH*R?#GA:U\,Q
M2+;K^\F;?-,X'F3'G[Q  XR< # K018OH[J[3;!]GBP5(::,RY()_A!7T!!W
M?A3C9J(]LTSS\GAR "",8(4 $?4&OA+_ (+*?\%D;'_@G]HB>#_",=GK7Q.U
MNU:1%:96C\.QM@1W$R;3O=LDI$<9"[F^7 ?\-?B'^WS\:_B;JWVKQ!\4O&FI
M3*Q\HRZI)LC4G.U0" %]A7U.2\)8S,:?MH6C#NS[7A_@7'YK2]O!J$.C?7T/
MZH;6UTO2=4\[R;7[9&OEJEI 7:W4@9!"@G_@1 XP,#OM+.TB[E1N@(W?+G/;
MU'XBOYM_V'_^"YOQH_9%\2V<.H:S<>/O!2OB[T/5"N_:3DM#<;3)')UZED.>
M4.!C]Z/V6?VLM-_;.^!/AWXA^!X[HZ;KENID@NC%Y=E.,":&3!WEXGRI*_*=
MN1D$&N+..'\3ETE[:SB]FMCSN(.%<=E$E]82<9;26Q[ MO\ :'CDFAA\Z,G8
MP.XIG@X) (R*1DNO-.)K?9V!B.?SW?TJMILM];I(^I-8JJ+NW0EE"@=2=W;^
M6*CMY;W4IV:.:&.Q93LE5")F.>P;*X_VL'/88P:\,^;-0KG'7KGK5+^T;/3K
MA;9&C61V_P!5$FX@GN0HX^IJ:&T:-OGN)IOFW#<0NWKQ\H&1]<]*8]SY406W
MC\]D81%8V4"/ZY/ '?&3[&@#Y+O/$^N?L]?M(WUO%9M>:'+=/>+8K@[(F)("
MCGYD1E(P?3/2OICPA\0K7XE^'8]0\.WEO,NT>9#<(WF1,?X7P<J1SV(..#WK
MS/X\WR^"OC+X/UB\O+; FW,F A SL8<] 5=<<DDH_88KLO$OP1M+W5&UOPW?
M7'AS6'12);/"V]S@A@)8\88' S^9ST-.UB==S>T_[-=ZS);ZE8VO]H>8_E2_
M8R%G0 #<'((S@D$;LUH:QX4L-=MTANH6>*,;519'10,8Z*0.E<A;?%NZ\%QP
MVOBZSFMYMVQK^VBW6;?-M!9LY4D8; ' 8=.E=W9WD.HVB36\T=Q#(,I)&P96
M'L1P:D::9GZ-X*TWP],TME;^1*R&/S-[.P4X.!N)[@?E6@+20#_CYG/U"?\
MQ-6**!E>.VDC9C]HEDR#@.J[5/;H ?UK'U8^);9F:T;2+I.<*T3Q./0??(/U
MX^E=!10!AZ%XF;496M9H5AOK>/=-;[L/G<0"H( *'&=P..0*7Q!X]TOPJW_$
MPFGM5SCS&M93'G&?OA2O?UK;(S575=5M=&L)KJ\N(+2VA7?)--((XXU]68\
M?6@"OH_B.UU]0UJTTD; D.8)$0X.#ABH!Y]_7TK2JGI#6L]C#+8M UI*@>)H
M&!B93D@KCC!SG(ZU<H ,8HHS10 4444 %%%% '\P/_!ZM_RE-\ _]DJT[_T[
MZQ11_P 'JW_*4WP#_P!DJT[_ -.^L44 ?T_4444 %%%% !1110!6^QP_;/M'
MEQ_:-GEF3:-^W.=N>N,G.*G)SUZ5F^*9KR#P[>/I\<DMZL1,*1[-S-V WD+^
M9Q7S&GQ"\2>(=6N[K5/&]YH:V\A$=A;2I)/<$%_E"H-H)P./<>E<&*QT:#2:
M;OVL=%'#RJ*Z>Q[-\;/'WC3P9J5JOA?P^=>BNHL.&B)2!PQYW*P/((ZC' P>
MM9&@ZY\7?%MJRW&G^&] 60*!(5D>:+GD@,Q7]#Q^%5OA]J/CFSTN;5/$.O1Z
M3X=A^:-]0@B:X9-Q 9CQ@L2N ?;&<@'F?!>H>*OVE?&FM6K>)-2T_P +Z5,8
M!]FA%NUX,X(8KAL,,\$].W45Q3Q#]I%>][VRT7X]C3V=HO;3J=:EG8MXKDM;
M=;OQMXEM"T<UY?@&TL'.X$;0,+@X)11CG[RG%<-\0+J[LH=;U*SD7Q!=:? \
MUWJ)BW6]@^]B4B& "=I'S?3NI%='\=_&R^#M:\/_  _\/0+9VVL.JZA+"2K6
MR,0(TW9R#($<'/.T =Z]#\1_!FQUKX5-X3MYI--L95B21X%_>.J,K,.O\6W!
MZ\$CTP5*7MY2IP:O'?UZ+_-CA4=-*7<POV=/AWY7A&SU[5KAM6U:^C$B33?,
M(5SD;!T!/7(]O?/HMMHEG8ZC<74-K;Q7-UCSI4C"O+CIN/?\:/#^C1^']$M;
M&'_5VT:Q@XQG'4_CUJ[C=7IX>C&G!1M_PYRSFY2;%HHHKI("AAD444 16EI'
M8VZQ0QK'&G 51@"I:** ,BTT6S\/$S^29;B1V+W'V??,Y;).2B].O8#\ZK)\
M0[&XN3':Q7]\5(5FM[=G52?4]OQ]*V;J 75O)$WF;9 5)1RC $8X8$$'W!R*
M6TM(["UCAB41QQ*%51V H C4R7D2DQR6YY.'8;E/;(4D$<],]JR]6_XE$#7%
MUKMY;QPH&DPD.,?=W8\LGJ1^7UK>K#U&ZTJSU"-IIE\Y<(D:EF P>!L7@D$$
MC()!^E*6P"Z/YFLVT=U#J6I?9Y,,GF0Q)YJ\$$ QA@#R.0">HXP3JK:+$B_*
M6\LY4N2Y'XG)JK9ZK-J,4;QV=Q"K\DW&(R!G!^7EL]\$#ZBN6OOC=X/A?_2M
M>@;RMRLRB3[.W&&Y V,."1DGVI@=6VJ?Z2L,,,TQD0N) /W(ZXR_U&, $\CC
M%<9\?DALOAEJ5S>7K)(IC:W'"IYH884+_$&P<Y)P"Q&*Q]2_:@LM;UZ#1_!N
MG77BB^N01Y\8,5K;M@XW,P&<8R<8'3YLYQQ_Q L]0G\5VZZUJ%MJ&K19O)[=
MG/\ 9VCQD#",,XW'  '<?,<\&@J'Q'?_ +.VO6OQ)^"UK#=6RW4%J3921W*B
M590F&7(;J,%<9]*=_P *IU3X<K)-X0U"?R<[SI-TP:W<YR=K'[F< ?B>:X?]
MGCQ'#X+^)M[X?BF^V66L?OX)_*,:HR[F(7L5R<#ZK7O5Y,;6UDD6-IFC0NJ+
MU<@=![FDXIA)69Q/AGXV6]U?+8:[8W7AO4-N<7HV02<D?)(<<9'&0 >@)-=T
M2<UE^*]!T_Q5H7V74K>.\L9F4-&PR'W':/\ T*O&_&W[.'C#P78SR?#3Q;?Z
M?;[S*NDWLIFA4DYVQNY.T<]^P')I:I=S*4FE=*Y[PG I?O5\>:5\>KW0-5;3
M_B?K'CSPM.F$\VT<QP8R/F8A"VW'.1S^=>I_#CXR?#_P3%<7R_$S6=9L[K"[
M=7NC<1Q$'@H3$&'<=<'OT%*-1-7,HXJ#W=O70]PR!1]ZN(M_VB/!MW%YD>N6
MSI@'<J2$8/3^'W%<C\4?VR]!\#FU@T>UN_$E]=,<I!')'%"HQRS[#R<\  ]#
MDCC-W1HZT$KW/9LUQ'Q*^/?A?X4>(-%TO6M1CMK[7K@06\>X?NU.1YLA) 2/
M(QN/?IG!QXIXO^*_B7XK^'A9/JFOZ(MT5#KH.E2I*X!W';*6+C/0[2,@8[G/
M)>'/@??>!;NUO/"OPNU#6O$4TH=]0\43 10J 1CR^ .3G.0?>LO:KH<\L5)_
M CZYL_!^C6GB6XUVWTO38]7OHEAGOX[9!<W$:XVJTH&YE&!@$X%:@VUXC\.;
M3XU3>*KS5->D\-V\-[&D0T\%GMK0)T:,*Y;<26+$L<Y _A4#O+WPSXRU=CGQ
M-I^F?)M'V+3 _/K^]9N?TX'%:IG1&HVKV9UMS<QVT8:1T12ZH"QP"6( 'U)(
M ]S4O2OG[4?V*;6(K?>(/B7XYO(;%_/,MYJO[N'G)(,A8)]1C%5_'O@KPW%H
MLD]O\;O&%CM.TRPZ_P#:]A]=D?/Y\=*+HQ]M-*\HV^:/HG)S_P#6H)P/O5\6
M?#*Y75/&ESI^J?'C7[JPC4"SGM]2DBFG?('S@@J!R<_2O6;K]DS7M9DCOK7X
MP>.IE9047[:_DN.W^K=0?K4QES;$4\7*HKQC^*/>@^1ZT9W"O.?@C\(=8^&F
MHWTNL:VWB![A D-S-)*TT2@Y*G>S<'COQM]Z]& PWM5'33E*4;R5AU%%%!H%
M%%% !1110 4444 %%%% !1110 4444 %(6YI>U>1_$C7/B'XA\9S:-X0GM-/
MAMG47%]=6'RPAER I8L'P"#G:.01BL:M3E5[-^@XJ[L6?C%\9=<\"^(4TW2=
M)M;JXFC\R$R>8_FYP!G 4+ALCAFX]*YC1_VC?&2ZC'8W&BZ%JVI-C=86$TD;
MQYQ]Z0EU'7ICVXJB?A3\3/BOJT>F^(_$%W9Z+82DS3+!#%)=G! VB-5XR/7&
M#6QX[\<^&/V6]#71?#-E;S>)+H1!(W1I"!(VWS9I,C@D$A-PR2,  YKS;U7)
MU92<8_(ZH\G*HI7D6OBU^T-JWPO@T[38-!TEO$6L "WLH]0,HA8XYD C3CJ.
M#SMX-6KK29O"N@7OC7XBS6EY>:;!YL5G;;OLUGP"(T4YR[-A<DG/')'2A9_
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M^(-!CF:5+>Z<7@N8^1L,V_#>F=O4<8->R$9IG?"3DKM!11106%%%% !1110
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M'1BUV%B\X[.K1Q!<XSC.\]#QZ>>S-^T'XH\</8-=:'X8L5B+B]@MX[BW9@.
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MB?PWX!UVXUC5H8-<U1Y':$S@O#;JS$X56SSC:O.>%]Z]JBB6")41555& JC
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M/J3G)]\UFVNBZ#>2;8;/2)7 )PD4;$#OT'O^M:EK:1V4*QPQI%&OW410JCZ
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M?_B?\?\ PS\++&_^W:G9R:A8V[3FPCDWS\*&4,J@E V5PS#'S#&:^=OBQ?\
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MJZSIOQ#M/"K(WBKX0^([F_T^&<LL=Y8EF\VW/3*E RC'5D7D<U[U^TQXRNO
MGP/\07VGRS0ZFUO]CL9(5W21SSL(8V4>JLX;OC;D@@5\'_";Q-K'[._B5/&E
MM'=7&BZ?I>HSZ]9IB5]6TVSN)&D95;@R>4X=0V,[3R-V:^;PM'GBVGKT1\K&
M,I248[GN5M\2=$\:I9:MH6AZ?K&B_$Z5EOM(NYVB_L_5$ >:(N "CR*2P/\
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M !1110 4444 ?S _\'JW_*4WP#_V2K3O_3OK%%'_  >K?\I3? /_ &2K3O\
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M/VW?C:UE8VW@[2?#]KK6M:I*8X);^'Y+2;8VUX5923(H.?,& @8$%B<5A_\
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ML-+ATSS/+$G[X[F+RLY8],DL2>F!] !V%7*** "BBB@ HHHH **** "BBB@
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M_P#Q_?.#G;_:7(_#S* &+\*_#J;<:+IXV A?W(X!ZTDWPF\-7/\ K-#TU_\
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MX)L_AQX)TO0=/#"RTFV2VAW==JC%;-%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MRM_\%_!NK:^VJ7/A/PS<ZHQD8W<VEP//F10LAWE=V64 -SR  :ZJB@#C;[X4
M;O$^J:E9ZM<6;ZQ+'-<QFSMIAN2)(AM9XRP!5$R"2,@D8R:>/AE>!B?[=?\
M\%EI_P#&ZZ^B@#BV^%M\QYU]C_W"K3_XW5J+P7K<$2QQ^*KN..,?*J:?;#\/
MN8Q] /K7544 <N?!^OM_S-UX/I86W_Q%;6BV5SIMCY=U>R:A-N)\YXTC)!/
MPH XJ]10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 ?S _\ !ZM_RE-\ _\ 9*M._P#3
MOK%%'_!ZM_RE-\ _]DJT[_T[ZQ10!_3]1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?S
: _\ !ZM_RE-\ _\ 9*M._P#3OK%%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>tm2223302d1_s4img005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2223302d1_s4img005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M:UJ$.G:+H=E-J6H7<H/EVMO%&9))6P,[5123["K&@^*+#Q)H=GJ5E<>?9:A
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB?\ L2?M)^,_V7O /A'0OVK+[PYX\\-RR/X@\7CP9:SMXF1F8HAMO-40[ 5
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M7\*^%M(_:=M=+^)&EW\MQK7C#_A![60:S;-O\N 6I?9%MW+E@<G;VKHOBO\
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M_!R5;I#_ ,$2/CL0H#+I^G 'T_XFME7W!H?_ "!;/_K@G_H(KXB_X.36W_\
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M">N32W$,]B5E576.5XTG19D254E15D5941P' (KU*M)_$9PV$*97%1&QA/\
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MZ1A-\KW11E)L5/S3 G&T=": /7K3_CUCP<C8.<8SQ4M16AS:1=_D'([\5+0
M4444 -DK-U]Y(M.F\D R[3L!. 3CC)],UI25E^*$,FBW(&<M$PX?9GC^]VJ:
MGPA'XD?G5_P3=_:A^,_Q+_:;_P"$:\:ZQXDO/L<UY-KD.J6-G;V<2_V?9?);
M/&BM)Y>HB[5/++CRMQ8G*,?T@/\ J,DY/2OS6_X(_P"C:#IFJ^"A#??"==:C
M\,+'<Z;IWPROM(\0VSB% \<^IS2[)F4@K(WECS2-PZU^E8"R0^QZ8[571>A*
M^)GS1^V-^W/K/[.WC34+#1?#^F:U:>$_#7_"7^(FN[IX9!8"Y6%DMMJD&4+Y
MC_/QA .^17_:]_X*!S?L]?$+0_#>AZ3INK:E=Z)/XFO3?W#VT4=A#+%$564*
M4B9C(3YL[)#'LR[@'-=E^T;^P]X=_:1\7S:KJ>K>)=)_M+13X=U:#3);=(M8
MT\W"3FWF\R%W4;E(W1-&VV1QNZ89\<?V&?#_ ,?+ZYFUC5O$5HVH:)>>&+[[
M"]M&+S2KIE:6S8-"P"#: KIME )^?/-3&VERI>1\G?\ !RG^U1\-](_X)7_&
M3X<:AX_\%VOQ!UC2=-N+/PQ-K=M'K%U&=3M7W1VI?S77;'(V0I&$8]C7Z0:'
MQHEG_P!<$_\ 017YI_\ !R=^QY\+K_\ X);?%_XFW7@'PO<?$'0='TRTT_Q%
M+IT3ZG91+J5K&$2<C>%"22*!GH[>M?I7H7_(%L_^N"?^@BJ MT444 >5_M8K
M#_P@.CFXD^(D:CQ)I15O!B2M>EOMD>!.(U8_8LX^T9P/)#Y->I)]Q?H*\P_:
MJ\2Z?X6\#:/<:EXL\3>#X9?$>EVT=UH=@+R>ZEDNXU2UD4V\^V"8D1R/M7:C
M$[TZUZ?%Q$N.F!B@!U%%% !1110 4444 %%%0W-Y':1,TCJBJ,EFZ*/>@#XO
M_P""FWBM/V@?C)\(_P!F2TC^WP?$[5%U[QG#'S]E\-Z;(MQ+YO\ =2YN8X;<
M?W@9!T#"OKCQ3XFT_P"'W@W4M5U*ZAL-*T>UEO;NXD(6.V@B0N[GT"JI/X5\
MD_\ !-VVT_\ :>^/_P 8?VDMAN+?Q)JW_"#^$+@\HNA:2QC>2+VGOS=R$^B(
M!TR6?\%8?'.K_%_Q'\-OV:?"<EP=2^-MZ_\ PE,MNOSZ;X5MBIU*0M_ 9@Z6
MZD]Y6QR* )_^"2VD^(/C9!XX_:.\96-U8ZK\:+U7\-6MTFR33/"UON&F18_A
M,JO)<-ZF<'IBO!_^#H3]HG4_#/[-_P .O@YX7;S?$_QA\76ELEJ@W27$%K+'
M,B =@]V;1<G@\@\$U^FGAO08/#6@V5A:PI;VMC"MO!#&N$BC4!54#L  ./:O
MS/\ '_PM@_;Z_P"#C32KB\B^W^$/V3O"L-W(HPT?]NWY:6%6]U3RY,#G,*=L
MT ?5OP(_9JT/]D+P=\"?AOH[^.EMO"6GW5DATI)&TB\D$ :>;4V"E<O(7>,N
M03([<DYKZ7KS7XD^(+#3OC;\/;*?Q+X@TNZU)[_[-I-G9K+8:ULA0L+J4PN8
MO*&&3$D6YB1\^,#TJ@ HHHH **** "BBB@ HHHH **** .%_:($9^"_BGSF\
M5QQ_V/=;W\,*[:RH\LY^QA 6^T?\\\#.[%;'PX(_X0C2-K:H8_L4.TZF&%\P
M\M<&<-AO-_O9 .[/%97Q_P!5MM#^#/BB^OM;U;PW9VFE7,L^JZ5;BXOM/C$;
M%IH(S')OD4<J/+?) ^4]*U_AS=Q7_@C2+BWOKW4H)[*"1+N[A$-Q=*8U(DD0
M(FUV&"5V+@DC:O0 '04444 %%%% !1110 4444 1SC(KX>_;%^!5CKW[8=EX
MD\:-\2KOP7%:0>9I^G>&]1\0:=J*JLB26ABLVE2.)]X,HN+1BY"E)00-GW*P
MR*^5O^"E'[:?C/\ 9#L?"R^#_"MMX@N_$LEY;+-=6]S/#%<);EK6#;!SOFF9
M0-Q5=L<G(.")V:92UT.__8YGT>Q\&3:'X6\-^/M%\)Z+A-/G\517<$T^]G9H
MH8[T_:UBBX"^8JJ RJF0O'M5>(?L"_'7Q5^T/^SOI_B+QEIUAI_B!KV_L9WL
M+6:VL[];:[F@CNX(YF:18IDC610S,</U(P3[?52O?4A2OJ%?,7_!2GPI?:IX
M7^'NH6.HZ] VG^/="WV=A.T<%RLE_ C-.J#<ZJF_Y2=GSDD$A2OT[44]HMQ]
M[-+JF4G8_.'X!:_X>\'?M$:?K6MZC::;\2-/^(OC"7Q[>7EPT5S;>&UBU0V;
MW3.0$L5"Z3Y1?$8.W8<[C7GG[5MS-J&B^/;_ ,!W%Q/\<+GQ/XF;4I=+DE?5
MY/#)TR^-JPV?-]E,?]GF$K\GF%"GSYK]2O&O@?3_ !WX3U#1M4A:XT[5('M;
MF'S&3S8W!#+E2",@D<'O5C1M"M](TVWM+>/R[>U18HD7HJ@8 _ 4^WD%V?D[
MH-KX/?XW:U!?R6?_  RZ997T=Y7D&C#6CH5F&\EB<>8)!.5V\_:?,*_OLUF_
M\%-_^"@/[0G[$/\ P2Q\'?VA\*++Q1X/\7_#6U\/>*O%.LZY]EU'2M7OK>6W
M:)K4YF=PFURQ7&YB&((-?L%]A3_:_.OS3_X.OO!^J>,O^"0NO6>BZ;J&JW-M
MXBTR[EAL[=YWBAC=VDE8*"0BKRS'@#K3OI81[5_P;]#'_!&_X \Y_P"*:Z_]
MO$U?9%?&W_!OL,?\$;/@#_V+?_MQ-7V32 *:SA%R2 /4T.VU,MTQS7Q;^W;^
MWQXL@^(K?!CX#PZ7JOQ$:V^U^*/$MZ/,T3X8Z=U:[OFR%-P8][Q0$Y;9EAMZ
M@&?_ ,%2_P#@JC#^SCK&E?!?X6QIXP_:(^)++IOAS1;4^:NC&;<@U&\(R(X8
M_F?:>6\LG 0,P^9=!^"?A'_@BWX3O/!GP?@L_B5^U=X\L&UCQ3XR\1S(UKX7
MLV.;G5M0F8J+2Q$F2D98-,_4L17E_P"Q;9>#_P!DGP7X]_:O;2=9\4?$#XEZ
MC+X2^#"^)+AY];\:2R *VKSJV"GVJ?#,0JI#:P  +O9F[7]A_P#8D'_!0'Q!
MXL_X2+Q'K/B'X3MJD=Y\0O%18V[_ !C\11<R6\$H V:!9\QQQ1!4D89!(&:
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M:AXEL+<R:MXQU*RADU;5)C\\UQ+<,"R;F+,0&  ]<9H \;_:&_X+\>&?A]X
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MG@ <"L5&=5WGI'MU?J_T1ZGUK"Y;[N$M4JK[;VB_[J>[\W\EU.0^#/P,\*_
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M7:T78[,9@\!5IK+<LK2<%K)QIM\\N[U5DNGEJ?>-WJ=OI\#2321QQJN\EG
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M>X^T?\$0_CNP[Z?IW3_L+65?<.A_\@6S_P"N"?\ H(K\I?\ @Y4^*WQKM/\
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M $[3-)^Z7Y=HRQ)/R_;\O*XKA/'_ .S_ .%/B=JUS?>(-!L=6GO='N/#\YN
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MN_AZUQH_AWQ)J'B*',=Y836P@M=,EW%?])NBWE)'D'Y@QR.U:O\ P3I_;O\
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M1Q(?(M<?ZZ=?+.Z->1N7UIU]^T-:Z?J-];MX?\8S'3_#H\1O)%HTC1RQG?\
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M-WE1Z? _E#&?N@< "L99AAHZRFE\T>M1X.SNLTJ6&F[[>ZSU/QY_P4Q\5?\
M!5GXT:SX+^*FJG3_ (,Z=;"=/A]\*9IM6U/X@SC#&U>]"JS6D>&\ZXQ%;@KM
M#$Y81?!;X*_&K_@HI))\-?@1HNC_   ^!$D[6FLR>%H ]C;+&=LBWNJ(PDU:
M^(R#%;R&W4GYY"5(/:?L*_"#X+_'"/5M$\82>!?V?_A;J#QK-X!\/^(+B;6/
M%LB@?\A;69D226WXXMXBH;DMTY_9CX&)X#\*?#C1]%\!2:!;>&-)M$M-.M=*
MDC^RV\*C"J@3C']2>YK2GBJ-17IS3]&<.9</YG@)<F-H3@_.+7YH\D_X)]?\
M$G?@W_P3?\&VUGX"\,V/_"1-;+#J?B:\@635M5;JQ>7^!2<GRX]J#T[U].H@
M ]:JK<JO.Y>13OMZK_&OUS71<\GE;+5%55OMP^]'FI!/N7K^5'F*S)=PI:A#
MMZFE\TJ/\:!$BKBEJLUR3W'TIK7>W^-5^IHN"39P'Q(>U/QK\ ^=_P )I]I)
MO_(_LWSO[)/[I-WV_9\GIY6_^(-CW])R?2O+OB+XEM;7XU^ ;63Q#K]A+='4
M-FGV=IYMAJ6V)2?M4OE,(MF04^=-S,1\V,5Z(FJ1.?EGC;Z-FBY7LZF[1>HJ
MK]M4'[ZG\:)+D,<[EP/?&:+BY663@^E(>E4QJL*H?WT.%]6Z5ROC?X^^#_A]
M!OUSQ1H>DJO4W-]'%^C'FIYHK5LWHX2O6?+2@Y/LDVSM6/R&JEQ?+:_,W0<'
MG@5\;_M"_P#!;;X2_"2":UT"]E\<:L@*I;Z<,0%^,!IV^3&>I7=T/!KX_P#B
M3_P5"\1?M&R7%KXB\6:MX=TF\8QQ^%? ^GF;4KM>Z/>R[=I(Z[%/4].E>76S
MK"TWRJ2D^R9^@Y/X4Y_C*:Q%:C*E2_FDG=^BM?YNR\S[._:@_:)U#X_?$EOA
M+X!U,Z7IL4BKXR\60SJL>CV_5K2!R0#=.,#@_NU8D\TGCSXW^$OV9/ACIOPG
M^!\>F:UXWU8&STK3["99VLV?_67UVZYPJ\NS.<L>.IKXX\$_LUZY\3X+>S^'
M_P"RM;VEK@#^V?'.H3/))ZR/&S(<\YX##TKZ(^"G_!+?XH>%+*6^3X@>%/AO
MJ=Y%Y4L'@_PQ"@1<YVFXD_>-^@X[]:X:>)Q%5N48-WZKHNRO;[SZ/'9+D^ A
M"A5Q,8*.O*VGS2[S]FYOY:::=SZ7_9B^ .A_LH_#>:WFU+[?KFI.=0U[6;V3
M_2=6NB/WDTC$]!T Z*H %?*G[8?_  4PN?BQXJM_ /PCU&[EM;YGBNM7TF W
M%]JK X:UTY<8SV:X/R1YZDBM+Q=_P1=\0?$*^-QXF^-7B/Q)D8,6HV[30_\
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M_:5@#^'O7Y;?&S]GOQ%\&?BOJW@W5U-EK.C78MY'!1$=&(\N4%V"!'4J06(
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M/<-J$5M)&HM8RLB>664R9<[L$+QUKU3]H/\ 8F\)?M'^,;+6-<FUFWDM[/\
MLR]@L;H0PZS9>?'<&TNE*DO%YL2'"E3C<N=K,#5^-7["GAGX_:O:7VOZIXA$
MT-O=:;<+:W4<":CIMS+'))ITX$?SVV8D  PX&1OY.1;(/Z_(^,/^#D?]N3X5
M6/\ P3,^*_PDOO'&B6/Q*\2:-IEY8>'9I"M[<Q-J-M*&5<8QLBD;KT0UR'Q3
M_P"#P']G7P18M8^"_"OQ,^(-];P(()H=.BTZPG8#D&2:3SEQ_P!<#7ZF:O\
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MEWZU\^+D8E&U?G;]RN(>?N' J/Q)_P $?/V;M6L->^W?"[0WCU_Q.GC;4?\
M2KM/.U6/=MN!ME!11O;]TFV(YY0X%<=3(<)):K\O\CZG!^,'$>'DI0J[?UT:
M/PS\5_$WX,>&M*V2>/O#]_<PEF>YT?Q!;7JR@[MH6%TB?(&._./RI_#_ /:&
MT#0=2BOO"OQ$DL6885K'5#IU\,^H1BH''_/0YK]:?V)?^"9O[-XN_$'A6[U'
M1/BMKVB?$>X^+5DDUC)IUQX:N+IE%NAC1P984,+A?,S&_P WR<5]#-_P2I^
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MN[]D+_@GG^SSX T3P7X%G_LGXB^/_A3H%UX2EUA[>:W>6&0_Z2LL4;F#S,2
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M+LYJWW)6/HB/_@KQ^S;$W'Q3\.CL!F3_ .)IZ_\ !7_]FU!_R53P[S_M/_\
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M>*5[[ ?+MW_P<Z_L@V2;IO&7B^$?9EO<OX*U5<0,0JR\V_W"2 &Z'/6H[O\
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M:/$_B#Q4=9O=2GF36H]16>2'2Y[48\N.*ZE23>C=+<$#+D5]QK;@4W["A7!
M/X4=;E7TL9_@Z:^N?".EMJEK#8ZD]I"UW;12F6."8H-Z*Y + -D!L#.,UK4B
MKM7%+0(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MKN; &35^[T_KL'8[A6S2T*,"C-( HHHH **** "BBB@ HHHH **** "BBB@
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M)+JRNFU"+R;R&.,RR21ONVNBQJSE@2 H)Z5F:%^U;\-/%'AS4M8TWQ]X/O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5%!6;N[?=JT<^*KRI4W.,>9]C]DE^)6@L.-9TL_2Z0_UJ0?$+10/^0MIO/\
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ML]/UG4#X2\.Z[X366RT73)M<DEW-<N6?3)8K((\<92,A5CC!8@QKX/\ MO\
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M*H=0N_LBV_A#PK>^(;J$[&;?)%:QNZ1_+C>0!D@9R:],HH ^*?B3^W]\+OC
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M\6?AWXC^&\.G7&L:7X\\/KHUXJ7PG:W*1>:[X*P.<L%X*D9S7TY7PW^Q>/\
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MA)+K]J)TU9)9@IL;?]XFVZFSMC;YL,1\IZ5ZLAW(/I0 ZBBB@ HHHH ****
M"HY)UAQG^+IQUI[-M%?&GCGQ1XA^.G_!9?PCX7TO4M2M?!WP3\&W'B/7HK6Y
M>*"]U/5&DM;.WG"D"0);QS3!&! 9XVZC@ ^S**** "BBB@#R7XK^+ET?]H;X
M8Z5_PG$F@R:P=3*>'5TY9_\ A*/+A1CF<@F'R,[^"-V[':O6J\O^)OBV;1OC
MA\.]+7Q=X8T:'6&U /HM]!OU'7S'$C#[(WF+L\HG=)\KY5A]W&:]0H ****
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M=*DUM FJ3:9M3R3<K@,&W^:!O <J%SG@U]SO"LGWE!XQ1' D7W5Q0 ^BBB@
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ML[XWDJ50 <U^?_\ P4&\8W^B?&_]GWP7K>@C2]:MO'&GW4LHOEN!)%YUNNP
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MVS_@N7\<B1QOT/I_V =.I[F?0^@?^"$?[07]J?#*V\)SW86ZT"]E>WCZ&5)
M'49_WMU?H'\2?%UGH/A6YU/49+B*4?/,I<_-R.%QSG.:^$_^",GP5NKKPIX)
M;3K?2H8XKXWNHW'EEKN9)(\;>F,9 [\8]:_0?]K'X164?PVU"ZOIS"N_;"J*
M9,'&[! YYYKTL?A:5'D=*HI<T;OR?8Y\+4G4YO:1Y;.R\UW^9^?WQ:^-'_")
M_%*/5_"DTK:A+"YEBE?"J$3"/@D ;<\*./:J_P#P1]U)M8_X(_?\%%KJ5V>2
M?PW%([,<DDVNHD\UY]^WA&_@SP6-;\J33;@V;K"K)L=E((R:Z_\ X(GN9/\
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M#P1*+^/4)9X]"O)9KG1Q;Q6,T9F!+ HPO'AW$)F2 X')"_>B,4B# ]1DDU\
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M>';#P9^RSX$TG2_#.J>"]-T_2(8+;0M1O%O+O2HP,+#+,KN'91U8.V?6O4:
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M]N>HU^6OQY^)FK_$7XA7UYJ[N9FD*^6W_+(;B=H';K7ZC_\ !% 9_P""*O\
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MZ_"K_DF'AO\ [!=K_P"BEKPK_@LG_P HGOVCO^R<ZY_Z12U[K\*O^28>&_\
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MKM>N_#<-K:^/O">BWUWX;U+P?J\^G^#;CRM2TV]=))9,3:E)*+[S!(QN9)9
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MH-0O-:^,^F7_ (7T2*U52(Y&@_>3RDD8C3>F<9)+K@=QZM_P1$_;8\)_MO\
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M=/O+O3VWVL\]NKRVS>J,1E3],5*/#5@MD;;[#:^0TOGF/RAL,F_?OQC&[?\
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M@W^EO+P5.6C(P>E?0G[47QGL_P!G[]G[QCXTO6*V_AG2KB_/^TR1DJH]26P
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MM#<IJUAX.M-)U"32[H+$+58();&2;RGQ,SNSR8(7[H.1]!?L0MXR?]EWP?\
M\)]=:E?>+/L;&_N+\P?:Y_WC[&F$ $2RF/9N5.%;(R<9J:;]QKS">LDSUS[@
MI@G(/S+CTK&\=-K!\,7W]@FQ&K>4PM3>%OLX?'!?;\Q4=<#KZCK7YUK^W/\
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M5YIWE_,*?*A'RS_P5J\,6?A#_@D+^T)I]C"EO9V/PTUF"WB7I%&MC*%4$\\
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MYSC*+(P)&3C/3/%>@V;QSJLD>QED <$?Q ],'O7X2_\ !P3_ ,$-?&'[7O\
MP4-TSX@:)\4/AYHUEX\MK32A8>+-<73Y]->!1&?LR-DSQ'(;;&-P=V&.03^S
MW[*GP;D_9Z_9U\"^!9M6N->E\'Z#9Z.^HSC#WC00K&9",G&[;G';B@#T>BHY
M6VFF22,BY_6@"=3D4UC@UG7FMPV3@230QYZ;W )_SFI;;5([V/=#)'(N<?(V
M14\R;L4X24>>VA>HIB'!I]42%%%% #&DV+ZUF:EXKT_2+B.&ZO+>"24XC625
M5:0^@!.35ZY? _.O@3XQ:!=7GQT\=S:3\*?#7QNANM3,=WJNK6V)M =88P;%
M&DC=943[P$)7!<AOFR3QXO$NC%.U[^OZ'K9/EJQM64'*UE?HOQ;2_P ]C[]@
MD$T6X=*_F1_X*W_&VS^ _P#P<G?$S6=2A6:P:]\-P3EAGRH_[,TAV;\ AK^B
MS]E."*U_9U\'Q6^I_P!L1QZ;$HNMCQ^80,$;7^==I!7:_P PVX8DYK^7+_@Y
M-N!'_P %U/C,,X99]!/7_J!Z;BNJ$N:*EW/-K4_9U94]^5M=MC]M+CQY9>,M
M>\/:UI5Q%<:1:P)(5!/Z9]QS7MNG?$"^\:^#[H6Z0_;%W&-)SE6QC:01S7PM
M^P5XF&J?!;1KI_-F,MBJRY!P<9 !S[XKZ.\):Y#!-Y)9XY7)0MN954>F:HS+
M7QK\7P> _P!CCQ]K6OW4?G6=G<O.JR_*3Y9.U1W%?E=_P1HU$:W_ ,$?/^"B
MUZ $%UH$4NT=LVNH'%?7'_!7WQ3-X0_9'\4VJL%COK*82#=C"[3C\Z^-_P#@
MB ^/^"+G_!0;'_0L0?\ I'J% 'U/_P &Y/Q[T8_L$WFCV-PEIJEA=RVMQ$H/
MSLV2I/U#"OU"\$^)\>%=+MY9;66Y8;IGC);>.I'^/X5^!W_!NQXACTW2?$5M
M+(T*2ZA'(QW<,N,'COVK]M/#5Y;Z9Y)@<%'^5VR=I4C^ ^N.M '7>(=0NO$'
MQ'BM_*BM]'5#Y<F01OR#C![G%?@E_P %BOB?I?B__@K_ /"_2+ ;[C0O$VFI
M<2 <9>\@PO3MM/YU^W_COQ:MQ"KJ(U,2$J\>1M"@X_'\*_G9_;6UQ_$7_!8K
MPI=, 7E\8:6"<\Y%[&/Z4 ?UOI]P?2EIL7^K7Z4Z@ HHHH 1VVK7S%_P4]\3
M_$CP_P#";P=_PJV.UG\3:AXUTFR>"]DFCL+FVDE998[IXHY'6W8<.0AX[5].
ML,K4!A67.12ZI@?)'[%/[,7Q%^"WQ/N+[6O@U^RM\/='N[)XY;_X;_:4U2X?
M*E8W#Z?;J8C@D_.<'&%/;ZY2 JG4=*?'&(XP!V%.)VBF);'B?QX_8>\*_'SQ
M^->U:[UZUDNK*VT[4[6RN8X[76;:WNUNX8;@-&S;1*ISY;(65V4D@XI/B=^Q
MU#\5?BWX;\9WWC7QM;W_ (2\YM+L87L7T^WEE+9G,$MJZM,L;>6LA^94'!R6
M9O;=PHWCU%&VB&?G)_P7?_9S\":7\*?A[X_C\%^%5\=S?%OP;;2^(_[(MQJ\
MT7]HPQ['N@GFE=BJN-V-J@8QQ7Z-I]VOAS_@OK\W[*'PX]_C#X-_].L=?<;-
MB@!:*CDEV G(P!FH5U&/9_K%- [-['E'[67A&[\7Z=X+6S\$^$/&C6/B[3+N
M6/Q!="!-)C2<%KZWRC;KF$#<B\9(P#7JMWJ<&FV33331QPQ(7=W8*J@#)))X
M P*^>?\ @H]\0?!GPX^&'A7Q'XXT#1]<T#P_XOTO4YI]1UQ-+30_*G##4%W,
M#<-#C>+= S2XVA6SBO@_X]?MV?$C_@K]\9]2^ /@?3M7^"/P6N-*^W>,_&^N
MJ++6[C2W8JL,,$A'V7[2%(03#S&C#L5"@A@1IZ'_ ,%*?!?QU_;9G^*_B;3O
M$7CO2? ]S=Z+\(/!GA#26UO5[A,^7?\ B2>",XBCEV)%;R2E0(V<KRV:\7_X
M*D?\%E]4_;*^(7AK]GOPM\"_C"/M6K12^*O"6J1VMAJOB10@GL['$$TSQ6SR
M*LMP3M;RD (4.6'U/)^TG^RG_P $:?V7K[PS\"G\%^+/B#+%'9:9X>T'4H]4
MU[Q5J/$47VF2$M(V&8%B<!%W!0 !7C7[!NF?#C_@E]KWB+QIXIO]9_:$_;"^
M*[O?Z]H'@RT76KS0I9G,LMHCQDQVL8=AYDLSKNV*%!  (!>_9=^&O[7'[*7P
MZ\=^/?%\/P(^"%]XJNCK'C/QMXTU236;IHXD\NW@M;2U:."&W@A CBB:;. /
MO$XJ_P#LY_L:?&__ (*_KK>K?M ?%3QE>?LY7S^7H'AZST^+PQ<^,U1AB^FA
MA4R06192T<<DC22#8QVC!/TE\.OV-OB)^V]\3="^)7[3FEZ+I>E^%[C[=X3^
M%EE="^T[2Y_X+[4I?N7=VH^ZH'E1$DC<>:^W+2UCM8%5%"[5"X X_*@#S/\
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M7?\ !O'HNM?#7P]>>(OVCOVQ-/\ $5WIEM-JEI#\31Y=M=-$IFC7_1V^57W
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MS,+QGZ]*_C4TB^DT_4(98&*RI(&4J<$'-?H!^SA_P4/\:Z=X/CTNW\4ZG:2
M#S(Q-O\ ,8=/E)]O2M*5*=2:ITU=LCF25V?JO^W#\4K3X2W]]J>GZA-;V#V$
M]Y?1S_=QM+ +^/&?>OP/^ ?B/_A)_P!OWP%J!ZWGC;3YR <X+7L9KUO]M[]L
M[QG\2K*YTS5=>U*ZN!^ZFB+[%V9Y!7K7S_\ L8R,?VP?A:<\_P#"6Z5DG_K[
MB%3.$H2<)*S0[IJZ/[IH^(Q]*=38O]6OTIU24%%%% #1,"*:9P*:BR%?F"J>
MG!IL*2$MN"CD@8.>* )ED#4C38J*XCE$1*!3)C@$X!-$$<AA'F !NX!SC\:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
6**** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>tm2223302d1_s4img006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2223302d1_s4img006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M&_?[&<C%1\ O!OHI\RZY/_?VF!Z0?^"M?[/B_P#-0/\ RAZE_P#(]'_#VO\
M9\'_ #4#_P H>I?_ "/7G!_X-^/V-B!M^ '@XGN&DN@?P_?4G_$/U^QJ'P?@
M#X.]AYEU_P#':%J[ >D_\/:?V??^B@?^4/4O_D>D;_@K5^SZ/^9__P#*'J7_
M ,CUYU)_P;[?L:*/^2!>#<8_YZW7'_D6G)_P;Z_L9.__ "0'P;G.#^\NNO\
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M?_1 ?!O_ '\NO_CM '??\/;/V?/^B@?^4/4O_D>C_A[9^SY_T4#_ ,H>I?\
MR/7 _P#$/;^QG_T0'P;_ -_+K_X[1_Q#V_L9_P#1 ?!O_?RZ_P#CM '??\/;
M/V?/^B@?^4/4O_D>C_A[9^SY_P!% _\ *'J7_P CUP/_ !#V_L9_]$!\&_\
M?RZ_^.T?\0]O[&?_ $0'P;_W\NO_ ([0!WW_  ]L_9\_Z*!_Y0]2_P#D>C_A
M[9^SY_T4#_RAZE_\CUP/_$/;^QG_ -$!\&_]_+K_ ..T?\0]O[&?_1 ?!O\
MW\NO_CM '??\/;/V?/\ HH'_ )0]2_\ D>C_ (>V?L^?]% _\H>I?_(]<#_Q
M#V_L9_\ 1 ?!O_?RZ_\ CM'_ !#V_L9_]$!\&_\ ?RZ_^.T =]_P]L_9\_Z*
M!_Y0]2_^1Z/^'MG[/G_10/\ RAZE_P#(]<#_ ,0]O[&?_1 ?!O\ W\NO_CM'
M_$/;^QG_ -$!\&_]_+K_ ..T =]_P]L_9\_Z*!_Y0]2_^1Z/^'MG[/G_ $4#
M_P H>I?_ "/7 _\ $/;^QG_T0'P;_P!_+K_X[1_Q#V_L9_\ 1 ?!O_?RZ_\
MCM '??\ #VS]GS_HH'_E#U+_ .1Z/^'MG[/G_10/_*'J7_R/7 _\0]O[&?\
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M.T?\0]O[&?\ T0'P;_W\NO\ X[0!WW_#VS]GS_HH'_E#U+_Y'H_X>V?L^?\
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M]+Z_-#_@BU_RE2_X**?]CYHW_HK4*_2^@#FOC+_R2+Q5_P!@>[_]$O7XJ?\
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MGB'PS<S7%@UMI<6^2)HVW"QME^ZP!ZJ>U?=FW:ZT-*Y)'J*[XU'O7Y[>./\
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M1P-_7'X4QI0I^^OXBDV!)N;_ &:<IR*@$P)^^M31GY>H/TH3 =1113 ****
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M_P 0:6UC8A<#IDG@T ?;'[?&O0> OV2?$EX_C;6/A_%9P(/[:TNVGN+BQP5
M*I"CR'/3Y5/4UZU\.+X:CX2L9ENI;[?#D3RHRO*,]2& (/U':O)OVS]5E?\
M9(U2Z7Q)X3\)RR6D4C:CXDT^&[TZWSM):2*:2-"#Z%AR:]?\"-YOANT?[3:W
MFZ/F>W0+%+[J 2,?CVH W**** "BBB@ HHHH ***:-V_VI-@.HI-W-,CE+GM
M0V!)1113 **** "BBB@"&4Y>H9954$]6'(J2>3/'ZUY[^T1\48O@Y\(O$'B"
M9U7^R[1YPI<*6*J3@>_%9RDHJ[-:5)U)**ZG;Q2QSE=DB>7'_"&SG_.:NVW"
M]L9[5X[^QSHVL:5\#=+N-?O+J\U>^\RYN#<2,S)ND;:,L2<;=O%>K1WGD^B_
M-S@=*=.7-'F6P5:;A-P[&ECFBL_^TU68+YD9;)P-W)JTLIE&*KT,Y1:5V345
M'$<9'7%24Q!1110 4444 %%%% !1110 4444 %%%% !03BBHKEBJG'7% $H&
M*"<57@N&*?-UZ\4R:\\J10W1J +6X4M4WNR .5#9P5ZFK:MF@!&DVG_ZU.#9
M%>;?M)_%/Q+\)?"$&H>%_!<WCC4)+A86L8[XV91#G+[Q%)T_W>_6O$4_;H^-
M"/S^SAJ>S.W/_"1M_P#(5 'U491&2Q"KV=L4WST7!_)CU_*OG7X6?M8_%+Q[
M\1-,T;6_@9>>&M)O'<7&J-KIG2VQ&S E/LJ9R0%^\/O55_;B^(NK?L\^*O!?
MQ$;6KZS\(Z1-/%X@LS,RVLD4P2*-G^;;\C,6&5/3C%3U'RL^D4<2$\*$'.1T
M;ZBD68&3Y /+SQGG!^G;ZU^6^H_\%A/$WPI^(>J,/#/BKQ5;^*;BXU'1UCCN
M+B)M/C<O 8%$;*/.BEC.Y/1>O%:VF?\ !2SXG>$O'OQ"\3'PU+J7@R37-$T[
M[#J.KM:7&C_:-+CFD"(\9(R4=MH5<EA2L[7*4+GZ:QRH=PQL7.X\'YO6@2*Z
M/NXZ$_Q''M7YW_#+_@JCX@U+1UM/#^@6MQ/:K>ZG>2>(?%*VZ2PI.?W44\T6
M#PX'RYVXQCBO+O!?_!:/Q9\,]4U+09/#^N^,-3:X%V)H))KZ-(S@>3&PC<=\
MY!]>*?+W(6NQ^M$2JB\\'N%'%2Q*"?I7+_"+QT_Q,^'.E:])I]UI4FIVZSFT
MN%82P9_A;(!S^ KJ(*?*@)****8!1110 4444 %%%!;% !12!@>]+0 4444
M?FA_P1:_Y2I?\%%/^Q\T;_T5J%?I?7YH?\$6O^4J7_!13_L?-&_]%:A7Z7T
M<W\8SCX1^*O^P/=_^B7K\4O^#:;'_#UC]L/V\0:Y_P"GA/\ &OVL^,O_ "2+
MQ5_V![O_ -$O7XH_\&U84_\ !5G]L+/_ $']=[]?^)NE'2P'[8>.IOL_@S53
M]G-XR6,I$"]9_D/R=^O3H>M?EG\)HH/"7Q8\%ZQHNHZU!KU]\0GM=3\*1R2[
MK:"345'FLOW515W9^0 @]>*_47X@Z!?>)_#-U9Z??R:3?R)_H]U''O\ +8<K
MD9&1D#@GFOE.P_9O^+H\>NX\0?#JSNO-'VC7(?#5D-4EB+=P '5L?Q>9G/-3
M#2JF6U='V%I[9MP2""0"<_2I)Y1;63R-]U5+'Z#D_I65X!T2XT+PQ:V5[?/J
M=S"F)KITVF9B2<D9..OK6M)&&5D*Y7!!![TY.R9"W/'/@-\?/AY^TQK?BFR\
M.V-O</X;U$VVH/<Z>8O-GC8'=EU&[!P0P)YZ'BLGX7_M&?"SQ?\ M/>*/ _A
MNQTP^,-%CCFUBYM=/"%F;S,*TX3YV!27(+'&>V><7X6_LV^)O@_XQ^)M[IVG
M:4;7QKJ;R6D,5W]C\F"1]KOE4.'5"6 '=0,C.:\B^%O_  27U;X0?M(^*O$V
M@>.]3L=(\21.\MP1(]YY[^8S;F,NX@-(<9-12E>R*EU/1_@'M?\ X*D?'+:N
M#]BTDY!Z_P#$OM*^M)#N9:^'/V&OAQJ'PJ_X**_'#3=0\07WB6X%KI;B[ND9
M9,?8;8X.68_Q8Z]J^X?XU_"JC\5B2*[;'S=@.?>O#_V/HM26X^(!U#P=HWA5
M?^$DD$#:=>6\YU%/L]L1/(854AR<KA\MA%R<8KW'41RA]_7%?/?[$&D#1KKX
MBHOA;Q?X9\[Q)+-G6[JYFCU#,%J//@,P 6,[2H"?+F-CG).&F!]%PON1?I3Z
M9%+YB@^HSQ3Z8!1110 COL7-1.WGC (]_:I).1[]N*@R OS?*3P<=Z /%_V_
M/BO_ ,*9_90\9ZDC9O[W39]*TN-6YDO;F)HK=1[F1EP*_'']IKPCJOB'X]_L
MV_"?3/WD?AC6["XU>,'<?[1U9HKWS",Y;RFDE4XS@MC*]*^H_P!N#]I36?C)
M_P %-8?A\FJS?\*[^$ND0^-_$-H(Q)%-);AKJ#+9Q]ZSDZ^IKP_]@NP;]IG_
M (+":#<WD5T)_#]G?>)Y'W,T3H;JTFLMW096!P%ST&<<4 ?JQ^UUIU]:?LK:
MG;67AC2?&-Y%;11KIFIW<%M!<$*N=SS@QCZ,#7K'@5I&\-6?F6L5B_E9:WB8
M,D1ST!'!'TKR;]OC2EU?]ESQ);OX9\2>+U*(/[+T"XN+>_NSD?ZMX 9%Q_LC
MM7J_P\_Y%6R_<W5M^[XBN=WFIST;=SF@#>HHHH **** "FLX0<TZH9E^3.>G
M./6ID^@$@D!7-1?:MQQQ55KG[(GF$@!?O@]C67X5\=:5XXLY+O2-1L]2@$KV
M[R6TRS*LB,49<J2,JRD$>HI--*X&Z&W-U[TYW C)R,_6J,KMC#?CCJ3["FRW
M"QRC+#<S<+Z\9Q[THQ5]1V9I+)A*;%<^8^.*J12[ASW.<9[_ -:D8LOR[N6/
M!$>0M:"+2R[FQD4^JL<GS[MR[6XX'.?\@U91=BXH 6BBB@"M<@R.?[H&2:^9
M/VUS_P +(\>^"/ 5M*)3?ZI%J.I1*=VZS3Y)%9?0^8O7\J^E-1N#;B1ONC;G
M)]J^8?V9;8_&O]ICQE\0I"TFFV+_ -CZ,77C:H5+@@].)H".]<^(N[174]++
MX\KE6>T5^9]%6&F+HNDQ1CY(85 Z8  XKY^\<?M9:U\3]8O-%^%>@W.N7-O,
MUM<:J[>5:64HP6Y==DF%]&[BNU_;0^,=W\)?@G?76GE3K%QB"RBZM)(3R .2
M?E#'&.U:'[*7P53X#_!G3]#7YIXAON9BOSW$FT+O;.220H')I22;]G%[&]-1
MA1^LU%>3=DOS9S/[-/[/'B+P+XEN_$GBSQ/=ZYX@U0AY44O%:Q [R0D6]D'+
M'D =!7NJ.[;<9^M1%.!RA.>@;!![U:B;RL_IS6\(\NQY6(K.K)2>@ZU8[CG[
MU6JAMW#DX&&SS4U49A1110 4444 %%%% !1110 4444 !;%%-F&8Z$_U?X4
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MT.>M7*"<"J)*2KN+;FSCVQ_^NN>^)?PST?XO>#KK0O$.G0ZAI-X );>9 RR
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M49% %D[0?O?K090HZBJD<GF2J0<_A31(WEJW!Q][(Q0!?#@]Z6JMA(K[MO\
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M$1?=C@#/<BO@SX@^+/B!_P %*_VD--\/6=NG@CP9\-[RTUO4'N63S;B5MLL
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M/%_[*NO_  [/AG1[;7K'6=0FAUBW,3-<);(8MTD>&'**SL?E;(7&.:^HWL
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M\57'B.?Q.NE1HGVC_A'Q$;_[PQL$A"^G4U[5\,[F*[\%Z=)#]J\IX<H+@#S
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M4*RKAA';031376[/8P)*.G?M7SI^QE_P5"\;>#/@1;>$M0^#OQ$US7_!C?\
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MS8S&D.5P,Q@_=SECZUY52>C4?O/:P>7<\?:U5Z+_ #\CLO#_ ,)=3^)6L_\
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M[J?\2Z";:/XKEVZN: /HBBBB@!B'$C4^HB?WK5+0!^:'_!%K_E*E_P %%/\
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M:_8<^.OAG]H7_@HE\<=>\(:D^IZ6;;2HA+)9SVI#"QMA@),B-U4\XQ7W(D@
M^M3UN-;$>H$+%R=HYR?PKY^_8D\3-XBU'XB[?B!I'CJ&T\3S6J)86D,']B 6
MUL?L;^7#'O=<[RS;SB5?F(  ]^U"?]T-O)SP*\4_9%N?$%SJ7CDZ\W@Z1?\
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M5:[@]-SV6;_@G+\/-0_:0D^*&IMXBUS7S-/<6UMJFJS7FGV,LUM):2-%#(Q
M'D33HL9)C03R;$7<:]9U7X7:+KC7+76FZ?-+=2Q3RS&V42M+$<Q2;QA@\?\
M X.Y2,@@UL)'^\V[1\O(/;'M4R?ZS!I7UL!X-^S9_P $X_A_^R[\1]0\7:'<
M>*-6\2W]@^EC4==U:749X+626.66-6?EFD>&%GED+RN84+.<<^G^-O@3X/\
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M*'UCQ+?RJ?O16X: #_OEZY_Q1^PQX?\ $&MG44USQE;W++_RQURY2/J>2@<
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MN/\ B9V;31(UR>!]V-W?JOW.AZ4<\GT97U>A#X)Q_$^C_ OP<T_PXOVJ\?\
MM+4)"3)<W.2>^ %)P!SV Z#TKL(<1*%P$)/\/0"OC+Q_=?'3X=?#KQCK5Q?W
MI;P] MQIL2)"QU,;96<=.HV)Z??_ "9;1_M#ZQ>0/;_;GT^ZO=(CCN#Y'-I=
M69FNY\=?]'FVQ]._1NM7&HU]EF$L+";O*JOQ/M974+C.?QJ1'4+Q_.OC?5O"
M_P"T#:ZWKT%G=W5Q:66J)9Z=*?)S?6QMTD:YZ=I6:/H#\OW>]1W^B_M#6O@S
M7;R":ZN-5L/$":?8VH,'^G:>7MU-V.G19)C@D?ZD?+S@OVTE]EF4L#1_Y^+\
M3[,,B]\?3-(70CV_&OB7PSK7QR\:^$];O=-U*^EO='\>W'A06S")3)I\-X('
MO_N]!%F7KV^YVJWI6E_M&7MSIHN?MT$=QKQTZY8&W)@L1,Z"[X]8PKX_VONC
MI1[>25^5DQP-+_GXOQ/M!953I2F8,.OZ_2OBO7?#G[1D'C.\M;6ZOGTN+7M,
ML(;H?9\R6,\CB[N^@_U"JK=.=W"MT&)\3M6^/'PU\<1V$^KZA)I%[XNT[P_I
M^HJD+_:+6>PDN)KD_+D>5-&8N5'/\)X:FJTFK\K#^SJ/_/Q?B?=WG*.Y_ TH
MG7'6OC"V\(?M%'PI'=R:G?-J1OS;FT M]OD; ?.^[ZY&,]NE3:!H7[06H^.K
M*QO[J^LM)FUS4;">_7R,164,"O:W7?\ UTI9.G&WHN<TO;2;MRLI9?26U1?B
M?97VE<8IGF+BOC'1M'_:$O?%FF65S-?6VGW.LZE97EV?(S:V=O/&EI<8YYGC
M9WQ@XV=%Z&KX*\0?&_QA?V2VMS>26G]O?V7J$K)&K6UKNE!N>1SC8O\ WWTH
M]K+LP^HP_P"?B/MKS%VTJRJJX'\Z^/\ 0[+X_:CX0\#7UVEW9ZAKU_/!XALS
MY).AP*EP8Y1U!W-'".K?ZWH,<'@*P^/^NP:#)K/VK2?[0TUKG4$!@)T^Y"2-
MY)^]G+*@XS][KZ/VO]UA]3A_.CZ_\U/4_A1YJ[?O-^=?$$WC;XV:/\7/AOX7
MU:2ZL_\ A.;K4X;V=4B(TQ+6V$T3D\X\QCMZ-^&*V+2#]H237DM98KB.T_M#
M6+<W*^3M\BVB5K&;KG_27++TXQT3K3]H_P"5D_4J?\Z/L7]V?[WYT[[2J# W
M&ODLZ+\=OL'AZ1KBY634$D.I)^Y_XEY!78.G.06]?N]JJ:-9?'R]TCP;<737
M<%SK.J26FN0*(2=(M@\ZK<#UW+'">K?ZWH.T^VE_*Q_4H?\ /Q'UWYH_VORI
MWG^GYDU\._ 7Q/\ '?XYZ!X;UF>2^T;2];\//JDLI6$?9[X3S1BTP<G[D:/T
M/W_O=JT=#TO]HR_\.Z?<7AOK:\N=(DNY[<&#%O=K"SK;D\]7 7.3][[U'MG>
MW*Q_4:36M1?B?::39Z]<TLT@Z>W8U\5^*-%_:)T;P]H4]C)>WUWJ/A6]U2^M
MU$'^@:K%;1206'88EF>2/J?N??'4U?$6K?&W2OB3H?AF/4[Z:_U;PC<>()%1
M(?W-Y#-;1"TR5QSYSG_MGPWJ_:/K$/[/I?\ /V/X_P"1]N!P,^GUH\_:>-OX
MFOCW2O"WQ^O]=GMKJ_NK:WCT7[8DX$.#>^=L^R]#_P L_GZ8_P!KM3?@WH'[
M0'C+6M#B\27EYX;M]0\/R7^H3GR#_9^H+<B-;3@,<F+=)G!''WNU5&5W<FI@
M:4-?:)_>?8Z-N/2IW%<O\.M.U72/"6GP:S=K?ZE%$%N;A1A)7[D<#^0KJJU/
M.>C"BBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 ?FA_P1:_Y2I?\ !13_ +'S1O\ T5J%?I?7YH?\$6O^4J7_  44_P"Q\T;_
M -%:A7Z7T <U\9?^21>*O^P/=_\ HEZ_%C_@V=_Y2O?MB?\ 8?US_P!.Z5^T
M_P 9?^21>*O^P/=_^B7K\6/^#9W_ )2O?MB?]A_7/_3NE '[F4444 03QL%^
M7DXZ4P!@,%>Y.<U:HI-75@*/V%D.["EB<@XZ4?9V0>W/!]^YJ]13ZW J,C%O
MF4;E_B]:22W9CQD CH#P*N44 <M\2/$__""^#+_5)D:6*QC,NT?>8#' QSG_
M  KY(_86_:Z^)WQ(^+ND:%X^N?#5[;^+/"L7BC3SI5E/;FR62XG@\J0O*X8_
MZ.QX ^^/0U]F^)],BUG3&MYHXY8Y059'4$-[<\5\W_L>_P#!-_1/V2?',NN6
M_C#QMXMG&G+I-DOB#4$NDTZU5VD6.$")-B[WD.!QESQS1'=B>I])I RQX"*%
MSD__ %JA:V8N.2,="QR2?3Z>U:*GY%.,;144P7;EL=<CV-9+0OF/@_XP_MZ?
M%+P+K_Q0T@Z3X<TF^T6]MK30%GA><#S+6.;S)RD^&R2> 4P& [9KVS]A#XS^
M,/BCH7C'2?'$^D7GB/P/X@?1)[W38)8;:Y MK>?<$D=V'^OQ][L*/CM_P3\\
M,_'9/'4EYJ_B'3[OQND?F7%A-%'<:>8X4@5K>0Q,8V*H.>>IKIOV1?V3+']D
M7P)J&CVGB#Q%XHN-8O6U&_U37[Q;N[O)C'''N>0(FX[8D&2,\=:T6BL2>L!%
M6+IPYSC'3-?-_P"VU\0_B;\.%LM4\&ZEX3T_3;$L[V>I6DUQ=:Y+\C):PB*9
M-C,0R;F7:#(N3Q7TC_JT.1P?NCTKYE_:P_X)TP_M4_%WPSXKE^)OQ1\)S>&6
M,L%AH6N"UL96)A8N\?E.2X,2X(8?>:E)7-#PKX>?\%!/B]XY^(?AS7;J#PQI
M_@V[UNR\.WFC/9S_ -H+/-<+ TBR>?LV@MD H3@&OT(@&^&(DGE>_4'Z^E?)
MNB?\$F?#VC_';2?&K>/?B%=1:7+#=MHL^J1MI=Y<1.)%GD@\GYI=XW%LYSSQ
M7UH#^ZPW*@=<<#/J/2J=FK,RBW?4H>*IKF'0[AK58?M04&+[1_J@V1C/(X_&
MOSB_X>&_&VW^(UU\,#J7@F3QAJ5Y(MAJ\NBWL-I!Y4?G/&(WG#RC9%)B1&V9
M<#.5(K]'/$GA5/%'A^XT^::YBCNE\KS(I-K@=<@^O:OCW4?^",7A_6M!F75/
MBA\6M0\2QGR]-\1W6N1RZKI$.<F&WN# 7A4YE&%P,3..]3%V=[&FZ/<_V(OC
M'KGQC^#\ESXH^PG7]'U&?2+N:TC>."XDAVJ7169B 3DX+$UZ^J>3ELC.3C^M
M>>_LS_L\V/[,WPGL?"]CJ6K:S]F)EFO]4E26\OI2JAII9%10\C;<EB,DDYZU
MZ+Q*FW@,!D;?X,]\T2U=R(NS/B3]OW_@JG'^S/\ M!>"_A[H,>FRWMUK4$?B
M.:_CE"V5F]O)(1'R@:0DPG(+@ M\N>17_9N_;1^*?C']H7PC%XBG\+W7A'XB
MS3PV%K964\5WIQCMI9@7D:9D;/DD<*/O5[O^T5^P7\-/VF]=TC5?$7AC0I]8
MTC4XM5^W)IEL]S=&.&2$1RO)$S-'AQ\N0<HISQ7&? K_ ()FZ#\"OC__ ,)S
M;^,/&VL):EC8Z'J-[%+IFE%D*$P0B%?*.UCG8W.:<8JUV4V^A]/LA9ON[E_N
MUP/[37C_ %3X7? GQ%K6B6:W^KV-J?L<# D33,0J X(XW,.X[\CK7I,<!\L?
M-VKD_B_\.X?BCX%U+0+C4=3TE-0CV"[T^7RKJ @@AHWP=I! YQ4M); F?GCX
M$_;X^.OBKPMI'A.]?PEX=^)U_8RZO>V]UI]S+!811QI*J82XP=^6 Q(<;>>H
MK[=_9!^,>H_''X#Z3KVJ0VR:E,9K6[^SJ5B>6&9X6=02Q"DH2,GH:\(\0?\
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M:\4_!'X$:OXC\(Z5::GJEB(W NV'E0H98U8D;T)^1F. >H%=W\(_AAIOP=\
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MM\B2Y\C>\/?8>.37U5\(/A;9_!7X;Z-X7TMI)+'1+1+2$R;=[(BA=S[552Q
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M9F7<4#H3@XX#"O?Y69)FRN0.AKR7]J_]E^U_:@\,:19R:O=:#<Z#JD.L65Y
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\%U=&T"S^),G_"O_ !),/AW<M:S;%?\ TAAYW*#ROF_U)^[GJ*^VOBEXKN?
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M)>'[N_>UNK[[&F_R;>)GE<^BJH))^@- &Z+A6I'N@G6OST?_ (+\:3'_ ,T
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MXJ_[ ]W_ .B7K\4O^#:@X_X*M?MA>O\ PD&N?^G=*_:SXQG/P@\5?]@>[_\
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MY9+=>NIX/J7_  30^%>I?#\:"^@!@MZ-1%XPB-V;@(8Q(7V?>V$KG'2J+_\
M!+;X4C0H-*CT>XBTF*?[5+81O$+:[E^7YI4V88_(G_?*^E>D6_[8'PSN_ ?A
MWQ-;>,M'O-!\6Z=/JVBWMLS3QZG:P6[7,TD6P$MLA5F( R-I&,\51\;?MQ?"
M7X=:)!J6K>.]%AL+G0X/$L4\3/<(^FSS16\%T#&K?NY9IHTC/\;,0N<' <IP
MNG?\$J_@[8>(I-03PO!&99Y+G[*D<(M89)#F0HFS(W< \\@#TK8\&?\ !.?X
M6^ ;^*YT_P .PK-;ZG'JT+,D1\J>-V9"OR<!=QQZ5>LO^"C/P1O_  -JGB1?
MB/X?32M%NK>PO3*9(KB"XN,_9XO(91,7EPVQ0A+['VYVMBQJW_!0'X*Z'>^$
MK>Z^)7A6.3QU##<:&?M>Y;Z.:801/N&0BO-^Z4N5S("@^8$!*Z?-U R?%7_!
M.3X5^.;C5)M3\+V-Q+K$)M[IS%&6EC+*Q!)3/51^5=5^S]^R5X1_9NANO^$=
MT]H[B_E::XNI]C7#E@@(WJH./D'Y"IO!/[8'PQ^(?QDU7X>Z'XVT/4O&6B^=
M]LTJ&?=-$8619U'&UFB:2-9%4DQEU#!2<5Z6K;ER*:T5D#U=RI;0-!*/NA3D
MG'5C[U<I"N32T 9NN:A#I5C<7-S-'#;0H7E>5L)$H&22>W'->1O^WG\(+/5'
MLYOB!X57R7VO.=2@$,;#@@MOX/\ ]>NP_:&"W/PQUB(Z--XA7[.XET^%V22X
M0H<JI5E.2,C[PZU\$:I^TS>?$OXW:9X)^'?@&R;1TV0WEA<V41>(X02?:),N
MZ@,6P48G')YX"4ES<I7+[O,?H[H^N6OB#1XKZUN$O+69=\<\#!XW'JI'!K2M
M8]ENH.,]R.YKF?A]X7L_ WA.STZPMOL-O;C(@$C.%)R2 6)/4GO736P\M O8
M<"F3;J22?=/7\.M?)O\ P5Q^ &B_%3]C#XC:UJL^I1W>@^$]3:V6WN%2-_W)
M/S@J2>@Z$5]:5X9_P4N@7_AWU\:#MY/@[4L_^ [T :'_  3]@^R_L4_"J$<K
M'X3TL*?4?8XJ]CKR+]@F,1_L8?"W _YE73!_Y*15Z[0 4'I10>E 'S__ ,%4
M/^49/[0?_9-O$/\ Z:[BODG_ (-0/^44/AK_ +"&I?\ ISO*^MO^"J'_ "C)
M_:#_ .R;>(?_ $UW%?)/_!J!_P HH?#7_80U+_TYWE 'Z9_\M/\ /M3Z9_RT
M_P ^U/I<J AD^Y4<S8@DS_=/6IIONGZBJFH_\>K>HIQ[!:[2/Q\\3X'_  <W
MM_V![/\ ]%VU?L'#_JESZ=Z_'GQ(1_Q$VR%>G]D6?7MF.VQ7[#1YQEF'3C%?
M29]:U!_W$9T];V(YP1;E3WKXH^)G_!(_2O%WQ>\1>+M)\4_$+0;SQ)>/=7BZ
M7KJVT4K,[,?E$1/&[C)K[9G.!G=WYS46Q 6.1ZG![=J^3J48S^(]C+<SK8-N
M=%V;/AVW_P""2%UM8_\ "T/C N22!_PE0Y';_EC3?^'1]T6_Y*A\8?\ PJ__
M +37W;' LD0]#S2F-$'3 '-<\L'1EIU/3_UHQC?,V?"7_#I&ZVG_ (NA\9?P
M\5C_ .,U\H?M)^!/%_['7[:OPKT/1_B+\1+ZSUNY\^YAU/6S<A@/.&.%7^Z*
M_9ASM8?-M&><5^57_!7619/^"B/P5VJRX)XQ_M3UPYAAU2IQ=-:W7YGU/">;
M8C'XB>'K*\7&3^Y,_4O2G\^QC;GYL8)^E:R?,OX5BZ)(CZ=&HSMV @UHBX9%
M&Q]YQC&.OO7MQ/S6O']X[#[IF5W/ &WK6!X[U._TSPA?76F1F[OHHBT"!"^Y
MO3 Y/X5MO)YJ98]3G [&FB/<OOFJEL33DDU<_,%?VS?VTY3\WP\M5YX_XIV]
M&!_WW7VQ_P $_/B-\2/B;\#Y-0^*6DIHWB4:C-&MNMI):@PA4*-LD);DEN?:
MO:AIL8'^K7I4ME;+:Q;57;STK"G0<)7;N>SC\VI8B@J$*,8M?:6[/!?^"HOC
M?Q)\-?V!/BMKWA/6;OP]XBTS0)9=.U&U8+-9S[E"R+D$9&>X/T-?/OP _:4\
M;_M3_$__ (5YXG\6:OX3\8:-\,K_ $WQI::7/]@DT/Q-;7]K$]Y$?G"JT<BS
MPN=T<D%Q&Q4JVVOMWXN?";P_\=/AQJ_A'Q5I_P#:OAW7H#:W]IY\D'GQD@[=
M\;*Z\@<JP->=_%;_ ()]?"+XU>-_$_B37_";/KOC30HO#&NWUAJU]IDVK:;'
M-YRVLS6TT>]"WRMGEXR8V+1G970>$?GKX'_;L^*'[0?[(?B3XE>)?'FO:0-)
M\8^!_A]/:^"HY7O&BDU/35U;4[6UMTFFF:_6Z8VCQAS+;>28H5,A\SM+WXS?
M$30?%$4-SXT_:"T7]GR\\7VL$OBC7?#M]8>)K=1HUY)+"%N+%;V*R>_2S42R
M6XR[.BR!&4'[D\0_L-_"OQ-XUM_$%SX1MX=3@BTB%397ES90%=)O4OM-#00R
M)$WV:XC4QED)"EH_]6[(=GX\?LQ>#?VE-#TW3_%NG:A<+HM^-3TZZT[6+W2+
M_3[GRY(C)#=6<L4\1:*66-MD@#)(RL""10!^;WPY_:^^+'Q@^%>I?$A?B5XQ
ML9OA7;^$;>WTQX+>R@\1&YUN>VOYM0MF@#227%JD:@*8@CAMB1-FO:OV,?C)
MX\U/X\_"G6];\=>+-?T_XVZ%XMU*_P!$U!X&LM'EL=0LC9?9(DC5H!';S2Q.
M"[[B4+;FR]?06H_\$UO@K?\ B3POJG_"&&UD\'VFG6&GVMEK-_9V$D.GRM-8
MK=6D4ZV]Y]GE9I(S<QRE')8$'FMGX2?L,?"_X&?%#4O&7A?P[=V&O:DMY&6D
MUF_NK6Q2[N%N;I+2UFF>WLUFG1))%MHXP[(I(.!0!Z_44V":EJ.2'?V_6@#C
M?CE+L^#?BS<6V_V->9 _ZX/7PK_P;%R+_P .O]-^;<JZ_=AB#U)@MA7Z*7>F
MPW\#1S1B2-U*LK'A@>""*S_"G@#1_ VD?8-%TVUTRSR6$%L@C0$X!.!]!^5*
M2NRKZ%K8VT9(RI^7';UKP;_@HRXA_9NE978JVL61W#U\WI7T(MFJ]%[8ZU3U
M/PU9ZQ9^1<VL-Q%E6V2C<N5Z'!]*7*',>9Q?L]>"_B_X6\':KXD\-Z/JVI:)
M:VT]C=W%LDDELP13\C,"17JMA J6L:H-JJ, =.*+>Q6&%(PH54  4#@ <8JP
MD83[O\Z:NE8D<HP****8!1110!^:'_!%K_E*E_P44_['S1O_ $5J%?I?7YH?
M\$6O^4J7_!13_L?-&_\ 16H5^E] ',_&48^$'BO_ + ]Y_Z(>OQ7_P"#:'G_
M (*L?MA?]C!KG_IW2OVI^,O_ "2+Q5_V![O_ -$O7XK_ /!M"=O_  5;_;#_
M .Q@US_T[I0!^T7Q6T>+Q!\.M>L+B?[%#>Z9<P2W60/(5HV4OSG[H.>1VK\H
MOV._V5M,T']M+]SX[\/7NGV^NVMY;"PT^^6[NY;6<LH>5X_*.YCAB, DY! K
M]5/CK9O?_!SQ5#''%,TVBWB+'*!Y<A,+ !L\8/>ORU_X)J_'/0=*^->E>$;C
MQ))#K4.L36PTN.?,"D7(78BC(QD@<$XXJ8M^U1525J39^N%B%\L '/&14_);
MWJMI[@A>?FZ'Z5:WCSNO>B78DF#9J.0YQ]:9YX4_?7\<T%MW?/(J@/E+X%K_
M ,;3?CG_ ->>E?\ I!:5]:5\F? DY_X*G?'/'7['I?\ Z;[2OK.@!&<*.:C%
MP@;[W8'^E)=G$74C/!(ZU41U(V_*1C!&.&^E %\N!2>:I;&>>M5([A/N%E)Q
MCV-264&QMP4+GJ!0!:HH'2B@!KOL7)IHN%)Z]LT3'*<<^V<55D=8ADG\",XS
MV% %R.02#BB7)3BF6SYC'^&*D+@4I; 5&RK\]>E0WEON3I@^_>K<L>\Y!^M0
MRHV1C\/2E$#\4O\ @M/_ ,$O/&?A3XO^(?C1X=_XGV@ZM,9]1M P:XL2TI)*
MCY?D'F$\;B-IKX\_9F^"GQ(^+?QB\)3?#_0=1N+JUUBWD2]7;'';M',NYBSD
M#Y2.<>E?TH^/&M8?!.J-?&)+>.SE$KRL!'L"$MNSQ@#.>V,U\K?\$G_CKX"\
M0?"[6O"^DZ]HL^NVOB?6Y391SIYHA;4)RC(N<E=NWIQC%?I65\8XJGE<J7LN
M9QLK]D^YPU,#2E64V]3ZR\ V%SI_A#2XKS_CZ2TB$YSU?8-W3WK<<@+S]:K6
MKC!QD#C&:L%O,2OS6<G*3DSNY4MB.:XVGY1QZUQWQJ^'P^*WPLUO0?,: ZK:
M26OF _<WJ5SSGIFNR<8'%1^6)%/&,<_6IE9JSV-L/4G1FJL7JM3Y"_X)7_\
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M)_P2:'_&R;]KOV\42?\ I3<5^CMP?]%;_=K\XO\ @DS_ ,I)_P!KS_L:9/\
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M/_ @4O;8_P#D7WE?V7PG_P!!L_\ P!GVE_PTQX'7_F9='_\  M?\:!^T[X(
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MU%]J]F,KH_-<135.K*GV;1<HHHJC$**** "BBB@ HHHH **** /S0_X(M?\
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M^UCS+=\9WKM_U)YYZUPXVBZD'!'TO"N.HX/&JM7^%)_EH?1?PL.SX?Z3D?\
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M '#]*6D?[A^E $,_-LW^[7YP?\$FR3_P4C_:Z*\9\42?A_I4]?H]<?\ 'O\
MA7YP_P#!)ML?\%'?VN/^QHD_]*IZ]/!?[M6?]U?F@/T>5<R_1JG5LU#_ ,MO
M^!5,HQGZUY74!:***H HHHH **** "BBB@ HHHH **** *MQ:^:<XY!.*B>Q
M(.XECCUJ\K;J5AD4 43;;NN&4]015FW3$0[@=*EH48% !1110 4444 %%%%
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M ,EU^EN*,4!9_P!?\.?FE_PM[_@JU_T2W]D+_P &.J?_ "71_P +>_X*M?\
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M#%&*8M?Z_P"'/S2'Q>_X*L*N/^%7?LA_CJ.J?_)=+_PM_P#X*M?]$M_9#_\
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MQ0%G_7_#GYI?\+>_X*M?]$M_9"_\&.J?_)='_"WO^"K7_1+?V0O_  8ZI_\
M)=?I;BC% 6?]?\.?FE_PM[_@JU_T2W]D+_P8ZI_\ET?\+>_X*M?]$M_9"_\
M!CJG_P EU^EN*,4!9_U_PY^:7_"WO^"K7_1+?V0O_!CJG_R71_PM[_@JU_T2
MW]D+_P &.J?_ "77Z6XHQ0%G_7_#GYI?\+>_X*M?]$M_9"_\&.J?_)=+_P +
M>_X*L?\ 1+?V0_\ P8ZI_P#)=?I9BC% 6?\ 7_#GY\_\$5_V+_CE^SU\;?VD
M/B5\=;'P/IGB;XWZ]IVKBS\,7DEQ:6Y@CN1)M$F6529U !=C\K9/2OT&HHH*
#/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>tm2223302d1_s4img007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2223302d1_s4img007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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MBC>!?_!_:?\ QRC_ (:J^%__ $4;P+_X/[3_ ..5SO\ PS%\*?\ H2]#_P#
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M_CE<[_PS%\*?^A+T/_P$H_X9B^%/_0EZ'_X"4<F#[R_\!7^8<V)_E7WG1?\
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M $)>A_\ @)1_PS%\*?\ H2]#_P# 2CDP?>7_ ("O\PYL3_*OO.B_X:J^%_\
MT4;P+_X/[3_XY1_PU5\+_P#HHW@7_P ']I_\<KG?^&8OA3_T)>A_^ E'_#,7
MPI_Z$O0__ 2CDP?>7_@*_P PYL3_ "K[SHO^&JOA?_T4;P+_ .#^T_\ CE'_
M  U5\+_^BC>!?_!_:?\ QRN=_P"&8OA3_P!"7H?_ ("4?\,Q?"G_ *$O0_\
MP$HY,'WE_P" K_,.;$_RK[SHO^&JOA?_ -%&\"_^#^T_^.4?\-5?"_\ Z*-X
M%_\ !_:?_'*YW_AF+X4_]"7H?_@)1_PS%\*?^A+T/_P$HY,'WE_X"O\ ,.;$
M_P J^\Z+_AJKX7_]%&\"_P#@_M/_ (Y1_P -5?"__HHW@7_P?VG_ ,<KG?\
MAF+X4_\ 0EZ'_P" E'_#,7PI_P"A+T/_ ,!*.3!]Y?\ @*_S#FQ/\J^\Z+_A
MJKX7_P#11O O_@_M/_CE'_#57PO_ .BC>!?_  ?VG_QRN=_X9B^%/_0EZ'_X
M"4?\,Q?"G_H2]#_\!*.3!]Y?^ K_ ##FQ/\ *OO.B_X:J^%__11O O\ X/[3
M_P".4?\ #57PO_Z*-X%_\']I_P#'*YW_ (9B^%/_ $)>A_\ @)1_PS%\*?\
MH2]#_P# 2CDP?>7_ ("O\PYL3_*OO.B_X:J^%_\ T4;P+_X/[3_XY1_PU5\+
M_P#HHW@7_P ']I_\<KG?^&8OA3_T)>A_^ E'_#,7PI_Z$O0__ 2CDP?>7_@*
M_P PYL3_ "K[SHO^&JOA?_T4;P+_ .#^T_\ CE'_  U5\+_^BC>!?_!_:?\
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M6AWG$XN884\TOGYI/E"X&:/=[?F!^EQ&#COW'I12#V.X>N,9]?US2T>[V_,
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M8Q] *]Q_X*2_LYW/[4O[/DWAC3=9TW1]:35K74M*CU%\Z?JEU;2^;':7*?\
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M_P"G*VK-_:6^-WAS]F[X1:AXT\527,>D:.J>9]GC,DKEF"A54=>3GV -7/\
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M/JWDW.H^/_#?A:#09KF34Y[K3K)VAB6[:T@D.V)9WC+<#H2,#I7V2?#-J?\
MGI_WW1_PC5KZ-[G=R>2?ZF@#YC^%O_!-CX5?!KXW)X\T+3M9CU*RNKJ^TO3[
MC5I[C2=#N+C>)9K2T8^7"["209 X\QL;<UV6K_LG^"M<\!>,O#-Q87#:/X]U
MT^)-7B%P=\MZ9H)BZ-U4;[:$X_V?>O:O^$9M?^FG_?5'_",VO_33_OJ@#YYU
MG]A'X?>(?VCH?BA>PZ_<>([6]75(+9]9G.EP7JQ>4+I;0MY8E"XP<8!4'&1F
MJ6D?\$\/AIX<^.LGQ TNVU_2M2DU0ZXVF6>LSPZ*;\G<UT;-6$?F,WS-_"6
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M^(^'YH[#]LW_ ),]^*G_ &*&K?\ I'-7I:?=7Z5YI^V;_P F>_%3_L4-6_\
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MYG68W##S_M!:=\R>9QA=H7%>W$C%!&:X7K=O^M+?DRHZ+E6W_!O^9\6^*_\
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M#5\*_P"KN/\ KK_05KUD>%?]7<?]=?Z"M5WVT .HIOF4Y3D4 %%([;5I!)0
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M46G[2O\ V2OQ1_Z:+JN"_88_Y,E^#W_8D:+_ .D$% 'J=%%% !1110 4444
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M@_\ I=%7O3]/QKP7]N+_ %'PP_[*%H/_ *715U8+^+]_Y,PQ'P_-'8?MF_\
M)GOQ4_[%#5O_ $CFKTM/NK]*\T_;-_Y,]^*G_8H:M_Z1S5Z6GW!]*QE_"7J_
MT''^*_1?J&>/UK@OVD[;X?WOP,\1P_%/_A&U^'\EMLUK_A(&C73/)+*/WYDP
M@3=M^]QTKO#R17G?[5'@?Q!\2OV??%>@^%['P3J6O:M9-;6EMXPM'O-#F9B
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MT_B^E4/%<OF^#]4]?L<N>/\ 8:D,^;?^"6'_ "CB^"O_ &*EG_Z!7OE>!_\
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M'R*ZL=*\#:3X;U.\UN*RLI-3B<PZ4KV][(]I<HDGF&X06J-R$_UA&T8!)'5
M?I#_ ,)(I&1"Y'L?R_K^5)_PDJE<B-F7=@$'KWS],5^;]Y_P5 ^,>MZ3HW]D
M^&_ MMJ&M^'6\99N&N'M[:P73)[K[/D$;IO-M9$+< "9>,@YC\:_\%0?B1\0
M?&7C3PYX9\-0^'[.+0)[NSU"Y@S)HHCL4N/MDI$H9H9-TBK^[7&Y&W$!J:W
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M"4S2'_@FY\%/- 67_A$K'>H_A;RQD?GFOH&O ?\ @E?_ ,HY/@O_ -BI9_\
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MAG@/_!5__E%I^TK_ -DK\4?^FBZK@OV&/^3)?@]_V)&B_P#I!!7>_P#!5_\
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MYJ[D#]L@$$_AZ5YY\$/'WB?QOXA\00ZS?>$;VST>\^Q;M&63S!+Y44OS%I7
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MGPC^S?\ \)%KUC>7=G90P>,BLE\T$C)T-EA<A2>2<>]<$_\ P6<9/VQ%T_\
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M_P#!-?QCI/@C_@F?\&+W6=4T[2;-?"MFIN+VY2",'RR0,L1_=-?0.A>)M/\
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M='_#1/P__P"AZ\&_^#JV_P#BZM?\.>/V3_\ HVWX'_\ A%Z?_P#&JYSX;?\
M!#K]DWX8Z%=:?#\!?ACK(NM0O-0\_6?#MG?7$?VB=YO)1WCRL,0<11H/NQQH
M"2<L0#9_X:)^'_\ T/7@W_P=6W_Q='_#1/P__P"AZ\&_^#JV_P#BZL2_\$?_
M -D^"-F;]F_X'JJC+$^"]/  ]_W5<_\ #_\ X(<?LF?#U=9$7P#^&&JKK.IR
MZF1JOARSO?L1D5%,$!>,F.!=F5C!PI9L=: -C_AHGX?_ /0]>#?_  =6W_Q=
M>L?L_?$?P]X]T*]70=>T76FM9\S"POHKGR0RKC=L8XS@XSZ&O,?^'/'[)_\
MT;;\#_\ PB]/_P#C5<UI?_!$/]D>T^)6H>*X_@/\+9VUK3K6P33I/#UE)I4
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M%2"(Y)44.XR 3N8Y(!.3S7K50 4444 %%%% #7Z?C7@O[<7^H^&'_90M!_\
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M[?4M)TOQ)8W;66HZK<ZGI5T-7$S 6ORRW*NK*,AGQCG)(KPKX&?MF?%31?\
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MPQ_::\$_%OX3^'?'&D:Y''X8\5V":GI=YJ4$NF_:;:22...0I<*CH':6()O
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MZ=%75@]*OW_D<^(MR_-'8?MF_P#)GOQ4_P"Q0U;_ -(YJ]+3[J_2O-/VS?\
MDSWXJ?\ 8H:M_P"D<U>EH?D'TK&7\)>K_0J/\5^B_46BBBLS8**** "BBB@
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MZ7_A3/Q4_P"BP1_^$G:__%T457URIV7_ (#'_(CZK3\_O8?\*9^*G_18(_\
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M_P"$G:__ !='_"F?BI_T6"/_ ,).U_\ BZ**/KU7M'_P&/\ D'U6GY_>Q/\
MA3/Q4_Z+!'_X2=K_ /%USUK9^*K[XDW7@R']H3P[-XPL;%-3N="CT2P;4K:T
M=BB7#VXE\Q8F8%0Y7:2" <T44+'5.9*T?_ 8]K]B98:"BVK_ 'ON=%_PI;XI
M,.?C!'CT_P"$3M?_ (NF/\%?BDY^;XOQ\'(_XI.UX_\ 'Z**KZY4\O\ P&/^
M0WA:?G]['GX*_%$G_DKL?M_Q2EKQ_P"/TU_@I\47'_)78_\ PE+7I_WW111]
M:J>7W+_(?U:'G][#_A2GQ0!_Y*]'_P"$K;=?^_E ^"GQ24\?&",?]RI:]/\
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MXR?!?4/%GAV**XU71+;PQ-+J.F12C,3SVZZP9(E<<J74!NV:**?MI7Z?<O\
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M/AS_ .$/>?\ RVHHH]M+R^Y?Y!["/G][_P P_P"$3^,)/_(^?#G_ ,(>\_\
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FKB3Y2%VS/J,RKAMI.8VR 1P3N'>CI116,Y.3U_R_(TC!16A__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>tm2223302d1_ex5-1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2223302d1_ex5-1img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M]F+_ )-M^'O_ &+.F_\ I+'0!_/O_P $-_ ]A_P5X_X+O_&;XJ?&JWA\;?\
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M&P6<RN)7 $:WEZ0J+&"1&B9_>")BWT%_P=R((_VT?V)E7A5UJ^  '0?;M(H
M\L\.^,_%W_!IO_P5)NO"]Y_PD'B/]E#XO31W%M/=MYLD$0V*]RA1=IO;,OMD
M15!GA,9(4M&4V_\ @X5\9:7\1/\ @O%^Q'KVA:A9ZOHNM6GA:^L+ZTE$L%W!
M+XBE>.2-QPRLI!!'4&OV&_X*<?\ !-?P'_P5,_9DO?AOXZ^TV?ES?VAHNKV@
M'VK1+]4=(YT!X=<.RO&>'5B,J<,/Y9O#OA3XJ? S_@K#\ ?@M\6)+C^U/@CX
M_P!&\+Z7'*A CL3KBW49B<@%X':X>6-C_!*H&    ?V,ZA?P:18375S-';VM
MO&TLLLKA4B11EF8G@  $DFOYI/V,OV^?AK\"_P#@LS\:_C9XA\$R>,/V7?CA
MXVO_  X?B!XA\.FYM]&NY9#=KY<CJRK"6?YHCA_L_EN5!CV'^D+XL^ (OBO\
M+O$OA>XN)+6#Q)I5UI4DT8!>%9X7B+ '@D!LC/I7\\GPM\6_%O\ X)T?L>?$
M#]BGX\?L8^//C;X%OM8O/^$?UOPK:7,,>IM)+O2>*XCMI@[B14EBD!\V,$(Z
M';M !^Q-Q^W=^SE^Q!\4_@_\$?"MKI^FR?&J9K[PA8>#-*CET:9;FXRUR&MR
M(HXGD=Y"Z@J0':OH[XV?\D9\7?\ 8%O/_1#U_-]_P2#_ &>/C1^P/_P4%^#O
MC+X^?LW_ !RU[P7%I=QI'@6Z-K=:J?AM!<7DQ,]Q!;PL5V&XN"T<BPL!<O,L
M9(11_2!\:SN^#'B[_L"WG_HAZ /YD_\ @W=_X+R?"7_@D=\$/B%X9^(GAOXB
M:]?>+-=@U.TD\.65G/%%&EN(B)#/=0D-D=@1CO6Y_P %J_\ @NSX1_X+@:5\
M/_@C\/\ PW;_  [\,KXF@U>?Q=\0KZWL/LLHMYH0'\EIDMX )W9W#NS;4 4<
M@^C?\&I/_!2;X!_L/_LX?%32/B]\1- \%ZEKGB6WO+""_AF=KB%;4(SKLC88
M#<<UZ]_P<<_\%8?V,_VM/^"=NK>&/">O>&OB=\3+B]ME\+2Z?I\JW'AZ03QO
M<7/VAXE\N,PH\90$^874;< LH!].?\%:/A+H?P&_X-@/$W@KPWKUOXHT'PKX
M"\/:78:S;S+-#JT4-WIZ+<HZDJ4DQO&TE<,,<8KP?_@E+_RI_P#Q:_[$OQ]_
MZ*O:Y3P]X>\8>&?^#*?7+?QC'>0W$VE?:-+ANU*S1Z;)XBB>VR",[60[T_Z9
MNF.,5U?_  2E_P"5/_XM?]B7X^_]%7M 'GO_  :L?\%._@#^Q?\ \$\_%7A?
MXI?%/POX)\07GCR\U*"QU*5UEDMGL;"-90 I^4O%(/JIK+_X.BO^"MO[/O[<
M'[*'A'X2_"/Q#9_%#QQ<>++;4TGTJPFDCTN)(9H]J2L@WRS-,B".+=P&W8(4
M-C_\&R7_  1?_9O_ ."B/[!7B;QM\7OA[)XJ\2Z=XWN]'M[Q=?U*P\NUCLK&
M58]EM<1H</-(=Q7=\V,X QYROPBT[_@UJ_X+4Z+JGBCPS9_$'X->-K9SH'B'
M4--1M0T&UEE"2202E6Q>6@;9+L(\Z&4'"&554 ^IO^"MWP8\2?L[_P#!IE\.
M?!?B^UN-/\2Z!:>&8-1LYO\ 6V,QF#F!^N&CW!".Q0BOT,_X(5?\H?/V=_\
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M_P"/U]K44 ?%/_$.E^Q5_P!$!\+?^!M]_P#'Z^DOV@OV3?AE^U?X1CT+XE>
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5'>1D4-(?=R3[UZ'110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !] )0# 2(  A$! Q$!_\0
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M4I=6:]!BNQ&%@N"BL-@/(Z&O<O"_@/PWX.5SHNFI#,XP\[DO(P]-QY ]A@4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
3!1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
